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4ABSTRACT
In the UK, 7-10% of the child and adolescent population are currently considered obese 
according to International Obesity Task Force (IOTF) definitions, and this proportion is 
expected to rise to 14% over the next 20 years. Childhood obesity is associated with 
complications including dyslipidemia, insulin resistance, and respiratory problems, and 
childhood body mass index (BMI) is correlated with BMI in adulthood. However, the ways in 
which overweight and obesity in early life impact on long-term health are not well understood.
This thesis reviews the current evidence for the associations between overweight in childhood 
and disease outcomes in adulthood, and discusses the limitations of methods that have 
commonly been used to examine this topic. To investigate the effects of childhood and 
adolescent overweight on long-term health, pooled data from three British National Birth 
Cohorts (the 1946 National Survey of Health and Development, 1958 National Child 
Development Study, and 1970 British Cohort Study) are analysed. The findings of this analysis 
indicate that being overweight in childhood and adolescence may contribute to increased risk of 
type 2 diabetes and coronary heart disease, but not hypertension or non-cardiovascular 
outcomes. Projections from a micro-simulation model show that overweight and obesity in the 
current UK child population could present a substantial burden in terms of disease prevalence 
and healthcare costs by the year 2050, and the effects of different obesity interventions on long­
term burden are explored.
Overweight and obesity in childhood may have important implications for long-term 
cardiovascular risk, and current trends in childhood obesity prevalence are likely to have a 
substantial impact on long-term health burden in the UK. Early intervention to reduce 
overweight in childhood is likely to have an important role in reducing future obesity-related 
disease burden.
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1. INTRODUCTION
1.1. Background
Childhood obesity prevalence has doubled or tripled in high-income countries since the 1980s,1' 
2 and is rapidly rising in a number of low- and middle-income countries.3-4 It is currently 
estimated that 155 million children aged 5-17 years worldwide are overweight or obese.5 
Obesity is associated with a number of co-morbidities, including type 2 diabetes, cardiovascular 
diseases (CVD) and several cancers,6 and is one of the leading preventable causes of death and 
disease worldwide.7'8 Increasing understanding of the progressive nature of many of these co­
morbidities,9'10 and awareness of the difficulties in treating adult obesity, 11 have shifted the 
focus from adult adiposity and its control to early life factors and prevention.12 Reducing 
childhood obesity prevalence is a major priority for the UK government, as outlined in their 
‘Healthy Weight, Healthy Lives’ cross-government strategy.13
The impending disease burden associated with childhood obesity has been variously described 
as ‘a health time bomb,’14 ‘a massive tsunami,’15 and even a national security threat.16 It is 
known that childhood obesity is associated with a number of long-term health problems,17 but 
the pathways from excess adiposity in early life to outcomes in adulthood are unclear. 
Furthermore, the scale and nature of the childhood obesity health burden are unknown. Key 
questions that arise from consideration of these issues include, what does childhood obesity 
today mean for health tomorrow? What are the wider implications of the childhood obesity 
epidemic, and what can we do to prevent or mitigate these effects?
As the number of obese children in the UK and worldwide continues to rise, the need for 
answers to these questions becomes increasingly urgent. Central to understanding the long­
term implications of current childhood obesity is an examination of whether obese children who 
become obese adults are exposed to additional long-term health risks compared to non-obese 
children who become obese adults. Information about the expected burden of childhood obesity 
is essential for public services planning, resource allocation, and appropriate strategies for 
intervention.
1.2. Aims and objectives
The primary aim of this thesis is to investigate the impact of childhood obesity on future health 
burden in the UK.
Three main objectives are addressed. The first relates to whether overweight and obesity in 
childhood and adolescence are risk factors for long-term health outcomes; associations between
14
overweight in childhood and adolescence and morbidity in adulthood are examined to test the 
hypothesis that overweight in youth is associated with increased risk of obesity-related diseases 
in adulthood (type 2 diabetes, hypertension, coronary heart disease, stroke, asthma, arthritis, gall 
bladder disease, and selected cancers). One possible explanation for associations between 
childhood overweight and adult disease is that obesity tracks into later life ,18 so the effects of 
adult overweight may account for the observed disease risks. Therefore the second objective of 
this thesis is to examine the contributions of overweight and obesity at different life stages to 
disease outcomes, and to test the hypothesis that overweight in childhood and adolescence 
confer increased risk of obesity-related diseases in adulthood, compared to obesity in adulthood 
only. In addition to identifying whether childhood obesity contributes to long-term disease 
risk, it is of interest to know the implications of the current childhood obesity epidemic for long­
term health burden. The Department of Health have used a micro-simulation model to estimate 
obesity burden in the UK in the year 2050 19; the final objective of this thesis is to estimate the 
health burden and healthcare costs associated with current levels of childhood obesity, and to 
explore the impact of interventions for preventing and treating obesity on future burden of 
childhood obesity. Addressing these objectives will further our understanding of the 
relationships between childhood overweight and adult disease, and provide insight into the 
potential future burden of the current childhood obesity epidemic.
1.3. Overview o f the research
In this thesis, pooled secondary data from three British National Birth Cohort studies are 
analysed to address the first two research objectives, supported by the findings of a systematic 
review of the literature. The 1946, 1958 and 1970 birth cohorts are prospective studies that 
have followed up between 5,362 and 17,638 individuals born during one week in each year. 
Cohort members for whom there are height and weight data in childhood, adolescence and 
adulthood, and information on disease outcomes in adulthood, form the population for the main 
analyses. Despite some differences in data collection methods, these datasets have comparable 
target populations, and provide longitudinal data on participants at several points during 
childhood, adolescence and adulthood, making them ideal for studying life-course effects. The 
final objective is examined using a micro-simulation model developed by the National Heart 
Forum, which was designed to project future disease burden and costs associated with current 
obesity trends. Estimates generated from this model have been used by the Department of 
Health as the basis for predictions of future obesity burden in the UK.
Ethical approval for this work was obtained from the London School of Hygiene and Tropical 
Medicine Ethics Committee (see Appendix 1). Funding to support this work was from an 
Economic and Social Research Council (UK) 1+3 studentship.
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1.4. Structure o f the thesis
This thesis is organised as follows: Chapter 2 begins with an overview of the research area, 
discussing the effects of childhood obesity on health, and approaches to measuring obesity 
burden. This is followed by a systematic review of studies that have investigated the 
associations between childhood overweight and adult disease in Chapter 3. Chapter 4 describes 
the analytical approaches and methods used in the thesis. Chapter 5 describes the British 
National Birth Cohort data, giving an overview of patterns of response, participant 
characteristics, and the distributions of the variables used in the main analyses. Chapter 6 
presents the results of analyses of the British National Birth Cohort data relating to the effects of 
childhood and adolescent overweight and obesity on adult disease. Chapter 7 presents the 
results from examination and application of the National Heart Forum obesity model for 
projecting disease burden attributable to childhood overweight and obesity in the UK, and 
assessment of the effects of different approaches to obesity interventions. Finally, Chapter 8 
discusses the main findings of the thesis, their strengths and limitations, and their implications.
16
2. CHILDHOOD OBESITY: EPIDEMIOLOGY AND CONSEQUENCES
2.1. Introduction
The dangers of excess body fat for health were recognised more than two millennia ago in 
ancient Greece, when Hippocrates wrote that corpulence led to disease and early death, and 
observed that changes in the diet could lead to improvements in health.20-21 However, it is only 
in recent decades that obesity in childhood has occurred on a scale and to an extent that has led 
to wide concern. In this chapter, I begin with an overview of childhood obesity definitions and 
epidemiology, and go on examine the evidence on the effects of childhood obesity on health and 
approaches to measuring obesity burden.
2.2. Childhood obesity: definitions and epidem iology
2.2.1 Measuring childhood obesity
Obesity is a condition in which there is excessive accumulation of body fat, to the extent that 
health is likely to be compromised.22 Direct methods for estimating fat mass, such as magnetic 
resonance imaging (MRI) and dual energy x-ray absorptiometry (DXA), provide detailed 
information on aspects of body composition but require expensive equipment and skilled 
technicians. In large population-based studies, obesity is usually assessed using indirect 
methods, the most common of which is body mass index BMI, a measure of weight for height 
(weight in kilograms divided by the square of height in metres (kg/m2)). Obesity in adults is 
defined by the World Health Organization (WHO) according to BMI cut-off points that relate to 
increased risk of co-morbidities and mortality (Table 2-1).
Table 2-1: Classification of overweight and obesity in adults (non-Asian populations)22
Classification BMI (kg/m2)
Underweight <18.5
Normal range 18.5-24.9
Overweight (pre-obese) 25-29.9
Obese Class I 30-34.9
Obese Class II 35-39.9
Obese Class III >40
Measuring obesity in children and adolescents (aged <19 years) is complicated by the fact that 
height and body composition are continually changing. The proportion of fat to lean mass 
varies with sex, age and physical maturity, 23-24 making it problematic to define physiological 
norms. Consequently BMI adjusted for age and sex, expressed as centiles or standard deviation 
scores (BMI SDS or Z-score) of the BMI distribution in a reference population, are the most 
commonly used measures of adiposity in children and adolescents.
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UK clinical guidelines on childhood obesity 2526 recommend that children with BMI >91st 
centile ol the 1990 UK reference population J  should be considered for clinical intervention, 
with assessment of co-morbidities at BMI >98lh centile. This is in contrast to population-based 
studies such as the National Child Measurement Programme, 2* which use cut-offs at the 85th 
and 95lh centiles of the 1990 reference population to define overweight and obesity respectively. 
The WHO growth references for children aged up to 19 years 29‘30 are based largely on US data 
(more countries were included for development of infant and early childhood references), and 
use cut-offs at +1 SD and +2 SD to classify overweight and obesity, which are equivalent to 
BMI 25 kg/m2 and BMI 30 kg/m2 at age 19 years.
International definitions of childhood overweight and obesity have been developed for children 
aged 2-18 years by the International Obesity Task Force (IOTF), based on BMI centiles 
averaged across six countries (Brazil, USA, Great Britain, Netherlands, Hong Kong and 
Singapore), and which correspond to BMI 25 and 30 kg/m2 at age 18 years. 31 Reference centile 
curves were litted to these data using Cole's LMS method, an approach which summarises the 
BMI distribution at a specific age according to its median (M), coefficient of variation (S). and a 
measure of skewness (L, based on the Box-Cox power needed to transform the data to a normal 
distribution).32 L, M and S at each age are used to draw smoothed curves, with the M curve 
representing the 50th centile curve for BMI.
Examples of child BMI cut-offs can be seen in Figure 2-1. The use of different references 
produces different estimates of obesity prevalence, 33 which can make comparison of results 
across studies problematic. The use of standardised definitions of obesity, such as the IOTF 
references, can avoid this issue.
Figure 2-1: Comparison of WHO and IOTF cut-offs for obesity in boys aged 5-19 years. Source: WHO
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A limitation of BMI as a measure of adiposity is that it does not account for variation in body 
composition, fat distribution or body proportions. Abdominal fat and visceral adipose tissue (as 
opposed to subcutaneous adipose tissue) have been shown to be independently associated with 
increased cardio-metabolic risk, 34 35 and measures of abdominal obesity such as waist 
circumference can provide additional information on cardio-metabolic risk.36-40 However, 
despite its limitations, BMI is highly correlated with adiposity and is a reproducible indicator of 
cardio-metabolic risk, 41 and its simplicity and reproducibility mean that it is a reliable measure 
of adiposity in large population-based studies. 42 Furthermore, BMI has been shown to be a 
stable measure of adiposity change in growing children. 43 For these reasons, BMI and IOTF 
cut-offs are used as measures of overweight and obesity in childhood, and the WHO cut-offs are 
used for adults throughout this thesis.
2.2.2 Epidemiology o f childhood obesity
At the individual level, obesity can be attributed to an imbalance between energy intake (via 
diet) and energy expenditure (via physical activity), 44 except in the case of rare genetic or 
endocrine conditions. However, the etiology of obesity is complex, with influences on diet and 
physical activity acting at the individual, household, regional and societal levels to contribute to 
patterns of obesity.45-46
Since the 1980s, the prevalence of childhood obesity has doubled or tripled in most regions of 
the world, regardless of the method used to define obesity (Figure 2-2). The rate of increase in 
obesity prevalence and the global nature of this trend makes a genetic explanation unlikely, 
although genetic factors are likely to have an important role in individual variation in adiposity. 
47 Changes in lifestyle at the population level have contributed to current trends, characterised 
by changing energy content, portion sizes and foodstuffs in the diet, decreased levels of physical 
activity, and increasing sedentary behaviours such as television viewing. 48
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Figure 2-2: Global increases in childhood obesity prevalence. Source: Ebbeling et al 2002 2
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In the UK, 7-10% of children are considered obese by IOTF definitions,45 which are among the 
highest rates in Europe.1 The distribution of obesity is not uniform across socio-demographic 
groups, and overweight and obesity among children and adolescents has been associated witli a 
number of factors, including older age, higher parental weight, lower socioeconomic status 
(although the reverse was true until the latter half of the 20lh century, and the opposite effect is 
observed in many developing countries today 1 ), ethnicity, reduced physical activity levels, and 
sedentary behaviours.50-53 Data from the NCMP 2007/08 indicate that obesity prevalence at 
age 10-11 years is double the prevalence at age 4-5 years (18.3% versus 9.6%, >95lh centile of 
UK 1990 reference), and is higher among boys than girls.54 Obesity prevalence among Black 
(prevalence 26.4%) and Asian (21.5%) children is higher than the national average, and lower 
among Chinese (13.7%) and White (17.3%) children. There is also variation in prevalence of 
overweight and obesity between UK constituent countries and regions; analysis of 13,194 
children from the UK Millennium Cohort Study at age 3 years showed that children from 
Northern Ireland and Wales were more likely to be overweight or obese than children in 
England, while within England, children from the East and South East regions were less likely 
to be overweight than children from London, even after adjustment for individual socio­
demographic characteristics and risk factors for overweight. 55
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Obesity prevalence in England among children aged 2-11 years, defined according to IOTF 
criteria, increased from 1.7% in 1984 to 5.4% in 2002 among boys, and from 2.6% to 7.8% 
among girls over the same time period. 56 This is equivalent to an overall annualised change in 
prevalence of 0.7%, assuming linear change. However, the picture of change is more complex 
than one of a generalised increase in BMI. For example, the distribution of BMI has become 
increasingly positively skewed, such that the greatest increases in BMI have occurred amongst 
the heaviest children at the upper end of the distribution while the BMI distributions at the 
lower end are relatively unchanged.57 Children are also becoming obese at younger ages than 
previous generations. 58-59 More recently, there is evidence from several countries, including the 
UK, Sweden, France, Australia, Japan and the USA, to indicate a plateauing of childhood 
obesity trends, although this stabilisation of trends is more apparent in higher socioeconomic 
status (SES) groups.60-61
2.3. Childhood obesity and health
The effects of childhood obesity on health can be divided into those that occur, a) concurrently 
(in childhood), or b) in the future. Many of the immediate and long-term health effects of 
childhood obesity have common causes, which are the result of metabolic and endocrine 
changes associated with obesity. For example, the metabolic syndrome, non-alcoholic fatty 
liver disease and polycystic ovary syndrome (in girls) share common features.62 Disorders 
observed in childhood may also represent early stages of progression to other clinical outcomes 
that manifest in later life, such as in the case of metabolic syndrome, atherosclerosis and 
cardiovascular disease. Therefore from a public health perspective, childhood obesity 
represents a primary through to tertiary prevention challenge.
2.3.1 Concurrent co-morbidities of childhood obesity
Cardio-metabolic complications
Childhood obesity is associated with the development of atherosclerosis and related cardio- 
metabolic risk factors. Atherosclerosis in youth was first documented by Enos et al in an 
autopsy study which reported the presence of fibrous lesions in the coronary arteries of young 
US soldiers (mean age 22.1 years) killed in the Korean War. 63 Two contemporary US studies 
have expanded on these findings by relating atherosclerosis at autopsy to risk factors in 
childhood, adolescence and young adulthood. 9-10 64-65 The Bogalusa Heart Study, a series of 
cross-sectional surveys of children followed up into adulthood, found that cardiovascular risk 
factors observed at age 3-18 years, including BMI, were associated with the severity of 
atherosclerosis at post-mortem autopsy. 9-10 The Pathobiological Determinants of 
Atherosclerosis in Youth (PDAY) study, a multi-centre autopsy study of more than 2,000 young 
people who had died at ages 15-34 years of external causes, showed that cardiovascular risk
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factors assessed from medical records and at autopsy were associated with atherosclerotic 
lesions in the arteries. 64-65 These studies confirmed that atherosclerosis begins in early life, and 
that the severity and extent of lesions is associated with obesity and other cardio-metabolic risk 
factors.
The metabolic syndrome MetS, also known as the insulin resistance syndrome and syndrome X, 
describes the clustering (co-occurrence) of risk factors for cardiovascular disease and type 2 
diabetes, namely central obesity, hypertension, dyslipidemia (elevated LDL-cholesterol or 
triglycerides, or lowered HDL-cholesterol), and glucose intolerance or insulin resistance.66 
Clustering of cardio-metabolic risk factors has been observed in several studies of overweight 
children and adolescents,37 67-74 and the number of risk factors has been shown to be correlated 
with the extent of atherosclerosis. 10 In the Bogalusa study, the relationship between obesity 
and cardio-metabolic markers was studied in a sample of 2,816 children and adolescents (age 5- 
17 years), and showed that measures of both total and central adiposity were associated with 
insulin, triglyceride, cholesterol and apolipoprotein levels.75 Analysis of data from a nationally 
representative sample of 2,430 US children aged 12-19 years showed that 4% of all adolescents, 
7% of overweight, and 29% of obese adolescents (BMI>95th centile) met the National 
Cholesterol Education Program criteria for M etS.70 A clinic-based study of obese children and 
adolescents in the UK (aged 2-18 years; BMI >95lh centile) reported that 70% had at least one 
other component of the metabolic syndrome (insulin resistance or impaired glucose tolerance, 
dyslipidemia or hypertension), while 33% had multiple risk factors. 69 The prevalence of MetS 
has been shown to increase with the degree of overweight, reaching up to 50% among children 
with significant obesity.76 Ethnic minority children are at higher risk of metabolic 
complications than white children. 7477 Weight loss studies have shown improvements in 
cardio-metabolic risk factors with reduction in overweight.78-79
More recently, noninvasive techniques have been used to assess atherosclerosis in young 
people, and have confirmed the relationship with classic risk factors. A number of studies have 
shown increased carotid intima-media thickness (CIMT),80-83 and increased left ventricular mass 
(LVM) 36 81 84 in children and adolescents with increased BMI and other risk factors. As an 
example, analysis of a sample of young people aged 13-27 years from the Bogalusa Heart Study 
showed that increased insulin levels were associated with increased LVM among participants in 
the highest tertiles for weight and adiposity.84
Type 2 diabetes
Insulin resistance and insulin deficiency can result in high blood glucose levels, and eventually 
type 2 diabetes. The condition is rare in youth, but prevalence has increased more than 10-fold 
in recent years, and is strongly associated with obesity.85 One study of children in the UK and 
Ireland showed that 95% of those diagnosed with type 2 diabetes at age <17 years were
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overweight or obese, while 83% were obese.86 This study also showed that children of black 
and South Asian origin were overrepresented, with an incidence of type 2 diabetes that was 
between 4 and 11 times higher than that in white children (incidence in black children estimated 
at 3.9 cases per 100,000 per year, compared to 0.35 in white children). The progression from 
impaired glucose tolerance and MetS to overt type 2 diabetes may be accelerated in youth 
compared to adults,87 but children can also revert from impaired to normal glucose tolerance if 
overweight is reduced, highlighting the importance of early intervention and weight 
maintenance during childhood. 7988
Fattv liver and gallbladder disease
Non-alcoholic fatty liver disease (NAFLD, an early stage of liver disease), is the most common 
form of liver disease in children and adolescents, and is associated with overweight and 
obesity.89'90 A recent review found that there is a growing body of evidence that NAFLD shares 
many features of the MetS in children and adolescents.91 The largest of the studies in this 
review was an autopsy study of 817 individuals who had died of external causes at age 2-19 
years, which showed that there was evidence of atherosclerosis in 30% of children with fatty 
liver, compared to 19% of those without fatty liver (OR 1.8; P <0.001). 92 Other studies in the 
review showed a relationship between fatty liver and cardio-metabolic risk factors including 
obesity, dyslipidemia, hypertension, insulin resistance and CIMT. Lifestyle intervention studies 
have shown that reduction in overweight is associated with improvement in liver enzymes and 
NAFLD. n '9A
Gallbladder disease is also related to overweight in youth. One study of pediatric cases of 
gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis) showed that 60% 
of idiopathic cases were in overweight adolescents.95 The degree of overweight is also 
associated with gallstones, with higher risk in obese adolescents than in overweight. 96 
However, the relationship is complex, and there is evidence that gallstones may be associated 
with weight loss as well as overweight. One study of 493 German children and adolescents with 
BMI Z-score >2, found that those with gallstones had lost an average of 10.1 ±7.0 kg prior to 
the study, compared to 5.8 ± 5.0 kg among those participants who did not have gallstones.96
Respiratory problems
An association between overweight, obesity and asthma has been reported in a handful of 
prospective studies in children. A systematic review of longitudinal studies examining the 
relationship between BMI in childhood or adolescence and asthma in adolescence found an 
association between elevated BMI and persistence and intensity of asthma symptoms in 8 out of 
10 studies. 97 As an example, one study of admissions to a US pediatric intensive care unit over 
a 10-year period showed that children with recurrent asthma exacerbations (asthma attacks)
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were twice as likely to be overweight when compared to those with one admission for asthma 
(OR 2.3; 95% Cl 1.1, 4.9).98 Other components of the metabolic syndrome may also be related 
to asthma. One study of Mexican adolescents (n=500) showed that the prevalence of MetS was 
higher among obese adolescent boys with persistent asthma than in those without asthma, but no 
effect was observed in adolescent girls.99
Obstructive sleep apnoea is another problem associated with obesity in childhood. In a case- 
control study of 399 children and adolescents (age 2-18 years) in the US, obesity was associated 
with a more than four-fold increase in odds of sleep-disordered breathing (OR 4.59; 95% Cl 
1.58, 13.33).100 Sleep apnoea may also be related to other cardiovascular risk factors. In a 
small study of 28 children and adolescents (age 2-18 years), sleep apnoea was associated with 
increased LVM and abnormal LV geometry, after adjusting for age, sex and BMI. 101
Orthopaedic problems
Obese children and adolescents are at greater risk of musculoskeletal discomfort, mobility 
problems and orthopaedic complications, such as slipped capital epiphyses (SCE) and Blount’s 
disease, than their normal weight peers. It is estimated that up to 80% of children with SCE 102 
and Blount’s disease 103 are obese. Cross-sectional studies have also indicated a dose-response 
effect, as children with SCE in both hips have higher BMI than those with unilateral disease.102
Gvnaecologic problems
Polycystic ovary syndrome (PCOS) has been related to the MetS and NAFLD in women, with 
obesity as a common factor in both.104 It is reported to be a growing problem among adolescent 
girls, and has been associated with elevated BMI in cross-sectional studies. 105 107 Such studies 
have also shown a higher prevalence of MetS 107 108 and liver dysfunction in obese adolescent 
patients compared to their normal weight peers.109
Neurological problems
Idiopathic intracranial hypertension IIH (or pseudotumor cerebri) is an uncommon condition 
(prevalence 1 per 100,000) that can lead to visual impairment and blindness. 110 It occurs more 
frequently in those with obesity than in lean populations. In an Israeli study, it was estimated 
that up to 60% of children with IIH (aged <16 years) were overweight or obese.111
Psychological well-being
Obese children face stigmatisation and are often subject to negative stereotypes.112113 
Although evidence for an association between obesity and indicators of psychological well­
being such as self-esteem and depression remains equivocal,114 studies have shown that obese 
children have lower health-related quality of life,115'116 greater body dissatisfaction,114 and more 
emotional and social problems than their normal weight peers.117 They are also more likely to
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have problems with school attendance and perceived academic performance.117 These problems 
are especially common among adolescent girls. 114
2.3.2 Future health problems associated with childhood obesity
Tracking of obesity into adulthood
Tracking refers to the persistence of values or ranks of continuously distributed traits over 
repeated measurements over tim e.118 BMI in childhood has been shown to track into 
adulthood, with the strength of associations increasing with childhood age; a systematic review 
of the literature on the tracking of overweight from childhood into adulthood found that 
longitudinal studies consistently reported an increased risk of overweight in adulthood for 
overweight and obese in youth. 18 In one study of children in the US (n=854), overweight or 
obesity at age 1-2 years was associated with OR 1.3 (95% Cl 0.6, 3.0) for obesity in adulthood 
(age 21-29 years), compared to OR 17.5 (95% Cl 7.7, 39.5) for overweight or obesity at age 15- 
17 years, after adjusting for parental overweight.52 In another example, analysis of data from 
2,610 participants in the Bogalusa Heart Study showed that BMI measured at ages 2-17 years 
was associated with BMI, adiposity (skinfold thickness) and overweight in adulthood (ages 18- 
37 years).119 Analyses of data from the Fels Longitudinal Study have shown that BMI in 
childhood or adolescence can be used to predict the probability of overweight or obesity in 
adulthood, with better predictions with increasing age in childhood. 120
Tracking of childhood overweight into adulthood, with its attendant health risks in later life, and 
the increasing association with childhood age, emphasize the difficulty of reducing overweight 
in later life and the benefits of early intervention.
Childhood obesity predicts cardiovascular risk in adulthood
In addition to persisting into adulthood, childhood overweight predicts other components of
MetS and markers of atherosclerosis in later life. A recent systematic review of childhood
obesity and adult cardiovascular disease risk reported consistent positive associations between
BMI in early life and cardiovascular risk factors such as blood pressure and CIMT in adulthood. 
121 In the Bogalusa Heart Study, overweight adolescents (age 13-17 years) had adverse levels 
of body fatness, blood pressure, serum lipids, insulin and glucose at age 27-31 years, compared 
to those who were lean in adolescence.122 The Muscatine Study, a population-based 
longitudinal study of cardiovascular risk factors in children, young adults and family groups, 
showed that CIMT in 725 men and women aged 33-42 years was associated with BMI and 
cholesterol levels in childhood.123 Analysis of data from the Bogalusa Heart Study and the 
Cardiovascular Risk in Young Finns Study, a population-based prospective cohort in Finland, 
showed that high BMI at age 9-18 years was associated with increased risk of high CIMT and 
type 2 diabetes at age 24-41 years. 124
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Other cardiovascular risk factors that cluster with obesity in childhood have also been shown to 
track into adulthood in longitudinal studies. Analysis of the Bogalusa Heart Study showed that 
clustering of systolic blood pressure, insulin level and ratio of total to HDL-cholesterol persisted 
from childhood (age 5-17 years) to adulthood (up to age 25 years), and also that tracking of 
multiple risk factors increased with baseline ponderal index (a measure of adiposity, 
weight/height3) . 125 Multiple risk factors in childhood are associated with increased 
cardiovascular risk, as demonstrated in the Cardiovascular Risk in Young Finns study; pulse 
wave velocity and arterial stiffness (markers of atherosclerosis 126-127) in white adults aged 24-45 
years were associated with the number of classic risk factors (obesity, high LDL-cholesterol, 
low HDL-cholesterol, elevated blood pressure and smoking) in childhood and adolescence.128' 
129 Furthermore, a reduction in overweight between childhood and adulthood was associated 
with lower pulse wave velocity, indicating a beneficial effect of weight management in youth 
for prevention of atherosclerosis.128
Childhood obesity and adult disease
There is some evidence that obesity in youth is associated with increased risk of a number of 
chronic diseases, including type 2 diabetes, hypertension, asthma, CVD, and cancers, and 
mortality in adulthood. 130-134 A study of 18,513 Israeli army personnel showed that odds ratios 
OR for hypertension at age 26-45 years were 1.75 (95% Cl 1.66, 1.86) for men who were 
overweight at age 16-19 years, and 3.75 (95% Cl 3.45, 4.07) for those who were obese, after 
adjusting for age and blood pressure. 135 Similarly, analysis of data from the Muscatine Study 
showed that childhood adiposity (measured at age 7-18 years) was positively correlated with 
adult blood pressure (age 20-30 years).136 Analysis of data from 4,719 participants in the 1966 
Northern Finland birth cohort found that obesity in adolescence was associated with a doubling 
of odds of doctor-diagnosed asthma in adulthood (OR 2.09; 95% Cl 1.23, 3.57).137
The association between childhood BMI and adult disease may be stronger for BMI measured 
later in childhood. For example, a systematic review and meta-analysis of studies relating BMI 
at ages 2-30 years to later CHD risk found no strong evidence for an association with BMI 
measured in early childhood (age 2-6 years), but there was a positive association with BMI 
measured at ages 7-18 years (RR of CHD associated with 1 SD increase in BMI: 1.09; 95% Cl 
1.00, 1.20) and 18-30 years (RR 1.19; 95% Cl 1.11-1.29). One study, which used data from the 
1958 British birth cohort, showed that BMI measured at ages 11 and 16 predicted obesity and 
history of diabetes and hypertension at age 33, while BMI at age 7 gave less satisfactory results 
(using receiver operating characteristic analysis).138 The evidence on long-term morbidity and 
mortality associated with childhood obesity is reviewed systematically and discussed in greater 
detail in Chapter 3.
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Childhood obesity and long-term psychosocial outcomes
In addition to the relationship with disease outcomes, longitudinal studies have related 
childhood obesity to adverse social and economic outcomes in later life, especially among 
women. As an example, the National Longitudinal Survey of Youth, a US study of 10,000 men 
and women, showed that women who were obese at age 16-24 years had fewer years of higher 
education, lower family income, higher rates of poverty and lower rates of marriage than those 
who were not obese at those ages.139 These effects remained even after adjusting for parental 
income and education. Analyses of the 1958 British birth cohort found that obesity at age 16 
years was associated with lower hourly earnings at age 23 years among women, after 
adjustment for parental social class and arithmetic and reading test scores in childhood; this 
effect remained even among obese adolescents who were no longer obese at age 2 3 .140 An 
effect of adolescent obesity on earnings was not observed among male cohort members. 
Similarly, analysis of data from the 1970 British birth cohort showed that obesity at both ages 
10 and 30 years was associated with poorer employment and relationship outcomes in women, 
but not in m en.141 However, this study did not find an effect in obese children who moved into 
the normal weight category in adulthood.
2.4. Burden of childhood obesity
The burden of a disease or risk factor can be described as the impact of the health problem in a 
population, in terms of economic cost, morbidity, premature mortality, quality of life or other 
indicators.7 In the case of obesity, its contribution to incidence of type 2 diabetes, CVD, 
respiratory problems, cancers, liver disease, psychosocial problems, mortality, and the costs 
associated with these, would all contribute to its burden. Quantification of disease burden 
enables an assessment of the scale of a problem, monitoring of change over time, and estimation 
of the impact of various policy options on projected health outcomes. This information is 
essential for effective prioritization of resources and health services planning.
2.4.1 Measuring health burden
There are a number of ways in which the burden of an exposure or disease may be assessed.
The simplest measures describe a single aspect, such as estimates of disease prevalence, 
incidence, or mortality rates attributable to the exposure in the population. Other summary 
measures combine different dimensions of ill health, such as disability-adjusted life years 
(DALYs), which take into account morbidity and mortality7; one DALY is conceptually 
equivalent to one lost year of health in the population. The DALYs for a specific disease are 
calculated as the sum of years of life lost (YLL) due to premature mortality and ill-health and 
disability due to the disease or exposure. Quality-adjusted life years (QALYs) or health- 
adjusted life expectancies (health expectancies) account for the quality of life as well as the 
amount of life lived 142; typically, each year of life lived in perfect health is assigned a value of
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1, death is assigned a value of 0, and values in between these limits indicate years that are not 
lived in full health. Other dimensions of burden, principally economic costs associated with ill 
health, including healthcare expenditure and loss of productivity due to poor health, may be 
incorporated into the calculation of health burden.
Two general models for attributing health outcomes to causes (exposures) have been described 
previously 143: 1) categorical attribution, and 2) counterfactual analysis. Categorical attribution 
describes an approach in which an outcome is attributed to a single cause (or group of causes) 
according to defined rules, such as when attributing road traffic accidents to alcohol 
consumption. This approach has an advantage in that the numbers attributed to each of the 
causes will add up to 100%, but the main disadvantage is that it cannot account for multi-causal 
outcomes, such as death due to CVD in a person with type 2 diabetes. In counterfactual 
analysis, the contribution of a risk factor to the health outcome is estimated by comparing the 
measure of disease burden with the expected burden in an alternative hypothetical scenario (the 
counterfactual), such as in the absence or reduction of the risk factor, which provides an insight 
into the potential gains in population health (or money saved) that may be achieved by reducing 
an exposure. The contribution of the exposure is usually expressed as a population attributable 
fraction (PAF), which estimates the reduction in disease or mortality that would occur in the 
counterfactual scenario, where the distribution of the risk factor is different but all other factors 
are unchanged.
2.4.2 Obesity burden
Current burden
Studies show that obesity accounts for a substantial and growing proportion of disease burden 
worldwide. Analysis of the Global Burden of Disease (GBD) database showed that across 
developed regions, high BMI was the fifth leading cause of disease burden, accounting for 7.4% 
of DALYs.144 As the prevalence of obesity has risen, its contribution to mortality has also 
increased. In one study, it was estimated that more than 40,000 deaths, a loss of 1.05 years of 
life expectancy, 77% of deaths from diabetes, and 14% of CVD mortality could be attributed to 
overweight and obesity in England and Wales in 2003 145; projections to the year 2015 showed 
that the contribution of obesity to mortality would be likely to increase over the period.
As a consequence of its contribution to healthcare expenditure, obesity is also associated with a 
substantial economic burden.146-148 There is some debate about whether lifetime medical costs 
for obese individuals may be attenuated to some degree by reduced life expectancy,149 but 
studies of elderly populations have indicated that those obese people who survive to age 70 will 
live as long as their normal weight peers, but with fewer disability-free life years and 
substantially higher expenditure on healthcare.150 Recent analyses estimated that overweight
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and obesity-related ill health cost the NHS £5.1 billion in 2006-07.151 In addition to the costs of 
co-morbidities, the costs of treating obesity itself have risen substantially in recent years, with 
increases in the number of anti-obesity drug prescriptions 152 and bariatric surgical procedures.
153 *m_The increasing proportion of people with extreme obesity also has implications for other 
public services, ranging from the need for wider furniture and equipment in schools and 
hospitals, to increased demand for assistance from fire services to lift patients or housebound 
individuals. 154-155 Furthermore, obesity presents indirect costs to the economy, such as through 
working days lost to ill health. 156-158
Future burden
In the case of childhood obesity, there are both concurrent and long-term contributions to 
disease burden. A study of concurrent childhood obesity co-morbidities in the European Union 
(EU) used conservative estimates of disease prevalence from the literature, and estimated that at 
least 20,000 obese children in EU have type 2 diabetes, over 400,000 have impaired glucose 
tolerance, over 1 million have increased cardiovascular risk, and more than 1.4 million have 
early signs of liver disease.159 The large number of children with risk factors for later disease, 
including CVD and liver disease, highlights the potential contribution of current childhood 
obesity to future disease burden.
Studies of future burden associated with obesity incorporate two elements: 1) predicting the 
nature of the obesity epidemic, based on some assumptions about the association between 
current and future BMI distribution, and 2) estimating the disease burden and/or costs 
associated with these. Such studies may also explore the impact of behavioural and 
environmental influences on obesity and policy interventions.160 In one example, an 
Australian study estimated the future costs (in 2024/25) of obesity-related cancer and CVD in a 
cohort of young adults bom 1970-1980.161 For this, the authors modeled four scenarios of 
obesity distribution: one in which the prevalence of obesity was projected using an age-cohort 
logistic regression model (based on cross-sectional surveys at 5-year intervals), one which 
predicted a linear increase in obesity prevalence (based on two surveys), one in which obesity 
prevalence in 2024/25 was equal to the age-specific prevalence in 2004/05, and another in 
which obesity prevalence remained at the same level as in youth (age 25-34). Relative risks of 
disease from the literature were used to calculate PAFs, and applied to hospital discharge, 
mortality and direct healthcare cost data. Using this method, it was estimated that if obesity 
prevalence in 2024/25 remained at the same level as in youth, the number of hospitalisations 
due to cancer and CVD could be halved, with 200 fewer deaths, and more than $51 million 
saved, compared to a more than doubling of costs in the worst case scenario.
Using the micro-simulation model (also called an individual-based model) that is used later in 
this thesis (described in Chapter 7 ) ,162 the 2007 Foresight Obesity report estimated that the
29
obesity prevalence in the UK would continue to rise over the next forty years, and that by 2050, 
the direct costs to the NHS would have increased by £5.5 billion. 1945 This figure did not 
include the costs of increased disability, work absenteeism, early retirement and early death. In 
an updated analysis, it was estimated that by 2030, the prevalence of obesity among adults 
would increase from 26% to 41-48% in men, and from 26% to 35-43% in women, equating to 
an increase in the number of obese adults of 11 million,163 which would result in rises in cases 
of diabetes, CVD and cancer, and a large reduction in the number of disability-free years. 
Medical costs associated with these diseases were estimated to increase by around $2 billion 
p.a. by 2030.
2.5. Summary
Childhood obesity prevalence has increased dramatically over the past three decades, and is now 
present in the population on a scale beyond that which has been seen previously. Due to its 
associations with health problems in both childhood and in later life, obesity presents a 
considerable burden and public health challenge.
The emphasis of the UK government is on preventing and reversing the recent trends in 
childhood obesity. Many of the concurrent and future health problems associated with 
childhood obesity appear to have common features, and disorders observed in children may 
represent early stages of progression to chronic diseases in adulthood, such as in the case of 
metabolic syndrome and cardiovascular disease. These features draw attention to the potential 
long-term effects of childhood obesity, and the role that early management of childhood obesity 
may have in the prevention of future chronic diseases. However, the extent to which the 
childhood obesity epidemic will contribute to future health burden, beyond that attributable to 
the tracking of overweight into adulthood, is unclear. Characterisation of the relationship 
between childhood obesity and adult disease, and estimation of the future burden of childhood 
obesity can contribute to the debate on the effectiveness and cost-effectiveness of early 
interventions to promote healthy weight, and may inform how resources should be allocated.
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3. CHILDHOOD OBESITY AND LONG-TERM HEALTH: A SYSTEMATIC 
REVIEW OF THE LITERATURE
3.1 Introduction
As discussed in the previous chapter, there is growing evidence to indicate that the most 
common obesity-related diseases originate in early life, and that risk factors for these diseases 
track from childhood into adulthood. However, it is unclear whether individuals who were 
overweight in childhood have increased risk compared to others of the same weight status in 
adulthood who were not overweight in childhood. Previous reviews have explored the 
relationship between childhood obesity and disease in adulthood,17130 but have not focused on 
whether the effects of childhood obesity are independent of adult obesity.
In this chapter, I review the evidence on the relationship between childhood or adolescent BMI 
and morbidity and mortality in adulthood, with particular focus on the effect of early life BMI 
independent of adult BMI. The objectives were to systematically evaluate the current evidence 
on the relationship between childhood BMI and morbidity and mortality in adulthood, and to 
assess whether childhood BMI status contributes to adult disease risk, independent of adult 
BMI. I also examined the methods used to explore the independent effects of childhood 
obesity, and considered the strengths and limitations of these approaches, and the implications 
for future research.
The work that forms this chapter has been published in Obesity Reviews journal (Park, M. H., C. 
Falconer, R. M. Viner and S. Kinra. (2012). "The impact of childhood obesity on morbidity and 
mortality in adulthood: a systematic review." Obesity Reviews doi: 10.111 l/j.1467- 
789X.2012.01015.X).
3.2 Methods
A systematic review of published studies investigating the associations between childhood BMI 
status and morbidity and mortality in adulthood was conducted. The main outcomes of interest 
were: type 2 diabetes, hypertension, cardiovascular diseases (coronary heart disease and stroke), 
asthma, arthritis, gall bladder disease, cancers, and mortality. These outcomes were selected 
based on background knowledge and previous reviews of the literature.45164
3.2.1 Search strategy
Ovid MEDLINE (1948-July 2011), EMBASE (1980-2011 Week 18) and the Cochrane Library 
(1990-2011) were searched electronically for relevant publications, and reference lists from 
selected articles were hand-searched for additional studies. The search terms (shown in Table 
3-1) were based on terms used in previous Cochrane reviews of childhood obesity,165 and
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incorporated tested search filters for study design used by the Scottish Intercollegiate Guidelines
Network (SIGN) (available at: http://www.sign.ac.uk/methodology/filters.html').
3.2.2 Study selection
Potentially relevant titles were screened for initial assessment of eligibility using the following
inclusion criteria:
1) Prospective or historical follow-up or case-control designs (i.e. childhood exposure and 
adult outcomes measured in the same individuals);
2) BMI from directly measured weight and height at one or more ages in childhood (mean age 
2-12 years) or adolescence (mean age 13-19 years). Only studies with data on measured 
childhood BMI were included as the review by Reilly and Kelly 166 showed that evidence 
from recalled weight status was less consistent than evidence from measured BMI. Infant 
size was not included as an exposure of interest, as the relationships between infant size and 
growth and adult disease may be more complex and distinct from those with weight status 
in childhood;167
3) Childhood BMI status calculated using national reference charts or IOTF criteria31, or BMI 
treated as a continuous measure;
4) Any of the outcomes of interest assessed (clinically or self-reported) at one or more stages 
in adulthood (age >19 years);
5) English language articles published after 1980.
Exclusion criteria were:
1) Studies that recruited participants for an obesity intervention or health promotion 
programme;
2) Participants from select clinical populations, e.g. preterm babies, childhood cancer 
survivors;
3) BMI calculated from parent or self-reported height and weight in childhood;
4) Studies that reported risk factors without a disease end-point as the outcome, e.g. blood 
pressure but not hypertension.
Abstracts were double-screened (by me, MHP and Catherine Falconer, CF) for retrieval of full-
text articles, and inter-rater agreement was assessed using kappa coefficients (k).168
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Table 3-1: Search terms used in systematic review of childhood and adolescent weight status and adult morbidity
D a ta b a s e
M E D L IN E E M B A S E  C o c h ra n e  l ib ra ry
1. exp  C hild / 1. ch ild / “asthm a, hypertension,
card iovascu lar d isease, type 2
2. exp  A dolescen t/ 2. ado lescen t/ d iabetes, arthritis, gallb ladder
3. juven ile .m p .
disease, cancer” A N D
3. ped ia trics/ “ch ild* , ado lescen* , teen*”
4. exp  Infan t/
A N D  “obes*, overw eight” in
4. childS.m p. Title> A b stra c t o r  K eyw ords
5. child$.m p. 5. adolescen$.m p.
6. adolescen$.m p. 6. infan$.m p.
7. infan$.m p. 7. teen$.m p.
8. teen$.m p. 8. p?ediatric$ .m p.
9. P?ediatric$ .m p. 9. juvenile .m p.
10. P ed ia trics/ 10. o r /1-9
11. 1 o r 2 o r  3 o r 4  o r 5 o r  6 o r  7 o r 8 
o r 9  o r 10
11. exp  O B E S IT Y /
12. overw eight.m p.
12. (obes$ o r obesity).m p.
13. (obes$ o r obesity).m p.
13. exp  O besity /
14. exp  body  m ass/
14. exp  O verw eigh t/ o r  exp B ody 
W eigh t/ 15. (B M I or body m ass index o r 
body-m ass-index  o r  w eight-for-
15. (B M I o r body m ass index or 
body-m ass-index  o r  w eight-for- 
height).m p.
height).m p.
16. 11 o r  12 o r 13 o r 14 or 15
16. exp  B ody M ass Index/ 17. exp  A ST H M A /
17. 12 o r 13 o r 14 or 15 o r 16 18. (asthm $ or resp ira tory  
condition).m p.
18.(asthm $ or respiratory  
condition).m p. o r exp A sthm a/ 19. exp  H Y P E R T E N SIO N / or 
hypertension.m p.
19. exp  H ypertension / o r 
hypertension.m p. 20. card iovascu lar d isease.m p. 
o r  exp  card iovascu lar d isease /
20. card iovascu lar d isease.m p. o r  exp 
C ard iovascu lar D iseases/ 21. exp  non insulin  dependent 
d iabetes m ellitus/ o r  type 2
21. exp  D iabetes M ellitus, T y p e  2 / o r 
type 2 d iabetes.m p.
diabetes.m p.
22. arthritis.m p. o r  exp
22. arthritis.m p. o r  exp  arth ritis/ A R T H R IT IS /
23. gall b ladder d isease.m p. o r  exp  
G allb ladder D iseases/
23. gall b ladder d isease.m p. o r 
exp  gallb ladder d isease /
24. cancer.m p. o r exp  N eop lasm s/ 24. cancer.m p. o r exp  neoplasm /
25. 18 o r 19 o r  20 o r 21 or 22  o r 23 
or 24
25. 17 o r  18 o r 19 o r 20  or 21 o r 
22 o r  23 o r 24
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26. exp  C ase-C ontro l S tud ies/
27. exp  C ohort S tud ies/
28. case control.tw .
29. (cohort adj (study o r  studies)).tw .
30. C ohort analy$.tw .
31. (Fo llow  up  adj (study or 
studies)).tw .
32. (observational adj (study o r 
studies)).tw .
33. L ongitud inal.tw .
34. R etrospective.tw .
35. 26 o r 27 o r 28 o r 29  o r 30 or 31 
o r 32 o r  33 o r 34
36. 11 and 17 and 25 and 35
37. lim it 36  to  (hum ans and 
y r="1980  -C urrent")
26. exp  case con tro l study/
27 . exp  longitudinal study/
28. exp  retrospective study/
29. exp  p rospective study/
30. exp cohort analysis/
31. (C ohort adj (study o r 
studies)).m p.
32. (C ase con tro l adj (study or 
studies)).tw .
33. (fo llow  up adj (study or 
studies)).tw .
34. 26  o r 27 o r 28 o r 29 or 30 o r 
31 o r 32 o r 33
35. 10 and  16 and 25 and 34
36. lim it 35 to (hum an and 
y r="1980  -C urrent")
3.2.3 Study quality
Study quality of case-control and cohort studies was assessed using a checklist adapted from the 
Newcastle-Ottawa Quality Assessment Scale (available at:
http://www.ohri.ca/programs/clinical epidemiology/nosgen.pdf). Studies were assessed based 
on the following domains:
y  Selection bias: one star awarded if overweight/obese children were drawn from the same 
community as normal weight children; one star awarded if the study demonstrated that the 
outcome of interest was not present at the start of the study (for cohort studies); 
y  Comparability: one star awarded if comparison of age and sex at baseline between exposure 
groups demonstrated comparability, or if analyses controlled for age and sex; one star 
awarded if analyses controlled for socioeconomic position, a potential confounder of the 
association between childhood weight status and disease outcomes; 
y  Assessment of outcomes: one star awarded if outcome in adulthood was assessed by a
trained health professional or through health records; one star awarded (for cohort studies) if 
follow up sufficient for outcomes to manifest -  a mean age at follow-up of >35 years was 
selected as the cut-off as diabetes and hypertension diagnosed at <35 years of age has been 
considered as early onset in the literature 169'170;
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^  Adequacy of follow-up: for cohort studies, one star awarded if all subjects were accounted 
for at follow-up, or if subjects lost to follow-up were unlikely to introduce bias (<20% lost 
to follow-up, or a description of those lost suggest no difference from those followed up).
3.2.4 Data extraction and synthesis
The data were double-extracted independently using a pre-designed extraction form. The 
principal outcomes that were extracted from each study were measures of the association 
between adult disease risk and childhood BMI (expressed as regression or correlation 
coefficients) or childhood BMI category/status (expressed as risk ratio, hazard ratio or odds 
ratio and confidence intervals), and these measures after adjustment for adult BMI. The 
following information was also extracted: study design, exposure(s), disease outcome(s), 
methods of measuring exposure/outcome, child age, adult age, sample size, sex of participants, 
country of study, years of birth, measures of tracking of BMI/overweight, and study quality 
measures (see above). Due to the diverse nature of outcomes, study designs and measures of 
effect included in the selected studies, data were synthesised and are presented in a narrative 
fashion. Publication bias was assessed using a funnel-plot in Stata 12 (StataCorp, TX). To 
assess potential bias due to different methods of assessing outcomes, results of studies using 
self-reported disease were compared with those using objective measures.
3.3 Results
3.3.1 Search results
The initial search yielded 7,890 results, which were narrowed down to 118 abstracts for full-text 
screening (Figure 3-1). Studies that did not meet inclusion criteria but which reported outcomes 
relevant to the review are summarized in Table 3-4. A total of 40 studies were included in the 
review; two of these were case-control studies,171172 and the remaining 38 were cohort studies 
(including three manuscripts presenting pooled analyses of cohort studies 173'175). Inter-rater 
agreement was substantial (84%, k=0.62). Sample sizes n ranged from 181 131 to 1,145,467.176 
The majority of studies were from Western Europe (Denmark, Finland, Norway, Sweden, the 
UK, the Netherlands), and the US (including Hawaii). Two studies were conducted in 
Australia, 177 178 and a further two in Israel. 135 179 The mean ages at which BMI was measured 
ranged from birth up to 19 years. Full descriptions of the included studies can be seen in Table 
3-2.
Figure 3-1: Study selection process
Table 3-2: Description of included studies
Reference
(study
design)
Exposure measure(s) Disease outcome(s) Age at last 
follow-up, 
years
Population Main effect size Adjustment 
for adult 
BMI
Ahlgren 2004
180
(cohort)
BMI quintiles at age 
14 y
Breast cancer 
(registry data)
Time to 
event
117,415 Women in 
Copenhagen, b. 1930- 
75
Lower BMI at age 14 associated with increased risk of breast 
cancer: RR per 1 unit increase in BMI: 0.97 (95% Cl 0.96, 0.98)
A1 Mamun 
2009 177
(cohort)
BMI z-score at age 5 
y; overweight & 
obesity (IOTF)
Type 1 and type 2 
diabetes
(self report)
21 2,639 Men & women 
(51% $) in Australia, b. 
1981-84
1 unit increase in BMI z-score at age 5 associated with 60% 
increase in odds of diabetes (OR 1.61; 95% Cl 1.24,2.09); 
overweight/obesity vs non-obese: OR 2.60; 1.29, 5.22
Andersen 
2010 173
(cohort)
BMI at age 7 y CHD -  nonfatal and 
fatal
(registry data)
Time to 
event after 
age 25 y
216,771 Men & women 
(49% 9) Copenhagen, 
b. 1936-76 & Helsinki, 
b. 1924-44
Each unit increase in BMI at age 7 y associated with ~5-10% 
increase in odds of CHD event, after adjustment for birth weight
Baker 2007 
181
(cohort)
BMI z-score at age 7- 
13 y
CHD -  nonfatal and 
fatal
(registry data)
Time to 
event
276,835 Men & women 
(50% 9) in
Copenhagen, Denmark, 
b. 1930-76
<$: 1 unit increase in BMI z-score associated with 5-17% increased 
odds of nonfatal event, 10-24% increase for fatal event
9: 1 unit increase in BMI z-score associated with 2-11% increased 
odds of nonfatal event, 7-23% increase for fatal event
Barker 2002
182
(cohort)
BMI quartiles at age
i i  y
Type 2 diabetes, 
hypertension, CHD 
(registry)
20+ 13,517 Men & women 
in Helsinki, Finland, b. 
1924-44
ORs fori unit increase in BMI at age 11:
T2DM 1.18 (1.13,1.23); Hypertension 1.07 (1.04,1.09); CHD 1.06 
(1.03, 1.10) [Adjusted for age and sex]
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Barker 2002b
183
(cohort)
BMI Z-scores at ages 
1-12 y
Hypertension 
(registry data)
38-39 6,730 Men & women 
(47% ?) in Finland, b. 
1934-44
From age 8, high BMI associated with hypertension; cumulative 
incidence 13.7% (11.2-16.2) among men with BMI <16 at age 12 
vs 21.1% (18.4-23.8) among men with BMI >18
Bjorge 2004
184
(cohort)
BMI categories at age 
14-19 (medium 25- 
74th; high -84th; v high 
>85,h centile, US ref.)
Kidney cancer 
(registry data)
Time to 
event; mean 
age 45 y
227,221 Men & women 
(49% 9 ) in Norway, b. 
1943-1950S
(J: Very high BMI at age 14-19 y associated with 2.6 times risk of 
renal cancer compared to medium BMI category: RR 2.64 (95% Cl 
1.48,4.70)
9: No strong evidence of association between BMI category at age 
14-19 y and renal cancer
Bjorge 2008
183
(cohort)
BMI categories at age 
14-19 (medium 25- 
74th; high -84th; very 
high >85,h centile, US 
ref.)
Mortality: cause- 
specific and all­
cause
(registry data)
Time to 
event up to 
2005; mean 
age 40 - 43
y
226,678 Men & women 
(49% 9 ) in Norway, b. 
1943-1950s
Highest BMI category vs. medium [RR (95% Cl)].
All-cause mortality: <$: 1.4 (1.3, 1.6); 9 : 1-4 (1.2, 1.5) 
Cancer (all): $: 1.2 (0.9, 1.5); 9 : 1.2 (1.1,1.5)
Ischemic heart disease: S': 2.9 (2.3, 3.6); $: 3.7 (2.3, 5.7) 
Cerebrovascular diseases: <$: 1.9 (1.2, 3.2); 9:1-5 (0.9, 2.6)
Burgess 2007
178
(cohort)
BMI z-score quartiles 
at age 7 y; overweight 
and obesity (IOTF) vs 
non-obese
Incident asthma 
after age 7 y
[adult-onset: 
age>21 y]
(self reported)
32 753 Men & women 
(52% 9 ) in Tasmania, 
Australia, b. 1961
$: No strong evidence of association between BMI z-score quartile 
or overweight at age 7 and asthma at age 32
9 : Each increase in BMI z-score quartile at age 7 associated with 
OR 1.73 (95% Cl 1.17, 2.17); overweight at age 7 OR 3.05; 1.28, 
7.29
OR 1.73 
->1.51 (0.98, 
2.31);
3.05 -* 2.13 
(0.82,5.57)
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Chu 1991m  
(case-control)
Overweight (BMI 
>85th centile) at age 
18 y
Breast cancer 20-54 4,742 cases; 5,698 
controls. Women in 
USAb. 1926-1962
No strong evidence of association between BMI category and post- See results 
menopausal breast cancer risk; RR pre-menopausal breast cancer 
for obese women 0.6 (0.2,0.9), no association with overweight
RR premenopausal: not overweight at 18/overweight adult 1.5 (1.2, 
1.9); overweight at 18/not overweight adult 0.9 (0.6,1.5); 
overweight at 18/overweight adult 0.9 (0.6,1.2)
Menopausal: not overweight at 18/overweight adult 1.8 (1.2,2.6); 
overweight at 18/not overweight adult 0.9 (0.4, 2.1); overweight at 
18/overweight adult 0.8 (0.4,1.5)
De Stavola 
2004 186
(cohort)
BMI-SDS at ages 2, 
4,7, H and 15 y
Breast cancer 
(registry data)
53 2,i87 Women in UK, b. 
1946
No strong evidence of association between BMI-SDS at any age 
and breast cancer
Engeland 
2003 187
(cohort)
BMI categories at age 
14-19 (medium 25- 
74th; high -84,h; v high 
>85,h centile, US ref.)
Ovarian tumour 
(registry data)
Time to 
event, up to 
age 100 y or 
2001
111,883 Women in 
Norway, b. 1943-61
Being in high and very high BMI categories in adolescence 
associated with increased risk of ovarian cancer compared with 
medium BMI category.
High: RR 1.43 (1.00, 2.04); Very high: RR (1.56 (1.04, 2.32)
Engeland 
2003 188 
(cohort)
BMI categories at age 
14-19 (85th-94th, >95th 
centile vs. reference 
category 25th-75th 
centile)
All-cause mortality 
(registry data)
Time to 
event, mean 
31.5 years 
follow-up)
227,003 men and 
women in Norway, b. 
1948-68
Obesity (BMI >95tn centile) at age 14-19 was associated with 
increased risk of all-cause mortality in adulthood (RR in men 1.82; 
95% Cl 1.48,2.43, RR in women 2.03; 95% Cl 1.51, 2.72)
Eriksson 
1999 189
(cohort)
BMI categories at age 
l ly  (BMI <15.5;- 
16.5;-17.5; >17.5)
CHD deaths 
(registry data)
Deaths
during
1971-95
3,641 Men in Finland, 
b. 1924-33
BMI at age 11 positively associated with risk of CHD death. 
Compared to baseline group (BMI<15.5) at age l l y :  BMI 15.5- 
16.5: HR=1.28; BMI 16.5-17.5: HR=1.35; BMI >17.5: HR=1.53
Eriksson 
2001 190
(cohort)
BMI z-score; BMI 
categories at age 6 
(BMI <13.6;-14.2;- 
14.8;-15.4; >15.4)
CHD
hospitalizations & 
deaths (registry)
Events
during
1971-97
4,630 Men in Finland, 
b. 1934-44
No strong evidence of association between BMI z-score and CHD
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Eriksson 
2003a 191
(cohort)
BMI at ages 1-12 y Type 2 diabetes 
(registry data)
Diagnoses 
1964-98 at 
age >40 y
8,760 Men & women 
(47% ?) in Finland, b. 
1934-44
Cumulative incidence of T2DM positively associated with BMI at 
each age from 4 years onwards
Falkstedt 
2007 192
(cohort)
BMI category in late 
adolescence (BMI 
<18.5; 18.5-20.9; 21- 
22.9; 23-24.9; 25- 
29.9; >30)
CHD and stroke, 
fatal and nonfatal
(registry data)
40-55 46,156 Men in Sweden, 
b. 1949-51
CHD: BMI >30 kg/m2 at age 18-20 years associated with 4 times 
risk compared to BMI 18.5-20.9 (HR 4.3; 95% Cl 3.1-5.9). Stroke: 
HR in highest BMI category=2.4 (1.3, 4.5); lowest risk in BMI 
category 21.0-22.9 (HR 0.9; 95% Cl 0.7, 1.1).
Field 2005 
(cohort)
BMI z-scores and 
centiles (categories - 
< 10th; -25th; -50th; - 
75th; -85th; >85,h 
centile, US ref.) at age 
8-15 y
Hypertension
(self report of 
medication or 
clinical assessment)
18-26 286 Men & women in 
Boston USA, b. 1963- 
73; results reported for 
male subjects only
Compared to reference group (BMI <75,h centile in childhood) 
individuals with BMI 75th-84th centile had 3 times risk of 
hypertension in adulthood (OR=3.6; 95% Cl 0.7, 18.2); individuals 
with BMI >85lh centile had 5 times risk (OR=5.1; 95% Cl 1.4, 
18.1).
Same point 
estimate, 
wider CIs
Forsen 2004
194
(cohort)
BMI z-score at age 11
y
CHD -  hospital 
admissions and 
deaths (registry)
27-64 4,130 Women in 
Finland, b. 1934-44
No strong evidence of association between BMI z-score and CHD 
risk. Compared to baseline group BMI <15.9 kg/m2, HR for CHD 
among BMI >18.4 was 1.79 (0.89, 3.60).
Gunnell 1998
195
(cohort)
BMI categories at 
ages 2-14 (<25th;25- 
49th; 50,h-75th; >75th 
centile, UK90 ref.)
Mortality -  all 
cause, CVD, IHD, 
stroke
(registry data)
Up to July 
31,1995
2,990 Men & women 
(51% 9) in Britain, b. 
1922-37
BMI in 50-75th centile vs. 25tn-49th centile: All cause HR 1.4 (1.1, 
1.8), CVHR 1.6 (1.1,2.5), IHD HR 2.1 (1.3, 3.6).
BMI >75Ih centile vs. 25tf,-49'h centile: Alt cause HR 1.6 (1.1, 2.3). 
No strong evidence of association with stroke mortality.
Hoffmans 
1989 196
(cohort)
BMI at age 18 y and 
BMI categories 
(<18.9; 19-19.9; 20- 
24.9; >25 kg/m2)
Mortality -  CHD 
and cancer
(death certificates)
18-49 (32 
years
follow-up)
78,612 Men in the 
Netherlands, b. 1932
Compared to reference group with BMI 19-19.9 kg/m2
CHD mortality: BMI 20-24.9 associated with 30% increase in risk 
(HR 1.31; 1.02, 1.67); BMI >25 HR 2.42 (1.36,4.30).
Cancer mortality: No association with BMI category.
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Hypponen 
2003 197
(cohort)
BMI-SDS tertiles at 
ages 7, 11, 16, 23 y
Type 2 diabetes 
(self-reported)
41 10,683 Men & women 
in Britain, b. 1958
Compared to ref. group (BMI-SDS in middle tertile)
Age 7: Upper tertile OR 3.97 (95% Cl 1.7, 9.1); 1 unit increase in 
BMI-SDS OR 1.44 (1.2,1.7). Age 11: Upper tertile OR 3.59 (1.7, 
7.5); BMI-SDS OR 1.78 (1.5, 2.1). Age 16: Upper tertile OR 4.18 
(2.1,8.4); BMI-SDS OR 2.04 (1.7, 2.4).
Adjusted for 
BMI at 23 
years -> no 
association
Israeli 2007
135
(cohort)
Overweight (BMI 25- 
30 kg/m2) and obesity 
(BMI>30) at ages 
16.5-19 y
Hypertension
(medical history or 
clinical assessment)
26-45 18,513 Men in Israel, 
recruited to Israeli 
Defense Forces 1976-96
Adjusted for age and blood pressure at baseline, compared to 
normal weight, overweight in adolescence associated with 
hypertension risk (OR 1.75; 95% Cl 1.66,1.86); obesity associated 
with nearly 4 times risk (OR 3.75; 3.45,4.07).
Jeffreys 2004
198
(cohort)
BM-SDS at ages 2-14
y
Cancers: All, breast, 
colon, prostate, 
lung; cases and 
mortality (registry)
Cases up to 
Dec 2001, 
deaths to 
Jan 2003
2,347 Men & women in 
Britain, b. 1922-37
All cancers: Compared to lowest BMI-SDS quartile, being in 
highest quartile associated w/ 40% increase in risk (OR 1.43; 95% 
Cl 1.01, 2.04); 1 unit increase in BMI-SDS OR 1.14 (1.00,1.29); 
stronger association w/ cancers related to smoking. No association 
w/ other cancers
Juonala 2011 
174 (cohort)
Overweight and 
obesity (IOTF) at ages 
4-19 y
Type 2 diabetes and 
hypertension 
(clinical 
assessment)
Mean length 
of follow­
up: 23 y
6,328 men and women 
in the US, Australia and 
Finland
Type 2 diabetes: RR for overweight or obesity 2.4 (95% Cl 1.6, 
3.6)
Hypertension: RR for overweight or obesity 1.8 (95% Cl 1.5, 2.1) 
Analyses adjusted for age, height, cohort and length of follow-up
Overweight
as child but 
nonobese as 
adult - similar 
risk as 
nonobese as 
child & adult
Lawlor 2005
199
(cohort)
BMI z-score at 
primary school entry 
(mean 4.9 y); BMI z- 
score
quartiles;overweight 
& obesity (IOTF)
CHD and stroke 
hospital admissions 
and mortality
(registry data)
Follow-up 
period 
began on 
January 1, 
1981
11,106 Men & women 
in Scotland, b. 1950-56
For CHD, stroke and CHD/stroke: No strong evidence of 
association with BMI z-score quartile at school entry; no strong 
evidence of association with overweight/obese status.
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Lawlor 2006a 
200
(cohort)
BMI z-score at 
primary school entry
Diabetes diagnosis 
at age >20 y (self- 
reported)
46-50 5,793 Men & women in 
UK, b. 1950-56 
(singleton births only)
Each unit increase in BMI z-score at school entry associated with 
22% increase in risk of diabetes in adulthood (OR 1.22; 95% Cl 
1.10,1.36)
Adjustment 
for adult BMI: 
OR 1.07 
(0.96,1.19)
Lawlor 2006b 
201
(cohort)
BMI z-score in 
childhood and 
adolescence; 
overweight and 
obesity (IOTF)
IHD and stroke 
(registry data)
Up to 30 
Nov 2004
2,586 men & women in 
Britain b, 1922-37; 
1,420 men b. 1936-69; 
10,555 men & women 
b. 1948-68
Pooled results; no strong evidence of an association between BMI 
z-score in childhood and risk of mortality from IHD or stroke
Le Marchand 
1988 172
(case-control)
BMI tertiles at age 
<25 y
Breast cancer 
(registry data)
29-65 3,208 Women in 
Hawaii, b. 1918-43
No strong evidence of association between BMI fertile at age <25 y 
and breast cancer risk
L i2ÖÖ7 BMI-SDS at ages 7, 
11,16; overweight
Hypertension 45 9,297 Men & women 
(50% 9) in Britain, b.
BMI-SDS at all ages positively associated w/ hypertension: Adjustment 
for BMI at
(cohort) and obesity (IOTF) (clinical assessment 
or medication)
1958 Age 7, OR 1.10 (1.04,1.17); Age 11, OR 1.22 (1.15,1.28); Age 
16, OR 1.27 (1.20,1.34)
Overweight/obese associated w/ increased risk of hypertension:
Age 7, OR 1.35 (1.13,1.64); Age 11, OR 1.66 (1.39,1.97); Age 
16, OR 1.96 (1.64, 2.35)
age 45 y ->no 
association
Magnussen 
2010 124
(cohort)
BMI Z-scores at ages 
9-18 y; overweight 
and obesity ( IOTF)
Type 2 diabetes
(clinical
assessment)
24-41 1,781 Men & women 
(56% $) in US & 
Finland
BMI>75'1' centiie in childhood RR 3.4 (95% Cl i.8‘-6’.4) 
[adjustment for other MetS components, RR 3.0; 1.6-5.7]
IOTF overwcight/obesity RR 3.4 (1.7-6.8) [adjustment for other 
MetS components, RR 3.4; 1.7-6.7]
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Morrison 
2010203
(cohort)
BMI at age
12.4±3.3 (Princeton 
Follow-up Study) 
10.0±0.5 (National 
Growth & Health 
Study)
Type 2 diabetes
(clinical assessment 
or self-report)
PFS:
38.6±3.6
NGHS:
19.1±0.7
PFS: 822 men & 
women (53% $) in the 
US b. 1960s
NGHS: 1,067 women in 
the US
PFS: BMI in top fifth centile at baseline associated with 4-fold 
increase in risk of T2DM (OR 4.00; 95% Cl 1.28, 12.5)
NGHS: no strong evidence that BMI at baseline associated with 
T2DM in stepwise logistic regression model
Must 1992 ^  
(cohort)
BMI categories at 
ages 13-18 y 
(overweight: 
BMI>75'”centile; 
lean BMI between 
25th and 50Ih centiles, 
US ref.)
Mortality; 
Morbidity: CHD, 
angina, diabetes, 
athero-sclerosis, 
stroke, hip fracture, 
cancer, arthritis 
(self-report)
73±1 181 Men & women 
(55% $) in the US, b. 
1914-16
9 -  no strong evidence of association between overweight in 
adolescence and mortality
S -  overweight in adolescence associated with all-cause mortality 
(HR 1.8; 1.2, 2.7); CHD mort. (HR 2.3; 1.4,4.1); stroke mort. (HR 
13.2; 1.6, 108.0); colorectal cancer mort. (HR 9.1; 1.1, 77.5)
No strong evidence of association between overweight in 
adolescence and angina, diabetes, atherosclerosis, stroke, colorectal 
cancer or stroke; CHD risk increased in men (HR 2.8; 1.1, 7.2)
Adjustment 
for adult BMI 
no
association
Neovius 2009 
205 (cohort)
BMI categories at age 
16-20 y (under-, 
normal, overweight, 
obese; WHO)
Mortality (registry 
data)
Follow-up
to
September
2007
45,884 men in Sweden, 
b. 1949-51
Overweight (HR 1.33; 95% Cl 1.15,1.53) and obesity (HR 2.14; 
95% Cl 1.61,2.85) associated with increased risk of death 
(adjusted for muscular strength, age socioeconomic status and 
smoking).
Nieto 1992 
206 (cohort)
Quintiles of relative 
weight derived 
internally at age 5-18
y
Mortality (death 
certificates)
Follow-up 
to June 
1985
13,146 men and women 
(50.3% ?) iu the US, b. 
1915-40
Relative weight in highest quintile (prepubertal and postpubertal) 
associated with increased risk of mortality (OR 1.5; 95% Cl 1.0, 
2.4)
Nguyen 2008
207
(cohort)
BMI at ages 4-18 y Type 2 diabetes
(clinical
assessment)
19-44 1,988 Men & women 
(57% ?) in the US, b. 
late 1950s-1990
Each unit increase in BMI since childhood associated with 
increased risk of adult diabetes (P 0.09; 0.06, 0.12)
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Osmond 2007 
208
(cohort)
BMI at ages 1-11 y Stroke -
hospitalization or 
death
(registry data)
59-69 12,439 Men & women 
(48% $) in Finland
Each unit increase in BMI associated with reduced risk of all stroke 
at ages 2 (HR 0.84; 0.77, 0.92) and 7 y (HR 0.85; 0.76, 0.94) [same 
pattern with hemorrhagic and thrombotic stroke]; no strong 
evidence for association with BMI at age 11 y
Shaheen 1999
20»
(cohort)
BMI and BMI 
quintiles at age 10 y
Asthma in the 
previous year
(self reported)
26 6,420 Men & women 
(55% 9) in Britain, b. 
1970
BMI at age 10 y not associated with asthma at age 26 y
Silventoinen 
2009 176
(cohort)
BMI categories at 
conscription (under-, 
normal, overweight, 
obese, very obese; 
WHO)
CHD and stroke -  
hospitalization and 
mortality
(registry data)
39-44
(follow-up 
to end 2006)
1,145,467 Men in 
Sweden, b. 1951-76
Hazard ratios (reference group: normal weight)
CHD: Overweight 1.74 (1.64,1.84); Obese 2.50 (2.22,2.81); Vety 
obese 3.23 (2.54,4.10)
Stroke: Overweight 1.37 (1.26, 1.47); Obese 2.08 (1.78, 2.42);
Very obese 3.20 (2.40,4.26)
Tirosh 2011 
210
BMI percentile at age 
17 y
Type 2 diabetes and 
coronary heart 
disease
25-45 (mean 
age
30.6±5.3)
37,674 Men in Israel 
Defense Forces (IDF) 
Medical Corps
HR for incident diabetes in adulthood for top decile of BMI in 
adolescence vs bottom decile; 2.76 (2.12, 3.58)
Diabetes HR 
1.01 (.75,1.4)
(cohort) HR for incident CHD: 5.43 (2.77,10.62) CHD HR 6.85
(clinical (3.3, 14.2)
assessment)
c5'=male; $ = fe m a le ; b .= bom ; ref.= reference popu la tion ; B M I= body  m ass index k g /m ,  C H D =coronary  h ea rt disease; H R = hazard  ratio ; O R = odds ratio ; R R =risk  ratio ; 95%  
0 = 9 5 %  co n fidence  in terval; IO T F = In tem ationa l O besity  T ask  Force defin ition  o f  childhood overw eight/obesity ; N G H S = N ational G row th  and  H ea lth  Study; 
P F S = P rince ton  fo llow -up  study; W H O = W orld  H ea lth  O rgan iza tion  defin ition  o f  overw eight/obesity
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3.3.2 Childhood or adolescent BMI and long-term health
Of the 40 included studies, 11 reported on type 2 diabetes, six on hypertension, 15 on coronary 
heart disease (CHD), eight on stroke, two on asthma, three on cancers (multiple), two on colon 
cancer, one on kidney cancer, four on breast cancer, one on cervical cancer, one on ovarian 
cancer, and six on all-cause mortality (some studies considered multiple disease outcomes). 
Evidence of associations between childhood or adolescent BMI status and adult disease 
outcomes (not accounting for the effect of adult overweight) are summarised by outcome in 
Table 3-3.
Type 2 diabetes
There was consistent evidence that overweight in early life was associated with increased risk of 
type 2 diabetes in adulthood. Of 11 studies that analysed the relationship between BMI or BMI 
status in childhood (ages 0-18 years) and type 2 diabetes in adulthood, 10 reported a positive 
association (n ranged from 822 203 to 37,674 179), including one study which analysed data from 
the NCDS 1958 cohort.197 Odds ratios for one unit increase in BMI-SDS ranged from 1.22 
(95% Cl 1.10 to 1.36) at school entry (n 5,793), 200 to 2.04 (1.7 to 2.4) at age 16 (n 10,683).197 
One small US study (n 181) found no strong evidence of an association between overweight at 
age 13-18 years and diabetes at age 73 .204 A study from Norway (n 226,678)185 reported 
mortality from endocrine, nutritional and metabolic diseases as an outcome (mean age at follow­
up 40-43 years), and found a positive association with BMI categories at age 14-19 years (RR: 
2.5, 95% Cl 1.4 to 4.5 in men, RR 5.7, 95% Cl 3.0 to 11.0 in women).
When seven studies using objectively assessed type 2 diabetes (from registry data or clinical 
examination) 124 174 182 191 203207210 were considered separately from those using self-reported 
data, all seven showed that increased BMI or overweight at ages 1-18 years were associated 
with increased risk of type 2 diabetes in adulthood; the largest effect size was observed in a 
study of 822 men and women from the US, which reported OR 4 (95% Cl 1.28, 12.5) for BMI 
in the top fifth centile at mean age 12 years; another US study showed that each unit increase in 
BMI at age 4-18 years was associated with a 9% increase in diabetes risk at age 19-44 years 
(95% Cl 6-12).
Three of the included studies explored the effects of childhood obesity independent of adult 
BMI by simultaneously adjusting for adult BMI in regression analyses. In an analysis of data 
from a British birth cohort, associations between BMI-SDS in childhood and adolescence and 
self-reported type 2 diabetes at age 41 were no longer observed after adjustment for BMI at age 
23 years (n 10,683).197 For example, one unit increase in BMI-SDS at age 11 years was 
associated with OR for type 2 diabetes of 1.78 (95% Cl 1.5 to 2.1), while one unit increase in
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BMI-SDS at age 23 was associated with OR 2.25 (1.9 to 2.6); after adjustment for BMI at age 
23, the odds ratio for one unit increase in BMI-SDS at age 11 was reduced to 1.06 (0.8 to 1.3). 
Similarly, in a study of BMI z-score at primary school entry and self-reported diabetes at age 
46-50, each 5 kg/m2 increase in adult BMI was associated with an OR of 1.65 (95% Cl 1.43 to 
1.90); OR per BMI-SDS at school entry decreased from 1.22 (95% Cl 1.10 to 1.36) to 1.07 
(0.96 to 1.19) after adjustment for adult BMI (n 5,793).200 The same effect was observed in an 
analysis of Israeli data, when the HR for incident diabetes in adulthood for adolescents with 
BMI in the top decile compared to the bottom decile was reduced from 2.76 (95% Cl 2.12 to 
3.58) to 1.01 (0.75 to 1.4) after the inclusion of BMI in adulthood in the regression model (n 
37,674).210
A pooled analysis of four cohort studies compared outcomes for participants categorised into 
four groups according to their overweight status in childhood and adulthood,174 and showed that 
cohort members that had been overweight or obese in childhood but not obese in adulthood had 
similar risk of diabetes as those who had been normal weight in childhood and adulthood (RR 
1.3; 95% Cl 0.4,4.1).
Hypertension
Six studies from Israel, Finland, Britain (NCDS cohort), Australia and the US, reported on 
hypertension (n from 286 193 to 18,513 135); all studies showed that increased BMI or overweight 
in early life (ages 1-19) was associated with an increased risk of hypertension in adulthood 
(ages at follow-up ranged 18-45 years). Odds ratios for obesity in childhood ranged from 1.35 
(95% Cl 1.13, 1.64) 202 at age 7 to 3.75 (3.45,4.07) at age 16-19 y .135 All six studies used an 
objective measure of hypertension as the outcome, although one study used a combination of 
clinical examination and self-report of use of antihypertensive medication.193
Two of the five studies reported findings adjusted for adult BMI. In one study, individuals who 
had been overweight at age 8-15 years were shown to have five times the risk of hypertension in 
early adulthood compared to those who were normal weight (OR 5.1,95% Cl 1.4, 18.1); after 
adjustment for BMI at age 18-26, the effect size remained the same, but the confidence interval 
was wider and included O R = l.193 Similarly, in the other study, associations between BMI-SDS 
at ages 7, 11, and 16 and clinically assessed hypertension at age 45 were no longer observed 
after controlling for BMI at age 45 years. 202 The pooled analysis of four studies,174 showed that 
those who had been overweight or obese in childhood but not obese in adulthood had similar 
risk of hypertension as those who had been normal weight in childhood and adulthood (RR 0.9; 
95% Cl 0.6, 1.4).
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Coronary heart disease
15 studies explored the relationship between BMI or BMI status in childhood/adolescence and 
CHD events (fatal and non-fatal). Of these, 10 studies (n ranged from 2,990 132 to 1,145,467 176) 
reported that increased BMI or overweight at ages 2-25 years was associated with increased risk 
of CHD in later life (ages 39+); half of these studies were in male study populations 176189 192 196 
210 Hazard ratios ranged from 1.53 for CHD mortality associated with high BMI at age 11 189 to 
5.43 (95% Cl 2.77, 10.62) for incident CHD associated with high BMI at age 17 21°). In one US 
study (n 181) higher BMI at ages 13-18 was associated with increased risk of CHD morbidity 
and mortality in males but not females.131 The remaining 4 studies (n 4,130 194 to 14,561175) 
found no association between childhood BMI (ages 2-22 years) and CHD at ages 25-80 years. 
All studies used objective measures of CHD or CHD mortality as outcome measures.
One of the included studies of CHD looked at the effect of childhood obesity independent of 
BMI in adulthood. In this large study (n 37,674), the hazard ratio for incident CHD at age 25- 
45 for men with BMI in the top decile at age 17 (compared to those with BMI in the bottom 
decile) increased from 5.43 (95% Cl 2.77 to 10.62) to 6.85 (3.3 to 14.2) after adjustment for 
BMI in adulthood.210 Another study (n 181), which reported an association between 
overweight in adolescence and CHD mortality among men, found that this association was 
attenuated to the null after adjustment for adult BM I.204
Stroke
Of the 8 studies that reported on stroke outcomes, two large studies from Sweden (n 46,156211 
and 1,145,467 176) showed that overweight and obesity in late adolescence (ages 16-25) were 
associated with increased risk of stroke in adulthood at ages 39-55. HRs ranged from 1.4 (95% 
Cl 1.3, 1.5) for overweight to 3.2 (2.4,4.3) for very obese children. One study from Norway (n 
226,678) reported an association between high BMI at age 14-19 years and stroke mortality in 
males (RR 1.9, 95% Cl 1.2, 3.2) at ages up to 62 years;212 a further study (n 181) observed this 
association in males.131 One Finnish study reported an inverse relationship213; among 12,439 
men and women, increased BMI at ages 2 and 7 years was associated with a 15-16% reduction 
in risk of stroke at ages 59-69. Three British studies {n 2,990 132 to 14,561 175) found no strong 
evidence of an association between childhood BMI and stroke. All studies used objective 
measures of stroke, namely hospital admission and mortality data from registries.
One small study (n 181), which reported an association between overweight in adolescence and 
stroke mortality in unadjusted analyses, found that adjusting for adult BMI attenuated this effect 
to the null, and the association was no longer observed.204
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Asthma
Two studies reported on self-reported asthma as an outcome. One study from Australia (n 753) 
showed that overweight at age 7 was associated with OR 3.1 (95% Cl 1.3,7.3) for adult-onset 
asthma in women,178 while analysis of data from the BCS70 cohort (n 6,420) found no strong 
evidence of an association between BMI category at age 10 and asthma at age 26 .209 A 
Norwegian study reporting on deaths from diseases of the respiratory system showed an 
increased risk with higher BMI at age 14-19.212
In the Australian study of self-reported asthma and overweight at age 7, the odds ratio was 
attenuated from 3.1 to 2.13 after adjustment for BMI in adulthood, and the 95% confidence 
interval was widened to include OR=l (0.82 to 5.57).178
Cancer
Evidence for an association between BMI status in childhood and cancers was mixed. Three 
studies reported on cancers (not cause-specific) from objective measures (registry or mortality 
data); one study of 2,347 British men and women showed that cohort members with BMI-SDS 
in the highest quartile at age 2-14 years had a 40% increase in risk of cancer (morbidity and 
mortality, up to age 80).214 In a Norwegian cohort, having a very high BMI at age 14-19 was 
associated with a 20% increase in risk of cancer mortality among women only.212 An analysis 
of data from 78,612 Dutch men showed no association between BMI at age 18 and cancer 
mortality at ages 18-49.196 Colorectal cancer mortality was shown to be associated with BMI in 
adolescence (ages 13-19) in two studies (RR 2.1 to 9 .1 )1312I2; this effect was observed among 
men only in one of the studies.131 In a Norwegian study (n 227, 221), high BMI at ages 14-19 
was associated with kidney cancer among men (RR 2.6 [1.5,4.7]).184
Of four publications that looked at breast cancer outcomes, one study of 117,415 Danish women 
showed that increased BMI at age 14 years was associated with a reduction in risk of breast 
cancer in adulthood (RR 0.97, 95% Cl 0.96, 0.98).180 Another study (case-control study of 
>10,000 women) reported that the risk of pre-menopausal cancer was lower among women who 
were obese at age 18 (RR 0.6, 0.2 to 0.9), but there was no association with post-menopausal 
cases.171 The remaining studies from the UK and Hawaii 172 found no strong evidence of an 
association between BMI at ages 2-25 years and breast cancer in later life. One study analysing 
cervical cancer mortality among Norwegian women showed that very high BMI at ages 14-19 
was associated with an almost doubling of risk (RR 1.9 [1.1, 3.2]),212 while another Norwegian 
study looking at ovarian cancer in 111,883 women showed that high BMI at ages 14-19 was 
associated with 43-56% increase in risk of ovarian tumour.187
The US study which showed that overweight at age 13-18 years was associated with colorectal 
cancer mortality reported wide confidence intervals for the hazard ratio (HR 9.1, 95% Cl 1.1 to
48
77.5) (n 181), which widened to include HR=1 when adjusted for adult BMI. 204 This study also 
reported on a variety of other morbidity and mortality outcomes, and no associations with 
adolescent obesity were observed after adjustment for adult BMI. The case-control study of 
breast cancer 171 assessed outcomes according to weight status at ages 18 and in adulthood, and 
showed that women who were not overweight in adolescence but overweight in adulthood had 
an increased risk of pre- and post-menopausal breast cancer compared to those who were not 
overweight in either period (RR for premenopausal cancer 1.5, 95% Cl 1.2 to 1.9); there was no 
difference in risk for those who were overweight at age 18, regardless of weight status in 
adulthood.
All-cause mortality
Six of the included studies reported on the relationship between BMI status in early life and all­
cause mortality. Two studies from Norway (n 226, 678 185 and 227,003 188) one from Sweden (n 
45,884 men 205), one from the US (n 13,146206) and another from Britain (n 2,990)195 showed 
that high BMI at ages 2-19 was associated with 40-60% increase in risk of all-cause mortality in 
adulthood. In a small US cohort (n 181), an association was observed among men but not 
women 204; when this estimate was adjusted for adult BMI, there was no longer any strong 
evidence for an association.
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Table 3-3: Summary of included studies
Outcome Number Summary of Description 
of evidence
studies
T ype 2 11 + + + + + + + + + + ? io  studies 124 174 177 182 191 197 200 203 2072I0: increased
diabetes B M I/overw eight at various ages in ch ildhood  and
adolescence associated  w ith  increased risk  o f  type 2 
d iabetes in adulthood
1 study: no  a s so c ia tio n 204
H ypertension  6 + + + ++ +  5 studies 135 174 182' 183 193 200 202204 207 21°: increased
B M I/overw eight a t various ages in  ch ildhood  and 
adolescence associated  w ith  increased risk  o f  
hypertension  in adulthood
Coronary...........Î5.............. ' '  'l 0 ¡‘tudiës ‘73 Î76'  “  Î83 >89 Î95' 196'  2‘°ïin^rëasëd
heart d isease B M I/overw eigh t at various ages in childhood and
+ ( 3 )  ado lescence associated  w ith  increased risk  o f  C H D
(nonfatal and  fatal) in adulthood
1 study 204: P ositive association  betw een B M I in 
adolescence and C H D  m ortality  in  m en only
4  studies 190 194 199 20I: no  association
Stroke 8 + ++  - ? ? ?  2 stud ies 176 192: increased  B M I/overw eight in
adolescence associated  w ith  increased  risk  o f  stroke in 
+ ( 3 )  adulthood
1 study 185: h igher B M I in adolescence associated  w ith 
increased risk  o f  dea th  from  cerebrovascu lar d iseases
1 study 204: positive association  betw een B M I in 
adolescence and stroke m ortality  in  m en only
1 study 208: increased  B M I at ages 2 and  7 associated  
w ith  reduced  risk  o f  stroke in  adulthood
3 stud ies 195 199 201 : no associa tion
A sthm a 2 ?
+ ( ? )
1 study 178: increased  B M I in  ch ildhood  associated  w ith 
increased  risk  o f  asthm a in  w om en only
1 study  209: no association  betw een  B M I a t age 10 y 
and asthm a in adulthood
All cancers 3 + ? 1 study  198: H igher B M I-SD S in ch ildhood  associated 
w ith  increased  odds o f  cancer (cases and m ortality);
+ ( 9 ) stronger associa tion  w ith cancers re la ted  to  sm oking
1 study  185: h igher B M I in  adolescence associa ted  with 
increased risk  o f  cancer m orta lity  in  w om en only
1 study 196: no association  betw een B M I category  at
age 18 y and  cance r m ortality
C olon cancer 2 ++  2 studies 185 204: H igher B M I in  adolescence associated
w ith increased  risk  o f  colorectal cancer m ortality
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K idney
cancer
1 + 0 ) 1 study 184: H igh B M I in adolescence associated  with 
increased  risk  o f  renal cancer in  boys
B reast
cancer
4 - ? ? ? 1 study 180: low er B M I at age 14 y associa ted  w ith 
increased  risk  o f  breast cancer in adulthood
3 studies 171 172 , 86; no  association
C ervical
cancer
1 + 1 study 185: H igher B M I in  adolescence associa ted  w ith 
increased  risk  o f  cervical cance r m ortality
O varian
cancer
1 + 1 study 187: H igh  B M I in  adolescence associa ted  w ith 
increased  risk  o f  ovarian  cancer
A ll-cause
m ortality
6 +++++  
+ (<?)
5 studies 185 188 195 205'206: increased  B M I in 
ch ildhood/adolescence associa ted  w ith increased risk 
o f  m ortality . 1 study 204: h igh  B M I in childhood
associated  w ith  all-cause m ortality  in m en only
+  indicates positive association  betw een BM L/weight status and d isease ; -  ind icates negative association; 
? indicates no strong ev idence o f  association; c?=male; $ = fem a le
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Table 3-4: Summary of excluded studies relevant to the review
S tu d y O u tco m e(s) M a in  r e s u lt M a in  re a so n  fo r  
exc lu sion
X u e t a l l i ' A sthm a (physician  
d iagnosed)
O besity  a t age 14 y  associated  
w ith  doubling  o f  asthm a risk  (O R  
2.09; 95%  C l 1 .23 ,3 .57 )
B M I from  self-reported  
w eight and heigh t at 
age 14
B aer et al il3 Pre-m enopausal 
b reast cancer
H igher B M I at ages 5, 10 and 20 
y associa ted  w ith low er risk  o f  
b reast cancer
B M I from  recalled  
w eight and heigh t at 
ages 5 ,1 0 , 20
B ardia et al ‘!l(> Post-m enopausal 
b reast cancer
A bove average w eigh t at age 12 
y associa ted  w ith  low er risk o f  
b reast cancer (R R  0 .85 ; 95%  C l 
0.74-0 .98)
R ecalled  w eight status 
at age 15 years
M erten  et al 21' A sthm a, diabetes, 
hypertension
O besity  in  adolescence (age 2-19 
y) associated  w ith  increased  risk  
o f  hypertension ; obesity  in  
adolescence and  in  adulthood 
(age 19-26) associated  w ith  all 
outcom es
B M I from  self-reported  
height and  w eight in 
adolescence
Sanderson et al 218 Pre-m enopausal 
b reast cancer
N o association  betw een 
perceived  w eight sta tus at age 15 
y and la ter b reast cance r risk
R ecalled/perceived 
w eight status at age 15
U rsin e t al ny Pre-m enopausal 
b reast cancer
N o association  betw een  B M I at 
age 18 y and  la ter breast cance r 
risk
B M I from  recalled 
w eight and heigh t at 
age 18
V erla-T ebit et al m Pre-m enopausal 
breast cancer
L arger body  bu ild  at m enarche 
associated  w ith low er risk  o f  
b reast cancer (O R  0 .69 ; 95%  C l 
0 .4 9 ,0 .9 6 )
R ecalled/perceived 
body  build  at m enarche
W eidcrpass et a l721 Pre-m enopausal 
b reast cancer
H eavier bu ild  at age 7 and 18 y 
associated  w ith  low er risk  o f  
b reast cancer
R ecalled/perceived 
body  shape in 
ch ildhood
L ubin e t a l 111 O varian  cancer H igher B M I at age 18 y 
associated  w ith increased risk  o f 
ovarian  cancer
B M I from  recalled  
w eigh t and height at 
age 18
Ferraro  et al Ui A ll-cause m ortality O verw eight a t age 12 y 
associated  w ith low er risk  o f  
m ortality) R R  0 .68 ; 95%  C l 0.59, 
0 .80)
R ecalled/perceived 
w eight sta tus a t age 12
Franks e t a l i l4 M ortality  -  a ll­
cause , ex ternal and 
endogenous
BM I > 95m centile  at m ean  age 11 
y associated  w ith  increased risk  
o f  death  from  endogenous causes 
(incidence rate ratio  1.90; 95%
C l 1 .37 ,2 .65 )
Partic ipan ts from  select 
A m erican Indian  
population
Van D am  e t al 134 A ll-cause m ortality O verw eight and  obesity  a t age 18 
y associated  w ith  all-cause 
m ortality  (H R  for obesity  2 .79; 
95%  C l 3.04, 3 .81)
B M I from  self-reported  
w eight and heigh t at 
age 18
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3.4 Summary and im plications
This review has found that there is a consistent body of evidence that shows associations 
between childhood overweight and cardiovascular outcomes and mortality in adulthood. 
However, few studies have assessed the effects of childhood overweight on adult disease 
independent of adult weight status.
The finding that childhood overweight is associated with type 2 diabetes, hypertension, 
coronary heart disease, and mortality, unadjusted for adult BMI, is in line with a recently 
updated systematic review of overweight in childhood and mortality and adult morbidity.17 
Evidence for stroke outcomes is mixed, with half of the included studies reporting a positive 
association with early life BMI, and half reporting the inverse or no association. A systematic 
review which explored the relationship between childhood obesity and asthma in adolescence 
concluded that obesity precedes, and is associated with, asthma 97; however, based on the two 
studies included in this review, there is no strong evidence for an effect of childhood BMI on 
adult-onset asthma. There is limited evidence that childhood BMI is associated with increased 
risk of colorectal and kidney cancers. Three of four studies found no association between 
overweight in youth and breast cancer; one study showed that higher BMI in adolescence was 
associated with reduced risk of breast cancer,180 as has been observed in studies using BMI from 
recalled height and weight in adolescence.215 216 These findings are in line with a previous 
review, which found no consistent evidence of associations between relative weight in 
childhood or adolescence and breast cancer risk. 225 High BMI in adolescence may be 
associated with cervical and ovarian cancers; however pooled analysis of data from six cohorts 
with recalled weight at age 18 or 20 found no association between BMI in early adulthood and 
ovarian cancer risk. 226 Inspection of a funnel-plot 227 using effect sizes unadjusted for adult 
BMI revealed asymmetry, indicating the possible presence of publication bias.
This review has expanded on previous reviews 17 by assessing the evidence for the effects of 
childhood overweight on adult disease, independent of the association with adult BMI. The 
issue of independent effects is important to understanding the progression of long-term disease 
risk in overweight children. A handful of studies have examined the independent effects of 
childhood BMI. These have mostly assessed independent effects by simultaneously adjusting 
for BMI in adulthood, and most of them showed that effect sizes were attenuated after 
adjustment for adult BMI. For example, in a study of diabetes (n 10,683) the odds ratio for one 
unit increase in BMI-SDS at age 11 was reduced from 1.78 (95% Cl 1.5 to 2.1) to 1.06 (0.8 to 
1.3) after adjustment for BMI at age 23 197; in a small study of hypertension (n 286), adjustment 
for adult BMI did not lead to a change in the point estimate for the association with childhood 
overweight, but confidence intervals were wider.193 In contrast, a study of CHD (n 37,674) 
reported that the hazard ratio for incident CHD for men with BMI in the top decile in
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adolescence increased from 5.43 (95% Cl 2.77 to 10.62) to 6.85 (3.3 to 14.2) after adjustment 
for adult BM I.210
The results of such analyses are generally interpreted as evidence that observed associations 
between childhood BMI and adult disease risk can be accounted for by adult BMI, and that 
childhood BMI has no underlying effect on disease risk. However, adjusting for adult BMI in 
this way has limitations. In particular, adult BMI is likely to be on the causal path from 
childhood BMI to later disease; consequently, adjustment for adult BMI can introduce 
overadjustment biases, which tend to pull effect estimates towards the null.228 A statistical 
effect called the ‘reversal paradox’ has been described, in which adjustment for variables on the
A 4 A  A A A
causal pathway lead to artifactual associations between exposures and outcomes.
Furthermore, adjustment for adult BMI does not enable us to differentiate between the effects of 
early life BMI and change in size (or BMI) over the period between measurements, 231 232 as 
inclusion of adult BMI in a regression model is effectively adjusting for the change in relative 
size between periods.231 It is therefore difficult to conclude that childhood overweight has 
long-term effects on health based on the results of standard analyses. A number of alternative 
statistical approaches to studying the effects of early life BMI on later health have been 
suggested, including structural equation modelling, 233 and random effects models. 234 Another 
approach has been to use different combinations of exposure to overweight in childhood and 
later life as the predictor variable, as was used in the pooled analysis of cohort data looking at 
hypertension and type 2 diabetes.174 Examination of relative risks in this way allows insight 
into the effects of exposure to overweight at different developmental periods. The limitations of 
standard adjustment and alternative methods are discussed in more detail in Chapter 4.3.2.
Given the high and rising prevalence of childhood overweight in all parts of the world, it is 
increasingly important to know whether childhood obesity has long-term effects on health 
which may contribute to future health burden. This review has shown that evidence that 
childhood obesity has effects on long term health, independent of adult BMI, is lacking. Direct 
effects of obesity in early life on long-term health may not be detected due to limitations in the 
statistical analyses and study designs that are commonly used. Studies that use alternative 
approaches to analysis may address some of the issues associated with standard adjustment for 
adult BMI. If it was found that childhood obesity had a direct effect on long term health, this 
would place the imperative on prevention and early treatment in childhood, and could provide 
important insight into the underlying mechanisms of disease progression and potential targets 
for intervention.
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4. METHODOLOGICAL ISSUES AND APPROACHES TO ANALYSIS
In this thesis, data from three British National Birth Cohort studies are analysed to explore the 
relationships between overweight and obesity in childhood and adolescence and disease 
outcomes in adulthood; a life course perspective informs the approaches to analysis. The aim of 
this chapter is to introduce the datasets, and to describe the theoretical grounding, 
methodological issues and approaches to analysis in this thesis.
4.1 A life course approach
Life course epidemiology has been described by Kuh et al as the study of the long-term effects 
on health or disease risk of biological, behavioural and psychosocial exposures during gestation, 
childhood, adolescence, early adulthood or across generations. 235 Much of the recent interest in 
the effects of early life nutrition on adult health has its roots in the ‘foetal origins of adult 
disease hypothesis’, which was developed by David Barker and colleagues, and in its most 
recent incarnation is known as the Developmental Origins of Health and Disease (DOHaD) 
hypothesis. 236 In their analyses of historical cohorts, Barker et al showed that small size at birth 
was a risk factor for coronary heart disease (CHD), stroke, diabetes and associated risk factors. 
2i3 237-238 j^ese fincjingS were interpreted as evidence for long-term effects of undemutrition in 
utero. Further studies have shown that small size at birth (early life undernutrition) followed by 
catch-up growth (improved postnatal nutrition) may increase disease risk in adulthood.
This effect may be associated with body size over the life course; a systematic review found that 
early rapid growth was associated with later overweight and obesity.240
The focus on the long-term effects of early life size and growth has increasingly informed 
approaches to the study of childhood overweight and obesity and chronic disease risk. 223 The 
chronic diseases that are commonly associated with obesity, notably type 2 diabetes and 
coronary heart disease and stroke,241 are end stage outcomes of progressive cardio-metabolic 
changes which have their origins in early life. 242 243 There is also emerging evidence that 
metabolic abnormalities in early life are associated with asthma risk, 244 and that airway 
remodelling in children with asthma is associated with continued impaired lung function into 
adulthood. 245 With the life course approach, the temporal ordering of exposures (overweight 
and obesity) over the life course is conceptualised and incorporated into analysis. Different 
conceptual models for the effects of risk factors on disease risk over the life-course have been 
proposed: 235 246
1) The ‘accumulation-of-risk’ model corresponds to a model in which the effects of exposure 
to overweight over the life-course accumulate to determine overall disease risk. A recent 
analysis of the Framingham Cohort Study, which included data from adults who had been
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followed up every two years for up to 48 years, showed that the number of years of obesity 
was associated with all-cause, cardiovascular, cancer, and other-cause mortality. 247 These 
findings are consistent with an accumulation of risk model, in which each year lived with 
obesity contributes to future risk of mortality.
2) The ‘critical period’ model represents the case where individuals have increased 
vulnerability to effects of overweight during specific periods of the life-course, resulting in 
permanent changes in disease risk. The critical period model is consistent with the foetal 
origins of adult disease hypothesis, which suggests that undemutrition in utero leads to 
lasting anatomical and metabolic changes that increase risk of chronic diseases such as 
cardiovascular disease, diabetes and hypertension. However, this model does not necessarily 
preclude later effect modification. For example, the effects of low birth weight on 
cardiovascular diseases may appear stronger in individuals who are also obese in later life.
238 248
3) The ‘sensitive period model’ represents an overlap between the accumulation of risk and 
critical period models, and proposes that there are periods when the effects of overweight or 
obesity have greater impact on later health than exposure at other periods, and that changes 
may not be permanent or may be reversible outside the sensitive windows. 235 A US study 
of weight status in adolescence (age 12-19 years) and early adulthood (age 19-26) showed 
that obesity during adolescence and early adulthood was associated with increased risk of 
asthma, diabetes, high cholesterol and hypertension in adulthood.217 Obesity in 
adolescence only was associated with increased risk of high cholesterol and hypertension, 
while obesity in adulthood only was associated with increased risk of diabetes, high 
cholesterol and hypertension, relative to those cohort members who were not obese in both 
periods. These findings are consistent with an accumulation of risk model for obesity 
(assuming similar duration of obesity in childhood and adulthood), but also reveal that 
obesity isolated to a single period can have an effect on disease risk, as in the case of 
adolescent obesity and hypertension.
4.1.1 Defining life stages
In developmental terms, childhood refers to the period from infancy (ages 0-2 year) to the onset 
of puberty, and usually encompasses ages 0-12 years. Adolescence describes the transitional 
period between childhood and adulthood, from the onset of puberty to maturity.249 During this 
time, a number of physiological and psychological changes take place which make this life 
stage biologically and socially distinct. For example, early adolescence is a high-risk time for 
weight gain due to the effects of metabolic and behavioural changes 25°; furthermore, obese 
adolescents are more likely to be stigmatised and subject to negative stereotypes than are 
younger obese children. 112113 Although the timing and duration of puberty varies among 
individuals, adolescence is usually considered to include ages 13-19 years.
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Figure 4-1: Life stages of interest and approximate ages included in these stages
Childhood Adolescen e Early adulthood Middle adulthood Late adulthood
0 13 20 40 65
Age in years
Adulthood begins once a person has reached full maturity, and in Western industrialised 
societies can be further subdivided into life stages commonly identified as: early adulthood 
(ages 20-39.9 years), middle adulthood (ages 40-64.9), and late adulthood (ages 65+). Whilst 
childhood and adolescence are often marked by significant biological changes and cultural rites 
of passage, the exact definitions of life stages in adulthood vary according to the conceptual 
framework that is adopted. For example, ageing may be viewed as both a biological process 
and a social phenomenon: in women, decline in fertility and menopause may be seen as a 
biological signal of middle age, while reaching pensionable age might mark entry into late 
adulthood. Different stages of adulthood are also associated with marked differences in 
experience of disease, especially the chronic diseases that are of interest in this thesis. For 
example, results from the 2007 General Household Survey showed that the prevalence of 
longstanding illnesses of the heart and circulatory system was 1.4% among men and women 
aged 16-44 years, 12.8% among those aged 45-64 years, and 27.7% among those age 65-74 
years.2M Similar patterns in disease prevalence were observed for problems of the 
musculoskeletal system (5.7% at age 16-44, 18.2% at age 45-64, and 27.3% at age 65-74), and 
for endocrine and metabolic disorders (1.6% at age 16-44, 7.7% at age 45-64 and 11.0% at age 
65-74).
4.2 The British National Birth Cohorts
Prospective longitudinal studies arc ideal for studying life course effects because they present 
the opportunity to measure exposures that act over the life course. The British National Birth 
Cohorts from 1946 (MRC National Survey of Health and Development NSHD), 1958 (National 
Childhood Development Study NCDS) and 1970 (British Cohort Study BCS70) are nationally 
representative prospective cohorts that have collected data from birth and followed up 
participants at several points during childhood, adolescence and adulthood. x M The three 
cohorts have comparable target and sample populations, and data collection at similar life stages 
(Table 4-1). They have data on anthropometric measurements in childhood and adolescence and 
health outcomes in adulthood, in addition to numerous other variables such as educational and 
employment history, relationships, family circumstances, and health-related lifestyle choices. 
Consequently, these cohorts provide a unique opportunity to study the development of health 
outcomes over a long period of time.
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Table 4-1: Summary of British National Birth Cohorts from 1946,1958 and 1970
MRC NSHD 1946 254 NCDS 1958 253 BCS 1970 252
Target population/ 
inclusion criteria
All singleton babies 
bom to married 
women in England, 
Wales and Scotland in 
one week in March 
1946
All babies bom alive 
or dead in England, 
Wales and Scotland in 
one week in March 
1958
All babies bom alive 
or dead after 24th week 
of gestation in E&W, 
Scotland and N 
Ireland in one week in 
April 1970
Sample All births to women 
with husbands in non- 
manual or agricultural 
jobs and !4 of births to 
women with husbands 
in manual jobs
All births; immigrants 
to Britain bom during 
same week 
incorporated at 7, 11, 
16 years
All births; participants 
from NI dropped in all 
subsequent sweeps; 
immigrants 
incorporated at 5, 10, 
16 years
Sample size at 
baseline
5,362 17,638 16,567
Participant
characteristics
Representative of the 
national population of 
similar age. 49% male, 
51 % female at most 
recent data collection.
Representative of the 
national population of 
similar age. 49% male, 
51 % female at most 
recent data collection
Representative of the 
national population of 
similar age.
Data collection 
occasions
22 occasions 9 occasions 8 occasions
Ages for which 
data available
Birth to 53 years Birth to 47 years Birth to 34 years
Sample size at last 
follow-up
2,948 9,534 9,656
Notes Strati fied-sample 
design: sample should 
be weighted to 
account for this. Pre- 
NHS; mothers living 
during World War 2. 
Data obtained from 
the Medical Research 
Council NSHD team 
at University College 
London.
Includes stillbirths, 
non-singleton births 
and immigrants to 
Britain. Data 
downloaded from UK 
Data Archive, 
University of Essex
255-260
Includes stillbirths and 
non-singleton births. 
Data obtained from 
the UK Data Archive.
The oldest of the British National Birth Cohorts is currently approaching late adulthood, and the 
youngest cohort is entering middle adulthood. The endpoints of interest in this thesis are 
disease outcomes at ages 34-53 years. As the cohort studies vary in the ages at follow-up, for
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each of the life stages (childhood, adolescence, and adulthood), the measurement taken closest 
to the mid-point age of the defined interval was used (Table 4-2).
Table 4-2: Ages at measurement in British National Birth Cohort Studies that are closest to mid-point age for each 
life stage of interest
Life stage Age range Mid-point Age at measurement closest to mid-point
(years) age (years) age
NSHD 1946 NCDS 1958 BCS 1970
Childhood 0-12 6 7 7 10
Adolescence 13-19 16 15 16 16
Adulthood
(middle)
40-64 52 53 46 34
4.3 Analysis o f longitudinal data
Analysis of data from longitudinal studies raises issues because exposures over the life course 
tend to be correlated within individuals because of common causal pathways or lifestyles. 233 
For example, overweight in childhood tends to persist into later life ,18 while cardiovascular risk 
factors cluster in childhood71-72 and track into adulthood.261 These temporal and causal 
hierarchies mean that observations on a subject will be more similar to each other than to 
observations on other subjects, thereby violating any assumption of independence. The 
presence of collinearity must be accounted for in statistical analyses to ensure that standard 
errors of parameter estimates and confidence intervals are correctly estimated.262
4.3.1 Tracking of overweight and obesity
Tracking refers to the persistence of values or relative positions/ranks of a certain trait over 
time. Two broad concepts are involved: 1) the relation between early measurements and those 
later in life (the longitudinal stability of a variable); and 2) the predictive value of early 
measurements for future values. 118 These concepts can be operationalised using a tracking 
coefficient and a predictive value or risk measure.
There are a number of approaches to measuring tracking (Table 4-3). For example, the degree 
of tracking between two measurements at T1 and T2 may be quantified using a correlation 
coefficient such as Spearman’s rank or Pearson’s linear correlation coefficient, or by dividing a 
population into subgroups according to percentile ranking (e.g. into tertiles, quartiles or 
quintiles) and calculating the proportion of individuals who stay in the same group. With the 
latter approach, the magnitude of the tracking coefficient depends highly on the way in which 
the population is divided into subgroups, which can make the assessment of tracking 
problematic.
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In longitudinal studies with two or more time points (T>2), Cohen’s kappa (k) can be used.
This coefficient counts the number of times that a given individual is in a particular percentile 
(or other defined) group, and compares this with the value that would be expected if the 
individuals were randomly assigned to the different groups at each measurement, k takes values 
of between 0 and I, and Landis and Koch suggest the following cut-offs as criteria for 
agreement:168 k<0.40 indicates poor agreement (or tracking), k=0.4 1-0.60 is moderate 
agreement, k=0.6 1-0.80 is substantial agreement, and k>0.81 indicates excellent agreement. A 
weighted k can also be used, in which the movements between percentile groups are weighted 
according to the distance moved, k coefficients can be interpreted as intraclass correlation 
coefficients (ICC).118 When T>2, Kendall’s coefficient of concordance W can be used to 
describe tracking. Kendall’s W is calculated on the basis of changes in individual rankings over 
time, and is directly related to the average Spearman correlation coefficient. W takes values of 
between 0 and 1 and indicates the degree of association between rankings at each measurement, 
but W is not equal to 0 for random numbers and has to be rescaled accordingly for comparison 
with other coefficients. An alternative approach to describing tracking has been used by Lauer 
et al, 263 in which each value of the variable of interest is expressed as a percentile rank, and for 
each individual the average of percentile ranks over time is calculated. A regression line is then 
calculated for each individual which describes the change of percentiles over time (the trend in 
rank), and the goodness of fit of the regression line is measured as the residual standard 
deviation (RSD, which measures variability over time and is inversely related to goodness of 
fit). Individuals with strong trends and low variability are said to track, and the proportion of 
individuals who belong to this group is calculated. Lauer’s coefficient is based on a different 
definition of tracking, and is not comparable to the other coefficients described previously.
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Table 4-3: Nonparametric tracking coefficients (adapted from Twisk et al 'M athem atical an d  analytica l aspects o f  
tracking' Epidemiologie Reviews. 1994; 16(2): 165-183 ll8)
Coefficient Range (min. to 
max.)
Tracking criterion* Data pointsf
Spearman’s p -1 to 1 Arbitrary 2
% at high risk 0 to 100% >20% (quintiles) 2
or >25% (quartiles)
Lauer’s % 0 to 40% Arbitrary All
Cohen’s k Oto 1 >0.75 good All
>40 moderate
Nishio’s T1
Quintiles 1 to 8.3 Arbitrary 2
Quartiles 1 to 4.0
Kendall’s W Oto 1 Significance All
"■Criterion to decide whether a variable tracks; tNumber of data points used to calculate 
the coefficient
The benefit of Cohen’s k, Kendall’s W and Lauer’s coefficients for the assessment of tracking is 
that they can be used with more than two longitudinal measurements, thus making use of all the 
available data. These coefficients are also relatively simple to compute. As nonparametric 
approaches, they make fewer assumptions about the distribution of the data than parametric 
methods, and can be used for categorical variables such as overweight status. The advantage of 
k over the other two methods is that it is on a 0-1 scale (0 for no tracking and 1 for perfect 
tracking) that is easily interpreted and comparable to other measures.
The predictive value of early measurements for those in later life can also be assessed in a 
number of ways. For T=2, predictive value may be defined as the proportion of individuals in a 
high risk group at initial measurement that have stayed in that group at the second measurement 
period. For multiple measurements, various regression analysis methods can be used, in which 
the value of the last measurement is the outcome variable and values of earlier measurement are 
the exposure variables. A systematic review of the literature on tracking of childhood 
overweight into adulthood showed that correlation coefficients, relative risks of overweight and 
percentages of overweight children who remain overweight in adulthood are commonly 
reported measures of tracking. 18
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4.3.2 Childhood overweight and outcomes in adulthood: analytical approaches
A standard approach to studying the effects of obesity in early life on later outcomes is to fit 
measures of adiposity at different ages as the exposures, with adjustment for current obesity or 
BMI, as described in the studies in the literature review (Chapter 3). However, this approach is 
problematic for a number of reasons.
One issue is that adult BMI, which is correlated to childhood BMI, is a likely intermediate 
variable on the causal path from childhood BMI to later disease outcomes; consequently, 
adjustment for adult BMI is likely to introduce overadjustment biases, which tend to pull effect 
estimates towards the null.228 In the context of the foetal origins hypothesis, a statistical effect 
called the ‘reversal paradox’ has been described, in which adjustment for variables on the causal 
pathway lead to artifactual associations between exposures and outcomes. 229-230 In a series of 
simulations, Tu et al, 230 showed that a genuine positive association between birth weight and 
adult blood pressure could be attenuated after adjusting for current weight, and even reversed 
when the correlations between birth weight and current weight and between current weight and 
blood pressure were increased. These same effects are relevant to the study of childhood 
overweight and adult disease, particularly given the correlation between childhood and adult 
BMI. Furthermore, multiple regressions that use several closely spaced BMI measurements are 
subject to issues of multicollinearity 264; the interdependence of the BMI measurements reduces 
the amount of information that they contribute to explaining variance. The result is inflated 
variance for regression coefficients and less robust parameter estimates.
There are also problems with the interpretation of results from standard analyses 233; adjustment 
for adult BMI does not enable us to differentiate between the effects of early life BMI and 
change in size (or BMI) over the period between measurements. 231-232 For example, the 
parameter estimate for childhood BMI in a regression model adjusted for adult BMI can be 
interpreted as the effect of childhood BMI in individuals who all have the same adult BMI; 
however, inclusion of adult BMI in the model is also effectively adjusting for the change in 
relative size between time childhood and adulthood, therefore another interpretation can be the 
effect is associated with the change in adiposity between childhood and adulthood.231 Since 
these effects cannot be distinguished, it is difficult to conclude whether childhood BMI has any 
long-term effects on health based on the findings of standard analyses.
A number of statistical approaches have been suggested to address these issues in studies of life 
course obesity. One approach is structural equation modelling (SEM), including path analysis, 
233 265 which specifies causal and temporal pathways between variables in a model, and uses 
simultaneous equations to produce estimates of the direct and indirect effects of variables on 
each other and on the outcomes. This approach requires specification of a model which 
explicitly details the interrelationships between variables, and assumes that there are no
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unmeasured variables that are associated with both the exposure and the outcome; for a given 
scenario there may be several potential model specifications, and in complex systems the causal 
relationships may not be well known.266 This issue may be avoided if information on potential 
confounders is excluded (or unavailable 265) but this is likely to result in biased estimates.
Other studies have used multilevel or random effects models in a two-step approach to study the 
effects of BMI change or growth on later outcomes. In the first step, growth is modelled using 
multilevel models, which explicitly account for clustering by including one or more random 
effects which are assumed to have mean zero and to vary randomly between clusters (or 
individuals, in the case of repeated measures). For example, the model could allow each 
individual a different random intercept (baseline BMI) and a random slope (linear change in 
BMI). This model would enable estimation of BMI growth velocity for each individual over a 
certain time period. In the second step, growth parameters from the growth model (such as the 
BMI growth velocity) are used as predictors of the outcome of interest in another model. To 
characterise growth trajectories in detail, multiple measures of weight and height in childhood 
are required. A study of the Northern Finland Birth Cohort 1966 (NFBC1966), which had data 
on height and weight measurements on several occasions between birth and age 2 years, fitted 
polynomial random effects growth curves to the height and weight growth data and used these 
to derive peak height velocity and peak weight velocity in infancy. 234 These growth parameters 
were then used as predictors in models with metabolic traits at age 31 years as the outcomes. In 
a meta-analysis of data from 8 cohorts, growth curves were fitted on BMI in infancy and 
childhood, and the relationship of growth parameters with variation at the FTO locus was 
explored. 267 Other studies have used splines (linear growth between specified knots) rather 
than complex polynomials to characterise growth, as complex polynomials are often difficult to 
interpret. 268 Growth modelling using piecewise linear random coefficients models was used to 
describe BMI trajectories in the British National Birth Cohorts.268
Another approach that has been adopted in previous studies of obesity has been to use different 
combinations of exposure to obesity over the life course as the predictor variable. 269 In these 
cases, individuals are categorised according to the life stages at which they were obese. For 
example, in an analysis of the NFBC1966, odds ratios for abdominal obesity at age 31 years 
were estimated for cohort members with different combinations of weight status at age 14 years 
(normal weight or overweight) and at age 31 years (normal, overweight or obese). 270 In a study 
of adult socioeconomic, educational, social and psychological outcomes associated with 
childhood obesity by Viner and Cole,141 individuals from the BCS70 cohort were categorised 
according to whether they were obese in childhood only, obese in adulthood only, obese in 
childhood and adulthood; the risks of negative outcomes for each subgroup were then compared 
to risk in those who were not obese in either period. To test for potential bias due to the 
categorisation of exposure variables, the authors then entered childhood obesity and adult
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obesity as main effects in the model and tested for interaction between these variables. A 
similar approach was used by Merten in his study of weight status in adolescence (ages 12-19 
years) and early adulthood (ages 19-26), and their associations with diagnosis of asthma, 
diabetes, high cholesterol and high blood pressure in early adulthood.217 As in the study by 
Viner and Cole, individuals were categorised according to whether they were obese in 
adolescence only, obese in adulthood only, obese during adolescence and adulthood, and never 
obese. These categories were then used as exposures in regression models to examine their 
association with health outcomes. Wills et al also defined ‘overweight trajectories’ in this way 
based on weight status at three ages in adulthood for individuals in the NSHD cohort,271 and 
used regression models to estimate mean blood pressure for different trajectories. Similarly, in 
a recent pooled analysis of data from four cohort studies of cardiovascular risk factors, 
participants were assigned to one of four groups according to whether they were normal weight 
or overweight/obese in childhood and adulthood (group 1: normal BMI in childhood and non- 
obese in adulthood; group 2: overweight/obese in childhood and non-obese in adulthood; group 
3: overweight/obese in childhood and adulthood; group 4: normal BMI in childhood and obese 
in adulthood), and relative risks of cardiovascular outcomes were estimated for each group. 174 
The disease outcomes of interest in this thesis are conditions which develop over time, therefore 
studies that examine their association with exposure to overweight at a single time point ignore 
the combined effects of exposures that potentially act over longer periods. The advantage of an 
approach that uses different combinations of overweight as an exposure is that it can provide 
insight into the contribution of overweight at different stages of the life course to outcomes, 
with important implications for understanding the progression of disease and approaches to 
intervention.
4.4 Conceptual framework
In observational studies like the British National Birth Cohort studies, establishing causality is 
complicated by the presence of biases and confounders, some of which may be hidden or 
unmeasured. These issues are particularly salient when studying childhood obesity and adult 
health, as the exposure and outcome are separated by a long time period, and there may be 
several possible explanations for the data.
Figure 4-2 shows the causal directed acyclic graph (DAG) for the relationships between 
childhood overweight, chronic disease outcomes and the key covariates of interest that informs 
the analyses in the following chapters. The key covariates and their relationships with 
childhood obesity and chronic disease were selected based on a review of the literature and 
available data for the three cohorts (Table 4-4). The process of selecting the statistical models 
for analyses in the following chapters was informed by this conceptual framework.
64
Figure 4-2: Generic causal directed acyclic graph (DAG) for childhood BMI status and adult disease
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Table 4-4: Key covariates in the relationship between childhood overweight and chronic diseases in adulthood identified in the literature, strength of the evidence and categorisation as 
confounders, effect modifiers or mediators
Covariate Correlated with the exposure? f  Risk factor for the outcome? { Effect modifier? On the causal Summary
pathway?
A dult B M I 
status
O verw eigh t in  adulthood  is 
associa ted  w ith overw eigh t in 
c h i ld h o o d .18120 (++)
R R  fo r be ing  overw eigh t in 
adu lthood  (age 19-35) fo r 
overw eigh t ch ild ren  aged  9-11 y 
(B M I >  85 th  cen tile) vs. norm al 
w eig h t ch ild ren  =  1.9. 272
R R  fo r be ing  overw eigh t in 
ad u lthood  (age 18-37) for 
ov erw eig h t ch ild ren  aged  2-17  y 
(B M I >  95 th  cen tile) vs. norm al 
w eig h t ch ild ren  =  3 .2 , R R  for be ing  
o bese  in  adulthood  fo r overw eigh t 
ch ild ren  (B M I >  95 th  cen tile) vs. 
norm al w eigh t ch ild ren  =  1 0 .1 .273
O R  (95%  C l) fo r be ing  obese in  
adu lthood  (age 24-54) for 
overw eigh t ado lescen ts aged  14-19 
y  (B M I >  85th  cen tile) vs. 
ado lescen ts w ith  B M I 25 th -74 th  
cen tile  m ales/fem ales = 1 5 (1 4 - 1 7 )  
/  12 (11-13). 274
A dult overw eigh t is a  risk  factor fo r 
num erous d isease ou tcom es (++)
R R  (95%  C l)  fo r ischem ic stroke for 
overw eigh t vs. norm al w eight =  1.22 
(1 .05 -1 .41 ), fo r obesity  vs. norm al 
w eigh t =  1.64 (1 .3 6 -1 .9 9 ) .275
M en: 5  un it increase in B M I is 
associa ted  w ith  oesophageal 
adenocarc inom a (R R  =  1.52), thyroid 
cance r (1 .33), co lon  cancer (1 .24), 
and  rena l cance r (1 .24). W om en: 5 
u n it increase in  B M I associa ted  w ith 
endom etria l cancer (1.59), 
ga llb ladder cancer (1.59), 
oesophageal adenocarcinom a (1.51), 
and  renal cancer (1 .34). 276
H R  (95%  C l) for overall m ortality  
w ith  each  5 un it increase in  B M I 
above 22 .5-25 kg/m 2 =  1.29 (1.27- 
1.32), fo r vascu lar m ortality  = 1 .4 1  
(1 .37 -1 .45), for diabetic m ortality  = 
2 .16  (1 .89-2 .46), for neoplastic 
m orta lity  =  1.10 (1 .0 6 -1 .1 5 ) .8
T he rela tionsh ip  betw een 
ch ildhood  B M I and disease 
ou tcom es m ay b e  m odified  by 
adult B M I (+)
Poo led  analysis o f  da ta  from  
four cohorts show ed that 
overw eigh t/obesity  in  
ch ildhood  w as n o t associa ted  
w ith  increased  risk  o f  type 2 
d iabetes, hypertension  and 
o ther C V  risk  fac to rs in  those 
w ho w ere non-obese in  
adu lthood , b u t ch ildhood  
overw eigh t w as associated  
w ith  these  ou tcom es in those 
w ho  w ere obese in adulthood  
174(not stric tly  ev idence o f  
effec t m odification , bu t 
accum ulation  o f  effects).
A dult B M I sta tus is 
likely  to  be  on  the 
causal pathw ay 
betw een  ch ildhood  
B M I sta tus and d isease 
outcom e.
P ositive associa tions 
betw een  ch ildhood  
B M I and adult 
ca rd iovascu la r r isk  
fac to rs a re  generally  
attenuated  after 
ad ju stm en t fo r adu lt
A dult B M I sta tus is 
positively  associated  w ith  
childhood B M I status and 
w ith disease risk , and is 
likely to  be  on the causal 
pathw ay betw een  
childhood B M I status and  
disease outcom e. A dult 
B M I status m ay be an  
effect m odifier o f  the 
relationship  betw een  
ch ildhood  B M I sta tus and  
d isease outcom e, such th a t 
being overw eigh t in 
childhood is m ore strongly  
associated  w ith d isease in  
those  w ho are overw eigh t 
also  in  adu lthood  than in  
those w ho are  no t 
overw eigh t in  adulthood .
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Sex Sex is  associa ted  w ith ch ildhood  
B M I status (++)
A m ong  con tem porary  U K  child ren , 
p reva lence  o f  overw eigh t and 
obes ity  is h igher am ong boys than 
g irls (p revalence ov  and ob 
com bined : a t age 5 24.0%  versus 
21 .1% ; at age 11 34.3%  versus 
3 0 .7 % )54, a lthough  the o pposite  
w as true fo r o ld e r  cohorts, i.e. 
h ighe r p reva lence  o f  overw eigh t 
am ong  g irls  than  boys. 277
Sex is a  r isk  factor fo r num erous 
d isease ou tcom es (++)
T he  inc idence o f  coronary  heart 
d isease  m orb id ity  and  m ortality 
am ong m en is tw ice that in  w om en, 
a lthough  the sex d ifferentia l is 
reduced  am ong  post-m enopausal 
w om en. 278 Som e outcom es are sex- 
specific  (o r very  ra re  in the opposite 
sex), e .g . endom etria l cancer, b reast 
cancer, p ro sta te  cancer.
Sex is  like ly  to  be  an effec t N o, ch ild  B M I status
m odifier in the rela tionsh ip  does not affec t sex.
betw een ch ildhood  B M I status 
and d isease ou tcom e (++)
A study o f  m o rta lity  and 
m orbidity  ou tcom es at age 73 
show ed tha t B M I status a t age 
13-18 (overw eigh t o r lean) 
w as associa ted  w ith  all-cause, 
card iovascu lar and  co lorecta l 
cancer m orta lity  in m en, bu t 
w as no t associa ted  w ith  any o f  
these ou tcom es in  w o m e n .131
Sex is associated  w ith 
childhood B M I status and 
disease risk. It is likely  to  
be an effec t m odifier o f  the 
relationship  betw een 
ch ildhood  B M I and adult 
d isease risk.
V ery  h igh  B M I a t age 14-19 
w as associa ted  w ith m ore than 
doub ling  o f  renal cancer risk  
am ong m en, bu t no 
associa tion  w as observed  in
ISA
w om en.
E thnicity E thn ic ity  is associa ted  w ith  
ch ildhood  B M I sta tus; generally  
ch ild ren  from  ethnic m inority  
backg rounds hav e  h igher 
p reva lence  o f  obesity  than  W hite  
ch ild ren  (++)
In  the U K , obes ity  preva lence  
(B M I > 9 5 th  cen tile  o f  U K  
refe ren ce  popu la tion ) am ong  B lack  
(p revalence  26 ,4% ) and  A sian
E thn ic ity  is a  r isk  factor fo r num erous 
d isease ou tcom es 279 (++)
Sou th  A sians have a h igher 
p reva lence  o f  coronary  heart d isease 
(C H D ) and  card iovascu lar m ortality  
com pared  w ith Europeans; A frican- 
A m ericans have h igher rates o f  C H D  
and  stroke; A frican/C aribbeans in  the 
U K  hav e  low er C H D  rates and higher 
stroke  ra tes than  B ritish  Europeans.
T he  rela tionsh ip  betw een 
ch ildhood  B M I and disease 
ou tcom es is like ly  to  be 
m odified  b y  ethn icity  (+)
In  adu lts, p eop le  o f  South 
A sian  d escen t have a  m ore 
adverse card iovascu lar risk  
p ro file  than  those o f  E uropean  
descen t a t th e  sam e B M I. 280 
S im ilarly , Sou th  A sian
N o, ch ild  B M I sta tus 
does no t affect 
e thnicity
E thn icity  is associated  
w ith  ch ildhood  w eight 
sta tus and adult d isease 
risk. E thnicity  is like ly  to 
m odify  the e ffec t o f  
ch ildhood  B M I status, 
such that the risk  o f  
d isease ou tcom es is h igher 
am ong ethn ic  m inority  
groups than am ong W hite
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(21 .5% ) ch ild ren  is h igher than the 
national average, and  low er am ong  
C h inese  (13 .7% ) and  W hite 
(17 .3% ) c h i ld re n .54
O ther non-E uropean  groups such as 
the C h inese and  Japanese have high 
rates o f  stroke but no t C H D ; M exican 
A m ericans have a h igher prevalence 
o f  stroke and  C H D ; N orth  A m erican 
native Ind ians have h igh rates o f  
C H D .
adolescents are m ore insulin
resistant than  w hite E uropean
adolescents. 77 T h is is due to
d ifferences in  body
com position  and  fat
d istribu tion  betw een  ethnic
groups at sam e B M I, e.g. B M I
underestim ates body  fat
percen tage in  A sians
com pared to  C a u c a s ia n s .281' 
282
groups a t sam e BM I.
B irth  w eight B irth  w eigh t is positive ly  
co rre la ted  w ith ch ildhood  B M I 
sta tus (++)
In  one U S  study, each  1 kg  increase 
in  b irth  w eigh t w as associa ted  w ith  
a  30%  increase in  o dds o f  
overw eigh t (B M I 85 th-94 th  
cen tile ) a t age 9 -14  y  and  40%  
increase  in  odds o f  obesity  (B M I 
> 9 5 th  cen tile) 283. In  a  D anish  
study, each  0.5 kg  increm en t in  
b irth  w eigh t w as associa ted  an 
increase  in  re la tive r isk  o f  
overw eigh t at age 6-13 y. 284
L o w  b irth  w eight is  a  risk  fac to r fo r a 
num ber o f  adverse health  outcom es 
(+)
E .g. B irth  w eigh t is inversely 
associa ted  w ith systolic blood 
p ressu re  285‘286. L ow  b irth  w eight is 
associa ted  w ith  a 70%  increase in 
od d s o f  chronic k idney  disease. 287 A 
system atic  review  show ed tha t low  
b irth  w eigh t w as associated  w ith 
ischaem ic heart disease, 288 b u t larger 
size  in  in fancy  m ay be associated  
w ith  increased  risk  o f  insulin- 
d ependen t d ia b e te s .167
B irth  w eight m ay  m odify  the 
rela tionsh ip  betw een  
ch ildhood  B M I and d isease 
(+)
N o, ch ild  B M I status 
does no t a ffec t b irth  
w eigh t
G iven  tha t low  b irth  w eight 
and  ch ildhood  overw eight are 
associa ted  w ith  disease 
ou tcom es, it is expected  tha t 
those ch ild ren  w ith  low  b irth  
w eigh t +  ch ildhood  
overw eigh t are m ore like ly  to 
have adverse ou tcom es that 
those w ith  h ighe r b irth  w eight 
+  ch ildhood  overw eight. O ne 
study show ed th a t am ong 
m ales w ho had  the sam e B M I 
a t age 18 y, those w ho w ere o f 
low er b irth  w eigh t had on 
average h igher b lood  pressure
B irth  w eight is  associated  
w ith bo th  childhood 
w eight status and adult 
d isease outcom e, b u t is no t 
on the causal pathw ay 
betw een them . T here m ay 
be effect m odification  
betw een b irth  w eigh t and 
childhood B M I, such that 
the com bination  o f  low  
b irth  w eight and  ch ildhood  
overw eight is associated  
w ith  a  h igher risk  o f 
d isease than h igher b irth  
w eight and childhood 
overw eight in  a non­
additive way.
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and increased  risk  o f  
h y p e rte n s io n .289
C hildhood
socioeconom ic
position
C hildhood  S E P  is associated  w ith 
ch ildhood  B M I sta tus (++)
In  m ost W estern  countries, 
p revalence o f  overw eight is h igher 
am ong  ch ild ren  from  less affluent 
fam ilies, w h ilst the opposite is true 
in  develop ing  co u n tn es. In 
A L S P A C , h igher p revalence o f  
o verw eigh t w as observed  am ong 
11 year o ld  boys w hose m others 
h ad  lo w er educational attainm ent; 
in  g irls, the  sam e pattern  w as 
observed , in addition  to  an 
associa tion  w ith  low er fam ily 
in c o m e .53 In  a  study o f  L ondon 
schoo l ch ild ren , the preva lence  o f  
overw eigh t and obesity  w as h ighest 
am ong  those  from  the m ost 
d ep rived  qu in tile  at a ll ages. 9
L ow  ch ildhood  SE P  is a risk  factor 
fo r num erous adverse health  
ou tcom es in  adulthood  (++)
E .g. ch ildhood  SE P  is inversely 
associa ted  w ith  adu lt cardiovascular 
ou tcom es an d  risk  factors. 292 A 
system atic  rev iew  o f  the literature 
show ed  th a t poor socioeconom ic 
cond itions in  early  life w ere 
associa ted  w ith  increased risk o f  
m o r ta li ty .293 In  another study, 
ch ildhood  SE P  w as a  p red ic tor o f  
inc id en t d iabetes 294"295.
C h ildhood  SE P  m ay  be  an  N o, child  B M I status 
effec t m od ifie r o f  the does no t affec t
rela tionsh ip  betw een  ch ildhood  SE P
ch ildhood  B M I and d isease 
outcom es.
In a  F inn ish  sam ple , rap id  
B M I increase in  early  life  w as 
associa ted  w ith  hypertension  
in  adult life ; th is  effec t w as 
large am ong  ch ild ren  liv ing  in  
po o r social conditions, and 
sm all am ong  those liv ing  in 
good  liv ing  c o n d itio n s .183
C hildhood SE P  is 
associated w ith  ch ildhood  
BM I status and  adult 
d isease outcom e. T here 
m ay be  effect m odification  
o f  the association  betw een  
childhood B M I status and  
adult disease risk  by 
childhood SEP.
The effects o f  early  life 
SEP are  likely  to  act 
through m any o f  the o ther 
risk factors d iscussed  here , 
including birthw eigh t and 
childhood height.
A dult A d u lt SE P  is associa ted  w ith
socioeconom ic ch ildhood  B M I status (- +) 
position
A m ong  w om en, hav ing  a B M I 
> 90 th  cen tile  a t age 11 w as 
associa ted  w ith  3.5%  low er incom e 
a t age 23 ; th is effec t w as no t 
o bse rved  in  m e n .1
A du lt S E P  is associated  w ith m ost 
hea lth  ou tcom es 296 (++)
A m ong  A frican  A m erican w om en, 
inc idence  o f  type 2  d iabetes w as 28%  
h igher am ong  w om en w ith  <12 y 
edu ca tio n  com pared to those w ith 
> 17  y  education , 57%  higher for
T here is  no t m uch evidence 
that adu lt S E P  m odifies the 
rela tionsh ip  betw een  
ch ildhood  B M I and adult 
d isease 183 (- + ), bu t it has 
been  show n tha t obesity  is less 
likely  to  persis t from  
ch ildhood  in to  adulthood
Som e ev idence tha t 
ch ildhood  B M I sta tus 
can  affec t adult SEP  
am ong w om en.
In  fem ales, there  w as 
an  inverse re lationship  
betw een  obesity  at age
Low  SEP in  adulthood 
m ay be associated  with 
childhood overw eigh t and  
is a strong risk  fac to r for 
d isease outcom es. In 
w om en, adu lt SEP m ay be  
on  the causal pathw ay 
betw een ch ildhood  B M I
69
those w ith  househo ld  incom e am ong w om en w ith  a 16 and  earnings a t age status (specifically , in
< $15 ,000  com pared  to  >$100,000, un iversity  degree versus 23, independen t o f adolescence) and  adu lt
and  65%  h igher am ong those liv ing elem entary  degree . 298 It m ay paren tal social class disease. T here is no d irec t
in  low est q u in tile  o f  neighbourhood be expected  that an  individual and ch ildhood  ability evidence o f  effec t
SES com pared  to  the h ig h e s t.297 w ho has been  overw eigh t in 
ch ildhood  and  has low  SE P  in 
adulthood  m ay b e  m ore likely 
to  have an  adverse outcom e 
than an  ind iv idual w ho has 
been  overw eigh t in  childhood 
b u t has a  h igh  SE P  in 
adulthood.
test scores; th is effec t 
persis ted  regard less o f  
w hether w om en stayed 
obese or becam e lean 
(this re la tionsh ip  not 
seen am ong  m e n ) .140 
O besity  p re ­
ado lescence does not 
seem  to im pact on
m odification  b y  adu lt SEP, 
and an  effect independen t 
o f  adult B M I status seem s 
unlikely. T he  effec t o f  
SE P  on disease ou tcom es 
m ay b e  m ediated  by 
health-related  behaviours 
that are  m ore com m on in 
low  SE P  groups (such  as
adult S E P .141 sm oking).
A du lt sm ok ing  F ew  stud ies have  exp lo red  the 
behav iour associa tion  betw een  ch ildhood
obesity  and  ad u lt sm oking 
b eh av io u r (+). H ow ever, it  is 
know n tha t ch ild ren  o f  m others 
w ho  sm oke are  at g rea ter r isk  o f  
overw eigh t, 299 and th a t ch ild ren  
w hose paren ts are sm okers are  also  
m ore like ly  to  sm oke them selves. 
300-301 T htis it m ay be  expected  tha t 
th e re  w ill b e  an  associa tion  
betw een  ch ildhood  B M I sta tus and 
adu lt sm ok ing  behaviour.
S m oking  is a risk  factor fo r m ost 
d isease ou tcom es (++)
S m oking  is  a  r isk  factor for m any 
ch ron ic  d iseases 302 and m o rta lity .303 
E .g . sm ok ing  is  a  know n risk  factor 
fo r co ronary  heart d isease. 304
T here is no c lea r evidence that 
sm oking m odifies the 
rela tionsh ip  betw een  
ch ildhood  B M I sta tus and 
disease ou tcom es (—)
E.g. N o strong ev idence tha t 
survival is  d ifferen t betw een  
adult sm okers and  non- 
sm okers at sam e B M I, 305 nor 
fo r IH D  o r  s t r o k e .175
N o  d irec t ev idence that 
ch ildhood  B M I sta tus 
can  affec t adult 
sm oking behaviour, 
a lthough  po ten tia lly  
being  overw eigh t in 
ch ildhood  could  lead  to  
psychosocia l p roblem s 
w h ich  m ay m ake 
sm oking  m ore likely .
It m ay be expected  that 
childhood overw eigh t is 
associated w ith  adult 
sm oking, although  d irec t 
evidence fo r th is w as no t 
found. Sm oking is a 
strong risk  fac tor for m ost 
chronic d iseases, bu t does 
no t seem  to  be  an  effec t 
m odifier in  the rela tionsh ip  
betw een  B M I sta tus and  
disease. T he  absence o f  
evidence fo r effect 
m odification  is 
unexpected , bu t th is m ay  
be due in part to  issues o f  
statistical pow er in tests
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fo r interaction. 
Furtherm ore, sm oking  is 
associated w ith low  SEP, 
w hich is a  risk  factor for 
overw eight and  m any 
d isease outcom es.
C hild  height B M I is  no t independent o f  heigh t 
(++)
H eigh t and B M I at age 9  y show ed 
a linear associa tion  am ong ch ild ren  
in  th e  U S, w ith  each  1 cm  increase 
in  heigh t associa ted  w ith  0.18 
k g /m 2  increase  in  B M I 306. In  the 
N C D S  1958 B ritish  b irth  cohort, 
b e in g  ta lle r w as associa ted  w ith  
b e in g  o v erw eigh t a t age 11 y in  
b o th  g irls and b o y s .140
H eigh t is a r isk  fac to r fo r som e 
d isease ou tcom es o f  interest, 
a lthough  few  studies have addressed 
the associa tion  betw een childhood 
heigh t and  adu lt disease d irectly  (+)
In  a S co ttish  study, height w as 
inve rse ly  associa ted  w ith all cause, 
C H D , stroke, resp ira tory  disease and 
stom ach  cancer m ortality , bu t risk  o f 
co lo rec ta l and  prostate cancer 
m orta lity  increased  w ith heigh t 307. In 
a  study  o f  U S physicians, m en in  the 
ta llest he igh t ca tegory  (> 185.4) had  a 
35%  lo w er risk  o f  M I than m en in  the 
sho rtes t heigh t category  (<170.2) [R R  
0.65; 95%  C l 0 .4 4 -0 .9 9 ].308
C hildhood  heigh t and 
ch ildhood  B M I m ay in teract 
to affect ad u lt d isease risk  (+). 
E.g. A m ong overw eigh t 
children , be ing  ta lle r is 
associated  w ith  h igher B M I in 
young  adu lthood  (w hich 
affects risk  o f  d is e a s e )306
C hildhood  B M I is 
associated  w ith  heigh t, 
bu t the casual 
re la tionsh ips betw een  
these are unclear.
C hildhood heigh t is 
correlated  w ith childhood 
B M I, and is also  a risk  
factor fo r several d isease 
outcom es (heigh t is likely  
to be an  ind icator of/proxy 
for early  life exposures, 
e.g. nutrition). T he causal 
association  betw een  these 
variables is unknow n. 
T here m ay be  effec t 
m odification betw een 
childhood heigh t and  B M I, 
as children  w ho are tall 
and overw eigh t are m ore 
likely  to  be  overw eight 
a d u lts .306
Y ear o f  b irth  P revalence o f  ch ildhood
overw eigh t and  obesity  have 
increased  o v er tim e 309 and  over 
successive  coho rts 277 (++)
Y ear o f  b irth  is  a  risk  fac to r fo r m any 
d isease ou tcom es (+)
E .g . A ge standard ised  rates o f  b reast 
cancer and  colorectal cancer 
inc idence have increased over the 
pas t 4  decades, w hile stom ach and
Y ear o f  b irth  m ay m odify the N o, ch ildhood  B M I 
associa tion  betw een  ch ildhood  sta tus does no t affec t 
B M I and  adult d isease risk  (+) year o f  b irth .
T he p revalence o f 
card iovascu lar risk  factors, 
e.g. hypertension , have
Y ear o f  b irth  is associated  
w ith  ch ildhood  B M I sta tus 
and is also a risk  factor fo r 
d isease outcom es. T he 
relationship  betw een 
childhood B M I status and  
adult disease m ay be
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cerv ica l cance r have declined. decreased over tim e across all
BM I groups; the grea test 
reductions have been  observed 
am ong overw eigh t/obese 
groups, such  tha t the risk  
associated  w ith overw eigh t is 
low er for those b o m  m ore 
recen tly  than  fo r those bom  
e a r l ie r .311
f  BMI status; $ Disease outcomes; — No strong evidence; -+ Mixed evidence; + Indirect evidence; ++ Direct evidence
m odified by the yea r o f  
birth.
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4 .5  Definition o f  variables
4.5.1 Main outcome: obesity-related diseases
The main outcomes of interest in the main analyses were determined based on previous reviews 
of the literature.45 The comprehensive review conducted for the Foresight Obesities report 
identified that increasing body fatness was associated with type 2 diabetes, hypertension, 
coronary heart disease and stroke, respiratory problems, cancers, arthritis and liver and 
gallbladder disease.
For analysis, these outcomes were defined as binary measures (ever had/never had the 
condition), based on self-reported questionnaire responses. At each follow-up, an individual 
was classified as having a disease outcome of interest if they reported ever having had that 
disease, or treatment for that disease in response to direct questions about the outcome, e.g. 
“Have you ever had or been told you had asthma?” These responses were combined with 
information on self-reported long-standing illnesses, reasons for medical supervision or recent 
hospital admission, which were coded according to ICD-9 or ICD-10 codes. Although blood 
pressure data were available, cohort members were not classified as having hypertension on the 
basis of single casual measurements, which can be unreliable as indicators of hypertension.312 If 
an individual reported ever having had an outcome at an earlier wave but did not report it at a 
later wave, they were classified as having had the disease. If an individual provided 
questionnaire responses at a given wave but had missing data in response to a question about a 
specific illness, they were classified as not having the disease (unless they reported the outcome 
in a previous wave). In NSHD, diabetes was classified by a clinician at the MRC Unit for 
Lifelong Health and Ageing (Dr Mary Pierce), as type 1, type 2, gestational, unknown or 
unsure, according to use of medication and insulin, and age at diagnosis or diagnosis during 
pregnancy. For NCDS and BCS70,1 classified diabetes cases according to self-report of 
whether diabetes was insulin or non-insulin dependent, as reported at ages 42 (NCDS) or 30 y 
(BCS70); additionally, cases of type 2 diabetes were identified from ICD codes for self-reported 
long-standing illnesses at age 47 or 34 years (Table 4-5).
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Table 4-5: International Classification of Diseases (ICD) codes used in generating outcome variables
Outcome ICD classification
ICD-9 ICD-10
Asthma 493 J45
Gallbladder disease 574, 575 K80- K82
Hypertension 401,402 110,111
Type 2 diabetes 250 E11.E14
CHD 410-414 120-125
Stroke 430-432 161-164
Arthritis 715 M15-M19, M47
Colorectal cancer 153,154 C18-C20
Breast cancer 174,175 C50
Uterine cancer 182 C54, C55
Oesophageal cancer 150 C15
Liver cancer 155 C22
Kidney cancer 189 C64, C65
Individuals with any of the reported disease outcomes before age 20 years were excluded from 
analysis of that disease to account for pre-existing conditions which could have biased the 
outcome. Similarly, cohort members that had congenital defects related to the outcome, such as 
heart defect for coronary heart disease, were excluded from analyses of that outcome. The only 
exception was in the case of asthma, where cases reported before age 20 were included because 
the usual age of onset for asthma is in early childhood even though asthma relapse may occur in 
later life.313 Data on age at onset were available for varying numbers of respondents. For 
example, information on age at onset was available for 27.3% of cohort members who ever had 
hypertension, 409 out of 463 (88.3%) individuals with diabetes, and 168 out of 173 (97.1%) 
individuals with CHD.
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4.5.2 Main exposure: BMI categories
BMI categories (also referred to also as weight categories) were the main exposures of interest. 
Cohort members’ BMI values at each wave were categorised as: normal, overweight, or obese, 
and treated as ordered categorical data. In childhood and adolescence (age <19 years), weight 
categories were generated by applying IOTF definitions to BMI measurements 31 using the 
z b m ic a t command in Stata (authors: Vidmar, Carlin, Hesketh and Cole). BMI measurements 
before age 2 years were not included as exposure variables, as obesity is not typically 
recognised in this age group. In adulthood, these groups were defined according to BMI cut-off 
points proposed by the W HO3I4: normal (including underweight) <25 kg/m2, overweight 25- 
29.9 kg/m2, and obese >30 kg/m2. Underweight individuals (BMI <18.5) were not considered 
as a separate group in these analyses, as the aim was to explore the effects of overweight and 
obesity on excess or additional disease burden, relative to the rest of the population.
In NSHD, weight in underclothes and standing height without shoes were measured at ages 7 
(childhood) and 15 years (adolescence) by the school doctor. At age 43, standing height in 
centimetres and weight in kilograms were measured in a physical examination. In NCDS, 
childhood (age 7 y) height without shoes to the nearest inch or centimetre (cm), and weight in 
underclothes to the nearest pound were measured in a medical examination. Height was 
measured using a pocket stadiometer, which was issued to schools. Adolescent (age 16 y) height 
in bare feet was measured to the nearest inch or cm using a steel or wooden measuring rod, or if 
not available, a steel tape measure; weight in underclothes was recorded to the nearest pound, or 
in kilograms (kg) to two decimal places using a beam balance or other weighing apparatus, as 
available. At age 42 years, height and weight were self-reported by respondents in a computer 
assisted interview. In BCS70, height to the nearest 0.1 cm and weight to the nearest gram were 
recorded by the school nurse at ages 10 and 16 years. Height was measured using a steel or 
wooden measuring rod or steel tape measure, or if not available, the stadiometer on the back of 
a weighing machine. Weight was measured using a beam balance or other weighing apparatus. 
At age 34, respondents self-reported their weight in either kilograms or stones and pounds, and 
height in metres and centimetres or feet and inches in a computer assisted interview.
BMI was calculated as weight in kilograms divided by height in metres squared. Height and 
weight data reported in imperial measurements were converted to metres and kilograms using 
the conversion factors shown in Table 4-6. Height and weight data were plotted and checked 
for extreme values.
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Table 4-6: Conversion factors for weight and height -  imperial to metric measurements
Imperial Metric
1 foot 0.3048 metres
1 inch 0.0254 metres
1 stone 6.3503 kilograms
1 pound 0.4536 kilograms
4.5.3 Birth weight
Birth weight was included as a potential confounder, as several studies indicated that low birth 
weight (< 2,500 grams) was a risk factor for a number of adverse health outcomes, including 
components of the metabolic syndrome and coronary heart disease and stroke, as 
well as being correlated with BMI in later life. Birth weights to the nearest ounce were 
extracted from birth records, and were converted to grams (using conversion factor 28.3495).
4.5.4 Year o f birth
The potential effect of calendar time or cohort on the association between BMI/weight category 
and disease outcomes was assessed by testing for interaction by year of birth (1946, 1958, 
1970).
4.5.5 Sex
Sex was extracted from baseline survey data. Sex is a potentially important effect modifier in 
the relationship between weight status is early life and disease outcome in later life. This effect 
was assessed by the inclusion of interaction terms.
4.5.6 Exact age a t measurement
Exact age at height and weight measurement was calculated using date of birth and the date of 
measurement. Where these data were unavailable (exact age at measurement could not be 
calculated for 15.9% of participants), mean age at measurement for other cohort members in the 
wave was used as the imputed value. Imputation using the group mean can be problematic as 
this approach can lead to underestimation of the standard deviation,317 but this approach did not 
seem unreasonable given that these were birth cohorts with data collection in waves and 
therefore ages did not vary greatly at any given data collection point.
4.5.7 Multiple births
The NSHD 1946 cohort included only singleton births. Multiple births are more likely to be 
preterm and of low birthweight than singleton births,318 and are at increased risk of consequent 
developmental and health problems. To ensure comparability of analyses across cohorts, those 
cohort members who were multiples at birth were excluded from analysis of the 1958 and 1970 
cohorts.
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4.5.8 Ethnicity
For these analyses, ethnicity was originally classified into five broad categories: 1) 
White/European; 2) Black African/Caribbean; 3) Indian/Pakistani/other South Asian; 4) Other; 
5) Mixed. Self-identified ethnicity at ages 42 or 33 years was used preferentially over assigned 
ethnicity (at ages 11 or 16 years) where this information was available.319 Ethnic minority 
groups (non-White) were later grouped into a single category and ethnicity treated as a binary 
variable in the main analyses, due to small numbers in some of the categories. Information on 
ethnicity was not available for the NSHD cohort, although it can be assumed that <1% of the 
population would be from ethnic minority groups.320
4.5.9 Socioeconomic position
Socioeconomic position (SEP) is an important potential confounder of the relationship between 
early life weight status and later health, 297 as SEP is associated with both the likelihood of 
being overweight50 53 and with many of the disease outcomes of interest. Indicators of 
socioeconomic position include education, housing tenure/conditions/amenities, income, and 
occupation based measures. 321-322
The British National Birth Cohorts had data on occupation, education, income and housing 
characteristics. There were also various derived occupation based measures, including the 
Registrar General’s Social Class (RGSC), Social Class based on occupation (SC), socio­
economic group (SEG) and the National Statistics Socio-economic Classification (NS-SEC).
For this study, occupation was categorised using the six-category RGSC classifications: i) 
Professional; ii) Managerial/technical; iiia) Skilled (non-manual); iiib) Skilled (manual); iv) 
Partly skilled; and v) Unskilled, to ensure comparability across waves. SEP in early life has 
been shown to predict health outcomes in adulthood. 323-324 Cohort members were assigned a 
childhood social class based on the occupation of their father (or head of household if not the 
father) at birth. In cases where this information was missing, father’s occupation at the earliest 
wave available in childhood was used. If there was no information on father’s occupation at 
any age in childhood, mother’s occupation was used. Social class in adulthood was categorised 
using the current/most recent occupation of the respondent.
4.5.10 Smoking behaviour
Smoking is a potential confounder of the association between weight status and health 
outcomes. 302 Current smoking behaviour of each individual was categorised into three groups:
1) Never smoked, 2) Ex-smoker (cohort member previously smoked at least one cigarette per 
day for 12 months or longer), and 3) Current smoker. Smoking status was defined according to 
participants’ responses to the question, ‘Have you ever smoked cigarettes regularly? By 
regularly, I mean at least one cigarette a day for 12 months or more.’ Reported smoking status at
last follow-up (in adulthood) was used. If missing, smoking status at the previous wave was 
used (last observation carried forward) to maximise the data.
4.5.11 Height
In children, BMI is not independent of height, and it has been suggested that BMI may 
consequently overestimate overweight and obesity in taller children. As a result, a common 
approach has been to further adjust for height. 141
4.5.12 Other considerations
In a small number of cases where the cohort member was unable to participate in an interview 
or complete a self-administered questionnaire, short proxy interviews were undertaken with a 
family member or carer. These interviews covered the same general topics as the cohort 
member interviews, but in less detail. Proxy responses (n=53) were excluded from these 
analyses as these data were less complete and subject to different biases than self-reported data.
4.6 Missing data
Missing data are commonly encountered in research, but are particularly an issue in longitudinal 
studies such as the British National Birth Cohorts, which follow participants over tim e.325 
Missing data present a potential source of bias, as participants who remain in a study may be 
different to those who drop out with respect to variables that are relevant to the analysis. For 
example, if overweight participants who suffer from ill health are more likely to drop out of a 
study than those in good health, an analysis of only those remaining in the study may 
underestimate the impact of weight status on disease outcomes.
There is no universal method for handling missing data, as the missingness mechanism (the 
reasons why observations become missing) is usually unknown; analysis of missing data 
requires additional assumptions to be made, which cannot be tested using the data. The 
sensitivity of the conclusions to different assumptions therefore needs to be investigated.326 
There are a number of ad-hoc ways to deal with missing data, including complete case analysis, 
simple mean imputation, regression mean imputation, creating an extra category for missing 
values and last observation carried forward (LOCF). 317 Other methods for analysis of missing 
data include multiple imputation and inverse probability weighting, maximum likelihood 
methods, and probability weighting.327
In order to maximise the available data, last observation carried forward was used for 
socioeconomic position, smoking behaviour, and outcomes in adulthood, as described above.
As a sensitivity check, a complete case analysis excluding those individuals with incomplete 
data was carried out and compared with LOCF results.
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4.7 Statistical analysis
Following analysis of each cohort separately, individual level data from the three British 
National Birth Cohorts (NSHD 1946, NCDS 1958, and BCS70 1970) were pooled for the main 
analyses. This was considered to be reasonable given the similarities in study design and target 
populations among these cohorts, as described in Chapter 5, and on inspection of the odds ratios 
from analysis of individual cohorts. Tests for homogeneity of odds ratios from Mantel- 
Haenszel estimates controlling for cohort indicated that ORs (for main effects) were not 
statistically different, except in the case of hypertension and combined disease outcomes. 
Further inspection of ORs for hypertension showed that these were similar for NCDS (OR 1.74, 
95% Cl 1.44, 2.11) and BCS70 (2.22, 95% Cl 1.54, 3.20), with no association observed in 
NSHD (OR 0.93, 95% Cl 0.75, 1.14). The same pattern was observed for the composite disease 
outcome; given the smaller sample size of NSHD, it was thought that pooled analyses for these 
outcomes would not be unreasonable. Variables for the pooled analysis were harmonised across 
the datasets and these were appended to create the pooled dataset. Data on asthma outcome in 
adulthood were available only for NCDS and BCS70. Throughout the thesis, I refer to 
conventional levels of statistical significance as p<0.05, although interpretation of results does 
not necessarily rely on this cut-off. All data management and statistical analyses were 
performed using Stata SE, version 12.1 (StataCorp, TX, USA).
Data collected at three life stages were used: childhood, adolescence and adulthood (age at 
adulthood corresponds to the last age for which data were available, and is also referred to as 
‘current age’). For NSHD, BMI data at ages 7, 15 and 43 years were used, with disease 
outcomes measured at age 53 years; for NCDS, BMI at ages 7, 16 and 42 years, and disease 
outcomes measured at age 47 years; for BCS70, BMI at 10,16 and 34 years, and disease 
outcomes at age 34 years. A variable for birth cohort was generated and included as an 
additional key covariate in the analyses. All covariates and their relationships to the key 
variables were described. Analyses were restricted to singleton births, and in the main analyses 
modification of the main effects by sex and cohort was assessed by the inclusion of interaction 
terms. Study participants who experienced the outcome of interest before age 20 (pre­
adulthood) were excluded for those analyses, except in the case of asthma, for which individuals 
who were diagnosed in childhood were included. The weighted sample design in NSHD 
(sampling of all births to women with husbands in non-manual or agricultural jobs and lA of 
births to women with husbands in manual jobs) was accounted for by applying sampling 
weights to the dataset, using the p w e ig h t command in Stata.
For the main analysis, two main approaches to analysis were adopted; the first approach used a 
series of logistic regression models of increasing complexity to model different life course 
effects (referred to as the ‘stepwise’ approach), while the second compared relative risks of
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disease for different combinations of overweight over the life course (the ‘overweight patterns’ 
approach). Each of these is described in detail below.
4.7.1 The Stepwise approach
In the stepwise approach, logistic regression analyses were carried out to assess the association 
between weight category (normal, overweight or obese) at different life stages (childhood, 
adolescence and adulthood) and each disease outcome of interest. A series of models was fitted, 
with adjustment for potential confounders and effect modifiers in stages (selected a priori, see 
Table 4-4). The approach was based on that proposed by Lucas, Fewtrell and Cole (1999),231 
which seeks to disentangle early and later life effects of body size on adult disease through a 
series of regression models:
1) Early Model -  regression used to relate early size to outcome;
2) Combined Model -  adds later size to the early model;
3) Interaction Model -  adds the interaction of early and later size to the combined model; and
4) Late Model -  regression used to relate later size to outcome, to help interpretation of the 
relative importance of early and later size independently and in combination.
Adjustment for covariates was in two stages, ‘early’ and ‘late’, according to the point in the life 
course at which they were considered to have an effect. Based on the proposed causal DAG for 
the relationship between childhood BMI status and generic adult disease, it was shown that a 
sufficiently adjusted model could be achieved by adjusting for birth weight, childhood SEP, 
ethnicity and sex. Due to the small proportion of ethnic minority groups (4%) there was no 
adjustment for ethnicity; analyses were stratified by sex. The goodness-of-fit for each model 
was assessed using a Hosmer-Lemeshow test adjusted for survey data.328 The analyses were 
repeated using BMI instead of weight category, yielding an estimate of the relative risk of each 
disease outcome associated with a one unit increase in BMI (kg/m2). In each model, all 
available cases were used to maximise the data. The main outcome measures were reported as 
odds ratios with 95% confidence intervals, stratified by sex. The models are described in more 
detail in Chapter 6.3.
4.7.2 The 'Overweight patterns' approach
The ‘Overweight patterns’ approach was based on that adopted by Mishra et al, 269 in their 
analysis of the effects of SEP over the life course on BMI in adulthood in the NSHD cohort, as 
an alternative approach to standard adjustment. Similar methods have been used by Merten 217 
in his study of weight status in adolescence and asthma, diabetes, hypertension and high 
cholesterol in early adulthood among participants in the US National Longitudinal study of 
Adolescent Health, and by Viner and Cole in their study of childhood obesity and adult 
socioeconomic, educational and psychological outcomes in the BCS70 cohort.141 In these
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studies, different combinations of a binary exposure over the life course were treated as the 
exposure variables, to represent different life-course histories.
A similar categorisation of exposures was used in this thesis in an attempt to determine the 
effects of different life course exposures and to assess the relative contribution of BMI status at 
different stages of the life course to disease outcomes. Cohort members were categorised into 8 
groups, according to weight status in each of childhood, adolescence and adulthood. Weight 
status referred to whether cohort members were normal weight or overweight in childhood and 
adolescence, where overweight included overweight and obesity as defined by IOTF BMI cut­
offs, 31 and nonobese or obese in adulthood, as defined by WHO cut-offs.314 Overweight and 
obesity in childhood were combined for these analyses because of the low prevalence of obesity 
in childhood and adolescence in these cohorts. Cohort members were categorised as follows:
Table 4-7: Categorisation of overweight patterns according to overweight/obesity in childhood, adolescence and 
adulthood
Overweight pattern Weight status
Childhood Adolescence Adulthood
Never overweight 0 0 0
Childhood only 1 0 0
Adolescence only 0 1 0
Adulthood only 0 0 1
Childhood + adolescence 1 1 0
Childhood + adulthood 1 0 1
Adolescence + adulthood 0 1 1
Persistent overweight 1 1 1
In childhood and adolescence, 0= normal weight; l=overweight or obese. In adulthood, 
0=nonobese; l=obese.
For each disease outcome, a logistic regression model was specified to calculate odds ratios of 
the outcome and 95% confidence intervals for each overweight pattern, with never overweight 
as the reference category. These models were adjusted for sex, year of birth, exact age at 
measurement of childhood weight and height, birth weight, SEP at birth, SEP in adulthood, and 
smoking status in adulthood. Coefficients for different patterns of overweight were compared 
using an adjusted Wald test.
As an extension of the overweight patterns approach, sensitive period and accumulation of risk 
models 269 were explored to assess whether overweight or obesity at particular life stages, or the 
number of life stages exposed to overweight or obesity was associated with disease outcomes.
In these analyses, individuals were categorised according to the life stages (sensitive periods) at 
which they were exposed to overweight or obesity (Table 4-8), and the number of life stages at
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which they were overweight (accumulation of risk score). For each sensitive period, logistic 
regression models were specified to calculate odds ratios of disease outcomes for overweight in 
the sensitive period and overweight in any other periods, compared to a reference category of 
never overweight. Coefficients for overweight in each sensitive period and overweight in the 
other periods were compared using an adjusted Wald test. The accumulation of risk model 
compared odds of disease for exposure at each number of time points to odds for never 
overweight. Tests for trend of odds were carried out to assess whether there was a relationship 
between the increasing exposure and disease outcomes. As above, these analyses were adjusted 
for sex, year of birth, exact age at measurement of childhood weight and height, birth weight, 
SEP at birth, SEP in adulthood, and smoking status in adulthood.
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Table 4-8: Categorisation of overweight patterns according to sensitive periods of overweight/obesity and 
accumulation of risk
Life course hypothesis Overweight patterns 
Sensitive period
Child 1 ,0 ,0 Childhood only
1 ,1 ,0 Childhood+adolescence
1,0,1 Childhood+adulthood
1,1,1 Persistent overweight
Other periods 0, 1,0 Adolescence only
(not childhood) 0 ,1 ,1 Adolescence+adulthood
0 ,0 ,1 Adulthood only
Adolescent 0 ,1 ,0 Adolescence only
1, 1,0 Childhood+adolescence
0 ,1 ,1 Adol escence+adulthood
1,1,1 Persistent overweight
Other periods 1 ,0 ,0 Childhood only
(not adolescence) 1,0, 1 Childhood+adulthood
0, 0,1 Adulthood only
Adult 0, 0, 1 Adulthood only
1,0,1 Childhood+adulthood
0 ,1 ,1 Adolescence+adulthood
1,1,1 Persistent overweight
Other periods 1 ,0 ,0 Childhood only
(not adulthood) 0 ,1 ,0 Adolescence only
1 ,1 ,0 Childhood+adolescence
Accumulation of risk
1 time point 1 ,0 ,0 Childhood only
0, 1,0 Adolescence only
0, 0, 1 Adulthood only
2 time points 1. 1,0 Childhood+adolescence
1,0, 1 Childhood+adulthood
0 ,1 ,1 Adolescence+adulthood
3 time points 1,1,1 Persistent overweight
In childhood and adolescence, 0= normal weight; l=overweight or obese. In adulthood, 
0=nonobese; l=obese.
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As a sensitivity check, the analyses were re-run under the following conditions: 1) Excluding 
ethnic minority groups, 2) Adjusting BMI measurements for self-reported weight and height; 
the sex- and BMI-specific adjustments in Table 4-9 were used to account for underreporting of 
weight and overreporting of height, as observed in a sample of men and women aged 35-76 in 
England, 329 3) Complete case analysis, including only those cohort members with complete 
data on all variables, and 4) Survival analysis using Cox regression models for time to event 
data; time to event results were not treated as the primary outcomes in order to maximise the 
data.
Table 4-9: Sex- and BMI-specific adjustments used to account for self-reported weight and height in adulthood. 
Source: Spencer et al (2002) "Validity of self-reported height and weight in 4808 EPIC-Oxford participants" Public 
Health Nutrition 5(04): 561-565.
BMI
category
BMI adjustment (kg/m2)
(kg/m2) Men Women
<20 -0.61 -0.19
20-24.9 +0.60 +0.44
25-29.9 +1.02 +0.96
>30 +1.66 +1.35
4.7.3 Power calculations
Consideration of power issues informed the interpretation of results, and the limitations 
associated with these are discussed in the following chapters. Power calculations were 
performed and are presented for selected outcomes in Table 4-10. Calculations were based on 
methods for logistic regression with binary interaction (between obesity in childhood and 
obesity in adulthood) as described by Demidenko (2008).330
The assumptions in these calculations were based on estimates from analyses of the cohort data:
-  Prevalence of obesity in childhood (age 10 years) is 2%
-  Prevalence of obesity in mid-adulthood (age 40 years) is 20%
-  OR of obesity in adulthood given obesity in childhood is 3
-  alpha=0.05
-  Minimum detectable OR of interaction effect=1.5 
Hypertension
-  OR of hypertension associated with childhood obesity is 2 (unadjusted)
-  OR of hypertension associated with obesity in adulthood is 4
-  Prevalence of hypertension is 17%
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Type 2 diabetes
-  OR of type 2 diabetes associated with childhood obesity is 4 (unadjusted)
-  OR of type 2 diabetes associated with obesity in adulthood is 10
-  Prevalence of type 2 diabetes is 2%
Disease (all outcomes combined)
-  OR of disease associated with childhood obesity is 1 (unadjusted)
-  OR of disease associated with obesity in adulthood is 2.5
-  Prevalence of disease is 30%
Table 4-10: Study power for different sample sizes under combined model for hypertension, type 2 diabetes and 
all disease outcomes combined (unadjusted)
Cohort Size Power (%)
Hypertension Type 2 diabetes Disease
5,000 14 10 15
10,000 24 16 26
15,000 34 21 37
20,000 43 27 46
25,000 52 32 55
50,000 81 57 84
90,000 97 81 98
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5. DESCRIPTION OF THE BRITISH NATIONAL BIRTH COHORT DATA
In this chapter, the British National Birth Cohort data 252-254 are explained in more detail, and the 
results of descriptive analyses are reported. Overviews of the patterns of response, data 
collection, and characteristics of the study cohorts are presented. BMI trajectories over the life- 
course, patterns of overweight, and key relationships between the variables of interest are 
explored, and differences in these characteristics between the three cohorts are examined.
5.1 Patterns o f response
Of the 5,362 births in NSHD, 4,956 cohort members contributed data at more than one wave 
(406 cohort members present at baseline were not observed again). All cohort members were 
singleton births. The patterns of response to 11 waves of the survey (ages 2 to 53 years) are 
shown in Table 5-1. A fifth of cohort members (20.1%) contributed some data at all 11 waves, 
but patterns of response were varied. At age 53 years, some data were available for 2,948 
cohort members.
Table 5-1: Patterns of response to NSHD 1946 waves 1-11 for cohort members with >1 follow-up; T '  indicates 
that some data are available at that wave; '0' Indicates that there are no data available
Pattern Frequency Percent
11111111111 994 20.06
11111111000 184 3.71
01111111111 167 3.37
11111011111 145 2.93
11111111110 142 2.87
111111.1111 141 2.85
11111110000 139 2.80
11111100000 103 2.08
10000000000 71 1.43
other patterns 2870 57.91
total 4956 100.00
In NCDS, 18,558 cohort members were observed, of whom 17,638 were present at baseline 
(additional children bom in the same week who immigrated to the UK were recruited to the 
study in later waves n=920). The patterns of response to the first 8 waves of the NCDS (ages 0- 
46) are shown in Table 5-2. More than a third of cohort members (37.3%) contributed some
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data at all waves. The second most common pattern of response (18.8%) was for cohort 
members to have data at the first 4 waves, and to be lost to follow-up after age 16 years. At age 
46, some data were available for 9,534 cohort members; 1,240 cohort members had died, 1,306 
had emigrated, 612 refused to participate, and 4,893 were lost to follow-up.331 428 stillbirths, 
abortions and early neonatal deaths, 590 pre-term births (gestational age <36 weeks), 357 
multiple births and 3 cohort members of unknown sex were excluded from the main analyses, 
for reasons explained in Chapter 4.5.
Table 5-2: Patterns of response to NCDS1958 waves 0-7 for cohort members with >1 follow-up; '1' indicates that 
some data are available at that wave; '0' Indicates that there are no data available
Pattern Frequency Percent
11111111 6924 37.32
11110000 3492 18.82
11111000 1522 8.20
11111110 1382 7.45
11110111 913 4.92
11111100 863 4.65
11111011 638 3.44
11111010 355 1.91
11110110 309 1.67
other patterns 2157 11.62
total 18555 100.00
In BCS70 (data downloaded from UK Data Archive, University of Essex 332'338), 18,126 cohort 
members were observed, of whom 16,567 were present at baseline. Data at more than one wave 
were available for 15,832 cohort members. The patterns of response to the 7 waves of BCS70 
(ages 0-34) are shown in Table 5-3. More than a quarter of cohort members (26.1%) 
contributed some data at all 7 waves of the study. The second and third most common patterns 
of response (8.6% and 6.8% respectively) were to have data missing at wave 4 (age 26), or to be 
lost to follow-up after age 16 years. At age 34 some data were available for 9,665 cohort 
members; 800 cohort members had died, 451 had emigrated, 1,393 refused to participate, and 
4,962 were lost to follow-up. 223 prenatal and neonatal deaths, 748 pre-term births and 236 
multiple births were excluded from analyses.
Table 5-3: Patterns of response in BCS70 waves 0-6, for cohort members with >1 follow-up; '1' indicates that 
some data are available at that wave; '0' Indicates that there are no data available
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Pattern Frequency Percent
1111111 4129 26.08
1111011 1363 8.61
1111000 1078 6.81
1110000 930 5.87
1110111 720 4.55
1111110 664 4.19
1111010 510 3.22
1011111 439 2.77
1110011 419 2.65
other patterns 5580 35.25
total 15832 100.00
Study response rates (as percentage of target sample) in the three cohorts can be seen in Figure 
5-1. Response rates in NSHD and NCDS decreased in a relatively regular fashion over time, 
while in BCS70 they fluctuated, with notably low response rate of 55% at age 26 years. In 
general, retention rates in NSHD and NCDS were higher than in BCS70 for any given age. For 
example, at age 15/16 years, the response rates in NSHD and NCDS were 89% and 87% 
respectively, compared to 70% in BCS70. At the final wave of each study, response rates were 
67% for NSHD. 63% for NCDS, and 64% for BCS70. Analysis of the characteristics of non­
respondents indicated that males, cohort members from lower socioeconomic positions, and 
individuals from ethnic minority backgrounds were more likely to be lost to follow-up. v">
figure 5-1: Longitudinal response rates by age in NSHD, NCDS and BCS70
Age (years)
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5.2 Data collection m ethods
Data collection methods for the key variables in each cohort are summarised in Table 5-4, Table 
5-5 and Table 5-6. In childhood and adolescence, all cohorts used a combination of maternal 
interview, medical records and health visitor examinations to collect information on weight, 
height, health and social class. Childhood and adolescent weight and height were measured by a 
trained assessor (doctor, nurse or health visitor). In adulthood, both self-completed and 
interviewer-administered (face-to-face or telephone) techniques were used for data collection, 
resulting in a combination of self-reported and measured variables. Notably, weight and height 
were self-reported at wave 7 of NCDS (age 41/42 years), and at all ages in adulthood in BCS70. 
Analyses were rerun using BMI adjusted for self-reported height and weight 329 as a sensitivity 
check. In NCDS and BCS70, computer-based methods, including computer assisted personal 
interviewing (CAPI) and computer aided self-interviewing (CASI)340 were used in recent waves 
of data collection. Health outcomes in adulthood were self-reported, either using self-completed 
postal questionnaires (NSHD) or interviewer-administered questionnaires (NCDS and BCS70). 
The key variables included in the main analyses and the methods used to collect this 
information are described in the following sections.
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Table 5-4: Data collection in MRC NSHD (1946)
Y e a r A ge
(y)
D a ta  co llec tion  
m e th o d
N W e ig h t 
&  h e ig h t
D isease
o u tco m es
S E P S m o k in g
1946 0 M atln t 5 ,362 bw N /A PaO cc
(Parln t)
N /A
1948 2 M atln t+  
reco rds+  HV 
assessm ent
4 ,689 M N /A N /A N /A
1950 4 M atln t+  
reco rds+  H V  
assessm ent
4 ,700 M N /A PaO cc
(Parln t)
N /A
1952 6 M atln t+  
reco rds+  
m edical exam
4,603 M N /A N /A N /A
1953 7 M edical exam 4,480 M N /A N /A N /A
1957 11 M atln t+  
m edical exam
4,281 M N /A PaO cc
(Parln t)
N /A
1961 15 M atln t+  
m edical exam
4,274 M N /A PaO cc
(Parln t)
N /A
1966 20 SCQ 3,899 SR N /A N /A C urren t sm oker
1971 25 SCQ 3,307 N /A N /A N /A N /A
1972 26 SCQ 3,604 SR SCQ C urrentO cc
(SC Q )
N /A
1977 31 SC Q + physical 
exam
N /A SC Q N /A C urrent sm oker; 
eve r sm oked
1982 36 SC Q + physical 
exam
3,322 M SC Q C urrentO cc
(SC Q )
C urren t sm oker; 
eve r sm oked
1989 43 SC Q + physical 
exam
3,262 M SCQ C urrentO cc
(SC Q )
C urren t sm oker; 
ever sm oked
1999 53 SC Q + physical 
exam
3,035 M SCQ C urrent sm oker; 
eve r sm oked
M atln t =  M aternal in terview ; SCQ  = self-com pleted  questionnaire; bw =  b irth  w eight; M =  m easured; SR
=  self-reported ; P aO cc =  father’s (or m ale H ead o f  H o u seh o ld ’s) occupation; C urrentO cc current 
occupation; H V  = health  v isito r
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Table 5-5: Data collection in NCDS (1958)
Y e a r A ge
(y)
D a ta
co llec tio n
m e th o d
N W e ig h t 
&  h e ig h t
D isease
o u tco m es
S E P E th n ic ity S m o k in g
1958 0 M atln t +  
reco rds
17,415 bw N /A PaO cc
(Parln t)
N /A N /A
1965 7 P arln t + 
m edical 
exam
15,051 M M edical 
h isto ry  and 
exam ination
PaO cc
(Parln t)
N /A N /A
1969 11 P arln t + 
m edical 
exam
14,757 M M edical 
h isto ry  and 
exam ination
PaO cc
(Parln t)
N /A N /A
1974 16 P arln t +
m edical
exam
13,917 M M edical 
h isto ry  and 
exam ination
PaO cc
(Parln t)
N /A C urrent 
sm oker, ever 
sm oked
1981 23 C M Int 12,044 SR C M Int C urrentO cc
(C M Int)
N /A C urren t 
sm oker, ever 
sm oked 
regularly*
1991 33 C M Int + 
SC Q
10,986 M C M Int C urrentO cc
(C M Int)
C M Int C urrent 
sm oker, ever 
sm oked 
regularly
1999/
2000
4 1 /
42
C A P I + 
C A SI
10,979 SR C A PI C urrentO cc
(C A PI)
SR C urrent 
sm oker, ever 
sm oked 
regularly
2004 /
2005
46 /
47
C A T I 9,534 M C A T I C urrentO cc
(C A TI)
N /A C urrent 
sm oker, ever 
sm oked
M atln t =  M aternai in terview ; P arln t =  Parental in terview ; C M Int =  cohort m em ber in terv iew ; SC Q  =  self- 
com pleted  questionnaire; C A PI = com puter assisted  personal in terview ing; C A SI =  com puter aided  se lf­
in terview ing; C A T I = com puter assisted te lephone in terv iew ing; bw  =  b irth  w eight; M  =  m easured ; SR  = 
self-reported; P aO cc =  father’s (o r m ale H ead  o f  H ouseho ld ’s) occupation ; C urren tO cc =  curren t 
occupation; * R egular sm oking defined as sm oking a t least one cigarette a day  fo r 12 m onths o r  longer
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Table 5-6: Data collection in BCS70 (1970)
Y ea r A ge
(y)
D a ta
co llec tion
m e th o d
N W e ig h t 
&  h e ig h t
D isease
o u tco m es
S E P E th n ic ity S m o k in g
1970 0 M atln t +
m edical
reco rds
16,571 bw N /A PaO cc
(Parln t)
N /A N /A
1975 5 M S Q  + 
P arln t + 
health  
reco rds
12,981 N /A P arln t PaO cc
(Parln t)
P arln t N /A
1980 10 M S Q  + 
P arln t + 
m edical 
exam
14,350 M P arln t and 
exam ination
PaO cc
(Parln t)
P arln t N /A
1986 16 M SQ  + 
P arln t +  
SC Q  + 
m edical 
exam
11,206 M P arln t, SCQ  
and
exam ination
PaO cc
(Parln t)
P arln t N /A
1996 26 SC Q 8,654 SR SCQ C urrentO cc
(SC Q )
N /A C urrent 
sm oker, ever 
sm oked
1999/
2000
30 C A PI + 
C A SI
10,833 SR C A PI C urrentO cc
(C A PI)
SR C urrent 
sm oker, ever 
sm oked 
regularly*
2004 /
2005
34 C A PI 9,665 SR C A PI C urrentO cc
(C A PI)
SR
M atln t =  M aternai in terview ; M SQ  = m aternal se lf-com pleted  questionnaire ; P arln t = Parental in terview ; 
C M Int =  cohort m em ber in terview ; SC Q  =  se lf-com pleted  questionnaire ; C A PI =  com puter assisted
personal in terv iew ing; C A SI =  com puter aided se lf-in terv iew ing; C A T I =  com puter assisted  telephone 
in terview ing; bw  = birth  w eight; M  = m easured; SR  =  se lf-reported ; PaO cc =  father’s (o r  m ale H ead  o f  
H ouseho ld ’s) occupation ; C urren tO cc =  curren t occupation ; * R egu lar sm oking defined  as sm oking at 
least one cigarette  a  day  fo r 12 m onths o r longer
5.3 BMI from height and w eight m easures
BMI data were available for 3,977 cohort members at age 7 in NSHD and 2,948 cohort 
members at age 53 (Table 5-8). In NCDS, BMI data were available for 12,985 cohort members 
at age 7 and 11,086 cohort members at age 42. In BCS70, BMI data were available for 11,283 
individuals at age 10 and 8,799 at age 34, with only 5,365 cohort members contributing data at 
age 16.
5.3.1 BMI distributions
Visualisation of BMI distributions using histograms showed that the distribution at each wave 
of NSHD was positively skewed. The variance and skewness of the BMI distribution increased 
with age (Figure 5-2). Similar patterns were observed in NCDS and BCS70 (Figure 5-3 and
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Figure 5-4), although more extreme values at the upper end of the distribution were observed in 
adulthood in these cohorts (Figure 5-5).
Figure 5-2: BMI distribution at ages 7,11,15, 26,36 and 53 in MRC NSHD
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Figure 5-3: BMI distribution at ages 7,11, 16, 23, 33 and 45 in NCDS
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Figure 5-4: BMI distribution at ages 10,16, 26, 30 and 34 in BCS70
s “O
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Figure 5-5: Box and whisker plot of BMI distribution in childhood, adolescence and adulthood for NSHD, NCDS 
and BCS70 cohorts.
Box represents interquartile  range (IQR); w hiskers represent upper and low er adjacent values 
(±1.5 x IQR). chbm i=BM I in ch ildhood, adolbm i=BM I in adolescence, adbm i=BM I in adulthood.
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5.3.2 BMl trajectories
Piecewise linear random coefficients models were applied to analyse the repeated measures of 
BMI for each cohort, and the coefficients from these models were examined to assess 
differences between BMI trajectories. Models were specified to start from age 7 years to avoid 
the adiposity rebound which usually occurs at around age 6 years,341 prior to which many non­
linear changes in adiposity occur (illustrated in Figure 5-6 using data from the 1946 NSHD 
cohort). Knots were selected at 16 years, and were used for all cohorts to ensure comparability. 
Models were tested for random effects and non-linearity.
Figure 5-6: Mean BMI for male cohort members from age 2 to 53 years in 1946 NSHD cohort
Figure 5-7 and Figure 5-8 show the observed means and estimated trajectories of BMI in the 
three cohorts, among males and females respectively. These plots show that BMI increase was 
faster in childhood (age <16 years) than in adulthood in all cohorts (p<0.01) (Table 5-7). 
Likelihood ratio tests indicated a linear trend in BMI gain in childhood, and in adulthood among 
females in NCDS, but a quadratic trend in adulthood for males in all three cohorts, and females 
in NSHD and BCS70. These results illustrate that mean BMI at any given age in adulthood 
increased with successive cohorts, hut this trend was not apparent in childhood. Comparison of 
the estimated BMI trajectories also revealed that the rate of BMI increase in adulthood increased 
with successive cohorts in both sexes, e.g. among females, BMI gain was at 0.083 kg/m' per 
year in NSHD, 0.211 in NCDS, and 0.337 in BCS70 (although slowing down with age, as 
indicated by the negative coefficient for the quadratic term) (Table 5-7).
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Figure 5-7: Estimated BMI trajectories and observed mean BMI at various ages for male cohort members in 1946 
NSHD, 1958 NCDS and 1970 BCS70. Knots are at 16 years.
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Figure 5-8: Estimated BMI trajectories and observed mean BMI at various ages for female cohort members in 
1946 NSHD, 1958 NCDS and 1970 BCS70. Knots are at 16 years.
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Table 5-7: Parameter estimates for 1946 NSHD, 1958 NCDS and 1970 BCS70 cohorts from piecewise linear model. 
Knot at 16 years.
P a ra m e te r
effec ts
M R C  N S H D N C D S B C S70
(fixed  effec ts)
C o e ffic ien t 9 5 %  C l C o e ffic ien t 9 5 %  C l C o e ffic ien t 9 5 %  C l
M a les
In tercep t 11.59 11.46, 11.71 12.25 12.15, 12.34 9.93 9 .7 4 ,1 0 .1 2
A ge 0.568 0 .5 5 6 ,0 .5 7 9 0.493 0.484, 0.501 0.675 0 .6 5 8 ,0 .6 9 2
(childhood*)
A ge (adult) 0 .280 0.270, 0.290 0 .424 0.414, 0.434 0.627 0 .6 0 7 ,0 .6 4 8
A ge2 (adult) -0 .003 -0 .003, -0.002 -0 .006 -0 .006, -0.005 -0.017 -0.018, -0 .016
F em ales
Intercept 10.99 10.85, 11.13 11.68 11.58, 11.78 9 .54 9 .3 4 ,9 .7 4
Age 0.637 0 .623 ,0 .651 0 .570 0 .561 , 0.579 0.745 0.727, 0.762
(childhood*)
Age (adult) 0.083 0.072, 0.094 0.211 0.206 , 0.216 0.337 0 .3 1 8 ,0 .3 5 7
A ge2 (adult) 0.002 0.002, 0.003 . - -0 .007 -0.008, -0 .006
* Childhood <16 years, adulthood > 16 years
5.3.3 Overweight and obesity prevalence
The prevalence of overweight and obesity in each cohort increased substantially between 
childhood and adulthood. In NSHD, 6.5% of male and 8.8% of female cohort members were 
overweight or obese at age 7, compared to 74.6% and 62.9% overweight or obese at age 53 
(Table 5-8). In NCDS, 7.9% of male and 10.9% of female cohort members were overweight or 
obese at age 7; at age 42, 70.2% of men and 49.2% of women were overweight or obese (these 
figures were based on BMI calculated from self-reported height and weight). In BCS70, 6.5% 
of boys and 10.7% of girls were overweight or obese at age 10, and these figures had risen to 
60.6% and 40.5% at age 34, although again this was based on self-reported measures of weight 
and height. There is indication of a cohort effect on obesity prevalence from adolescence 
onwards; younger cohorts appear to have higher prevalence of obesity at a given age, an effect 
which becomes more apparent at older ages. For example, among males, 0.6% in NSHD were 
classified as obese at age 15, compared to 1.5% of boys in NCDS at age 16, and 2.0% in 
BCS70. In contrast, 0.5% in NSHD were obese at age 7, 1.3% in NCDS at the same age, and 
0.3% in BCS70 at age 10. Compared to contemporary populations with childhood obesity
prevalence of 7-10%,45 obesity prevalence in childhood and adolescence was low in these 
cohorts, ranging from 0.5- 2.4%.
5.3.4 Overweight over the life course
Analysis of the relationships between overweight and obesity in childhood, adolescence and 
adulthood revealed positive associations between overweight over the life course. Table 5-9 
shows that cohort members in NSHD and NCDS who were overweight or obese in childhood 
(age 7 years) had more than double the odds of overweight or obesity in adulthood compared to 
those who were normal weight, while those that were obese in childhood had more than six 
times the odds of obesity in adulthood (NSHD: OR 6.55; 95% Cl 2.21,19.83, NCDS: OR 6.35; 
95% Cl 4.52, 8.93). In BCS70, those who were overweight in childhood had more than four 
times the odds of overweight or obesity in adulthood (OR 4.52; 95% Cl 3.66, 5.57), and a 
similar effect size was observed for obesity (OR 4.00; 95% Cl 1.68, 9.53). However, cross­
tabulations of weight status in childhood and in adulthood revealed that a sizable proportion of 
overweight children did become normal weight adults in these cohorts, and vice versa. For 
example, in NSHD, 20% of cohort members who were overweight at age 7 were normal weight 
at age 53, while 65% of those who were normal weight at age 7 became overweight or obese in 
adulthood; in NCDS, 24% of those who were overweight and 12% of those who were obese at 
age 7 were normal weight at age 42, and 58% of those who were normal weight in childhood 
were overweight or obese in adulthood.
The associations between weight status in adolescence (age 15-16) and adulthood (age 34-43 
years) were stronger than those between childhood and adulthood (Table 5-10). In all three 
cohorts, there was strong evidence that overweight/obesity in adolescence was associated with 
overweight/obesity in adulthood, and effect sizes were larger in younger cohorts, which had a 
shorter period of time between measurements (NSHD: OR 5.92; 95% Cl 3.81, 9.21, NCDS: OR 
6.83; 95% Cl 5.43, 8.61, BCS70: OR 8.01; 95% Cl 6.13, 10.45). Obesity in adolescence was 
associated with very large increases in odds of obesity in adulthood, and in contrast to 
overweight, effect sizes were smaller in younger cohorts (NSHD: OR 41.18; 95% Cl 10.66, 
159.04, NCDS: OR 13.65; 95% Cl 9.04, 20.61, BCS70: OR 10.36; 95% Cl 6.45,16.65). This 
stronger association was reflected in cross-tabulations, which showed that few cohort members 
that were overweight or obese in adolescence became normal weight adults; 13% of overweight 
and 0% of obese adolescents in NSHD, and 12% of overweight and 3% of obese adolescents in 
NCDS were normal weight in adulthood.
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Table 5-8: Mean BMI and prevalence of overweight and obesity at each age in NSHO, NCOS and BCS70 cohorts, by sex
C o h o r t, B M I, k g /m z P re v a le n c e  o f  o v e rw e ig h t +  o b es ity  " b P re v a le n c e  o f  obes ity  b
A ge a t
m e a su re m e n t
M a le F em a le M a le F em a le M a le F em a le
t M e a n  (SD ) n M e a n  (SD ) n % n % n % n % n
N SH D  1946 f 7 1 5 .9 (1 .4 ) 2,057 1 5 .7 (1 .8 ) 1,920 6.5 2,057 8.8 1,920 0.5 2,057 1.3 1,920
11 17.2 (2 .3) 2 ,050 17.5 (3.0) 1,887 6.4 2,050 10.2 1,887 1.0 2 ,050 1.8 1,887
15 19.6 (3 .0) 1,881 20.7  (3.7) 1,700 6.8 1,881 12.1 1,700 0 .6 1,881 1.9 1,700
26 23 .6  (3.4)* 1,822 22 .6  (3.8)* 1,782 27.9* 1,822 17.8* 1,782 2.7* 1,822 3.3* 1,782
36 25 .0  (3.6) 1,632 23.8  (4.9) 1,648 47.0 1,632 28.3 1,648 6 .4 1,632 7.2 1,648
42 25.9  (4.0) 1,617 25 .4  (6.0) 1,608 58.7 1,617 42.3 1,608 10.8 1,617 14.8 1,608
53 27 .6  (4.6) 1,452 27.7  (6.6) 1,496 74.6 1,452 62.9 1,496 23.1 1,452 27.0 1,496
N C D S  1958 7 1 5 .9 (1 .6 ) 6 ,717 1 5 .9 (1 .9 ) 6,268 7.9 6,717 10.9 6,268 1.3 6,717 2.2 6,268
11 17.3 (2 .4) 6 ,382 17.6 (2 .7 ) 6 ,117 8.7 6,382 11.9 6,117 1.6 6,382 1.7 6,117
16 20.3 (2 .7) 5,611 2 1 .0 (2 .7 ) 5 ,249 9 .0 5,611 12.6 5,249 1.5 5,611 1.9 5 ,249
23 23.1 (2.9)* 6,127 22 .2  (3 .3)* 6,148 19.9* 6,127 14.4* 6,148 2.3* 6,127 3.0* 6,148
33 25.7 (4 .7) 5 ,428 24 .6  (5 .5 ) 5 ,609 51.3 5,428 35.7 5,609 11.2 5,428 12.1 5,609
99
42 27 .3  (4.6)* 5,493 26.1 (5.3)* 5,593 70.2* 5,493 49 .2* 5,593 19.9* 5,493 18.3* 5,593
B C S 70  1970 10 1 6 .8 (1 .9 ) 5 ,756 17.1 (2.3) 5,527 6.5 5,756 10.7 5,527 0.3 5,756 0.5 5,527
16 20.8  (3.2) 2,591 21 .4  (3.3) 2 ,774 11.8 2,591 14.9 2,774 2 .0 2,591 2.4 2 ,774
30 26.3  (4.2)* 4 ,992 24.9  (5 .0)* 5,271 59.6* 4,992 38.4* 5,271 14.9* 4 ,992 13.4* 5,271
34 26.5  (4.5)* 4 ,253 25.5 (5 .2)* 4 ,546 60.6* 4,253 40 .5* 4 ,546 17.7* 4,253 15.5* 4 ,546
a O verw eigh t accord ing  to  IO T F  defin itions in  ch ildhood  and  ado lescence, and as B M I >25kg/m 2 fo r adults 
b O besity  accord ing  to  IO T F  defin itions in  ch ildhood  and  ado lescence , and  as B M I >30kg/m  to r adults 
* S elf-reported
t  A d justed  fo r w eigh ted  sam ple ; SD es tim ated  from  standard  erro r
¿T o  ensure com parab ility  o f  m easu rem en ts  ac ro ss the stud ies, m easures o f  B M I in ch ildhood  w ere cen tred  at ages using p red ic tio n s from  linear reg ression  m odels assum ing a linear 
trend  w ith  age o v er short p eriods o f  tim e.
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Table 5-9: Association between 1) overweight+obesity and 2) obesity in adulthood and childhood
O v e rw e ig h t (inc  obes ity )_________________ O b es ity  (k g /m  )
O R f
(95%  C l)
P -v a lu e O R }
(95%  C l)
P -v a lu e
N S H D  1946 2 .54
(1 .7 6 ,3 .6 8 )
<0.001 6.55
(2 .2 1 ,1 9 .3 8 )
0.001
N C D S  1958 2.64
(2 .2 1 ,3 .1 6 )
<0.001 6.35
(4.52, 8 .93)
<0.001
B C S 7 0  1970 4 .52
(3.66, 5.57)
<0.001 4 .00
(1 .6 8 ,9 .5 3 )
0 .002
tOR of overweight +obesity in adulthood for overweight+obesity in childhood; }OR of obesity 
in adulthood for obesity in childhood; adjusted for weighted sample in NSHD. NB. Weight 
status in adulthood calculated from self-reported weight and height for NCDS and BCS70.
Table 5-10: Association between 1) overweight+obesity and 2) obesity in adulthood and adolescence
O v e rw e ig h t (inc o b es ity ) O b es ity  (k g /m 2)
O R f P -v a lu e O R } P -v a lu e
(9 5 %  C l) (9 5 %  C l)
N S H D  1946 5.92 <0.001 41.18 <0.001
N C D S  1958
(3 .8 1 ,9 .2 1 )
6.83 <0.001
(10 .66 , 159.04) 
13.65 <0.001
B C S 7 0  1970
(5 .4 3 ,8 .6 1 )
8.01 <0.001
(9 .0 4 ,2 0 .6 1 ) 
10.36 <0.001
(6 .13, 10.45) (6.45, 16.65)
|O R  of overweight +obesity in adulthood for overweight+obesity in adolescence; }OR of 
obesity in adulthood for obesity in adolescence; adjusted for weighted sample in NSHD. NB. 
Weight status in adulthood calculated from self-reported weight and height for NCDS and
BCS70.
Table 5-11: Association between 1) overweight+obesity and 2) obesity in adolescence and childhood
O v erw e ig h t ( in c  o b es ity ) O b es ity  (k g /m 2)
O R t  P -v a lu e O R }  P -v a lu e
(9 5 %  C l) i9 5 %  C l)
N S H D  1946 11.72 <0.001 200.40 <0.001
N C D S  1958
(8.26, 16.62) 
10.24 <0.001
(6 6 .8 2 ,6 0 1 .0 6 ) 
38 .40 <0.001
B C S 70  1970
(8.64, 12.13) 
12.86 <0.001
(24.93, 59.14) 
27 .30 <0.001
(10.14, 16.31) (8.04, 92.66)
tOR of overweight +obesity in adolescence for overweight+obesity in childhood; }OR of 
obesity in adolescence for obesity in childhood; adjusted for weighted sample in NSHD
5.4 D iseases in adulthood
In all three cohorts, respondents were asked at each wave in adulthood if they suffered from any 
of a list of common health problems. Conditions covered included asthma/wheezing, hay fever, 
bronchitis, back problems, skin problems, arthritis/painful joints, diabetes, epilepsy, 
bladder/kidney problems, migraine, stomach problems, cancer and problems with teeth/gums. 
Cohort members were asked whether they had ever experienced these conditions and about 
health problems in the last 12 months. Respondents also reported other longstanding illnesses 
or health problems that required regular medical supervision, and these were coded using the 
International Classification of Diseases (ICD) 3 digit classification. For this study, self-report of
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ever having had any of: hypertension, gall bladder disease, coronary heart disease, stroke, 
arthritis or cancers (colorectal, breast, uterine, oesophageal, liver and kidney), were the 
outcomes of interest. The frequencies of these outcomes are described for each cohort below.
In NSHD, hypertension was the most common outcome, reported by 60% of men and 49% of 
women by age 53, followed by arthritis which was reported by 20.1% of women and 13.5% of 
men; 5.6% of men and 3.3% of women reported coronary heart disease (Table 5-12). Other 
outcomes were less common, with 3.1% of cohort members reporting gall bladder disease 
(1.4% of men versus 4.7% of women), 1.9% reporting type 2 diabetes (2.1% of men versus 
1.6% of women), and 1.4% reporting any of the cancers of interest (0.3% of men versus 2.4% of 
women). When all outcomes were combined, 61.9% of respondents had experienced at least 
one of the disease outcomes of interest; 64.5% of men reported ever suffering from any of the 
diseases of interest, compared to 59.3% of women.
Some disease outcome data at age 47 years were available for 9,198 cohort members in NCDS 
(Table 5-13). Asthma was the most common morbidity, reported by 15.8% of men and 19.5% 
of women. 12.7% of men and 14.9% of women reported ever having had hypertension. As in 
NSHD, other outcomes were less common, with 2.7% reporting gall bladder disease (1.0% of 
men versus 4.4% of women), 2.8% reporting type 2 diabetes (3.4% of men versus 2.2% of 
women), and <1% reporting CHD (0.5% of men versus 0.2% of women), stroke (0.3% among 
men and women), arthritis (0.6% of men versus 1.3% of women), and each cancer type. There 
were no reported cases of oesophageal cancer. When all disease outcomes were combined, it 
was shown that almost a third of respondents (32.5%) had experienced at least one of these 
outcomes. With the exception of type 2 diabetes, coronary heart disease (CHD), colorectal 
cancer and kidney cancer, disease outcomes were more commonly reported among women than 
men at age 47 years (35% of women versus 29% of men).
In BCS70, disease outcome data at age 34 years were available for 8,530 cohort members 
(Table 5-14). As in NCDS, asthma was the most commonly reported morbidity, affecting 
10.3% of men and 11.6% of women. Hypertension was reported by 4.7% of men and 5.6% of 
women. 1.2% of cohort members reported type 2 diabetes (1.4% of men versus 1.0% of 
women), while all other disease outcomes were reported by <0.2% of respondents. There were 
no reported cases of oesophageal cancer, liver cancer or kidney cancer. When all disease 
outcomes were combined in a single variable, it was shown that 16.7% of cohort members had 
ever experienced at least one of the morbidities of interest (15.6% of men versus 17.7% of 
women).
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Table 5-12: Frequency of self-reported disease outcomes (ever had) in NSHD (age 53 years), by sex
Number of self-reported cases n (%)
Men Women Total
Hypertension 1,103 894 1,997
(59.5) (49.0) (54.3)
Gall bladder disease 21 72 93
(1.4) (4.7) (3.1)
Type 2 diabetes 38 30 68
(2.1) (1.6) (1.9)
Coronary heart disease 82 51 133
(5.6) (3.3) (4.4)
Stroke 12 14 26
(0.8) (0.9) (0.9)
Arthritis 221 327 548
(13.5) (20.1) (16.8)
Colorectal cancer 5 3 8
(0.3) (0.2) (0.3)
Breast cancer N/A 32 N/A
(2.1)
Uterine cancer N/A 2 N/A
(0.1)
Oesophageal cancer N/A N/A N/A
Liver cancer N/A N/A N/A
Kidney cancer N/A N/A N/A
Female cancers* N/A 34 N/A
combined (2.2)
Cancers combined** 5 37 42
(0.3) (2.4) (1.4)
All diseases 1,196 1,082 2,278
combinedf (64.5) (59.3) (61.9)
*Breast and uterine cancers; **Colorectal, breast, uterine, oesophageal, liver and kidney 
cancers; f  All diseases listed in table
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Table 5-13: Frequency of self-reported disease outcomes (ever had) at wave 7 of NCDS (age 47 years), by sex
Number of self-reported cases n (%)
Men Women Total
Hypertension 562 700 1,321
(12.7) (14.9) (14.0)
Asthma 708 922 1,676
(15.8) (19.5) (17.6)
Gall bladder disease 43 205 255
(1.0) (4.4) (2.7)
Type 2 diabetes 152 105 266
(3.4) (2.2) (2.8)
Coronary heart disease 22 10 35
(0.5) (0.2) (0.4)
Stroke 11 12 23
(0.3) (0.3) (0.2)
Arthritis 25 61 86
(0.6) (1.3) (0.9)
Colorectal cancer 3 1 4
(0.07) (0.02) (0.04)
Breast cancer N/A 51 N/A
(1.0)
Uterine cancer N/A 20 N/A
(0.4)
Oesophageal cancer 0 0 0
Liver cancer 0 2 2
(0.04) (0.02)
Kidney cancer 1 0 1
(0.02) (0.01)
Female cancers N/A 71 N/A
combined* (1.4)
Cancers combined** 4 74 78
(0.1) (1.5) (0.8)
All diseases 1,312 1,673 3,090
combined! (29.3) (35.4) (32.4)
*Breast and uterine cancers; **Colorectal, breast, uterine, oesophageal, liver and kidney 
cancers; f  All diseases listed in table
104
Table 5-14: Frequency of self-reported disease outcomes (ever had) at wave 6 of BCS70 (age 34 years), by sex
Number of self-reported cases n (%)
Men Women Total
Hypertension 189 250 482
(4.7) (5.6) (5.1)
Asthma 416 521 1,037
(10.3) (11.6) (10.9)
Gall bladder disease 1 7 8
(0.02) (0.2) (0.1)
Type 2 diabetes 56 46 113
(1.4) (1.0) (1.2)
Coronary heart disease 3 1 4
(0.07) (0.02) (0.05)
Stroke 3 5 8
(0.07) (0.1) (0.1)
Arthritis 3 9 13
(0.07) (0.2) (0.1)
Colorectal cancer 0 2 2
(0.04) (0.02)
Breast cancer N/A 3 N/A
(0.07)
Uterine cancer N/A 4 N/A
(0.09)
Oesophageal cancer 0 0 0
Liver cancer 0 0 0
Kidney cancer 0 0 0
All female cancers N/A 7 N/A
combined* (0.2)
All cancers 0 9 9
combined** (0.2) (0.1)
All diseases 630 794 1,570
combined! (15.6) (17.7) (16.6)
*Breast and uterine cancers; **Colorectal, breast, uterine, oesophageal, liver and kidney 
cancers; f  All diseases listed in table
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5.5 Cohort characteristics: covariates o f interest
The distribution of the covariates of interest within each cohort can be seen in Table 5-15.
5.5.1 Sex
The distribution of sex was similar across all three cohorts, with men making up just over half 
of the study population at baseline.
5.5.2 Ethnicity
Information on ethnicity was not available for the NSHD cohort, although as previously 
discussed, it can be assumed that a small minority (<1%) of the population would be from 
ethnic minority groups.320 In NCDS, ethnic minority groups made up 3.1% of the population, 
compared to 4.5% in BCS70.
5.5.3 Social class based on occupation
In childhood, the pattern of social class distribution was similar for all three cohorts, with the 
majority of participants bom into manual social class III (skilled manual worker) households 
(46% in NSHD, 51% in NCDS, 46% in BCS70). Social class I (higher managerial, 
administrative or professional) made up the smallest proportion of study participants (3.0% in 
NSHD, 4.6% in NCDS, 5.6% in BCS70). 12-19% of study participants were from social 
classes II (intermediate managerial, administrative or professional) and IV (semi- and unskilled 
manual workers), and 6-10% were from social class V (casual or lowest grade workers, and 
those who depend on the state for income). In adulthood, the distribution of social class was 
shifted towards non-manual skilled occupations, with the majority of cohort members belonging 
to social class II (29.3% in NSHD, 41.4% in NCDS, 40.1% in BCS70), and with smaller 
proportions in skilled manual, semi- and unskilled and casual or lowest grade occupations, 
compared to in childhood. There were also expected trends across cohorts, with social class I 
growing and social class V shrinking over successive cohorts.
5.5.4 Smoking status
The distribution of smoking status was largely similar across cohorts, with nearly half of the 
cohort members being never smokers (40% in NSHD, 45% in NCDS, 44% in BCS70). There 
was evidence for different patterns of current and previous smoking according to cohort age; 
there was a higher proportion of ex-smokers in NSHD (34%) than in NCDS (27%) and BCS70 
(22%), while a larger proportion of BCS70 were current smokers compared to NSHD and 
NCDS (x2p<0.001). This may reflect people giving up smoking at older ages, as other studies 
have shown decreasing smoking prevalence with age.342
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Table 5-15: Characteristics of NSHD, NCDS and BCS70
Cohort %
NSHDf NCDS BCS70
Sex (at baseline) 5,362 17,611 14,325
Male 52.6 51.7 51.5
Female 47.4 48.3 48.5
Ethnic group - 15,923 15,628
White/European - 96.9 95.5
Ethnic minority group - 3.1 4.5
Childhood social class 4,673 15,581 14,032
i 3.0 4.6 5.6
ii 13.7 13.0 11.5
iii non-manual 9.0 9.7 13.7
iii manual 46.2 50.7 46.0
iv 18.9 12.1 16.9
V 9.1 9.9 6.3
Adult social class 4,159 8,264 7,802
i 4.9 6.0 6.9
ii 29.3 41.4 40.1
iii non-manual 23.6 20.4 21.0
iii manual 22.5 18.9 18.8
iv 14.9 11.0 11.0
V 4.8 2.3 2.2
Smoking status (adult) 2,988 11,845 11,633
Never smoked 40.3 45.2 43.9
Ex-smoker 34.1 26.5 22.3
Current smoker 25.6 28.3 33.8
t  Adjusted for weighted sample
5.6 BMI status by cohort characteristics
Table 5-16 shows the distribution of BMI status at age 43 in NSHD by the covariates of interest. 
The proportion of cohort members classified as obese was higher among women than men
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(13.9% of women obese versus 10.6% of men), but more men were overweight (44.8% versus 
25.9%), and fewer men fell in the normal weight category (44.7% of men versus 60.2% of 
women normal weight) (p from chi-squared test <0.001). A social gradient in BMI status can 
be seen, with higher proportion of obesity among lower social classes, for both childhood and 
adult social class (p<0.001); 4.9% of those in adult social class I (higher managerial, 
administrative or professional) were obese, compared to 22.3% of those in social class V (casual 
or lowest grade workers, and those who depend on the state for income). The patterning of 
overweight was more complex, with higher prevalence of adult overweight among cohort 
members who were in the lowest social classes in childhood, but high levels of overweight 
among cohort members in social class I in adulthood. However, overall, a higher proportion of 
overweight+obesity is seen among lower social classes, with more participants in higher social 
classes being classified as normal weight (52.2% normal weight in social class I, versus 44.6% 
in social class V). By smoking status, the highest prevalence of obesity was observed among 
ex-smokers (13.9% obese), and the lowest among current smokers (9.9%). A smaller 
proportion of ex-smokers fell into the normal weight category (48.7%) compared to never 
smokers (54.9%) and current smokers (56.2%) (p<0.001).
In NCDS (Table 5-17), higher levels of overweight and obesity in adulthood were observed 
among men than women at age 42; 50.5% of men versus 31.0% of women were overweight, 
while 19.9% of men versus 18.3% of women were obese (p<0.001). There was no strong 
evidence for differences in the prevalence of overweight and obesity by ethnicity (p=0.324).
The social patterning of obesity was similar to that observed in NSHD, with the highest levels 
of obesity in social class V and lowest levels in social class I (p<0.001); 20.8% of adults who 
were in social class V in childhood were obese, compared to 13.0% of those who had been in 
social class I, while 23.4% of adults currently in social class V were obese, compared to 15.4% 
of those in social class I. As in NSHD, overweight in adulthood showed different gradients for 
childhood social class compared to adult social class. Those who had been in lower social 
classes in childhood were more likely to be overweight than those who had been in higher social 
classes, whilst those in the highest social classes in adulthood were more likely to be overweight 
than those in social classes TV or V. Patterns of overweight and obesity by smoking status were 
similar to those in NSHD; the highest prevalence of obesity was observed among ex-smokers 
(21.1%) and the lowest in current smokers (17.8%) (p<0.001). A higher proportion of ex­
smokers were also overweight (42.6%) compared to never smokers (40.6%) and current 
smokers (38.4%).
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Figure 5-9: Distribution of weight status in adulthood within social class strata in NSHD
In BCS70, the prevalence of overweight and obesity in adulthood was higher among men than 
women (pcO.OOl); 17.9% of men were obese at age 34 compared to 15.4% of women, and 
42.9% of men compared to 25.0% of women were overweight. Among ethnic minority groups, 
18.7% were obese, compared to 16.5% of the white/European population; however, the 
prevalence of overweight was lower (28.7% versus 34.0%) and overall evidence for ethnic 
differences was weak (p=0.143). However, it is important to note that the BMI cut-offs used to 
define weight status were not ethnicity-specific, and may underestimate overweight and obesity 
in some groups, particularly South Asian populations. As in the two earlier cohorts, prevalence 
of obesity tended to be higher among lower social classes (p<0.001); 11.3% of cohort members 
who were born to social class I fathers were obese at age 34, compared to 21.1% and 20.4% of 
those in social classes IV and V, respectively. I 1.9% of those in social class 1 in adulthood 
were obese, compared to 20.5% in social class V. As in previous cohorts, patterns of 
overweight by social class were more variable, with higher proportion of overweight among 
those in the lowest social classes at birth compared to those in higher social classes, but those in 
the highest social classes in adulthood having similar levels of overweight than those in lower 
social classes. Patterns of weight status by smoking status showed the highest levels of obesity 
among ex-smokers (18.1 %), and the lowest among current smokers (14.6%), but prevalence of 
overweight was higher among current smokers (34.6%) than ex-smokers (33.9%) or never 
smokers (33.2%) (p=O.OIO).
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Table 5-16: BMI status in NSHD by covariates of interest; adjusted for weighted sampling (estimated n)
BMI status at age 43
Normal Overweight Obese Total
n(%) n (%) n (%) n(%)
Sex
Male 722 (44.7) 724 (44.8) 171 (10.6) 1,617(100)
Female 968 (60.2) 416(25.9) 224(13.9) 1,608(100)
Childhood social class
i 124 (63.3) 60 (30.6) 12(6.1) 196(100)
ii 363 (60.1) 194 (32.1) 47 (7.8) 604(100)
iii non-manual 293 (58.6) 155 (31.0) 52(10.4) 500 (100)
iii manual 474 (47.6) 381 (38.3) 141 (14.2) 996 (100)
iv 262 (45.6) 211 (36.8) 101 (17.6) 574(100)
V 88 (45.8) 81 (42.2) 23(12.0) 192(100)
Adult social class
i 107 (52.2) 88 (42.9) 10(4.9) 205 (100)
ii 639 (54.1) 421 (35.6) 122(10.3) 1,182(100)
iii non-manual 444 (60.0) 208 (28.1) 88(11.9) 740 (100)
iii manual 244 (42.7) 258 (45.2) 69(12.1) 571 (100)
iv 190 (50.0) 118(31.1) 72(19.0) 380 (100)
V 54 (44.6) 40 (33.1) 27 (22.3) 121 (100)
Smoking status
Never smoked 649 (54.9) 392 (33.1) 142 (12.0) 1,183(100)
Ex-smoker 474 (48.7) 365 (37.5) 135 (13.9) 974(100)
Current smoker 347 (56.2) 210(34.0) 61 (9.9) 618(100)
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Table 5-17: BMI status In NCDS by covariates of interest
BMI status at age 42
Normal Overweight Obese Total
n (%) n (% )  n (%) n (%)
Sex
Male 1,564 (29.6) 2,664 (50.5) 1,051 (19.9) 5,279 (100)
Female 2,733 (50.7) 1,669 (31.0) 986(18.3) 5,388 (100)
Ethnic group
White/European 4,397 (40.5) 4,391 (40.5) 2,064(19.0) 10,852 (100)
Ethnic minority group 84 (36.0) 98(42.1) 51 (21.9) 233(100)
Childhood social class
i 222 (49.5) 168 (37.5) 58(13.0) 448 (100)
ii 641 (47.5) 520 (38.6) 187(13.9) 1,348 (100)
iii non-manual 447 (44.7) 402 (40.2) 150(15.0) 999(100)
iii manual 1,863 (38.6) 1,956 (40.5) 1,008 (20.9) 4,827 (100)
iv 395 (33.9) 510(43.8) 259 (22.3) 1,164(100)
V 319(37.9) 348 (41.3) 175 (20.8) 842 (100)
Adult social class
i 173 (37.5) 217 (47.1) 71 (15.4) 461 (100)
ii 1,354 (42.0) 1,322 (41.1) 543 (16.9) 3,219(100)
iii non-manual 750 (47.2) 584 (36.8) 255 (16.0) 1,589 (100)
iii manual 433 (30.2) 695 (48.6) 303 (21.2) 1,431 (100)
iv 349 (41.8) 330 (39.5) 156(18.7) 835 (100)
V 60 (35.9) 68 (40.7) 39 (23.4) 167(100)
Smoking status
Never smoked 2,044 (40.7) 2,037 (40.6) 938(18.7) 5,019 (100)
Ex-smoker 1,072 (36.3) 1,256(42.6) 622 (21.1) 2,950 (100)
Current smoker 1,365 (43.8) 1,196 (38.4) 555 (17.8) 3,116(100)
I l l
Table 5-18: BMI status in BCS70 by covariates of interest
BMI status at age 34*
Normal Overweight Obese Total
n(%) n (%) n (%) n (%)
Sex
Male 1,560 (39.2) 1,708 (42.9) 711 (17.9) 3,979 (100)
Female 2,557 (59.6) 1,070 (25.0) 662 (15.4) 4,289 (100)
Ethnic group
White/European 4,390 (49.5) 3,013 (34.0) 1,466(16.5) 8,869 (100)
Ethnic minority group 163 (52.6) 89 (28.7) 58(18.7) 310(100)
Childhood social class
i 313(61.0) 142 (27.7) 58(11.3) 513(100)
ii 569 (54.9) 351 (33.9) 116(11.2) 1,036 (100)
iii non-manual 663 (53.8) 399 (32.4) 170(13.8) 1,232 (100)
iii manual 1,763(47.7) 1,273 (34.5) 658 (17.8) 3,694 (100)
iv 560 (45.7) 407 (33.2) 259 (21.1) 1,226(100)
V 168(41.8) 152 (37.8) 82 (20.4) 402 (100)
Adult social class
i 287 (55.0) 173 (33.1) 62(11.9) 522 (100)
ii 1,571 (51.6) 1.018(33.5) 453 (14.9) 3,042 (100)
iii non-manual 831 (52.3) 486 (30.6) 271(17.1) 1,588(100)
iii manual 569 (39.1) 599 (41.2) 287(19.7) 1,455(100)
iv 379 (45.7) 307 (37.0) 143 (17.3) 829 (100)
V 79 (47.6) 53 (31.9) 34 (20.5) 166 (100)
Smoking status
Never smoked 2,056 (49.6) 1,377 (33.2) 712(17.2) 4,145 (100)
Ex-smoker 1,039(48.0) 732 (33.9) 392(18.1) 2,163 (100)
Current smoker 1,458 (50.8) 993 (34.6) 420 (14.6) 2,871 (100)
*Note: Height and weight were self-reported
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Table 5-19 shows correlations between child, adolescent and adult BMI and key covariates for 
the three British National Birth Cohorts combined. Lower birth weight was correlated with 
lower social class in both childhood and adulthood. Birth weight was positively associated with 
childhood height, and BMI at all stages of life, although the correlation was highest with 
childhood BMI (0.13; p<0.001) and lowest with adult BMI (0.06; p<0.001). Lower social class 
in childhood was associated with smaller height in childhood, lower social class in adulthood, 
and being a smoker. Lower childhood social class was also associated with increased BMI at all 
stages of life, although this effect was weakest in childhood (0.01; p=0.048) and strongest in 
adulthood (0.12; p<0.001). Smaller height in childhood was associated with lower social class 
in both childhood (-0.08; p<0.001) and adulthood (-0.09; p<0.001). Height in childhood was 
positively correlated with BMI in childhood (0.25; p<0.001) and adolescence (0.19; p<0.001); 
as with birth weight, the correlation was strongest in childhood. Lower social class in adulthood 
was associated with smoking; there was no strong evidence of correlation between social class 
in adulthood and childhood BMI, but lower social class was correlated with BMI in adulthood 
(0.07; p<0.001). Smoking in adulthood was positively correlated with BMI in childhood (0.03; 
p<0.001) and adolescence (0.03; p<0.001), but negatively correlated with BMI in adulthood (- 
0.01; p=0.024). There were moderately high positive correlations between BMI in childhood 
and BMI in adolescence (0.55; p<0.001), between childhood BMI and adult BMI (0.31; 
p<0.001) and adolescent BMI and adult BMI (0.44; p<0.001); the magnitude of observed 
correlations was inversely related to the length of time between measurements. Tests for 
multicollinearity among study variable (using the - c o l l i n -  command in Stata) indicated that 
multicollinearity was not a problem (variance inflation factor values were <10).343
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Table 5-19: Correlation matrix of key study variables for NSHD, NCDS and BCS70 cohorts combined, gives Spearman rank correlation coefficient and n in each cell; birth weight, childhood height, 
and BMIs treated as continuous variables, social class and smoking status treated as ordinal variables
B ir th
w e ig h t
C h ild h o o d  
soc ia l c la ss
C h ild h o o d
h e ig h t
A d u lt social 
c lass
S m o k in g
s ta tu s
C h ild h o o d
B M I
A d o lesce n t
B M I
A d u lt  B M I
B ir th  w e ig h t 1
35,608
C h ild h o o d  
so c ia l c lass
-0 .0650  ** 
33,768
1
34 ,294
C h ild h o o d
h e ig h t
0 .1088  ** 
27,707
-0 .0809  ** 
27,218
1
29,790
A d u lt  so c ia l 
c la ss
-0 .0557  ** 
18,541
0 .2635  ** 
18,133
-0 .0944  ** 
16,717
1
20,225
S m o k in g
s ta tu s
0 .0203  * 
23 ,904
0 .0738  ** 
23,382
0.0106
21,532
0 .1 4 9 0 * *
18,984
1
26,466
C h ild h o o d
B M I
0 .1339  ** 
26,745
0 .0122  f  
26,271
0.2539  ** 
28,741
-0 .0084
16,140
0 .0317  ** 
20,777
1
28,741
A d o le sce n t
B M I
0 .0773  ** 
18,268
0 .0336  ** 
17,944
0 .1 9 2 0 * *
17,056
0.0014
12,424
0 .0277  ** 
15,222
0.5452  ** 
16,501
1
20 ,030
A d u lt  B M I 0.0631 ** 
21 ,279
0 .1 1 7 6 * *
20,793
-0.0042
19,242
0.0692  ** 
18,503
- 0 .0 1 4 9 1 
23,039
0.3121 ** 
18,593
0.4421 ** 
14,036
1
23,489
t<0.05; *<0.01; **<0.001
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5.7 Changes in social patterning o f overw eight and obesity over successive  
cohorts
Changes in the social patterning of overweight and obesity over successive cohorts were 
explored in further detail, as SEP is a key potential confounder of the relationship between 
overweight and disease outcomes, and the social patterning of overweight was considered to be 
an important way in which the three cohorts could differ. Table 5-20 shows that there was no 
strong evidence for an association between social class at birth and the odds of 
overweight/obesity in childhood (ages 7years) in NSHD or NCDS, but odds of 
overweight/obesity was higher with lower social class in BCS70. Similarly, there was no 
association with BMI treated as a continuous outcome for the NSHD and NCDS cohorts. For 
BCS70, there was evidence that lower social class at birth was associated with increased BMI at 
age 10 (coefficient 0.053; 95% Cl 0.020,0.085).
An association between social class at birth and overweight in adolescence was evident for the 
NCDS and BCS70 cohorts (Table 5-21); each unit change from highest social class I to lowest 
social class V at birth was associated with a 14-16% increase in the odds of overweight-l- obesity 
at age 16 years (NCDS: OR 1.16; 95% Cl 1.10, 1.23, BCS70: 1.14; 95% Cl 1.06, 1.22). 
Similarly, lower social class was associated with increased BMI in these two cohorts. In the 
NSHD cohort, there was no association between social class at birth and overweight or BMI in 
adolescence.
Social class at birth was strongly associated with overweight and BMI in adulthood (ages 34-43 
years) for all three cohorts (Table 5-22), with lower social class at birth predicting increased 
odds of overweight in adulthood. In NSHD, each unit change in social class (moving from 
highest to lowest) was associated with a 17% increase in odds of overweight+obesity (OR 1.17; 
95% Cl 1.10, 1.25); in NCDS there was 15% increase in the odds of overweight+obesity (OR 
1.15; 95% Cl 1.11,1.19); and in BCS70 there was a 16% increase in the odds of 
overweight+obesity (OR 1.16; 95% Cl 1.12,1.21). Each unit change in social class was also 
associated with an increase in BMI. Effect sizes were similar in all three cohorts.
Table 5-23 shows the associations between social class, and overweight and BMI in adulthood 
(ages 34-43 years). It can be seen that lower social class was associated with an increased odds 
of concurrent overweight in all three cohorts, although the effect sizes were smaller than for 
social class at birth; each unit change in social class was associated with a 9% increase in the 
odds of overweight+obesity in NSHD (OR 1.09; 95% Cl 1.03, 1.17), a 7% increase in NCDS 
(1.07; 1.03, 1.11), and a 13% increase in BCS70 (1.13; 1.09, 1.17). As with social class in 
childhood, effects sizes were similar across cohorts.
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Table 5-20: Association between 1) overweight+obesity and 2) BMI in childhood and social class of father at birth 
in three British National Birth Cohorts
_______O v e rw e ig h t (inc  o b es ity )__________________ B M I (k g /m  )___________
O R f  P -v a lu e  C o e ffic ien t P -v a lu e
(9 5 %  C l)______________________________(95%  C l)_________________
N S H D  1946 0.96 0 .464 -0.003 0.890
N C D S  1958
(0 .86 , 1.07) 
0 .99 0 .614
(-0 .0 4 8 ,0 .0 4 2 ) 
0 .003 0.816
B C S 70  1970
(0 .94 , 1.04) 
1.08 0.007
(-0 .0 2 3 ,0 .0 2 9 ) 
0 .053 0.001
(1 .02 , 1.14) (0 .0 2 0 ,0 .0 8 5 )
fOR of overweight for each unit change in social class at birth (from social class I to V; I being 
the highest and V being the lowest social class)
Table 5-21: Association between 1) overweight+obesity and 2) BMI in adolescence and social class of father at 
birth in three British National Birth Cohorts
O v erw e ig h t (inc  o b es ity ) B M I (k g /m z)
O R f  P -v a lu e C o e ffic ien t P -v a lu e
(95%  C l) (95%  C l)
N S H D  1946 
N C D S  1958 
B C S 7 0  1970
1.06
(0 .9 4 ,1 .1 8 )  
1.16
(1 .1 0 ,1 .2 3 )  
1.14
(1 .0 6 ,1 .2 2 )
0 .336
<0.001
<0.001
0.016
(-0 .0 7 2 ,0 .1 0 4 ) 
0 .107
(0 .0 6 2 ,0 .1 5 2 ) 
0 .139
(0 .0 6 6 ,0 .2 1 2 )
0.722
<0.001
<0.001
t O R  o f  o v e rw e ig h t  fo r  e a c h  u n i t  c h a n g e  in  so c ia l  c la s s  a t  b ir th  ( f ro m  so c ia l  c la s s  1 to  V ; I b e in g
th e  h ig h e s t  a n d  V  b e in g  th e  lo w e s t so c ia l c la s s )
Table 5-22: Association between 1) overweight+obesity and 2) BMI in adulthood and social class of father at birth
in three British National Birth Cohorts
O v erw e ig h t ( in c  o b es ity ) B M I (k g /m 2)
O R t P -v a lu e C o effic ien t P -v a lu e
(9 5 %  C l) (9 5 %  C l)
N S H D  1946 1.17 <0.001 0.382 <0.001
(1 .1 0 ,1 .2 5 ) (0 .2 5 1 ,0 .5 1 3 )
N C D S  1958 1.15 <0.001 0.376 <0.001
(1 .1 1 ,1 .1 9 ) (0 .2 9 9 ,0 .4 5 4 )
B C S 70  1970 1.16 <0.001 0.412 <0.001
(1 .1 2 ,1 .2 1 ) (0.322, 0.503)
tOR of overweight for each unit change in social class at birth (from social class I to V; I being 
the highest and V being the lowest social class)
Table 5-23: Association between 1) overweight+obesity and 2) BMI in adulthood and current social class in three 
British National Birth Cohorts
O v e rw e ig h t (inc  o b es ity ) B M I (k g /m 2)
O R t
(9 5 %  C l)
P -v a lu e C o effic ien t 
(9 5 %  C l)
P -v a lu e
N S H D  1946 1.09 0.006 0.381 <0.001
(1 .03 , 1.17) (0.229, 0.533)
N C D S  1958 1.07 0.001 0.171 <0.001
(1.03, 1.11) (0.084, 0.259)
B C S 7 0  1970 1.13 <0.001 0.271 <0.001
(1 .09 , 1.17) (0.182, 0 .360)
f O R  o f  o v e rw e ig h t  f o r  e a c h  u n i t  c h a n g e  in  so c ia l c la s s  in  a d u lth o o d  ( f ro m  s o c ia l  c la s s  I to  V ; I 
b e in g  th e  h ig h e s t  a n d  V  b e in g  th e  lo w e s t  so c ia l  c la s s )
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5.8 M issing data
Table 5-24 shows the frequency of missing data in the three cohorts for key variables in 
adulthood. While information on ethnicity, smoking status and adult BMI were relatively 
complete, more than 20% of participants had missing data on BMI in childhood or adolescence. 
In the case of BCS70, more than half of participants were missing data on BMI in adolescence. 
Overall, data in NSHD were more complete than in the two more recent cohorts, particularly for 
birth weight and social class variables.
Table 5-24: Frequency of missing data in adulthood for key variables, by cohort. % as percentage of all 
respondents in adulthood.
Cohort n (%)
NSHD
(n=2,948)
NCDS
(n=9,534)
BCS70
(n=9,665)
Sex (at baseline) 0 0 0
Birth weight 10 (0.3) 1,080(11.3) 955(10.1)
Ethnic group n/a 51 (0.5) 1 (0.01)
Childhood social class 155 (5.3) 1,189(12.5) 1,118(11.8)
Adult social class 65 (2.2) 1,270(13.3) 1,684(17.8)
Smoking status (adult) 0 4 (0.04) 31 (0.3)
Childhood BMI 506 (17.2) 2,027 (21.3) 2,015(21.2)
Adolescent BMI 688 (23.3) 2,805 (29.4) 5,453 (57.5)
Adult BMI 200 (6.8) 683 (7.2) 307 (3.2)
5.9 Summary and im plications
This chapter has described the datasets and variables that are used in the rest of the thesis, and 
has examined the relationships between key variables. Analysis of the patterns of response in 
the three cohort datasets indicated substantial attrition and loss to follow-up over time. 
Response rates also varied across the cohorts, with lowest response in the youngest cohort, 
BCS70. Previous analyses of the British National Birth Cohorts have shown that non­
responders were more likely to be male, from lower socioeconomic positions, and from ethnic 
minority groups. 339 In order to maximise data, last observation carried forward was used for 
some variables with missing data. To assess the effects of missing data, complete case analyses 
were carried out as a sensitivity check.
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Data on both directly measured and self-reported height and weight in adulthood were used in 
the main analyses. Self-reported weight and height data are subject to bias, which can vary 
systematically according to socio-demographic characteristics. Most validation studies report 
underestimation of BMI and prevalence of overweight when self-reported data are used, which 
is due to a combination of underestimation of weight and overestimation of height.344 347 
Factors such as gender, age, level of education, BMI and social desirability can influence 
reporting of weight and height. For example, population-based studies show that women tend 
to underestimate their weight whilst men do not,345"345 and that older adults (ages 60+) are more 
likely to misreport weight and height than younger adults. 346 348 Additionally, increasing level 
of overweight is associated with greater underreporting of weight. 346 The consequent 
differential misclassification of overweight status can bias risk estimates for disease outcomes, 
and may account for discrepancies in study findings. 345 349 To assess the potential effect of 
misclassification due to self-reporting, sensitivity analyses using an adjustment factor for self- 
reported BMI were carried out. The adjustment factors for BMI from self-reported weight and 
height were based on a validation study of self-reported height and weight in 4,808 middle-aged 
participants in the Oxford cohort of the European Prospective Investigation into Cancer and 
Nutrition (EPIC-Oxford).329 The implications of data collection methods and measurement bias 
are discussed.
Weights and heights in childhood and adolescence were directly measured (as opposed to self- 
reported or reported by parents). As expected, examination of BMI data revealed that the 
prevalence of obesity in childhood and adolescence was low in these cohorts relative to current 
levels (obesity prevalence in childhood ranged from 0.3 to 2.4%). These levels are comparable 
with those observed in contemporaneous studies.2 Power calculations in Chapter 4.7.3 showed 
that large sample sizes are required to identify clinically relevant differences in disease risk 
when studying the effects of childhood obesity at these prevalences. In an attempt to increase 
study power, in the main analyses of overweight patterns, overweight and obesity in childhood 
and adolescence were combined to create a single category. Furthermore, the inclusion of BMI 
as a continuous exposure was explored.
Disease outcomes were self-reported. The validity of self-reported health data varies for 
different conditions and according to how these are defined. For example, in a US study of 
2,037 middle-aged men and woman, 350 responses to a self-administered questionnaire were 
compared with medical records. Kappa scores for chronic disorders (diabetes, hypertension), 
and acute-onset diseases (myocardial infarction MI and stroke) indicated substantial agreement 
( k  ranged 0.71 to 0.80). However, there was differential misclassification, with younger age, 
being female, and being more educated being predictors of greater accuracy of reporting. The 
validity of self-reported cancer was assessed in the Malmo Diet and Cancer Study (MDCS), a 
population-based prospective cohort study in Sweden.351 On comparison with information
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from the Swedish Cancer Registry (SCR), sensitivity of questionnaire information for malignant 
tumours was 82%, and specificity was 98%. A k score of 0.72 indicated substantial agreement. 
Among men, under-reporting was associated with older age and obesity (obese men were 70- 
94% more likely to under-report cancer than normal weight men). Most of the health outcomes 
data in the three British national birth cohorts were collected using interviewer-administered 
questionnaires, which are considered to be more reliable and valid instruments for assessing 
medical history than self-administered questionnaires.352
In NSHD, the prevalence of hypertension was higher than would be expected given the age of 
the study population; in the Health Survey for England (HSE) 2009, 33% of men and 25% of 
women aged 45-54 were hypertensive, including current cases of controlled hypertension and 
untreated hypertension.342 Furthermore, comparison of self-reported doctor-diagnosed with 
survey-defined hypertension in HSE showed that prevalence of hypertension based on survey 
measurements of blood pressure was higher than self-reported hypertension. However, the 
measure of hypertension used in this thesis (report of ever having had hypertension) is not 
directly comparable to cross-sectional prevalence, as the thesis measure would include 
individuals who were diagnosed as hypertensive previously but managed their condition without 
medication (these cases would not be picked up in the survey). In addition, changing definitions 
of high blood pressure over time 353 may have picked up individuals as ‘hypertensive’ in the 
past who would not be diagnosed today; although the general trend has been towards lower 
blood pressure thresholds over time (and therefore would expect fewer diagnoses of 
hypertension historically), thresholds as low as 130/80 mm Hg have been recommended for 
individuals with co-morbidities such as diabetes in previous reports.354 Type 2 diabetes was 
lower in NSHD than in NCDS despite the more advanced age of the former, but the observed 
number of cases in NSHD was consistent with a previous analysis of self-reported outcomes in 
this cohort, 355 and contemporary assessments of prevalence, for example, in 1998, the 
prevalence of diabetes was 1.6% among men and 0.9% among women aged 35-54.342
Some of the a priori outcomes of interest, notably stroke and cancers, were rarely observed in 
these cohorts, which can be attributed to the late-onset nature of these outcomes (for example, 
the average age at first stroke in the UK is 71 years among men, and 77 years among women 
356), and the relatively young ages of cohort members at last follow-up. Given the small number 
of cases for these diseases, stroke and cancers were omitted from the main analyses and 
discussion; results for hypertension, asthma, gallbladder disease, type diabetes, coronary heart 
disease, and combined diseases are presented.
Comparison of key variables of interest across the three cohorts indicated the presence of cohort 
effects, notably increasing prevalence of overweight and obesity at comparable ages in 
adulthood. Such trends over time have been noted elsewhere.357'358 However, there were also
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many similarities among the three cohorts, such as the patterning of overweight by social class 
in adulthood and smoking status, and associations between overweight in early and later life. 
Given the similarities in target populations (all babies born in Great Britain in a given week), 
and the comparability of key variables, pooling these data to maximise study power, with 
adjustment for cohort and age effects, seemed a reasonable approach.
Analyses indicated the presence of moderate correlations between BMI in early life and in 
adulthood. These correlations were not high enough to be considered an issue with regards to 
multicollinearity, but may be sufficient to introduce effects akin to the reversal paradox (as 
discussed in Chapter 4.3.2). In order to address this, two approaches were adopted for the main 
analyses: one approach used a series of regression models with stepwise adjustment for 
covariates, and the other considered different combinations of overweight and obesity across the 
life stages and their relationships with disease outcomes. The results from these analyses are 
presented in the next chapter.
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6. THE CONTRIBUTION OF CHILDHOOD & ADOLESCENT WEIGHT 
STATUS TO DISEASE OUTCOMES IN ADULTHOOD
6.1 Introduction
As the literature review in Chapter 3 showed, our understanding of the contribution of 
overweight and obesity at different stages of the life-course to long-term health outcomes is 
incomplete. This is in part due to limitations of standard approaches to studying early life 
effects. Although some studies have indicated that contemporaneous obesity rather than 
exposure to overweight in earlier life explains most of the observed disease risk in adulthood,174 
others have shown that obesity isolated to a single period in youth may affect later health217; it 
remains unclear whether childhood obesity has long-term effects on health.
In these analyses, data from the three British National Birth Cohorts have been pooled to 
explore the relationships between overweight at different stages of the life course and morbidity 
in later life. These three datasets have not previously been analysed together in this way.
Pooling of these data increased the study power to explore the relationship between childhood 
and adolescent weight status and disease in adulthood. A life course approach 235 was adopted 
in analysing these relationships, and potential sensitive period and accumulation of risk effects 
were considered.
Findings for selected analyses have been presented at a conference (Park M H, Sovio U, Viner 
R M, Hardy R and Kinra, S. ‘Overweight in childhood, adolescence and adulthood and 
morbidity in later life’. Poster presentation, ECO 2012 The 19th European Congress on Obesity 
9-12 May 2012, Lyon, France). Selected results have also been written up and submitted for 
publication in a peer-reviewed journal.
6.2 Research questions
1. Are overweight and obesity in childhood and adolescence associated with increased 
morbidity in later life?
2. Do overweight and obesity in childhood and adolescence contribute to excess risk of disease 
outcomes in obese adults?
6.3 M ethods
The general methods have been described in Chapter 4.7. Pooled data from the three British 
National Birth Cohorts were analysed, firstly using a series of regression models relating BMI 
status at each life stage (childhood, adolescence and adulthood) to disease outcomes (the 
Stepwise approach). In the next stage, associations between different combinations of
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overweight at each life stage and outcomes were examined (the ‘Overweight patterns’ 
approach). The statistical models used for each approach are described below. The effects of 
severity of overweight on disease risk were examined by adjusting models for adult BMI, and 
also by repeating the analyses using obesity in childhood instead of overweight and obesity as a 
combined category.
The following sensitivity analyses were conducted: 1) Excluding ethnic minority groups -  due 
to the small proportion of ethnic minority groups, analyses were not stratified by ethnicity, and 
this assumption was checked by excluding ethnic minority (non-White) groups in a sensitivity 
analysis; 2) Adjusting BMI measurement for self-reported weight and height, using adjustments 
described previously; 3) Complete case analyses, including only cohort members with complete 
data on all variables; 4) Survival analysis for time to event data.
S T A T IS T IC A L  M O D E L S  U S E D  IN  T H E  S T E P W IS E  A P P R O A C H  T O  A N A L Y S IS
-  E x p o s u re :  C h i ld h o o d  B M I s ta tu s  (B M I1 );  A d o le s c e n t  B M I s ta tu s  (B M I2 );  A d u l t  B M I 
s ta tu s  (B M I3 ) , w ith  n o rm a l w e ig h t  c a te g o ry  a s  th e  r e fe re n c e  g ro u p
-  O u tc o m e : D is e a s e  o u tc o m e  (D IS E A S E )
EARLY MODEL- REGRESSION TO RELATE CHILDHOOD BMI STATUS TO DISEASE 
OUTCOME (SUFFICIENTLY ADJUSTED MODEL)
L o g  o d d s (D IS E A S E )  =  a +  p , .  B M I1
• Stratified by sex
•  A d ju s tm e n t  in  s ta g e s :
1. A d ju s te d  fo r  k e y  c o v a r ia te s  (y e a r  o f  b i r th  [ e q u iv a le n t to  c o h o r t] ,  e x a c t  a g e  a t  B M I 
m e a s u re m e n t)
2 . A d ju s te d  fo r  k e y  c o v a r ia te s  p lu s  e a r ly  l ife  v a r ia b le s  (b ir th  w e ig h t, c h i ld h o o d  S E P  a t 
b ir th ,  c h i ld h o o d  h e ig h t  a t  B M I m e a s u re m e n t)
COMBINED MODEL -  INCLUDES CHILDHOOD AND ADULT BMI STATUS
L o g  o d d s (D IS E A S E )  =  a  +  p ,*  B M I1 +  p 2* B M I3
• Stratified by sex
•  A d ju s tm e n t  in  s ta g e s :
1. A d ju s te d  f o r  k e y  c o v a r ia te s  (y e a r  o f  b ir th ,  e x a c t  a g e  a t  B M I  1 m e a s u re m e n t)
2 . A d ju s te d  f o r  k e y  c o v a r ia te s  p lu s  e a r ly  l ife  v a r ia b le s  (b ir th  w e ig h t ,  c h i ld h o o d  S E P  a t  
b ir th ,  c h i ld h o o d  h e ig h t  a t  B M I1  m e a s u re m e n t)
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3. Adjusted for key covariates, early life variables, and current variables (adult SEP, 
adult smoking status)
INTERACTION (EFFECT MODIFICATION) M ODEL-ADDS INTERACTION OF 
CHILDHOOD AND ADULT BMI STATUS IN COMBINED MODEL
Log odds(DISEASE) = a + pi* BMI1+ p2* BMI3+ p3* BMI1* BMI3
• Stratified by sex
• Adjustment in stages:
1. Adjusted for key covariates (year of birth, exact age at BMI 1 measurement)
2. Adjusted for key covariates plus early life variables (birth weight, childhood SEP at 
birth, childhood height at BMI1 measurement)
3. Adjusted for key covariates, early life variables, and current variables (adult SEP, 
adult smoking status)
LATE MODEL -  ADULT BMI STATUS RELATED TO THE OUTCOME 
Log odds(DISEASE) = a  + P)* BMI3
• Stratified by sex
• Adjustment in stages:
1. Adjusted for key covariates (year of birth)
2. Adjusted for key covariates plus early life variables (birth weight, childhood SEP at 
birth, childhood height at BMI1 measurement)
3. Adjusted for key covariates, early life variables, and current variables (adult SEP, 
adult smoking status)
THESE ANALYSES WERE REPEATED:
1. with adolescent BMI status (BMI2) as the exposure, and
2. using BMI (kg/m2) as a continuous exposure
STATISTICAL MODEES USED IN THE OVERWEIGHT PATTERNS APPROACH TO 
ANALYSIS
Main analysis
Exposure: Patterns of overweight (PATTERN), see Table 4-7, with pattern 1 (never overweight) 
as the reference group
Outcome: Disease outcome (DISEASE)
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Log odds(DISEASE) = a  + pj. PATTERN
1. Adjusted for sex, year of birth, birth weight, childhood SEP at birth, childhood height, 
adult SEP, adult smoking status
2. Inclusion of interaction terms for sex and cohort (PATTERN*sex and 
PATTERN*cohort)
3. Adjusted for variables above and adult BMI
4. Repeated using obesity in childhood and adolescence (instead of overweight and 
obesity) to define patterns of overweight
Sensitive period analysis
Exposure: Sensitive period variables. Childhood - SENS1, with three categories: never 
overweight, overweight in childhood, overweight in other periods; Adolescence -  SENS2, with 
three categories: never overweight, overweight in adolescence, overweight in other periods; 
Adulthood -  SENS3, with three categories: never overweight, overweight in adulthood, 
overweight in other periods, with never overweight as the reference group
Outcome: Disease outcome (DISEASE)
Sensitive period in childhood
Log odds(DISEASE) = a + pi. SENS1
Adjusted for sex, year of birth, birth weight, childhood SEP at birth, childhood height, adult 
SEP, adult smoking status
Sensitive period in adolescence
Log odds(DISEASE) = a  + p,. SENS2
Adjusted for sex, year of birth, birth weight, childhood SEP at birth, childhood height, adult 
SEP, adult smoking status
Sensitive period in adulthood
Log odds(DISEASE) = a  + pP SENS3
Adjusted for sex, year of birth, birth weight, childhood SEP at birth, childhood height, adult 
SEP, adult smoking status
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Accumulation of risk analysis
Exposure: Accumulation of risk score (ACCUM, with four categories: never overweight, 
overweight at one time point, overweight at two time points, and overweight and three time 
points), with never overweight as the reference group
Outcome: Disease outcome (DISEASE)
Log odds(DISEASE) = <* + &. ACCUM
Adjusted for sex, year of birth, birth weight, childhood SEP at birth, childhood height, adult 
SEP, adult smoking status
6.4 Results
The frequency of each disease outcome by weight status in childhood, adolescence and 
adulthood is shown in Table 6-1. Hypertension, type 2 diabetes, and gallbladder disease 
increased with overweight and obesity at all ages. For example, 16.3% of participants who 
were normal weight in childhood experienced hypertension in adulthood, compared to 18.2% of 
those who were overweight and 19.6% of those who were obese; 1.7% of participants who were 
normal weight in adolescence reported type 2 diabetes, compared to 3.9% of those who were 
overweight, and 15.6% of those who were obese. Asthma was reported more frequently in 
those who were overweight or obese in childhood and adulthood, but there was no pattern with 
weight status in adolescence. There were no clear patterns of coronary heart disease, stroke, 
arthritis or cancers by weight status in childhood or adolescence. For all diseases combined, 
there was a clear pattern of increasing frequency with overweight and obesity at all ages; 46.6% 
of those obese in childhood had any disease, compared to 33.2% of those who were overweight 
and 29.2% of those who were normal weight in childhood.
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Table 6-1: Frequency of each disease outcome in adulthood, by weight status in childhood, adolescence and 
adulthood, for 1946,1958 and 1970 cohorts combined
L ife  s ta g e  a t  w h ich  
B M I m e a su re d
N S e lf  r e p o r te d  cases in  w e ig h t c a te g o ry  %  (n)
N o rm a l
w e ig h t
O v e rw e ig h t O b ese T o ta l
A sthm a
C hildhood 14,246 14.3 15.9 18.1 14.5
(1 ,856) (178) (24) (2 ,058)
A dolescence 10,423 15.3 14.0 17.8 15.2
(1,405) (143) (35) (1,583)
A dulthood 18,030 12.8 14.3 18.1 14.3
(1 ,043) (960) (569) (2 ,572)
G allb ladder d isease
C hildhood 16,638 1.6 2.5 5.4 1.7
(238) (32) (8) (278)
A dolescence 12,636 1.9 3.3 5.6 2.1
(216) (40) (12) (268)
A dulthood 20,804 1.1 1.5 3.3 1.6
(102) (118) (114) (334)
H ypertension
C hildhood 18,138 16.3 18.2 29.6 16.6
(2,706) (252) (48) (3,006)
A dolescence 13,936 18.27 22.1 25.8 18.8
(2,266) (288) (60) (2,614)
A dulthood 21 ,254 13.5 17.2 24.6 16.7
(1,333) (1,351) (871) (3,555)
T ype 2 d iabetes
C hildhood 17,275 1.9 4 .4 8.3 2.1
(297) (58) (13) (368)
A dolescence 13,214 1.7 3.9 15.6 2.2
(202) (49) (35) (286)
A dulthood 21,254 0.8 1.5 6.0 1.9
(77) (117) (213) (407)
C H D
C hildhood 16,732 0.8 1.6 0.7 0.8
(117) (20) (1) (138)
A dolescence 12,711 1.0 1.8 0 1.0
(109) (22) (131)
A dulthood 20,813 0.5 0.8 1.5 0 .8
(52) (60) (51) (163)
A rthritis
C hildhood 16,948 3.1 3.5 3.3 3.1
(480) (46) (5) (531)
A dolescence 12,906 3.7 4.8 4 .6 3.8
(425) (58) GO) (493)
A dulthood 21,255 3.1 2.7 3.2 3 .0
(301) (215) (112) (628)
All d iseases
C hildhood 18,227 29.2 33.2 46.6 29.7
(4 ,869) (462) (76) (5 ,407)
A dolescence 14,005 31.6 37.1 42.3 32.3
(3 ,942) (485) (99) (4,526)
A dulthood 21,255 26.4 31.0 41.9 30.7
(2 ,602) (2,434) (1,484) (6,520)
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6.4.1 Results from the Stepwise approach
Table 6-2 shows the results from the stepwise regression models for the relationship between 
childhood overweight, obesity and BMI, and disease outcomes in adulthood. Results from the 
interaction model are not presented as the numbers were too low in certain combinations of 
categories for the model to converge. Among males, there was evidence for increased odds of 
type 2 diabetes with overweight and obesity. However, these associations were attenuated 
towards the null after adjustment for adult weight status, which also resulted in an improvement 
in model fit (p<0.05 from adjusted Wald test). An association between overweight (but not 
obesity) and CHD risk was observed, which was also attenuated after adjustment for adult 
weight status. Among female cohort members, overweight was associated with increased odds 
of asthma, hypertension, and all disease outcomes, after adjustment for early life covariates. 
Odds ratios for obesity were also in the same direction for these outcomes, but these estimates 
were not statistically robust (wider confidence intervals, including 1), which is likely to be a 
power issue given the low prevalence of obesity in childhood. Both overweight and obesity 
were associated with increased odds of type 2 diabetes; overweight was associated with a more 
than doubling of odds (OR 2.62,95% Cl 1.59,4.29) and obesity was associated with an almost 
seven-fold increase, although confidence intervals were wide (OR 6.70,95% Cl 2.63, 17.06). 
After adjustment for weight status in adulthood and later life covariates, weight status in 
childhood was not associated with any of the outcomes.
The relationships between weight status in adolescence and disease outcomes are presented in 
Table 6-3. Among male cohort members, overweight was associated with increased odds of 
hypertension, CHD and combined diseases, after adjustment for early life covariates. 
Associations between these outcomes and obesity were in the same direction, but confidence 
intervals were wider. After adjustment for later life covariates and adult weight status, 
associations were attenuated towards the null. Overweight and obesity in adolescence were 
associated with increased odds of type 2 diabetes, with increasing odds with greater degree of 
overweight. After adjustment for adult weight status, an association with obesity remained, 
although the effect size was smaller (OR 4.43 in the combined model, compared to OR 13.4 in 
the early model). Among female cohort members, hypertension, CHD, arthritis and combined 
diseases were associated with overweight but not obesity in adolescence. These effects were 
attenuated towards the null after adjustment for later life covariates. Overweight and obesity in 
adolescence were associated with gallbladder disease and type 2 diabetes, and odds for both 
outcomes increased with the degree of overweight (gallbladder disease: OR for overweight 2.04, 
OR for obesity 3.88; type 2 diabetes: OR for overweight 2.31, OR for obesity 13.46). After 
adjustment for adult weight status, an association with gallbladder disease was no longer
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observed; in the case of type 2 diabetes, as with male cohort members, the association with 
overweight was attenuated, but an association with obesity remained (OR 2.83,95% Cl 1.00, 
7.96).
Table 6-4 shows that overweight and obesity in adulthood were associated with most of the 
outcomes of interest, in both sexes. In men, obesity was associated with increased odds of 
asthma, gallbladder disease, hypertension, type 2 diabetes, CHD, and combined disease 
outcomes. These associations were generally unchanged after adjustment for early life 
exposures; examination of goodness-of-fit estimates showed improved fit with the inclusion of 
early life covariates, except in the case of asthma. Associations with overweight were in the 
same direction but weaker, and in the cases of asthma, gallbladder disease, type 2 diabetes and 
CHD, confidence intervals included 1. Among women, obesity in adulthood was associated 
with asthma, gallbladder disease, hypertension, type 2 diabetes, CHD, arthritis, and combined 
diseases. Associations with overweight were also observed for gallbladder disease, 
hypertension, and combined outcomes. As with men, these associations did not change greatly 
after adjustment for early life covariates.
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Table 6-2: Odds ratios of adult disease outcomes for overweight and obesity in childhood (reference category: normal weight in childhood) under different models in  the stepwise approach to
analysis, by sex.
Male Female
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
O R  (9 5 %  C l) O R  (9 5 %  C l) O R  (95%  C l) O R  (9 5 %  C l) O R  (95%  C l) O R  (95%  C l)
A sthm a n= 6 ,852 n= 6 ,4 5 4 n=5 ,708 n= 7 ,394 n= 6 ,962 n= 5 ,206
O verw eight 0 .75 (0 .5 4 ,1 .0 4 ) 0 .8 2 (0 .5 9 , 1.14) 0.71 (0 .4 9 ,1 .0 2 ) 1.38** (1 .1 3 ,1 .6 8 ) 1.43** (1 ,1 6 ,1 .7 6 ) 1.01 (0.77, 1.32)
O bese 0 .76  (0.30, 1.94) 0 .95 (0 .37 , 2 .46) 0 .84 (0 .2 8 ,2 .5 0 ) 1 .2 3 (0 .7 4 , 2 .05) 1.21 (0.72, 2 .04) 0 .96  (0.52, 1.77)
G allb ladder d isease n= 9 ,5 8 4 n = 9 ,1 5 9 n=8,239 n= 1 0 ,2 9 4 n= 9,821 n=7 ,883
O verw eigh t 2 .29  (0 .7 2 ,7 .3 0 ) 2 .38 (0 .7 7 ,7 .3 9 ) 1.94 (0 .6 0 ,6 .2 4 ) 1.41 (0 .8 6 ,2 .3 2 ) 1 .4 1 (0 .8 4 ,2 .3 7 ) 0 .90 (0.49, 1.65)
O bese 2 .27  (0 .30 , 17.26) 2 .34  (0 .2 8 ,1 9 .9 2 ) 2 .1 2 (0 .2 2 ,2 0 .7 5 ) 1.72 (0 .77 , 3 .84) 1.75 (0 .7 8 ,3 .9 3 ) 1 .0 2 (0 .3 8 ,2 .7 1 )
H ypertension n = l l ,5 9 6 n = l l ,1 3 8 n=8 ,238 n = l  1,912 n = l  1,406 n=7 ,858
O verw eigh t 0 .97  (0 .71, 1.34) 0 .99 (0 .7 1 ,1 .3 7 ) 0.91 (0 .6 0 ,1 .3 8 ) 1.26 (0 .9 7 ,1 .6 2 ) 1.32* (1 .0 2 ,1 .7 2 ) 1.05 (0.75, 1.46)
O bese 1.31 (0 .50 , 3 .39) 1.13 (0 .4 1 ,3 .1 5 ) 0 .7 7 (0 .1 8 ,3 .2 7 ) 1 .2 8 (0 .6 9 ,2 .3 6 ) 1.45 (0 .76 , 2 .72) 1.52 (0 .6 5 ,3 .5 8 )
T 2D M n = 10 ,336 n = 9 ,8 8 4 n=8,226 n= 10 ,938 n= 10,441 n=7,881
O verw eigh t 1 .77* (1 .12 , 2 .78) 1 .89**(1 .18 , 3 .02) 0.97 (0 .5 3 ,1 .7 9 ) 2 .65**  (1 .6 7 ,4 .2 2 ) 2 .6 2 * * 0 .5 9 ,4 .2 9 ) 1 .19 (0 .59 , 2 .39)
O bese 2 .60  (0 .8 9 ,7 .6 3 ) 3 .03*  (1 .0 1 ,9 .0 9 ) 2 .97 (0.97, 9 .08) 6 .99**  (2 .73 , 17.88) 6 .70**  (2 .63, 17.06) 2.06 (0.64, 6.67)
C H D n = 9 ,636 n= 9 ,2 0 0 n= 8 ,236 n = 10,202 n= 9 ,7 3 0 n=7,775
O verw eigh t 2 .37*  (1 .09 , 5 .14) 2 .55*  (1 .1 7 ,5 .5 2 ) 1 .64 (0 .62 , 4 .32) 1 .4 3 (0 .4 9 ,4 .1 7 ) 1 .6 0 (0 .4 9 , 5 .18) 1 .4 4 (0 .3 1 ,6 .7 6 )
O bese 1 .1 5 (0 .1 4 , 9 .64) 1.35 (0 .16 , 11.48) 1.44 (0 .2 1 ,9 .7 7 ) om itted om itted om itted
A rthritis n = 9 ,916 n = 9 ,4 7 7 n= 8,208 n= 10 ,483 n= 10,001 N =7,842
O verw eigh t 1 .3 7 (0 .6 6 ,2 .8 2 ) 1 .1 7 (0 .5 5 , 2 .50 ) 1 .1 3 (0 .4 4 ,2 .9 1 ) 1.26 (0.75, 2 .12) 1.37 (0 .8 1 ,2 .3 2 ) 1 .58 (0 .89 , 2.79)
O bese 2.21 (0 .35 , 13.86) 1.92 (0.28, 13.27) 3.35 (0.29, 38.79) 0.81 (0 .1 5 ,4 .4 4 ) 0 .88 (0 .1 6 ,4 .8 2 ) 1.09 (0 .2 0 ,6 .0 0 )
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D isease n = l  1,662 n = l l ,1 9 2 n=8,248 n = l  1,989 n = l  1,480 n=7 ,892
O verw eigh t 0 .93 (0 .7 2 ,1 .2 0 ) 0 .93 (0.72, 1.21) 0.81 (0.60, 1.10) 1.31** (1 .08 , 1.58) 1.33** (1 .10 , 1.62) 0 .98 (0 .7 6 ,1 .2 5 )
O bese 1.35 (0 .63 , 2.88) 1.36 (0 .6 0 ,3 .0 9 ) 1.23 (0.40, 3.80) 1.33 (0 .8 1 ,2 .1 8 ) 1.50 (0.90, 2 .48) 1 .3 8 (0 .7 6 ,2 .5 1 )
Model 1: odds ratios of risk of the outcome for overweight and obese compared to normal weight reference category in childhood, adjusted for current age; Model 2: 
Early Model, adjusted for cohort and current age, early life covariates (birth weight, childhood social class, childhood height, and age at BMI measurement); Model 3: 
Combined Model, adjusted for cohort and current age, early life covariates (birth weight, childhood social class, childhood height, and age at BMI measurement), late 
life covariates (adult social class, and adult smoking status), and adult weight category; all analyses adjusted for weighted sample in NSHD, n=effective population 
size from weighted analysis. CHD=coronary heart disease. T2DM=type 2 diabetes. * p<0.05 **p<0.01
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Table 6-3: Odds ratios of adult disease outcomes for overweight and obesity in adolescence (reference category: normal weight in adolescence) under different models in the stepwise approach
to analysis, by sex.
M a le F e m a le
M o d e l 1 M o d e l 2 M o d e l 3 M o d e l 1 M o d e l 2 M o d e l 3
O R  (9 5 %  C l) O R  (9 5 %  C l) O R  (95%  C l) O R  (9 5 %  C l) O R  (9 5 %  C l) O R  (9 5 %  C l)
A sthm a n=4 ,931 n= 3 ,9 4 7 n=3,487 n = 5,382 n= 4 ,357 n=3 ,339
O verw eight
O bese
0.78 (0 .5 6 ,1 .1 0 )  
0 .7 4 (0 .3 7 , 1.49)
0 .7 6 (0 .5 1 ,1 .1 2 )  
1 .0 2 (0 .5 0 , 2 .07)
0.65 (0 .4 2 ,1 .0 2 ) 
0 .96 (0.45, 2.04)
1 .0 0 (0 .7 9 , 1.26) 
1.69* (1 .05 , 2.71)
0.98 (0 .76, 1.27) 
1.31 (0 .75, 2 .30)
0.75 (0.54, 1.05) 
0 .4 6 (0 .1 9 ,1 .1 1 )
G allb ladder d isease n= 7 ,5 1 4 n= 6 ,3 2 3 n=5,733 n= 8 ,043 n = 6 ,828 n=5 ,642
O verw eight
O bese
0 .6 2  (0 .1 9 ,2 .0 6 )  
1 .4 9 (0 .2 0 ,1 1 .0 7 )
0 .48  (0 .1 1 ,2 .1 4 )  
2 .03 (0 .26 , 15.70)
0 .33 (0 .0 7 ,1 .5 0 ) 
1 .95 (0 .23 , 16.85)
1 .8 7 * * (1 .1 8 ,2.96) 
2 .9 1 * * (1 .3 8 , 6 .15)
2 .0 4 * * 0 .2 4 ,3 .3 6 )
3 .8 8 * * 0 .8 1 ,8 .3 7 )
1.28 (0.72, 2 .26) 
0 .95 (0.30, 3.04)
H ypertension n= 9 ,305 n = 7 ,927 n=5,735 n = 9 ,375 n= 8 ,062 n=5,620
O verw eigh t
O bese
1.62** (1 .19 , 2 .21) 
2 .20*  (1 .0 6 ,4 .5 6 )
1.62** (1.16, 2 .26) 
1 .9 4 (0 .8 8 , 4 .29)
0 .9 9 (0 .6 2 ,1 .5 8 )  
1.76 (0 .9 1 ,3 .4 0 )
1 .37* (1.06, 1.77) 
0 .8 0  (0.42, 1.52)
1.43* (1 .0 8 ,1 .8 8 )  
0 .82  (0 .4 1 ,1 .6 4 )
0 .9 4 (0 .6 5 ,1 .3 5 )  
0 .62 (0.16, 2 .47)
T 2D M n= 8 ,2 4 6 n= 6 ,9 6 0 n=5,727 n= 8 ,601 n= 7 ,348 5,638
O verw eigh t
O bese
2.35**  (1 .4 8 ,3 .7 3 )  
11 .83**(6 .54 , 21.40)
2 .62**  (1 .5 7 ,4 .3 6 )  
13 .40**(6 .86 , 26 .17)
1 .1 0 (0 .5 8 ,2 .0 9 )  
4 .43**  (1 .7 2 ,1 1 .3 9 )
2 .43**  (1 .3 2 ,4 .5 0 )  
15 .14** (7 .32 , 31.31)
2 .31*  (1 .1 9 ,4 .5 1 )  
13.46* (6.20, 29 .2)
1.08 (0 .47 , 2 .46) 
2 .83* (1 .0 0 ,7 .9 6 )
C H D n= 7 ,4 6 6 n = 6 ,284 n=5 ,668 n = 7 ,913 n= 6 ,724 n=5,543
O verw eigh t
O bese
2 .28*  (1 .0 9 ,4 .7 8 )  
om itted
2.58*  (1 .1 6 ,5 .7 4 )  
om itted
1.65 (0 .6 1 ,4 .4 7 ) 
om itted
2 .24  (0.86, 5 .82) 
om itted
3 .00*  (1 .05, 8 .63) 
om itted
1.84 (0 .5 4 ,6 .2 2 )  
om itted
A rthritis n = 7 ,856 n = 6 ,6 1 7 n= 5 ,654 n= 8 ,167 n=6,941 n= 5 ,600
O verw eigh t
O bese
1.23 (0 .6 1 ,2 .4 9 )  
0 .61 (0 .0 6 ,6 .4 0 )
1 .2 2 (0 .5 9 ,2 .5 0 )  
0 .9 5 (0 .0 8 ,1 1 .2 3 )
1.18 (0 .5 2 ,2 .6 8 ) 
om itted
1.92** (1 .2 3 ,3 .0 0 ) 
1 .6 4 (0 .5 7 ,4 .6 6 )
1.87* 0 .1 5 ,3 .0 6 )  
1.41 (0 .4 9 ,4 .0 7 )
1.62 (0 .8 7 ,2 .9 9 )  
0.83 (0 .2 0 ,3 .4 0 )
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D isease n=9 ,357 n= 7 ,966 n=5,742 n = 9 ,434 n= 8 ,117 n=5,647
O verw eight 1 .43**  (1.12, 1.83) 1.45** (1 .10 , 1.90) 0.93 (0 .6 6 ,1 .3 0 ) 1.37** (1 .13 , 1.68) 1.36** (1.10, 1.69) 0 .9 4 (0 .7 1 , 1.25)
O bese 1 .5 3 (0 .8 9 , 2 .64) 1 .6 0 (0 .8 8 , 2.90) 1.29 (0 .7 5 ,2 .2 3 ) 1.23 (0 .74 , 2.03) 1.11 (0 .64 , 1.92) 0 .5 0 (0 .2 1 , 1.19)
Model 1: odds ratios of risk of the outcome for overweight and obese compared to normal weight reference category in adolescence, adjusted for current age; Model 
2: Early Model, adjusted for cohort and current age, early life covariates (birth weight, childhood social class, childhood height, and age at BMI measurement); Model 
3: Combined Model, adjusted for cohort and current age, early life covariates (birth weight, childhood social class, childhood height, and age at BMI measurement), 
late life covariates (adult social class, and adult smoking status), and adult weight category; all analyses adjusted for weighted sample in NSHD, n=effective 
population size from weighted analysis. CHD=coronary heart disease. T2DM=type 2 diabetes. * p<0.05 **p<0.01
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Table 6-4: Odds ratios of adult disease outcomes for overweight and obesity in adulthood (reference category: normal weight in adulthood) under different models In the stepwise approach to
analysis, by sex.
M a le F e m a le
M o d e l 1 M o d e l 2 M o d e l 3 M o d e l 1 M o d e l 2 M o d e l 3
O R  (9 5 %  C l) O R  (9 5 %  C l) O R  (95%  C l) O R  (9 5 %  C l) O R  (9 5 %  C l) O R  (95%  C l)
A sthm a n= 8 ,129 n= 5 ,9 0 3 n=5,708 n= 8 ,681 n= 5 ,384 n=5 ,206
O verw eight 1 .0 2 (0 .8 8 ,1 .1 8 ) 1 .0 6 (0 .8 9 , 1.27) 1.08(0.90, 1.29) 1.23** (1 .07 , 1.41) 1 .1 4 (0 .9 6 , 1.36) 1 .1 4 (0 .9 5 ,1 .3 6 )
O bese 1.20* (1.00, 1.44) 1.41** (1 .1 3 ,1 .7 5 ) 1.49** (1.19, 1.87) 1 .75**  (1 .51 , 2.04) 1.73** (1 .4 1 ,2 .1 1 ) 1.73** (1 .4 0 ,2 .1 4 )
G allb ladder d isease n = l  1 ,218 n= 8 ,525 n=8,239 n = l  1,903 n = 8 ,172 n=7,883
O verw eigh t 1.54 (0 .7 2 ,3 .2 9 ) 1.66 (0 .7 1 ,3 .8 7 ) 1.57 (0 .6 7 ,3 .6 7 ) 2 .00**  (1 .3 7 ,2 .9 3 ) 2.21* (1 .3 7 ,3 .5 8 ) 2.26* (1.39, 3.69)
O bese 2 .75*  (1 .20, 6 .31) 2 .89*  (1 .1 6 ,7 .1 8 ) 2.64* (1 .0 3 ,6 .7 6 ) 3 .99**  (2 .76 , 5.76) 4.11* (2 .4 6 ,6 .8 7 ) 3.70* (2 .1 8 ,6 .2 8 )
H ypertension n = l  1 ,843 n = 8 ,524 n=8,238 n = 12 ,292 n= 8,147 n=7,858
O verw eigh t 1 .57**  (1 .3 1 ,1 .8 8 ) 1.87** (1.47, 2 .37) 1.85** (1.45, 2.36) 1 .55**  (1 .3 1 ,1 .8 3 ) 1.54** (1 .2 5 ,1 .9 1 ) 1.59** (1 .2 8 ,1 .9 8 )
O bese 3 .38**  (2 .6 8 ,4 .2 6 ) 4 .27**  (3.21, 5 .69) 4.34** (3.23, 5 .83) 2 .56**  (2 .09 , 3.12) 2.58** (1 .9 7 ,3 .3 7 ) 2.63** (1 .9 9 ,3 .4 8 )
T 2D M n = l  1,820 n= 8 ,5 1 2 n=8 ,226 n = 12,328 n = 8169 n=7,881
O verw eigh t 1 .2 6 (0 .7 5 ,2 .1 2 ) 2.02* (1 .0 2 ,4 .0 0 ) 1 .8 5 (0 .9 3 ,9 .0 8 ) 1 .1 3 (0 .6 0 , 2.11) 1 .1 8 (0 .5 1 ,2 .7 3 ) 1.20 (0 .5 1 ,2 .8 2 )
O bese 5 .74**  (3 .53 , 9 .33) 7.44** (3 .85 , 14.40) 7.32** (3.73, 14.36) 9 .05**  (5 .55, 14.77) 10.46** (5 .2 2 ,2 0 .9 ) 10.30** (5.09, 20.8)
C H D n = l  1,221 n = 8 ,5 2 2 n=8 ,236 n = l  1,880 n= 8 ,150 n=7 ,775
O verw eigh t 1.79 (0 .9 7 ,3 .2 9 ) 1.41 (0 .7 3 ,2 .7 4 ) 1.41 (0 .7 1 ,2 .8 3 ) 1.39 (0 .60 , 3.24) 0 .87 (0 .2 7 ,2 .8 7 ) 0.86 (0 .2 5 ,2 .9 8 )
O bese 4 .13**  (2 .07 , 8.28) 3 .78**  (1.72, 8 .33) 3.82** (1 .6 8 ,8 .6 6 ) 5 .56**  (2 .63 , 11.78) 6.44** (2 .6 8 ,1 5 .5 ) 6.34** (2 .5 2 ,1 5 .9 )
A rthritis n = l l ,8 0 0 n = 8 ,4 9 4 n=8,208 n= 12 ,280 n=8,131 n= 7,842
O verw eigh t 1.23 (0 .8 5 ,1 .7 7 ) 1.21 (0 .7 8 ,1 .8 9 ) 1 .1 6 (0 .7 3 ,1 .8 2 ) 0 .96  (0.69, 1.33) 1.01 (0 .6 8 ,1 .5 1 ) 1.01 (0 .6 8 ,1 .5 3 )
O bese 1.43 (0 .83 , 2 .47) 1 .3 9 (0 .7 2 ,2 .6 7 ) 1.41 (0 .7 1 ,2 .8 1 ) 1.74** (1 .2 0 ,2 .5 1 ) 1.91** (1 .21 , 3.01) 1.84* (1 .1 5 ,2 .9 5 )
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D isease n = l  1,855 n= 8 ,534 n=8,248 n = 1 2 ,3 4 7
00V-400IIE n = 7 ,892
O verw eight
O bese
1.33**  (1 .1 7 ,1 .5 2 )  
2 .36**  (2 .0 1 ,2 .7 7 )
1.46** (1 .2 4 ,1 .7 3 )  
2 .78**  (2 .30 , 3 .35)
1.46** (1 .2 4 ,1 .7 3 ) 
2 .88** (2.37, 3.51)
1.42** (1 .26 , 1.61) 
2 .52**  (2 .18 , 2 .90)
1.37** (1 .1 7 ,1 .6 0 )  
2 .62**  (2 .1 8 ,3 .1 5 )
1.40** (1 .1 9 ,1 .6 5 )  
2 .68** (2 .2 1 ,3 .2 5 )
Model 1: odds ratios of risk of the outcome for overweight and obese compared to normal weight reference category in adulthood, adjusted for current age; Model 2: 
Late Model, adjusted for cohort and current age, late life covariates (adult social class, and adult smoking status); Model 3: Combined Model, adjusted for cohort 
and current age, early life covariates (birth weight, childhood social class, childhood height, and age at BMI measurement), late life covariates (adult social class, 
and adult smoking status), and child weight category; all analyses adjusted for weighted sample in NSHD, n=effective population size from weighted analysis. 
CHD=coronary heart disease. T2DM=type 2 diabetes. * p<0.05 **p<0.01
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6.4.2 Results from the Overweight Patterns approach
Table 6-5 shows the frequency of different overweight patterns through childhood, adolescence 
and adulthood. Patterns of overweight were similar in males and females. The majority of 
cohort members (75%) were never overweight (not overweight in childhood and adolescence 
and not obese in adulthood). Upwards movement in weight categories was relatively common: 
10% of cohort members were normal weight in childhood and adolescence and became obese as 
adults, and 3.4% became overweight in adolescence and remained obese in adulthood. 2.3% 
were persistently overweight or obese at all three life stages. It was uncommon for cohort 
members who had been overweight in childhood and in adolescence to become non-obese in 
adulthood (1.4%), but 6.8% were overweight in childhood or adolescence only and normal 
weight/non-obese thereafter.
Table 6-5: Frequency of different overweight patterns through childhood, adolescence and in adulthood, by sex
O v e rw e ig h t p a t te r n n  (% )
M a le F em a le T o ta l
N ever overw eigh t 4 ,259 4,328 8,587
(76.0) (74.1) (75.0)
C h ildhood  only 150 224 374
(2.68) (3.8) (3.3)
A dolescence only 161 236 397
(2.9) (4.0) (3.5)
A dulthood  only 630 514 1,144
(11.2) (8.8) (10.0)
C hildhood  +  adolescence 47 114 161
(0.8) (2.0) (1.4)
C hildhood  +  adulthood 67 63 130
( 1 2 ) ( U ) (1.1)
A dolescence +  adulthood 180 208 388
(3.2) (3.6) (3.4)
P ersisten t overw eigh t 111 155 266
(2.0) (2.7) (2.3)
T otal 5,605
(100)
5 ,842
(100)
11,447
(100)
Associations between overweight patterns and disease outcomes
Associations between different patterns of overweight and disease outcomes are presented in 
Table 6-6. Comparison of odds ratios from analyses stratified by sex and by cohort indicated 
similar effect sizes; interaction terms for sex and cohort were not significant at conventional 
levels, therefore results for all cohort members combined are presented. Compared to those 
who were never overweight, cohort members who were obese in adulthood had increased odds 
of all outcomes (asthma, gallbladder disease, hypertension, type 2 diabetes, coronary heart 
disease, arthritis, and combined disease outcome). Those who were also overweight in
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childhood or adolescence (in addition to being obese in adulthood) had increased odds of 
gallbladder disease, hypertension, type 2 diabetes, CHD, and combined outcomes. Overweight 
in childhood only, and overweight in childhood plus adolescence, were not associated with any 
of the outcomes, although examination of point estimates indicated increasing CHD risk with 
overweight in adolescence and overweight in childhood plus adolescence (ORs 1.63 and 3.43, 
respectively). Examination of odds ratios for type 2 diabetes and CHD indicated that point 
estimates were higher for persistent overweight compared to overweight in adulthood only (type 
2 diabetes: OR for persistent overweight=12.60, OR for obesity in adulthood only=5.5; CHD: 
OR for persistent overweight=6.6, OR for obesity in adulthood only=3.8) (Figure 6-1). 
Comparison of the coefficients for adult obesity versus persistent overweight patterns indicated 
that these were different for type 2 diabetes (p-value from adjusted Wald test=0.015) but not for 
CHD (p=0.41).
Sensitive period and accumulation of risk models
Results from analysis of the effects of overweight and obesity at different sensitive periods 
(childhood, adolescence and adulthood) are presented in Table 6-7. Childhood and adolescence 
did not appear to be a sensitive periods for any outcome: comparison of coefficients for 
exposure in sensitive periods compared to exposure in other periods using an adjusted Wald test 
indicated no difference in effect. There was evidence for adulthood as a sensitive period for 
asthma, gallbladder disease, hypertension, type 2 diabetes, and combined diseases, but not CHD 
or arthritis.
Analysis of the accumulation of risk model showed that there may be an accumulation of risk 
effect for cardiovascular outcomes (Table 6-7). Compared to never overweight, overweight at 
one, two or three time periods in the life course was associated with increased risk of 
hypertension, type 2 diabetes, CHD and combined diseases. Visual examination of the ORs 
(Figure 6-3) indicated that overweight at an increasing number of life stages may be associated 
with increased risk for these outcomes. A test for trend of odds indicated a trend for overweight 
at an increasing number of life stages for type 2 diabetes (p=0.018), but no such trend for 
hypertension (p=0.13) or CHD (p=0.15).
Effects of severity of overweight
Cohort members who were overweight at more time periods had higher BMI in adulthood. 
Those who were overweight at one life stage had mean BMI 30.3 kg/m2 (SD ±5.36), compared 
to 32.8 kg/m2 (±5.51) among those overweight at two stages, and 36.4 kg/m2 (±4.82) among 
those overweight at all three. To investigate the possibility that the associations between
136
sensitive period and accumulation effects and type 2 diabetes may be confounded by the 
severity of obesity, BMI in adulthood was included in the logistic regression models, and its 
effect was assessed using an adjusted Wald test. The coefficient for adult BMI in sensitive 
period models was significant at conventional levels of statistical significance (p<0.0001); 
associations of type 2 diabetes with overweight in childhood and adolescence were in the same 
direction, but confidence intervals included 1 (OR for exposure in childhood=1.47, 95% Cl 
0.89, 2.45, p=0.13; OR for exposure in adolescence=1.47, 95% Cl 0.91, 2.39, p=0.11).
Under the accumulation of risk model, the coefficient for adult BMI was associated with the 
outcome (pcO.OOl), but the number of life stages exposed to overweight remained a predictor of 
type 2 diabetes. OR for overweight at one life stage was 1.99 (95% Cl 1.20, 3.31), for 
overweight at two stages was 2.28 (95% Cl 1.24, 4.18), and for overweight at three stages was 
4.00 (95% Cl 1.74, 9.19). Comparison of coefficients indicated that odds for overweight at 
three life stages may be different to those for overweight at one life stage (p=0.05), but there 
was no difference between overweight at two life stages versus three (p=0.14).
To assess whether combining overweight and obesity as a single exposure category in childhood 
and adolescence may have masked the effects of more extreme overweight in early life, the 
effect of using obesity as the exposure in childhood and adolescence (instead of overweight plus 
obesity) was explored for hypertension and type 2 diabetes, two outcomes with different 
associations with overweight patterns (Table 6-8). For hypertension, using more severe 
overweight in early life as the exposure amplified the effect sizes associated with childhood 
only and adolescence only, but evidence for these effects was weak; there was no strong 
evidence for an effect of obesity in childhood or adolescence on hypertension risk in obese 
adults (OR for persistent obesity 2.83; 95% Cl 0.35, 22.65, compared to OR 2.47; 95% Cl 2.00, 
3.05 for obesity in adulthood only). In contrast, for type 2 diabetes the use of obesity as the 
exposure in early life amplified effect sizes for all patterns that included exposure in childhood 
or adolescence, and the cumulative effect of obesity over the life course was apparent.
Compared to never being obese, obesity in childhood plus adulthood was associated with more 
than seven times the odds of type 2 diabetes (OR 7.64; 95% Cl 1.66, 35.15); obesity in 
adolescence plus adulthood was associated with a twenty-fold increase in odds of type 2 
diabetes (OR 19.45; 95% Cl 8.73,43.33), while persistent obesity was associated an even larger 
effect (OR 36.79; 95% Cl 10.42,129.9). Comparison of odds ratios indicated that the effect 
size for obesity in adolescence plus adulthood was larger than the effect size for obesity in 
adulthood only (p=0.003), as was the effect size for persistent obesity (p=0.004).
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Table 6-6: Odds ratio of disease for different overweight patterns through childhood, adolescence and in adulthood
O v e rw e ig h t P a t te r n A s th m a G B D H y p e rte n s io n T y p e  2 d ia b e te s C H D A rth r i t i s D isease
O R
(9 5 %  C l)
O R
(9 5 %  C l)
O R
(9 5 %  C l)
O R
(95%  C l)
O R
(9 5 %  C l)
O R
(9 5 %  C l)
O R
(95%  C l)
N ever overw eigh t 1 1 1 1 1 1 1
C h ildhood  only 1.01 2 .12 0.87 0.99 0 .44 1.19 0 .99
(0 .6 8 ,1 .5 2 ) (0.94, 4 .76 ) (0 .5 4 ,1 .4 0 ) (0 .3 5 ,2 .8 0 ) (0.20, 1.89) (0.56, 2.55) (0.68, 1.45)
A dolescence on ly 0.53* 1.09 0.97 0.88 1.63 1.67 1.03
(0 .33 , 0 .87) (0 .50 , 2 .37) (0 .6 1 ,1 .5 5 ) (0 .3 1 ,2 .5 0 ) (0 .3 7 ,7 .1 9 ) (0.86, 3 .25) (0 .7 3 ,1 ,4 6 )
A d u lthood  on ly 1.68** 2.07* 2.28** 5.47** 3.83** 1.79* 2.33**
(1 .36 , 2 .06) (1 .1 4 ,3 .7 6 ) (1 .7 6 ,2 .9 5 ) (3.39, 8.82) (1.98, 7 .42) (1.15, 2.79) (1.94, 2 .79)
C h ildhood  + ado lescence 1.09 0 .27 1.01 1.24 3.43 1.68 0 .92
(0 .6 1 ,1 .9 4 ) (0 .04 , 2 .01) (0 .4 6 ,2 .2 1 ) (0 .2 9 ,5 .2 5 ) (0 .6 0 ,1 9 .6 4 ) (0 .6 ,4 .3 4 ) (0 .4 9 ,1 .7 4 )
C h ildhood  +  adu lthood 0 .82 3.94** 2.91** 4.70** 1.10 2.77 2.10**
(0 .4 2 ,1 .5 8 ) (1 .63 , 9 .63) (1 .5 4 ,5 .4 9 ) (1.89, 11.67) (0.14, 8.48) (0 .7 8 ,9 .8 1 ) (1.28, 3 .44)
A do lescence +  adu lthood 1.17 3 .58** 3.01** 6.61** 3.74* 1.29 2.51**
(0 .7 9 ,1 .7 2 ) (1 .72 , 7.46) (2 .1 1 ,4 .2 9 ) (3.61, 12.09) (1 .3 5 ,1 0 .3 5 ) (0 .54 , 3.05) (1 .9 1 ,3 .3 0 )
P ersisten t overw eigh t 1.14 2 .04 2.56** 12.60** 6.62** 1.39 1.94**
(0.79, 1.72) (0 .66 , 6 .34) (1 .4 0 ,4 .6 8 ) (6.61, 23 .98) (1 .9 4 ,2 2 .6 5 ) (0.50, 3 .92) (1 .2 8 ,2 .9 4 )
OR is for odds of disease outcome compared to never overweight category; Adjusted for sex, year of birth, exact age and height at childhood BMI measurement,
birth weight, SEP at birth SEP in adulthood, and smoking status in adulthood; adjusted for weighted sampling in NSHD; * p<0.05; ** p<0.01
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Figure 6-1: Odds ratio of selected disease outcomes for different overweight patterns through childhood, 
adolescence and in adulthood (reference group: never overweight)
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C o ro n a ry  heart d is e a s e  G a llb la d d e r d is e a s e
Reference=Trajectory 1, never overweight. Trajectory: 2= childhood only, 3= ad o lescen ce  only, 
4=adulthood only, 5=childhood+ adolescence, 6=childhood+adulthood, 
7=adolescence+adulthood, 8=persistent overweight
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Table 6-7: Odds ratios of disease for overweight under different sensitive period models (childhood, adolescence and adulthood) and accumulation of risk model
O u tco m e S en sitiv e  p e r io d  m o d e l, O R  (95%  C l)
C h ild h o o d  A d o lescen ce  A d u lth o o d
A c c u m u la tio n  o f  r is k  m o d e l, O R  (95%  C l)
S en sitiv e
p e r io d
O th e r
p e r io d s
S en sitiv e
p e r io d
O th e r
p e r io d s
S ensitive
p e r io d
O th e r
p e r io d s
1 2 3
A s th m a 1.03 1.31** 0 .92 1.44** 1.36 ** 0 .69 1.28** 1.07 1.15
(0 .80 , 1.34) (1 .1 0 ,1 .5 7 ) (0 .7 3 ,1 .1 7 ) (1.20, 1.73) (1 .1 6 ,1 .6 1 ) (0.47, 0 .99) (1 .0 7 ,1 .5 3 ) (0 .7 9 ,1 .4 4 ) (0.73, 1.80)
G a llb la d d e r 1.87* 2 .10  ** 1.80* 2.20** 2.39** 0.81 1.85* 2.53** 2.04
d isease
(1 .0 6 , 3 .31) (1 .3 2 ,3 .3 3 ) (1 .06 , 3 .05) (1 .36 , 3.55) (1 .5 7 ,3 .6 5 ) (0.39, 1.70) (1.15, 2 .97) (1 .4 1 ,4 .5 7 ) (0 .6 6 ,6 .3 3 )
H y p e r te n s io n 1.38 1.97** 1.65** 1.85** 2.07** 0 .98 1.58** 2.23** 2.51**
(0 .9 9 ,1 .9 2 ) (1.59, 2 .44) (1 .2 4 ,2 .1 8 ) (1 .48, 2.32) (1 .6 9 ,2 .5 3 ) (0.65, 1.47) (1.26, 1.96) (1 .5 9 ,3 .1 1 ) (1 .3 9 ,4 .5 6 )
T y p e  2 d ia b e te s 4 .28** 4.62** 4.76** 4.36** 5.43** 0.97 3.63** 4.93** 12.65**
(2 .5 9 ,7 .0 6 ) (3 .04 , 7 .02 ) (3 .02 , 7 .51) (2.79, 6.80) (3 .6 9 ,7 .9 9 ) (0.40, 2 .31) (2.32, 5.69) (2.92, 8.32) (6 .6 3 ,2 4 .1 5 )
C H D 2.24 3 .25** 3 .22** 2.78** 3.21** 2 .05 2 .60** 3 .25* 6.60**
(0 .92 , 5 .45) (1.83, 5 .78) (1 .56 , 6 .64) (1 .4 9 ,5 .1 8 ) (1 .8 6 ,5 .5 5 ) (0.63, 6 .64) (1 .4 2 ,4 .7 6 ) (1.33, 7 .91) (1.92, 22.62)
A r th r i t is 1.47 1.66** 1.51 1.67** 1.58* 1.68 1.63** 1.58 1.39
(0 .9 0 ,2 .4 2 ) (1.16, 2 .39) (0 .9 7 ,2 .3 5 ) (1 .1 4 ,2 .4 6 ) (1 .1 1 ,2 .2 4 ) (0 .96, 2 .93) (1 .1 4 ,2 .3 3 ) (0.88, 2 .84) (0 .5 0 ,3 .9 1 )
D isease 1.30* 1.97** 1.51** 1.90** 1.99** 1.00 1.66** 1.87** 1.93**
(1 .02 , 1.66) (1 .69 , 2 .30) (1 .2 3 ,1 .8 5 ) (1 .6 1 ,2 .2 4 ) (1 .7 2 ,2 .3 1 ) (0 .7 4 ,1 .3 6 ) (1 .42, 1.95) (1.45, 2.41) (1 .2 7 ,2 .9 2 )
OR is for odds of disease outcome compared to never overweight category; Adjusted for sex, year of birth, exact age and height at childhood BMI measurement,
birth weight, SEP at birth SEP in adulthood, and smoking status in adulthood; adjusted for weighted sampling in NSHD; * p<0.05; ** p<0.01
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Table 6-8: Odds ratio of hypertension and type 2 diabetes for different overweight patterns through childhood, 
adolescence and in adulthood using different cut-offs for overweight in early life
O v e rw e ig h t P a t te rn H y p e r te n s io n T y p e  2 d ia b e te s
O v e rw e ig h t! O b e s i ty ! O v e rw e ig h tf O b esity }
O R
(9 5 %  C l)
O R
(9 5 %  C l)
O R
(9 5 %  C l)
O R
(9 5 %  C l)
N ever overw eigh t (or 
never obese)
1 1 1 1
C hildhood  only 0.87 1.99 0.99 2.95
(0 .5 4 ,1 .4 0 ) (0.38, 10.50) (0 .35 , 2.80) (0.37, 23.31)
A dolescence only 0.97 2.38 0.88 O m itted
(0 .6 1 ,1 .5 5 ) (0.78, 7 .24) (0 .3 1 ,2 .5 0 )
A dulthood  only 2.28** 2.47** 5.47** 5.67**
(1 .7 6 ,2 .9 5 ) (2.00, 3 .05) (3.39, 8 .82) (3.77, 8.52)
C hildhood + adolescence 1.01 0 .64 1.24 O m itted
(0 .4 6 ,2 .2 1 ) (0.04, 11.16) (0 .2 9 ,5 .2 5 )
C hildhood  +  adulthood 2.91** 5.00** 4.70** 7.64**
(1 .5 4 ,5 .4 9 ) (1.82, 13.76) (1 .8 9 ,1 1 .6 7 ) (1.66, 35.15)
A dolescence +  adulthood 3.01** 2.48 6.61** 19.45**
(2 .1 1 ,4 .2 9 ) (0 .72, 8.49) (3 .6 1 ,1 2 .0 9 ) (8 .7 3 ,4 3 .3 3 )
Persisten t overw eigh t (or 
persis ten t obesity)
2.56**
(1 .4 0 ,4 .6 8 )
2.83
(0 .35, 22.65)
12.60**
(6 .6 1 ,2 3 .9 8 )
36.79**
(10.42, 129.9)
tOverweight patterns refer to overweight defined using IOTF criteria in childhood and 
adolescence, and obesity in adulthood; tOverweight patterns refer to obesity defined using 
IOTF criteria in childhood and adolescence, and obesity in adulthood. OR is for odds of disease 
outcome compared to never overweight category; Adjusted for sex, year of birth, exact age and 
height at childhood BMI measurement, birth weight, SEP  at birth SEP  in adulthood, and 
smoking status in adulthood; adjusted for weighted sampling in NSHD; * p<0.05; ** p<0.01
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Figure 6-2: Odds ratio of selected disease outcomes for different sensitive period models (reference group: never 
overweight)
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Figure 6-3: Odds ratio of selected disease outcomes for accumulation of risk models (reference group: never 
overweight)
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Sensitivity analyses
Analyses of associations of raw BMI at each life stage with outcomes showed that childhood 
BMI was positively associated with asthma, hypertension and type 2 diabetes, while BMI in 
adolescence was positively associated with gallbladder disease, hypertension, type 2 diabetes, 
and combined diseases. These associations were attenuated to the null after adjustment for BMI 
in later life. BMI in adulthood was positively associated with all outcomes, and these effects 
remained after adjusting for early life BMI.
Exclusion of ethnic minority groups from analyses did not appreciably affect the results. For 
illustration, comparisons of odds ratios for type 2 diabetes from stepwise analyses are presented 
in Table 6-9. Adjustment for self-reported weight and height in adulthood in NCDS and BCS70 
increased the estimated prevalence of overweight and obesity. In NCDS, obesity prevalence 
among men increased from 19.9% to 27.5%, while overweight and obesity combined increased 
from 70.2% and 77.0%. Among women, the prevalence of obesity increased from 18.3% to 
22.0%, and the prevalence of overweight plus obesity increased from 49.2% to 53.5%. The 
pattern in BCS70 was the same, with obesity prevalence increasing from 17.7% to 23.3% 
among males (overweight plus obesity increased from 60.6 to 68.2%), and from 15.5% to 
18.0% among female cohort members (overweight plus obesity increased from 40.5% to 
44.1%). The results from sensitivity analyses adjusting for self-reported weight and height did 
not show a substantive change in the direction or magnitude of coefficients. Complete-case 
analyses resulted in associations in the same direction, but larger effects sizes for childhood 
obesity were observed. Comparison of hazard ratios from survival analysis with odds ratios 
from the original pooled analyses indicated similar patterns of association between overweight 
and obesity at each life stage and disease outcomes.
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Table 6-9: Results from sensitivity analyses for type 2 diabetes using Stepwise approach, 1) OR from pooled analyses of all male cohort members, 2) OR from analyses excluding ethnic minority 
groups, 3) OR from analyses using adjustment for BMI from self-reported height and weight, 4) OR from complete case analysis, and 5) hazard ratio from survival analysis. * p<0.05; ** p<0.01.
Type 2 
diabetes
All males 
OR (95% Cl)
Excluding ethnic m. 
groups, OR (95% Cl)
Adjusted for self- 
reported BMI, OR
(95% Cl)
Analysis of complete 
cases, OR (95% Cl)
Survival analysis 
HR (95% Cl)
Model 1 Child n=10,336 n=10,212 n=10,336 n=5,540 n=9,297
Obese 2.60 (0.89, 7.63) 2.66 (0.90, 7.82) 2.60 (0.89, 7.63) 4.88* (1.28, 18.65) 3.45** (1.39, 8.52)
Adolescent n=8,246 n=8,143 n=8,246 n=5,540 n=6,792
Obese 11.83** (6.54, 21.40) 11.64** (6.33, 21.4) 11.83** (6.54,21.40) 9.99** (4.27, 23.35) 9.01** (5.30, 15.32)
Adult n= 11,820 n= 11,644 n=11,820 n=5,540 n=9,717
Obese 5.74** (3.53, 9.33) 6.05** (3.67, 10.0) 5.14** (3.06, 8.62) 6.89** (3.18, 14.96) 5.81** (3.61,9.37)
Model 2 Child n=9,884 n=9,778 n=9,884 n=5,540 n=8,468
Obese 3.03* (1.01, 9.09) 3.03* (1.01,9.09) 3.02* (1.01,9.08) 5.41* (1.43,20.47) 4.01** (1.61, 10.02)
Adolescent n=6,960 n=6,905 n=6,960 n=5,540 n=5,657
Obese 13.40** (6.86,26.17) 13.56** (6.94,26.5) 13.30** (6.86, 26.14) 10.46** (4.42, 24.72) 9.92** (5.60, 17.60)
Adult n=8,512 n=8,427 n=8,512 n=5,540 n=7,036
Obese 7.44** (3.85, 14.40) 7.76** (3.96, 15.2) 6.84** (3.44, 13.63) 7.37** (3.34, 16.25) 5.87** (3.25, 10.61)
Model 3 Child n=8,226 n=8,145 n=8,226 n=5,540 n=6,795
Obese 2.97 (0.97, 9.08) 2.97 (0.97,9.11) 3.32* (1.08, 10.19) 3.11 (0.86, 11.21) 3.48** (1.38, 8.80)
Adolescent n=5,727 n=5,681 n=5,727 n=5,540 n=4,444
Obese 4.43** (1.72, 11.39) 4.45** (1.72, 11.6) 4.68** (1.85, 11.85) 4.20** (1.58, 11.21) 3.57** (1.54, 8.27)
Adult n=8,226 n=8,145 n=8,226 n=5,540 n=6,795
Obese 7.32** (3.73, 14.36) 7.62** (3.83, 15.2) 6.60** (3.27, 13.34) 7.27** (3.24, 16.30) 5.75** (3.13, 10.56)
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6.5 Summary and im plications
Stepwise analyses using standard adjustment for BMI at different periods showed that there 
were associations between overweight in early life and cardiovascular outcomes, which were 
attenuated after adjustment for BMI in adulthood, as observed in the systematic review of the 
literature in Chapter 3. However, results from a life-course approach to analysis indicated that 
overweight in childhood and adolescence increased type 2 diabetes risk in obese adults, and 
may have contributed to CHD risk. An effect of overweight in childhood and adolescence was 
not observed for other outcomes, including hypertension. Based on these results, a series of 
interpretations can be proposed which help to build a picture of pathways from overweight in 
early life to the different outcomes, notably cardiovascular outcomes (type 2 diabetes, 
hypertension and CHD) which have been consistently shown to be associated with childhood 
overweight.
Analyses of overweight patterns showed that persistent overweight through childhood, 
adolescence and adulthood was associated with higher odds of type 2 diabetes compared to 
obesity in adulthood only. This finding was in contrast to those of a previous study, which 
found no difference in the relative risks of type 2 diabetes between those with persistent 
overweight through childhood and adulthood, and those with obesity isolated to adulthood 174; 
however, the outcomes in this previous study were reported at a younger age than in the present 
analyses and there were fewer cases of type 2 diabetes, which may have reduced the power to 
detect a difference. The analyses in this chapter showed evidence of increasing type 2 diabetes 
risk with overweight at more life stages, a trend which was more apparent when obesity rather 
than overweight was treated as the exposure in childhood and adolescence. However, an effect 
of overweight or obesity in childhood and adolescence was not observed in cohort members that 
were not obese in adulthood; childhood and adolescence therefore did not appear to be critical 
periods for exposure. This finding is supported by studies which have shown that reduction in 
overweight in childhood or adulthood can lead to improvement in metabolic parameters 
and reversion from impaired to normal glucose tolerance.88 Adjustment for adult BMI 
indicated that the severity of overweight in later life associated with persistent overweight 
(which may also act as an indicator of cumulative exposure to overweight in adulthood271) did 
not account for all of the excess risk. Although the inclusion of adult BMI in the model is 
subject to overadjustment issues similar to those discussed in Chapter 4.3.2, this result lends 
support to a model of type 2 diabetes progression in which risk is affected by the duration or 
accumulation of exposures over the life-course rather than to the severity of overweight in 
adulthood. These collective observations would be consistent with a conceptualisation of type 2 
diabetes progression in which overweight contributes to (or is a marker of) increasing insulin 
resistance and gradual loss of beta cell function over time,361 eventually leading to type 2
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diabetes.362 Individuals that are exposed to overweight in childhood and become non-obese in 
adulthood may have increased levels of insulin resistance and glucose, which do not reach the 
threshold for a diagnosis of type 2 diabetes when levels of overweight in adulthood are reduced. 
A further consideration is that persistent overweight may indicate some underlying genetic 
predisposition to overweight and metabolic complications.363
In contrast to the findings for type 2 diabetes, exposure to overweight in early life did not 
appear to increase the risk of hypertension in obese adults; this was also the case when more 
extreme overweight in childhood and adolescence (obesity) was considered as the exposure. 
These associations are more consistent with a model in which obesity in adulthood accounts 
predominantly for hypertension risk, rather than longer term effects associated with overweight 
in childhood and adolescence. This is different to the findings of a previous study, which 
showed that overweight in childhood and adolescence was associated with additional 
hypertension risk compared to obesity in adulthood alone.174 However, other studies have 
shown that lower BMI in childhood in combination with overweight in adulthood is associated 
with the highest risk of hypertension,121 indicating that rapid growth over the life-course may 
be an important determinant of hypertension risk.223 Alternative explanations are that obesity 
has more immediate and temporary effects on blood pressure, or that obesity in adulthood is a 
marker for other risk factors which may either act over the life-course or more 
contemoraneously in adulthood, to determine hypertension risk. For example, body size in 
adulthood may be linked to lifestyle behaviours that are associated with hypertension, such as 
salt consumption,364 or to factors that act on hypertension risk through psychosocial pathways, 
such as anxiety and depression. 365 366 The mechanisms by which obesity leads to hypertension 
are not well understood, and there may be multiple pathways to elevated blood pressure367; 
further examination of the relative contributions of overweight and other risk factors to 
hypertension risk may identify where intervention efforts should be focused in order to reduce 
the burden of hypertension.
Point estimates for CHD indicated a possible trend for higher risk associated with overweight at 
more life stages. The relatively young ages at measurement of outcomes in these cohorts, which 
explained the small number of CHD cases, meant that the analyses had limited power to detect a 
difference. Elevated blood glucose levels and blood pressure are risk factors for cardiovascular 
disease. 368 369 Consequently, the relationship between overweight and CHD may have been 
driven in part by the associations of overweight with type 2 diabetes and hypertension. For 
example, a large study of data from 58 prospective studies indicated that BMI in adulthood did 
not improve prediction of CVD risk when information on systolic blood pressure, diabetes 
history and serum lipids was available.370 The contrasting relationships of type 2 diabetes and 
hypertension with overweight over the life-course may explain the intermediate effect on CHD 
that was observed in this chapter, with overweight acting on type 2 diabetes risk from early life
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and on hypertension risk at later ages. The effects of adjusting CHD models for type 2 diabetes 
and hypertension were examined (results presented as supplementary table in Appendix 3); 
adjustment for hypertension had little impact, while adjustment for type 2 diabetes led to 
attenuation of effect sizes, indicating that the associations of CHD with overweight patterns 
may be partly explained by the relationship between overweight and type 2 diabetes. Bringing 
together the findings for the different cardiovascular outcomes included in this analysis, a 
theoretical model may be proposed as a framework for understanding cardiovascular risk: 
childhood and adolescent overweight may contribute to high blood glucose levels (possibly 
leading to type 2 diabetes) and atherosclerosis, which in addition to high blood pressure and 
obesity in later life lead to further atherosclerosis and increased CHD risk. Disentanglement of 
the relationships between overweight and other cardiovascular risk factors, and their 
contributions to type 2 diabetes, hypertension and CHD over the life-course will be key for 
understanding the mechanisms to cardiovascular disease, and this will have important 
implications for approaches to interventions to reduce cardiovascular burden.
In these analyses, overweight in childhood and adolescence did not appear to contribute to 
asthma, gallbladder disease or arthritis risk; obesity in adulthood was associated with each of 
these outcomes, but there was no indication of a cumulative effect of overweight from 
childhood. As the review in Chapter 3 demonstrated, evidence for a relationship between 
childhood overweight and non-cardiovascular outcomes is relatively limited. One interpretation 
of these findings is that obesity in adulthood has the largest effect on these outcomes, while 
overweight and obesity in earlier life have little effect on long-term risk. Or it may be the case 
that obesity in adulthood is a marker of some other risk factor for these conditions. However, 
this study was limited by the relatively low prevalence of arthritis and gallbladder disease, and 
asthma may be subject to misdiagnosis, with respiratory problems attributable to other 
conditions being diagnosed as asthma.371 Furthermore, the transient nature of asthma symptoms 
makes it difficult to establish the relative timings of childhood overweight, initial diagnosis of 
asthma, and subsequent relapse. Cases of asthma that were first diagnosed in childhood were 
included in this analysis; it was not possible to identify individuals with asthma isolated to 
childhood (and no relapse in adulthood), as health questionnaires in adulthood asked only about 
whether there was any history of asthma, and symptoms in the past 12 months. Inclusion of 
these cohort members in the analyses may have masked any relationship between childhood 
overweight and asthma relapse in adulthood. Analysis of larger datasets with more cases is 
required to establish the effects of overweight and obesity in early life on these outcomes.
A common factor that is implicated in a number of obesity co-morbidities is inflammation; pro- 
inflammatory molecules are known to be expressed by adipose tissue,372 and exposure to 
overweight in childhood may have longer-term effects on disease risk. For example, 
inflammation has been associated with insulin resistance, atherosclerosis, and non-alcoholic
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fatty liver disease. 372 In the case of asthma, increased adipose tissue may lead to a systemic 
inflammatory state, which results in chronic inflammation of the airways, and even permanent 
changes in lung function.245 Persistent inflammation can also lead to joint problems including 
rheumatoid arthritis.373
The main limitations of this analysis include the use of self-reported outcomes, which may have 
been subject to measurement error and biases. Previous studies have indicated that misreporting 
is especially likely for less severe diseases or those with more transient symptoms, such as 
hypertension and asthma.352 Undiagnosed conditions may be more common among healthy 
weight individuals who are likely to have less contact with health services, which could lead to 
an overestimation of the effects of overweight. On the other hand, overweight individuals are 
more likely to be lost to follow-up, which may produce more conservative effect sizes. Another 
limitation of this analysis is the use of BMI measurements at single ages to represent exposure 
to overweight over a period of development. Increasing evidence indicates that patterns of 
growth over the life course (notably small size at birth and catch-up growth in later life) are 
related to body composition and body size, and to increased cardiovascular risk in later life.239 
Childhood overweight, measured using BMI at a single stage of development, could not capture 
the dynamic processes of growth and changes in body composition374"375 that take place over the 
life-course, which may have important implications for some health outcomes. 239 376 
Furthermore, the developmental stages of childhood, adolescence and adulthood encompassed 
different lengths of time over the life-course, therefore exposure in each life period (assuming 
that overweight spanned the whole life period) did not correspond to an equal ‘dose’ of 
overweight or obesity. Further examination of the relationships between age at onset and 
duration of overweight, and patterns of growth in early life may further elucidate the 
mechanisms underlying these associations. These analyses have considered multiple outcomes 
and several groups of exposures, therefore analyses are subject to multiple testing problems 377; 
given the large number of associations tested, the chance of type 1 errors (false positives) is 
increased, and single associations should be interpreted with caution, especially where effects 
are inconsistent, e.g. an association is observed with overweight but an association in the same 
direction is not observed with obesity. In the case of type 2 diabetes, a dose-response effect, 
small p-values and consistent findings across different model specifications and sensitivity 
analyses indicate that this association was not a spurious result.
The pooling of data from three cohorts had the advantage of increasing power over a single 
study, and these three British National Birth Cohort datasets have not been analysed together in 
this way previously. A clear benefit of using these data is that the comparability of target 
populations and similarities in data collection allow the harmonisation of datasets with minimal 
loss of information. However, there were some differences in BMI trajectories (as described in 
5.3) and variation in the ages at ascertainment of disease outcomes; pooled analyses may have
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masked individual cohort effects that were not detected in the test for interaction by cohort. A 
more general limitation of cohort studies with long-term follow-up concerns the generalisability 
of findings to contemporary populations of children. Notably for these analyses, children today 
are experiencing more extreme obesity and at earlier ages than was observed in the British 
national birth cohorts. The effects of obesity of this nature on long-term health may be distinct 
from those observed in historical cohorts; for example, the number of cases of type 2 diabetes 
among young people is rising, highlighting the more contracted nature of disease progression 
and health implications of severe obesity in childhood. However, in the absence of more robust 
study designs, such as randomised controlled trials of obesity interventions with long-term 
follow-up, data from observational studies are important for providing insight into these 
relationships.
Analyses based on a life-course perspective indicate that overweight in childhood and 
adolescence may contribute to excess risk for cardiovascular outcomes, notably type 2 diabetes, 
in obese adults. For other outcomes, more contemporaneous exposure to obesity appears to 
account for the excess risk associated with overweight. The associations between childhood 
overweight, adult obesity and later health outcomes have important implications for determining 
the nature and timing of obesity interventions.
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7. CHILDHOOD OBESITY AND LONG TERM HEALTH BURDEN
7.1 Introduction
The systematic review in Chapter 3 and analyses of the British Birth Cohort data in Chapter 6 
showed that overweight and obesity in childhood and adolescence are associated with several 
disease outcomes in adulthood, notably cardiovascular risk. There is widespread concern about 
the impending disease burden associated with current levels of childhood obesity,14'15 which is 
expected to present a considerable strain on health and public services and the economy over the 
coming decades. Consequently, reducing childhood obesity prevalence was highlighted as a 
major public health priority for the UK government in the 2008 Healthy Weight, Health Lives, 13 
and 2011 Healthy Lives, Healthy People 378strategies. However, while estimates of future 
trends in childhood obesity prevalence 379 and current burden of childhood obesity co­
morbidities 159 have been published, the expected long-term burden of the childhood obesity 
epidemic and its associated costs have not been quantified. Furthermore, the impact of 
different strategies for intervention on long-term outcomes has not been assessed in the UK 
population.380
The National Heart Forum Obesity model was developed by the modelling group at the 
National Heart Forum (NHF), London as part of the Office for Scientific Foresight Programme, 
19 which culminated in the 2007 Foresight Obesity report. The model has two components: a 
model of BMI trends and a micro-simulation (individual-based) stochastic model that has been 
used to project the future disease burden and NHS costs of current obesity trends, and to explore 
the impact of interventions; the estimates generated using this model have been used by the 
Department of Health as the basis for predictions of future obesity burden in the U K .45 This 
model was developed to simulate what happens in the UK population, but has not been used for 
estimating childhood obesity burden specifically.
This chapter begins with a summary of the model and assumptions, based on descriptions 
detailed in other publications 19163 and correspondence with the authors. The results of 
simulations that estimate the future disease burden and costs associated with obesity in the 
current cohort of UK children and adolescents are presented, and the effects of different 
approaches to intervention on this cohort are explored. This is followed by an examination of 
the model assumptions and fit of the model to historical data, with discussion of the 
implications of these exploratory analyses.
7.2 Overview of the National Heart Forum Obesity Model
The NHF Obesity Model comprises two distinct components (Figure 7-1). The first part is the 
BMI distribution model, which uses a regression model to produce cross-sectional BMI
distribution data. The second part is the health outcomes model, which implements a micro­
simulation model for the longitudinal analysis of populations and quantifies the effects of BMI 
distribution on selected health outcomes.
Figure 7-1: Schematic overview of NHF obesity model
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7.2.1 BMI distribution model
The BMI distribution model uses a series of cross-sectional datasets to estimate the distribution 
of user-specified BMI groups (e.g. using raw BMI cut-offs or IOTF cut-offs to define 
overweight and obesity) in the population overtime. These distributions can be specilied by 
age, sex, ethnicity, social class group and geographical region (data-permitting). Trends in the 
proportion of people belonging to any particular BMI group are extrapolated using a non-linear 
regression model, which allows for the total prevalence of all BMI groups in the population to 
add up to 100%, and any approach to 0 or 100% by any BMI group is asymptotic and cannot 
exceed these limits (Equation 1). Distributions can be extrapolated to 2050 and beyond. The 
posterior distribution of the parameters is used to define the contidcnce limits around the 
regression line, and can be specified by the user. The BMI distribution data that are produced 
using this model form the input to run the second component of the model.
£ ( 1  +  t a n h ( a k +  b k t ) )
k=1
a, = a,(Age,Sex,...) b, = b,(Age,Sex,...)
Pb,(*)s probability of belonging to bmi group B at time t
Equation l 19
For projections in the 2007 Foresight report, and in this thesis, data from the Health Surveys for 
England (HSE) were used. The HSE data are a series of annual cross-sectional surveys carried 
out by the Joint Survey Unit of the National Centre of Social Research and the Department of 
Epidemiology and Public Health at University College London. ,M The surveys are designed to 
monitor trends in health. The survey focuses on different health issues each year, but core 
variables including height and weight are measured each year. Children have been included in
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the surveys since 1995, and data are available up to 2008. All private households in the general 
population are eligible for inclusion, and a multi-stage stratified random sample is used to select 
up to two children aged 2-15 years from each household. The number of children included in 
the surveys has ranged from around 4,000 in most years, to 7,000 in boost years (1997, 2002, 
2005-2007). To account for the sampling method in the HSE, weighting factors are used. 
Additional data points may alter the projected BMI trends, as seen in a recent update of the 
childhood obesity projections presented in the Foresight report, 382 which showed that the 
upward trend in BMI may be levelling off.
7.2.2 Micro-simulation (health outcomes) model
The micro-simulation program can be described as five modules defining the demography, BMI 
distribution, disease, interventions and costs of the model population. The model simulates the 
changing BMI distribution and acquisition of overweight-related diseases in a population of 
individuals. Some individual characteristics are set from the start, such as sex, age and 
ethnicity, while other characteristics, notably the transition probabilities for movement between 
disease states, depend on events that occur during the lifetime of the simulated individuals, such 
as whether the individual becomes overweight and whether they have any other disease. The 
occurrence of events is stochastically determined, using Monte Carlo sampling from defined 
probability distributions. The simulation is based on rounds, with each round encompassing one 
year. The user can specify the number of runs, the dates at which the simulation begins and 
ends, any intervention scenarios, the diseases to include, and the years for which the output is 
required. Uncertainty is not modelled explicitly, but is quantified in error analyses which 
tabulate variability arising from the micro-simulation.
Demography
The demography input parameters determine the initial population composition and background 
mortality and fertility in the population. In the model, the most recent age- and sex-specific 
vital statistics from the Office of National Statistics are used, and the model does not allow 
these rates to vary over time (except for estimated changes due to changes in the BMI 
distribution). The initial population is defined by specifying the age-sex structure at the start of 
the simulated period (e.g. in year 2007). The age-specific fertility rates are used to calculate the 
number of births among women in each age group. The births are randomly allocated to women 
in each round. Age- and sex-specific mortality rates are used to calculate the background 
number of deaths in each round (before accounting for deaths due changes in BMI distribution). 
The model does not account for migration. Demographic outputs include disease-specific and 
total mortality in specified years, and life expectancy in the simulated population. Period 
estimates of life expectancy are calculated over 5-year intervals, based on death rates over the 
simulated period.
152
BMI distribution
User-specified age- and sex-specific BMI distributions for each year of the simulated period 
(which can be generated from the BMI distribution model) are used to determine probabilities 
of transfer between BMI groups (e.g. from overweight to obese) in each round. The model 
specifies that individuals stay on the same BMI centile from the start of the simulated period to 
the end (or until death if that occurs first). The outputs include BMI distributions and 
prevalence of overweight and obesity by age and sex.
Disease
Disease parameters allow simulated individuals to contract user-specified diseases with a 
probability calculated from the background age- and sex-specific incidence of the disease in the 
population, and the age-, sex- and BMI-specific relative risk of the disease, in each round.
Users can also specify whether disease probabilities are conditional on other disease states, such 
as CHD risk conditional on type 2 diabetes. Individuals who contract a disease can die from 
the disease with a probability determined by the age- and sex-specific disease-specific mortality 
rate. The model does not allow for individuals to be cured of a disease, they either continue to 
have the disease until the end of the simulation period or die (due to the disease or for some 
other reason). Disease outputs include disease incidence and prevalence by age and sex, and 
cause-specific mortality.
Interventions
This module changes parameters in the BMI distribution to model the impact of interventions 
on disease, mortality, and costs. The effect of an intervention is expressed in terms of BMI 
change or by imposing a cap on BMI. These intervention effects can be specified by age, sex 
and BMI, and target years (e.g. BMI is reduced by 1 unit in obese boys aged 6-12 in the years 
2015-2018). The output in terms of disease prevalence, incidence, mortality, life expectancy or 
NHS costs under different scenarios can be compared to estimate the impact of different 
intervention approaches.
Costs
Annual costs to the NHS of obesity-related diseases (e.g. from government reports 383) are 
multiplied by the number of cases to estimate the direct health costs. The costs attributable to 
changing BMI distribution can be estimated by comparison with costs at baseline or under 
different scenarios of BMI change. The model does not vary costs, inflation or the value of 
money over time. The model can also be used to estimate the wider economic costs of 
overweight and obesity by multiplying the estimated NHS costs by the current ratio of wider 
societal costs to NHS costs of overweight and obesity (e.g. in 2001 this ratio was estimated to 
be 1:6). In the model this ratio is held constant over the simulated period.
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7.3 Estimating the future d isease burden associated with childhood obesity
7.3.1 Methods
I obtained a copy of the NHF obesity model programme from the NHF modelling group, and 
ran all the projections on a standard desktop PC. Using the two-part modelling process 
described above, a virtual population of UK children and adolescents was projected from the 
year 2007 to 2050. This year was selected as the end point to enable comparison of estimates 
with previous projections of obesity burden in the UK population. I specified the population 
distribution for a population aged 2-19 years in 2007 (and therefore aged 45-62 years at the end 
of the simulation period) as a PF (.pf) file, based on the age-sex structure from mid-year 
population estimates from the Office for National Statistics. 384 The 2007 population was 
selected because the BMI, disease and cost data were valid for this year. The data that were 
used to specify the population size and age-sex structure can be seen in Appendix 4. Fertility 
rates were not applied, therefore the population did not increase in size over time. Using the 
BMI distribution model, HSE data from 1995 to 2008 were used to project BMI distributions by 
age (in 5 year groups) and sex to 2050. Weight categories were defined as previously, using 
IOTF cut-offs in childhood and WHO definitions in adulthood. In the simulation, BMI values 
were assigned probabilistically to individuals in the virtual population according to age, sex and 
year, based on the projected BMI distributions.
The disease and cost data that were used in the 2007 Foresight Obesity report were used in these 
simulations. Disease data were obtained from reviews of epidemiological publications, to 
determine age- and BMI-specific incidence, case-fatality rates, and relative risks of disease for 
type 2 diabetes, CHD, stroke, arthritis and obesity-related cancer. The sources of data inputs are 
summarised in Table 7-1. In each round of the simulation, each individual had an age-, sex- and 
BMI-specific probability of contracting a certain disease, if they were free of that disease in the 
previous year. Individuals who contracted a disease could die of the disease, depending on the 
survival and case-fatality data. Annual costs of each disease due to the changing distribution of 
BMI were estimated from governmental data or other published estimates; the direct cost per 
case was calculated as the total medical costs (including hospital care, healthcare professionals 
and drugs) divided by the number of patients. Diseases and the associated costs were assigned 
probabilistically to individuals as a function of their BMI history using a Monte Carlo 
simulation method 385 (transitions between states were randomly drawn from the specified 
probability distribution to determine events).
For each scenario, I simulated one million individuals ageing to 2050, and analysed the output. 
Estimates of annual disease prevalence, incidence and costs were extracted from the output 
TAB files into Microsoft Excel for analysis. The estimates based on simulations of one million 
individuals were scaled up to the size of the 2007 child and adolescent population (13.25
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million), to generate estimates of population burden. The diseases attributable to changes in 
BMI distribution and associated costs were calculated as the difference between estimates for 
each scenario and the reference scenario, which assumed that BMI distributions were fixed at 
the 2007 level, therefore producing an estimate of additional burden due to rising prevalence of 
overweight and obesity over the years of the projection. All results were applicable to the 
projected cohort of children and adolescents in 2007, and did not include cases in the wider 
population (other age groups).
Table 7-1: Sources of data inputs used in simulation
Population characteristics
BMI distribution 
Population size 
Incidence of disease 
Hypertension 
Coronary heart disease 
Type 2 diabetes 
Stroke 
Cancer 
Arthritis
Relative risks associated with obesity
Hypertension
Coronary heart disease
Type 2 diabetes
Stroke
Cancer
Arthritis
Disease-specific mortality and survival
Hypertension 
Coronary heart disease 
Type 2 diabetes 
Stroke 
Cancer 
Arthritis 
Costs
Hypertension
Coronary heart disease
Type 2 diabetes
Stroke
Cancer
Arthritis
Source
British National Birth Cohorts
British National Birth Cohorts
British Heart Foundation statistics 386
European cardiovascular disease statistics387 
British Heart Foundation statistics 386 
British Heart Foundation statistics386 
Cancer Research UK statistics388 
Office for National Statistics389 390
390UK Foresight Tackling Obesities programme 
International Association for the Study of Obesity 391 
International Association for the Study of Obesity391 
International Association for the Study of Obesity 391 
International Association for the Study of Obesity 391
<non-terminal>
* • 387European cardiovascular disease statistics 
British Heart Foundation statistics 386 
British Heart Foundation statistics 386 
Cancer Research UK statistics388 
<non-terminal>
British Heart Foundation statistics 386 
British Heart Foundation statistics 386 
NHS Information Centre392 
British Heart Foundation statistics386
390UK Foresight Tackling Obesities programme 
National Rheumatoid Arthritis Society report393
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Interventions: exploratory analyses
The effects of different intervention scenarios on disease burden and associated costs were 
explored using the simulation model. Long-term weight loss in adults has been shown to be 
associated with lower risk of type 2 diabetes, hypertension and cardiovascular disease.394 
However, systematic reviews have shown that most interventions for the prevention of 
childhood obesity do not have a large effect on BM I,165 while evidence for long-term effects of 
specific interventions for the treatment of childhood obesity is lacking. 395 This was also a key 
finding in a systematic review of pharmacotherapy for childhood obesity that was conducted as 
initial background work for this chapter (Appendix 5). Information on the sustainability of 
intervention effectiveness and associated future health outcomes is important for determining 
the long-term impact of childhood obesity interventions. However, current studies do not have 
follow-up of sufficient duration to address these data needs.396 Therefore scenarios were 
specified to reflect hypothetical long-term effects of large-scale interventions for childhood 
obesity prevention and treatment, based on the available evidence for current obesity 
interventions.
Intervention scenarios were defined in terms of their effect on childhood overweight, and were 
broadly categorised as population (general) or individual (high risk) approaches, as described by 
Geoffrey Rose in his seminal paper.397 The former term applies to interventions that are directed 
at the whole population, which aim to shift the entire distribution of a risk factor in a population 
towards a more favourable position. An example of such an intervention is the national 
Change4Life social marketing campaign in England, which is a government initiative that aims 
to help families make sustainable changes to their diet and physical activity through mass 
media, including television, print and online resources. The campaign presents obesity and 
healthy lifestyle as issues that are relevant to the whole population, rather than to any select 
group considered to be high risk. An evaluation of the Change4Life campaign showed that 
there was little impact of the print and online information on parenting behaviours or child 
health behaviours.398 The effect of this campaign on childhood BMI or overweight has not been 
assessed, but its effects on weight-related behaviours suggest that any beneficial effect is likely 
to be minimal. However, with a population approach, while the benefit to any given individual 
in the population may be small, if large numbers of people experience the benefit, the effect at 
the population level is potentially large, a scenario known as the Prevention Paradox.397 The 
impact of population approaches to obesity prevention on long-term burden, taking the 
Change4Life campaign as an example, was assessed using the simulation model.
The individual or high-risk approach refers to those interventions which target members of the 
population that are most susceptible to obesity or its co-morbidities. If effective, such 
interventions would truncate the distribution of BMI at the high risk end, while the rest of the
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distribution may remain unaffected. In the case of childhood obesity, individual-based 
interventions would include tailored interventions for overweight and obese children, such as 
the MEND (Mind, Exercise, Nutrition, Do It!) 7-13 programme.399 This intervention is aimed at 
children that are aged 7-13 years, and have BMIs above or equal to the 91slcentile of the UK 
1990 reference chart. Other MEND programmes aimed at younger children, teenagers, and 
adults are also available, but the 7-13 is the original and most evaluated programme. The goal 
of MEND 7-13 is to help families in implementing healthy lifestyle changes through education 
and physical activity sessions, which is delivered in 20 sessions over a 10-week period.
Families are usually referred to the programme by their GP or other health professionals.
MEND represents one of the most established and widely available child weight management 
programmes that is currently available in England and Wales, and has had more than 60,000 
participants since 2004. A randomised controlled trial of obese children (BMI >98* centile of 
UK 1990 reference) enrolled in the programme showed that among children that received the 
intervention, BMI z-scores were reduced by 0.23 at 12 months, which was equivalent to a BMI 
reduction of 0.1 kg/m2 (or approximately 0.5% reduction in BMI among overweight and very 
overweight children). The impact of this kind of targeted intervention on long-term health 
burden and costs was assessed.
The intervention scenarios that were simulated are outlined in Table 7-2. Scenario 1 simulated 
the effect of a population approach to obesity intervention in which BMI in the child and 
adolescent population was reduced by 0.2% at the start of the projection period. The 
individuals’ BMI centiles, on which they remained thereafter, were adjusted accordingly. This 
scenario was intended to represent a campaign such as Change4Life, in which all members of 
the population are targeted and encouraged to make healthy changes to lifestyle. A report on the 
Change4Life campaign after one year indicated that 99% of families had had an opportunity to 
see the campaign.400 There are no data available to indicate an effect of the Change4Life 
campaign on BMI, but the effects are likely to be very small 398; a 0.2% reduction in BMI in all 
members of the cohort may be an overestimate of the potential effects of this type of 
intervention, and can therefore be considered as a best-case scenario. Scenario 2 simulated the 
effect of a targeted intervention modelled on the MEND 7-13 programme. It assumed that all 
children eligible for the programme (aged 7-13 years with BMI>91st centile of the UK 1990 
reference population) in the 2007 population received the intervention and experienced a 0.1 
kg/m2 (approximately 0.5%) reduction in BMI, which is the effect size that was reported for 
obese children in an evaluation of the programme, described above.
The effects of interventions with comparable effects to those described in scenarios 1 and 2, but 
implemented in adulthood, were examined in scenarios 3 and 4. The intention was to compare 
whether the timing of interventions (in childhood and adolescence versus in adulthood) had a 
notable impact on their long-term benefits for health burden. Scenario 3 modelled the effect of
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a 0.2% reduction in BMI in early adulthood among all cohort members aged >20 years in 2017. 
The intervention effects were specified to take place in 2017, when cohort members would be 
aged 12-29 years, therefore those cohort members aged 20-29 in 2017 would be affected. 
Scenario 4 simulated a 1 kg/m2 reduction in BMI among overweight adults (BMI >25 kg/m2) 
aged 23-29 years in 2017; a one unit reduction in BMI was selected to approximate a 0.23 SD 
reduction in BMI (based on HSE data), as achieved in childhood in scenario 2, and was 
equivalent to a 2-4% reduction in BMI. The age group 23-29 years was selected to include the 
same range of ages in the population as would be affected by the intervention in childhood (ages 
7-13).
Weight regain is an important consideration in long-term evaluations of obesity interventions. 
Studies in adults have indicated that most people regain the weight that is lost during an 
intervention; a fifth of overweight individuals are able to maintain a weight loss of at least 10% 
of their initial body weight for at least one year.401 Based on this, two conditions were modelled 
for each intervention described in scenarios 1 to 4; one condition was without weight regain (the 
change in BMI remained in effect for the duration of the projection period), while the other 
specified 80% regain of the BMI loss after 1 year.
The impact of each intervention scenario on the number of cases of each disease and the 
associated costs at the end of the projection period in 2050 was assessed by comparing against a 
scenario with no intervention, i.e. BMI growth continued unrestricted as projected using HSE 
data. Intervention effects are presented as the number of cases prevented (in 2050 and 
cumulative over projection period) and the associated gain in costs (costs given in current rates) 
resulting from the change in BMI. The gains in costs are compared with the estimated 
intervention costs to provide estimates of the net costs or savings associated with different 
scenarios.
Table 7-2: Intervention scenarios modelled In simulation
Scenario Age Years
1. 0.2% reduction in BMI in childhood/adolescence 2-19 y 2007
2. 0.1 kg/m2 reduction in BMI in children with BMI>91S| 
centile of UK 1990 reference population
7-13 y 2007
3. 0.2% reduction in BMI in adulthood >20 y 2017
4. 1 kg/m2 reduction in BMI in adults with BMI >25kg/m2 23-29 y 2017
158
7.3.2 Results
Health burden and direct costs
Based on recent trends in BMI distribution (1995-2008), it was projected that the prevalence of 
obesity in the cohort would be 54-82% in 2050 (at ages 45-62), compared to a prevalence of 30- 
37% at the same ages in 2007 (the reference scenario). The prevalence of overweight was 
projected to be 14-20%, while 4-26% of the cohort were projected to be normal weight (BMI 
<25 kg/m2) by 2050, compared to 19-36% in 2007.
Figure 7-2 shows the prevalence of type 2 diabetes, coronary heart disease, hypertension and 
cancer in the simulated cohort over the projection period. This graph shows that diabetes and 
hypertension contribute the most to disease burden in terms of prevalence over the projection 
period. Hypertension shows the earliest onset, with prevalence increasing steadily over the 
projection period, while type 2 diabetes prevalence is relatively low over the first two decades 
and shows a dramatic rise from the 2030s, to increase more than six-fold and be nearly as 
prevalent as hypertension by 2050. CHD and cancer present a much lower disease burden, with 
very few cases pre-2030. However, prevalence of these conditions begins to increase over the 
last two decades of the projection period, to reach nearly 2,000 cases per 100,000 population by 
2050.
The simulation showed that the recent trends in BMI distribution would project an additional
36,000 cases of cancer, 118,000 cases of CHD and stroke, 16,000 cases of arthritis, 768,000 
cases of type 2 diabetes, and 447,000 cases of hypertension in the year 2050, compared to the 
reference scenario which assumed that BMI distributions were constant at the 2007 level.
Figure 7-3 shows the projected prevalence of type 2 diabetes and hypertension under recent 
trends in BMI distribution compared with the projected prevalence under the reference scenario.
Examination of the direct health care costs showed that recent trends in BMI distribution 
projected substantial cost implications, with higher costs associated with increasing age. 
Compared to the reference scenario, recent BMI trends projected annual costs of treating 
obesity-related diseases in the cohort that were £1.1 billion higher in 2050, with total costs of 
overweight and obesity in the cohort amounting to £12 billion. These figures did not include 
the costs of treating obesity-related diseases in the wider population, and were not cumulative 
over the projection period. The costs of hypertension in the cohort presented the largest 
economic burden, accounting for 42% of the total expenditure on healthcare for the selected 
diseases, while diabetes accounted for 40%, cardiovascular diseases (CHD and stroke) for 13%, 
cancer for 4%, and arthritis for 2%. In 2050, obesity (BMI>30 kg/m2) accounted for 91% of 
the excess costs, while overweight contributed to 9% of the economic burden.
Figure 7-2: Projected prevalence of type 2 diabetes, coronary heart disease, hypertension and cancer in the 
simulated cohort 2007-2050
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Figure 7-3: Projected prevalence of type 2 diabetes and hypertension under recent trend in BMI distribution 
versus reference scenario, 2007-2050
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Graphs by outcome. Reference scenario=BMI distributions remain at 2007 level
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Effects of obesity interventions
The projected effects of the different intervention scenarios described in the methods are 
presented in Table 7-3 and Table 7-4. Compared to a scenario in which recent trends in BMI 
distribution continued unrestricted, a 0.2% reduction in BMI among all children and adolescents 
in 2007 (scenario 1) with no weight regain was associated with a reduction of 169,000 cases of 
type 2 diabetes, 88,000 cases of hypertension, 23,000 cases of cardiovascular disease, and a gain 
in direct healthcare costs of £48 million in 2050. Between 2007 and 2050, the cumulative gain 
in direct healthcare costs associated with the intervention was £492 million for the cohort. A 
comparable intervention which affected all adults in the cohort in 2017 (scenario 3) was 
associated with a reduction of 123,000 cases of type 2 diabetes, 64,000 cases of hypertension,
16.000 cases of cardiovascular disease, and savings in direct healthcare costs of £47 million. 
Over the whole projection period, cost savings associated with these prevented cases of disease 
were estimated at £490 million.
An intervention which reduced BMI by 0.1 kg/m2 in overweight children aged 7-13 years in 
2007 (scenario 2) projected a reduction of 253,000 cases of type 2 diabetes, 147,000 cases of 
hypertension, 32,000 cases of CHD and stroke, 4,000 cases of arthritis, and a gain in annual 
costs of £51 million. Over the whole projection period, the total gain in direct healthcare costs 
was estimated at £519 million. A similar intervention which reduced BMI by 1 kg/m2 in 
overweight adults aged 23-29 years (scenario 4) was projected to result in a reduction of
104.000 cases of type 2 diabetes, 37,000 cases of hypertension, and 20,000 cases of 
cardiovascular disease in the year 2050. The annual gain in direct healthcare costs associated 
with these effects was £45.8 million in 2050, while the cumulative gain was estimated at £470 
million.
The cumulative gains in cost over the projection period ranged from £470 million to £519 
million for the four intervention scenarios without weight regain. The cost of the MEND 7-13 
programme was estimated at £415.77 per child in 2010.380 When applied to all children who 
would be eligible for the programme in 2007 (all children aged 7-13 years with BMI >91st 
centile of UK 1990 reference population, n=1.3 million), the total cost of the programme was 
estimated at £551 million. The cost gains associated with this intervention were estimated to be 
£519 million, therefore the net cost of the programme in this scenario was estimated at £32 
million over the projection period to 2050. When the same costs were applied to the projected 
population of overweight adults in 2017 (n=4.6 million people), the estimated net cost of the 
intervention increased to £ 1.5 billion. In contrast, the original Department of Health budget for 
the Change4Life campaign was set at £75 million over three years, therefore the cumulative 
gain in healthcare costs associated with this intervention (scenario 1, £492 million) was
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associated with a net saving of more than £400 million by the year 2050, and similar savings 
were associated with a population-wide intervention effect in adulthood.
When the effects of weight regain were included in the simulations, the estimated numbers of 
prevented cases of disease and associated gains in healthcare costs were substantially reduced 
(Table 7-4). For example, when 80% weight regain was incorporated into scenario 2, which 
modelled the effect of an intervention for overweight children aged 7-13 years, the number of 
cases of type 2 diabetes that were prevented decreased from 253,000 to 48,000, hypertension 
cases from 147,000 to 21,000, and cardiovascular diseases from 32,000 to 7,000. The 
cumulative gain in costs associated with this scenario was reduced from £519 million to £155 
million. Similarly, the cumulative gains in costs associated with scenarios 1, 3 and 4 were 
reduced from £470-492 million to £143-151 million. The net costs (or savings) associated with 
each intervention were increased (or reduced) accordingly. Scenarios 1 and 3 (population 
approaches) remained associated with net savings, while scenarios 2 and 4 (interventions 
targeted at overweight and obese members of the cohort) were associated with substantial net 
costs (between £396 million and £1.8 billion).
Table 7-3: Projected effects of intervention scenarios on disease prevalence and related health costs in 2050, 
compared to scenario reflecting recent trends in BMI distribution
Cases per year xlOOO (SE) Intervention scenario
1 2 3 4
Arthritis -3  (3) -4 (3 ) -3  (3) - 1 ( 3 )
Hypertension -88 (13) -147(12) -64 (13) -37 (13)
Type 2 diabetes -169(12) -253 (12) -123 (12) -104(12)
CHD and stroke -23 (6) -32(6) -16 (6) -20  (6)
Cancer -5  (5) -4 (5 ) -3  (5) -1  (5)
Gain in costs in 2050 
(£million)
£47.9 £50.6 £47.1 £45.8
Cumulative gain in costs 
2007-2050 (fmillion)
£491.6 £518.8 £ 489.9 £ 469.6
Scenario 1=0.2% reduction in BMI in children and adolescents aged 2-19 years in 2007; Scenario 2=0.1
unit reduction in BMI in overweight and obese children aged 7-13 years in 2007; Scenario 3=0.2% 
reduction in BMI in adults aged 20 years and older in 2017; Scenario 4=1 unit reduction in BMI in 
overweight and obese adults aged 23-29 years in 2017. Scenarios do not specify weight regain. Gain in 
costs calculated as healthcare costs for scenario with no intervention minus the healthcare costs 
associated with intervention. All figures are cases x1000 (SE), unless stated.
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Table 7-4: Effects of intervention scenarios on healthcare costs in 2050, with and without weight regain, compared to a scenario that reflects recent trends in BMI distribution
Scenario Age of target 
group
_ M ____________
Intervention effect 
(BMI change)
Weight regain 
after 12 months
Gain in costs in
20501
(fmillion)
Cumulative gain 
in costs 2007- 
2050 (£million)
Cost of
intervention
(£million)
Net cost ¥  
(£million)
1 2-19 -0.03 kg/m"* 0 £ 4 7 .9 £ 4 9 1 .6 £ 75 t - £ 4 1 7
1 2-19 -0.03 kg /m 2* 80% £ 2 0 .5 £  143.1 £ 75 f -  £  68
2 7-13 -0.1 kg /m 2 0 £ 5 0 .6 £ 5 1 8 .8 £ 5 5 1  t £ 3 2
2 7-13 -0.1 kg /m 2 80% £ 2 2 .1 £  155.1 £ 5 5 1  J £ 3 9 6
3 > 20 -0 .06  k g /m 2** 0 £ 4 7 .1 £ 4 8 9 .9 £ 75 f - £ 4 1 5
3 > 20 -0 .06  k g /m 2** 80% £ 2 0 .4 £  142.6 £ 7 5  t -  £  68
4 23-29 -1 .0  kg /m 2 0 £ 4 5 .8 £  469 .6 £ 1,921 § £  1,451
4 23-29 -1 .0  kg /m 2 80% £ 2 1 .4 £  151.2 £ 1,921 § £  1,770
in BMI associated with 0.2% reduction in BMI at age 20-30 years, based on projected BMI distribution in 2017; t  Based on original Department of Health budget for the Change4Life 
campaign; % Based on estimated cost per child of MEND 7-13 of £415.77,380 and number of overweight and obese children aged 7-13 years in 2007; § Based on projected number of 
overweight and obese adults aged 23-29 years in 2017 (n=4.6 million people) and assumed cost of £415.77 per person (same cost as in childhood); H Gain in costs calculated as 
difference between obesity-related healthcare costs with no intervention and obesity-related healthcare costs associated with the intervention scenario; ¥ Net cost calculated as
cumulative gain in costs (undiscounted) minus cost of intervention, negative number indicates net saving.
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7.4 Model assum ptions and com parison with observed data
As an exploration of the suitability of the NHF model for estimating childhood obesity burden 
and intervention effects, key model assumptions underlying the projections were examined. 
Simulations were run with input parameter values that were selected to approximate the BMI 
distributions and trajectories observed in the British National Birth cohorts, and the model 
output was compared with the observed cohort data.
Implementation of changes to the model which required additional programming, such as 
coding the simulation model to write individual-level data to an output file, was carried out by 
Martin Brown from the NHF modelling team. I prepared the baseline data specifying the cohort 
structure, performed the simulations, and managed and analysed the output data.
7.4.1 Methods
The face validity of model assumptions was examined by comparing model output with 
observed data from the British National Birth Cohorts. BMI centile trajectories of individuals in 
the three birth cohorts were plotted, and movement between weight categories was examined by 
cross tabulating weight categories at different ages (childhood, adolescence and adulthood). A 
weighted kappa statistic for agreement between weight categories at different ages was 
calculated, such that staying in the same weight category between time points counted for 
perfect agreement, and movement across one category, e.g. normal weight to overweight, or 
obese to overweight, counted for 50% agreement.
Scenarios corresponding to the population structure and BMI trajectories in each of the three 
birth cohorts were fitted, and the disease probabilities associated with different patterns of 
overweight over the life course were analysed. Population size and sex-age structure were taken 
from each of the three birth cohorts (as described in Chapter 5.3) to define the initial population. 
Observed BMI histories were assigned to the simulated individuals; the model required annual 
BMI data, therefore BMI values between any two measurements were interpolated assuming 
linear change. The model assumptions were constrained by specifying that age-, sex- and BMI- 
specific disease probabilities should be the same in all three cohorts, and probabilities were 
assigned as a function of the individual BMI histories. Disease simulations were modelled to 
start at the age of first BMI measurement and end at the last observed measurement. For 
NSHD, this period was between 1948 and 1999, for NCDS between 1965 and 2000, and for 
BCS70 between 1980 and 2004.
The Health Outcomes micro-simulation model Version 9.6.1 was used. For the purposes of 
these analyses, the model was programmed to produce individual-level output as a text file, 
displaying the annual BMI and assigned probability of disease for each simulated individual. 
Individual-level data allowed analysis of different BMI histories and their relationships with
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disease probabilities. Overweight and obesity were defined using IOTF criteria in childhood 
and adolescence and the WHO criteria in adults, and eight overweight patterns were defined as 
described earlier in the thesis (see Chapter 4.7.2), using the same ages to define life stages. The 
main comparison of interest was of mean probability of disease at the end of the simulation 
period against the observed proportion of disease at the same age (last-follow-up) for each 
pattern of overweight in childhood, adolescence and adulthood in the three cohorts. Output text 
files were converted and analysed in Stata 12.
Direct comparisons of disease probabilities in observed data with estimated probabilities were 
limited by the different ways in which outcomes were defined. In the observed cohort data, 
self-reported outcomes were used to estimate probabilities of ever having had a condition, while 
the input data used in the model were based on objectively measured outcomes. For these 
reasons, comparisons between model outputs and observed data were based on graphical plots 
and largely qualitative descriptions, focusing on general patterns and trends rather than using 
quantitative techniques such as goodness-of-fit tests, which have been recommended for 
validation of model components.402
7.4.2 Results
BMI trajectories
The simulation model specified that individuals stay on the same BMI centile over the duration 
of the simulated period. Examination of cohort data showed that centile crossing in the British 
National Birth Cohorts was substantial, particularly pre-adulthood (example from NCDS cohort 
presented in Figure 7-4). Furthermore, analyses showed that a substantial proportion of 
individuals moved from overweight to normal weight, and between overweight and obese 
categories between childhood and adulthood. For example, in the NCDS cohort, 24% of 
individuals that were overweight and 12% that were obese at age 7 years were normal weight at 
age 42 years, while 29% of cohort members that were obese at age 7 were in the overweight 
category at age 42. The weighted kappa statistic for agreement between weight categories, was 
0.01, indicating poor agreement. In contrast, when a simulated cohort was generated to have the 
same BMI distributions at ages 7, 16 and 42 as the NCDS cohort (with linear interpolation 
between time points), but did not allow for movement between centiles, there was no 
downwards movement between weight categories due to the rising prevalence of overweight 
and obesity with age; all individuals that were overweight at age 7 were overweight or obese at 
age 42, while all individuals that were obese at age 7 were obese at age 42. The weighted kappa 
statistic for agreement between child and adult weight categories was estimated at 0.454 for this 
simulated cohort, much higher than observed in the actual cohort data. Similar patterns were 
observed when agreement between adolescent and adult weight categories was examined, and 
when analyses were repeated for the 1946 and 1970 cohorts.
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Figure 7-4: BMI centile crossing in twenty randomly selected cohort members in NCDS
Overweight patterns
For the next stage of model validation, the observed BMI trajectories in the three British birth 
cohorts were incorporated into the simulation model to reproduce the movement of individuals 
across BMI centiles and weight categories. The distribution of patterns of overweight through 
childhood, adolescence and adulthood in simulated individuals was similar to the distribution in 
the observed data (Table 7-5). The proportions of individuals with overweight in childhood 
were slightly overestimated and the proportions with overweight in adolescence were 
underestimated in the simulated population, which can be explained by the linear interpolation 
between BMI measurements that was used to estimate missing data.
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Table 7-5: Distribution of overweight patterns in British National Birth Cohorts and In simulation
Overweight pattern %
Cohort Simulated
population
Never overweight 75.0 71.8
Childhood only 3.3 6.2
Adolescence only 3.5 1.9
Adulthood only 10.0 11.3
Childhood + adolescence 1.4 1.5
Childhood + adulthood 1.1 1.9
Adolescence + adulthood 3.4 2.3
Persistent overweight 2.3 3.0
Disease probabilities
Annual probabilities of disease for the simulated individuals were examined. Overall, the 
estimated disease probabilities at the end of each projection period had the expected 
distributions, with hypertension being the most prevalent condition, and stroke and cancers 
being relatively rare. Simulated disease probabilities also showed the expected age-dependent 
trends, with the lowest probabilities of disease in the youngest cohort (1970) and the highest 
probabilities in the oldest cohort (1946). However, the simulated disease probabilities in years 
1999, 2000 and 2004 did not generally provide a good fit to the data in corresponding years in 
NSHD, NCDS and BCS70, respectively. The model simulated lower probabilities of all 
outcomes, and estimates were notably lower for hypertension, gallbladder disease and arthritis. 
However, there was evidence of a cohort effect, with improved fit to the data for more recent 
cohorts. For example, the probability of hypertension was 42% lower in the simulated 1946 
cohort than in the observed data, compared to 6% lower in the 1958 cohort, and 3% lower in the 
1970 cohort (Figure 7-5). The same trend was observed when ratios of observed to estimated 
disease probabilities were compared, to account for the lower prevalence of disease in younger 
cohorts. The respective figures for coronary heart disease were 4%, 0.5% and 0.4%, and 1.5%, 
0.4% and 0.3% for type 2 diabetes.
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Figure 7-5: Observed and simulated probabilities of hypertension at the end of the simulation period in 1946, 
1958 and 1970 cohorts
H ypertension
observed estimated observed estim ated observed estimated
1946 1958 1970
Associations between overweight patterns and disease
The associations between overweight patterns and disease probabilities from the simulation 
showed a similar pattern for all outcomes; the lowest probabilities were associated with never 
overweight or overweight in childhood and/or adolescence, with similar probabilities observed 
for both patterns of overweight. Higher probabilities were associated with exposure to obesity 
in adulthood. A cumulative effect was observed for hypertension and type 2 diabetes outcomes; 
higher probabilities for these outcomes were associated with overweight in adolescence plus 
adulthood and persistent overweight patterns, compared to obesity in adulthood only, although 
the effect of persistent overweight on type 2 diabetes was not as apparent as in the observed data 
(Figure 7-6). The effect of persistent overweight was not observed for CHD, although the 
increased risk associated with obesity in adulthood was evident, and probabilities associated 
with all overweight patterns were small.
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Figure 7-6: Comparison of observed and simulated probabilities of a) type 2 diabetes and b) coronary heart 
disease, associated with different patterns of overweight in 1946,1958 and 1970 birth cohorts
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7.4.3 Summary of comparison with observed data
The analyses in this section showed that individuals do not stay on the same BMI centile over 
time as assumed in the simulation model, and that overweight and obese children may become 
normal weight adults. Analyses of more recent cohorts, with higher prevalence of overweight 
and obesity in youth, have shown that there is still some degree of centile-crossing and 
movement between weight categories. For example, data from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) cohort of more than 6,000 children bom in 1991-1992 showed 
that 21% of children who were overweight at age 7 became normal weight by age 11.403 This is 
relevant to understanding the future burden associated with childhood obesity because, as 
indicated by the analyses in Chapter 6, overweight history may be an important risk factor for 
some outcomes in adulthood, notably type 2 diabetes. However, these analyses also showed 
that exposure to overweight in childhood and/or adolescence only was associated with 
comparable disease risks as never being overweight, therefore it may not be necessary to model 
this downwards movement in weight categories.
The estimated disease probabilities from simulations provided a poor fit to historical data. The 
poor fit to data may be explained in part by data validity issues. The disease data used in this 
thesis were valid for the years 2004-2010 (see Table 7-1), therefore use of these data for 
projections outside of these years may have limited validity. The cohort trends indicated that 
the model parameters produced estimates of disease risk that were more accurate for more 
recent cohorts, and were in line with what is known about recent trends in the incidence of 
cardiovascular diseases and their risk factors. For example, analyses of global data have shown 
that between 1980 and 2008, systolic blood pressure fell by more than 2 mm Hg per decade 
among men and women in Western Europe, despite increasing BMI in the population,404 
accounting for a reduction in age-standardised hypertension and cardiovascular disease 
burden.405 As expected given these trends, results in this chapter showed that current disease 
input data simulate a much lower burden of hypertension and cardiovascular disease than is 
observed in historical cohorts. The trend towards more accurate estimates in younger cohorts 
indicates that the model may be suitable for predicting disease risk in more contemporary 
cohorts. A model which is able to predict future trends in the population is not necessarily 
informative about what happens to individuals in past populations, as these populations are 
likely to be different in terms of their characteristics and disease risk. The problems of data 
validity arising from differences between historical and contemporary populations are a central 
issue for long-term modelling exercises, and an important consideration when interpreting 
estimates from such projects. However, the main benefit of this kind of comparison between 
projection estimates and existing data is that it provides some empirical basis on which to 
evaluate the model output, and identify where the main limitations may arise. True predictive 
validation of the model would require waiting until the end of the projected time period and
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comparing the predictions of the model with observed data; although short term projections 
could reasonably be validated in this way, the usefulness of the model for predicting long-term 
future scenarios, which are the main outcomes of interest with regards to childhood obesity, 
would be diminished with this approach due to the lag-time involved. By examining model 
assumptions and parameters against historical data, we are able to assess whether the model 
produces reasonable or expected results over long time periods, and gives some indication of the 
usefulness of estimates derived from this approach.
7.5 Summary and im plications
Projections of future disease burden for a contemporary cohort of children and adolescents in 
the UK have considered the potential implications of the current childhood obesity epidemic for 
disease and healthcare costs by 2050. A continued increase in obesity prevalence was projected 
to result in an extra 36,000 cases of cancer, 118,000 cases of CHD and stroke, 16,000 cases of 
arthritis, 768,000 cases of type 2 diabetes, and 447,000 cases of hypertension in the year 2050. 
These increases in obesity-related diseases were associated with excess healthcare costs in the 
region of £1.1 billion a year, with hypertension and type 2 diabetes accounting for the majority 
of these costs. This is in relation to an estimated cost of £5.5 billion associated with increased 
overweight and obesity in the whole population in 2050,45 indicating that overweight in the 
current cohort of children and adolescents could account for around one fifth of the obesity- 
related burden in 2050. These projections also demonstrated the changing nature of the burden 
over the projection period, with the earlier onset conditions, type 2 diabetes and hypertension, 
being important causes of obesity-related ill health throughout adulthood, and cardiovascular 
diseases and cancer becoming increasingly important in late-adulthood. These estimates are 
based on recent trends in BMI distribution nationally, but close monitoring of trends in obesity 
prevalence will be important over the next few years, to gauge whether obesity in the population 
is likely to level off faster than would be indicated by recent trends.
The potential health burden and healthcare cost savings associated with different intervention 
scenarios were explored. These projections indicated that a 0.2% reduction in BMI in the whole 
child and adolescent population in 2007, equivalent to around 0.1kg weight loss for an average 
adolescent (based on BMI distribution from HSE data), could result in reductions in cases of 
type 2 diabetes, hypertension and cardiovascular disease, and around a 5% reduction in 
associated healthcare costs. The largest reductions in disease prevalence and costs were 
associated with an intervention targeted at overweight children, in a scenario modelled on the 
MEND programme, in which all of the target population benefited from the intervention. 
Confidence intervals could not be generated for these cost estimates, therefore it is possible that 
the gains in costs were not different; previous studies that have used the NHF model have
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indicated that there is a great degree of uncertainty associated with these estimates.163 
However, bearing this uncertainty in mind, the projections are useful for indicating general 
trends and patterns. These examples illustrate the potentially large cost savings associated with 
small, population-wide reductions in BMI, which could be implemented at lower cost than more 
intensive, targeted interventions, and at much lower net costs. However, it is important to note 
that the effectiveness of the Change4Life campaign in terms of BMI reduction has not been 
demonstrated in any studies, and this projection is based on a hypothetical scenario. 
Furthermore, it is unlikely that any intervention would benefit all members of its target group, 
as there would be individuals that could not be reached, others that would opt not to engage 
with the intervention, and some that would not respond to or benefit from the intervention.
These factors combined would reduce the effectiveness of the interventions, and lead to lower 
gains in health burden and associated costs. In addition to this, among those that did participate 
in a given programme, there may be differential effects on BMI, with some groups of 
individuals benefiting more than others. For example, differences by degree of overweight, 
ethnicity, sex, SEP or age, or the skills of the individuals involved in delivering the intervention. 
Individuals who have a smaller response to an intervention may require more intensive 
approaches or multiple interventions, which are likely to be associated with a larger cost.
Most data on effectiveness of obesity interventions in children and adolescents come from 
studies with short-term follow-up, therefore the estimates of sustained intervention effects in 
this chapter are likely to represent optimistic scenarios. The modelling of the two weight regain 
conditions and comparison of the associated savings for each intervention highlight the 
importance of sustainable intervention effects for long-term benefits. Intervention scenarios 
which accounted for weight regain were associated with much smaller gains in health burden 
and costs. Scenarios which incorporated the effect of weight regain following a successful 
intervention are likely to reflect a more realistic situation, as studies of long-term weight loss 
maintenance have shown that most individuals regain some or all of the weight loss within a 
year. The cumulative gains in costs over the projection period ranged from £143 million to 
£155 million for the four intervention scenarios with weight regain, with larger net costs (or 
lower net savings) associated with each scenario. As with intervention effectiveness, the extent 
of weight regain may also vary according to an individual’s characteristics or environment. For 
example, in the case of child weight management, it has been demonstrated that children with 
obese parents begin to regain weight sooner than those with non-obese parents after similar 
weight loss in the first 6 months, and those with non-obese parents were more likely to maintain 
their weight loss after several years.406 This long-term perspective leads to consideration of the 
potential intergenerational effects of interventions; parental behaviours and the home 
environment are known to be important determinants of childhood overweight status,407 
therefore changes in lifestyle behaviours and social norms as a result of effective interventions
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could lead to additional benefits in subsequent generations, with few additional costs. 
Sustainability of effects and the potential intergenerational implications are important 
considerations when evaluating interventions. Future studies of interventions should aim to 
report on long-term outcomes, and also provide detailed information on differential responses to 
interventions where these occur. This would enable the modelling of group-specific effects, and 
determine where different interventions would have the greatest impact.
One limitation of the modelling used in this chapter is that health burden and intervention 
effectiveness were considered only in terms of BMI change. It may be possible for an 
intervention to lead to positive changes in behaviour or other risk factors which impact on 
disease risk, without a measureable effect on BMI. On the other hand, an intervention may lead 
to reductions in BMI, but these may have to be balanced against adverse effects that lead to 
increased morbidity. Anti-obesity drugs provide examples of such effects; in January 2010, 
marketing authorisations for sibutramine, a drug shown to be effective in reducing overweight, 
were suspended across Europe following concerns about increased cardiovascular disease 
events in adults at high risk of heart disease.408 One way in which the NHF model may be 
developed in the future is to model the effects of different risk factors acting simultaneously on 
disease risk. For example, a model for estimating cardiovascular disease burden may include 
the various components of the metabolic syndrome, and the effects of changing any single risk 
factor versus changing multiple risk factors may be explored. However, the data requirements 
for this approach would be substantial, involving detailed information about the relationships 
between these risk factors and their associations with cardiovascular disease risk over the life- 
course, which may not be available.
These projections have focused on direct healthcare costs and have not included productivity 
losses, which are likely to make up a large proportion of the cost burden associated with 
childhood obesity.409 As described in Chapter 2, in addition to the concurrent productivity 
losses such as inability to work due to illness, there may be long-term productivity costs 
associated with overweight in childhood, such as lower income and poorer employment 
prospects. Furthermore, there may be other diseases or limiting conditions with less well 
established associations with obesity that will be shown to present an additional burden in the 
future, such as common mental disorders.410 Consequently, the estimates of disease and cost 
burden in this chapter may be considered to be conservative. Although exploration of different 
intervention scenarios has indicated reductions in disease burden and gains in healthcare costs 
associated with intervention effects, it is difficult to state whether there are likely to be overall 
cost savings at the population level, as individuals who do not become overweight may be 
associated with other costs over their lifetime. For example, projection over a longer period of 
time may show varying health burden and medical costs at later ages, as late-onset diseases 
become more prevalent and mortality has a larger impact on the population.1604,1-412 Rates of
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survival associated with obesity-related diseases may also change as a result of medical 
advances; improvements in survival would extend the number of years of life lived with a 
condition and contribute further to healthcare costs, particularly in the situation where improved 
survival is the result of a costly intervention. Predictions of future BMI distributions can also 
vary substantially according to the data points used. This issue was illustrated in a report by the 
NHF modelling team, which examined the effect of additional HSE data on estimated obesity 
trends for children aged 2-11 years. 382 This report compared projected obesity prevalence in 
2020 based on data from 1995 to 2004, to projections based on data from 1995 to 2007 (three 
additional data points), and showed that predicted prevalence decreased from 16% to 12%. This 
finding reflects the recent levelling off in childhood obesity prevalence in the U K.60
Previous studies of long-term childhood obesity burden have linked childhood overweight to 
adult overweight, and then linked adult overweight to health outcomes; they have not included 
potential effects of overweight pre-adulthood on the outcome. For example, one study by Wang 
et al incorporated the association between overweight at age 16-17 years to overweight at age 
40 (fixed proportions of individuals in each weight category in adolescence became obese 
adults), and linked this to the health consequences and medical costs associated with adult 
overweight after the age of 40, in the US population.413 Using this model, a 1% reduction in 
prevalence of overweight and obesity in adolescence was associated with 52,821 fewer obese 
adults, savings in lifetime medical costs of $0.5 billion, and a 0.006 per capita increase in 
QALYs. Compared to this approach, a key advantage of using a micro-simulation model is that 
it is able to incorporate the effect of overweight history on disease risk, which has been shown 
to be an important consideration for some diseases (Chapter 6). The use of annual disease 
probabilities in the micro-simulation model allowed a cumulative effect of exposure to 
overweight and obesity on increased disease risk to be modelled, as demonstrated in section 
7.4.2.
The potential impact of interventions has been explored by modelling effectiveness in terms of 
changes to BMI distribution. The findings in this chapter indicate that interventions targeted at 
overweight children to reduce BMI could result in reductions in disease prevalence and 
healthcare costs over the projection period, but may be more expensive than less intensive, 
population-wide interventions. Comparison of the NHF model assumptions against data from 
the three national British birth cohorts showed that the issue of data validity is likely to be an 
important consideration in interpretation of results. The model showed increasingly improved 
fit to disease data in younger cohorts, suggesting that the disease data used in the model are 
likely to be more appropriate for contemporary cohorts, and projections of future disease 
burden. However, it is difficult to predict how associations between obesity and disease may 
further change in the future, as advances in science, medicine and technology, as well as social 
changes, could impact on disease incidence and survival.
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Despite these limitations, quantification of the disease burden and costs associated with 
childhood obesity creates a starting point from which to discuss service planning and resource 
allocation, and provides an important impetus for action. These data projections indicate that 
increasing prevalence of obesity in the current child and adolescent population could have a 
substantial impact on health burden and its associated costs over the coming decades. The 
projections also highlight the potential long-term health and economic benefits of successful 
interventions to reduce BMI in childhood versus interventions in adulthood, providing an initial 
basis for decisions about future research directions and policy priorities.
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8 . DISCUSSION
This chapter begins with a discussion of the strengths and limitations of the study, and goes on 
to provide a brief summary of the main findings of the thesis. This is followed by a 
consideration of these results in the context of the relevant literature presented in Chapters 2 and 
3. Finally, the implications of the findings for approaches to obesity prevention and treatment 
and directions for future research are considered.
8.1 Strengths and lim itations
This study has a number of strengths and limitations, which will have an impact on the way in 
which the results are interpreted. Some of the specific issues have been addressed in detail in 
the summary of each results chapter, but more general considerations and their implications for 
the thesis are described here.
Type lan d  Type 2 errors
In the main analyses of the birth cohort data, multiple statistical tests were carried out due to the 
large number of outcomes and different exposures of interest. Carrying out a large number of 
tests in this manner will introduce the possibility of Type 1 (alpha) errors, where the null 
hypothesis is mistakenly rejected. In an attempt to minimise Type 1 errors and avoid data 
dredging, only those variables and models that were specified a priori based on the literature, 
were examined. Disease outcomes which had been shown to be associated with overweight in 
adulthood in previous studies, but had not necessarily been assessed in relation to childhood 
overweight were included to explore the potential life-course effects of exposure. Furthermore, 
interpretation of the findings was not based on single estimates of association, but on the whole 
body of results. For example, single positive associations which were anomalous in the context 
of other results for a given outcome, were treated as possible chance findings.
Type 2 (beta) error, failure to reject a null hypothesis when it is false, was an important 
consideration in this study due to the small numbers of individuals that were obese in early life 
and low prevalence of some outcomes, such as coronary heart disease and cancers. The pooling 
of data from three cohorts with similar data collection points and comparable target populations, 
was a way to increase study power. Overweight and obese categories in childhood and 
adolescence were combined to form a single exposure category, in an attempt to further 
maximise study power. Some outcomes that were initially selected for analysis, on the basis of 
the existing literature, were later excluded due to small numbers. However, the power 
calculations, based on initial analyses of the cohort data, indicated that the study is likely to 
have been inadequately powered for the less prevalent outcomes, even before accounting for the
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additional covariates that were included in the final models. Consequently, some associations 
may not have been detectable in these analyses.
Selection bias
Selection bias is an important consideration in cohort studies. At baseline, the participation 
rates for the three cohorts ranged from 95.9% to 98.8%. The high participation rates indicate 
that the baseline samples are likely to be generally representative of the target populations, and 
this has been supported by comparison of the cohort characteristics with census data.252'254 The 
main analyses were restricted to those cohort members with BMI data in childhood and 
adolescence, and data on disease outcomes in adulthood. Due to the combined effects of 
attrition and incomplete data, the possibility for selection bias is high. The highest rates of 
attrition in all three cohorts occurred in early adulthood, when cohort members became more 
mobile and name changes became most frequent. However, large efforts have been made to 
maintain contact with cohort members and to trace lost cohort members, and response rates of 
more than 60% have been achieved in recent follow-ups. Differential losses to follow-up 
between those who were overweight in childhood and those who were not overweight could 
introduce bias; it is known that cohort members from lower socioeconomic positions and those 
from ethnic minority backgrounds were more likely to have been lost to follow-up than others, 
and these groups are also more likely to be overweight or obese and to be at increased risk of 
the chronic conditions analysed in this study. If cohort members that were obese in childhood 
were also more likely to suffer ill health in later life and to leave the study, their exit from the 
cohort would underestimate the effect of childhood overweight on disease risk. The effects of 
missing data for some variables were examined by comparing results from complete case 
analyses with those incorporating last observation carried forward data, which showed that the 
direction and patterns of associations were similar under the two scenarios.
Measurement bias
Accurate measurement of exposures and outcomes is necessary to ensure that bias is minimised 
and findings are valid. Measurement bias is not likely to have been an issue for measures of 
weight and height for BMI in childhood and adolescence, and in adulthood in the NSHD 1946 
cohort. However, the use of self-reported weight and height in adulthood in the 1958 and 1970 
cohorts is likely to have introduced bias, as previous studies have shown systematic 
underestimation of BMI when self-reported data are used. To address this potential bias, BMI 
from self-reported weight and height was adjusted, based on the findings of a validation 
study.329 This adjustment indicated that the underestimation of BMI due to self-report of weight 
and height did not bias the results, and effect sizes were very similar before and after adjustment 
(Chapter 6, Table 6-9).
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The analyses presented in this thesis have focused on childhood overweight and its 
combinations with adult BMI status as categorical exposures. This categorisation may have 
resulted in loss of efficiency and power compared to treating BMI as a continuous exposure.414 
There is also the potential for misclassification. However, there are advantages to this treatment 
of the data. First, presenting risks relative to a reference group such as those who have never 
been overweight is easier to interpret and to communicate to the wider population; using these 
conventional categories, individuals and health professionals can identify the implications of 
weight status and history of overweight for health risk. The use of international cut-offs for 
overweight and obesity also allows the analyses to be replicated and compared across 
populations. Second, as the association between BMI and health outcomes is non-linear,8 
treating BMI as a continuous exposure could mask what is happening at the upper end of the 
distribution, at which public health efforts and resources are targeted; focussing on the upper 
end of the distribution allows us to identify what is happening among those with this more 
extreme phenotype.
The use of BMI as a marker of adiposity in children also has its limitations. BMI does not 
account for differences in body composition, which may influence the association between adult 
obesity and disease outcomes. For example, studies have indicated that differential gain in 
muscle mass and fat in childhood may be an important contributor to later cardiovascular 
outcomes.374 Therefore BMI may not adequately capture the exposure (adiposity). However, as 
described previously, BMI is highly correlated with adiposity and is a reliable measure in large 
population-based studies.41-42
Another source of measurement bias may arise from the use of self-reported disease data as the 
outcome measures. As described in the methods, the validity of self-reported data varies for 
different conditions. This may be due to errors in recall, misdiagnosis, or undiagnosed 
conditions. In general, self-report of chronic disorders and acute-onset diseases tend to show 
good agreement with medical records. Bias is likely to be an issue where there is differential 
misreporting or misdiagnosis between groups, such as under-reporting of conditions among 
obese compared to non-obese individuals.351415 Efforts were made to avoid missing cases and 
maximise information on health outcomes by including information on medical supervision for 
conditions and recent hospital admissions, as well as long-standing illnesses. If under-reporting 
of conditions is more common among overweight or obese participants than healthy weight 
individuals, the effect may be underestimation of the association between overweight and the 
disease.
Regression dilution bias
The use of just one BMI measurement as an indicator of adiposity over a period of the life- 
course may introduce regression dilution bias. Regression dilution occurs due to random
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fluctuations in a variable, which may be due to measurement error or real deviations from usual 
levels of the exposure, e.g. temporary weight gain. This is likely to be especially relevant for 
those individuals who move in and out of the overweight categories over the three life-stages. 
Individuals who exhibit changes in weight status are likely to have less extreme overweight than 
those individuals whose overweight status is more entrenched, and are classified as being 
persistently overweight (as demonstrated by the higher mean BMI among those cohort members 
with overweight at great number of life stages). The effect of regression dilution bias is usually 
underestimation of the association between usual exposure levels and disease.416
Survival bias
Survival bias arises when an exposure which is associated with an outcome also affects the 
chances of an individual being included in a study, for example by shortening survival.
Survival bias was not considered to be a major issue in these cohorts, as all members were 
recruited at birth (or in the case of some immigrants, in childhood), and data were analysed for 
ages at which mortality from the outcomes of interest was relatively rare. Mortality before the 
oldest ages considered in this study (53 years) is uncommon. For example, in England and 
Wales, the aggregate mortality rate for 2001-2006 was 91 per 100,000 among people aged 1-54 
years (from ONS data). However, there remains the possibility that cohort members may have 
left the cohort for other reasons that are associated with both overweight and disease outcomes, 
leading to a biased sample.
Reverse causality
The potential for reverse causality was addressed by excluding individuals that reported any of 
the outcomes or related conditions pre-adulthood. One exception for this was for asthma 
outcomes, for reasons described in the methods (Section 4.5.1). A possible mechanism for 
reverse causality in this relationship is that asthma may inhibit exercise and other forms of 
physical activity, conceivably leading to reduced levels of physical activity, a more obesogenic 
lifestyle, and increased overweight in individuals with the condition. However, other 
longitudinal studies have indicated that overweight precedes the onset of asthma in 
adolescence.97 In this thesis, there was no strong evidence for an association between 
overweight in childhood and adolescence and asthma, therefore reverse causality was not 
considered to be a major issue in the interpretation.
Confounding
Confounding is an important limitation in population-based cohort studies of this nature, as 
cohort members that are overweight or obese are also likely to differ from those who are healthy 
weight in ways that are important in respect to disease. Potential confounding factors were 
identified from the literature, and these were controlled for in the analysis by including them as
179
covariates in the final models. Key confounding factors that commonly affect studies of 
overweight and later disease include socio-economic position, ethnicity, and smoking status. 
Measures of socioeconomic position were based on occupation, which was classified using the 
Registrar General’s Classification of Occupations. This classification was selected as it has 
been applied to all occupation data across the three cohorts, and therefore allowed comparison 
across studies and data harmonization for pooling. A limitation of occupation-based measures 
in the context of these three datasets is that the profile of occupation types has changed over the 
years, with manual jobs having declined, and skilled jobs having become more prominent. 
However, despite the change in the distribution of occupations, the classification of jobs has not 
changed substantially over the time period considered here.417 There were some differences in 
the patterning of overweight across the three cohorts by social class at birth (Section 5.7), but 
associations of overweight with social class in adulthood were similar in the three datasets. A 
sensitivity analysis excluding the relatively small proportion of ethnic minority cohort members 
indicated that there was no observable effect of combining white and non-white groups in the 
analysis. Further investigation of ethnicity-specific effects was limited by the small number of 
ethnic minority individuals in the dataset. Smoking status has a complex relationship with 
overweight and health, as those who smoke are less likely to be overweight than those who have 
never smoked or those who have smoked previously, but smoking is an important risk factor for 
most chronic diseases. Some of those who give up smoking may do so because of ill health but 
go on to gain weight as a result, therefore the associations between overweight and later disease 
outcomes may be confounded by this relationship. An attempt to incorporate smoking history 
was made by treating ex-smokers as a separate exposure category, but information on reasons 
for giving up smoking were not available. Residual confounding due to measurement error or 
unmeasured confounding factors is a problem associated with observational study designs, 
which may have affected this study despite efforts to assess or account for the most likely 
confounders.
Gen eralisability
The data used in the main analyses are from cohorts that were bom more than four decades ago, 
which limits the generalisability of the findings to the current childhood obesity epidemic and 
its implications for the future. These older cohorts are likely to be different to current cohorts of 
children in several ways. For example, the 1946 cohort represents babies bom just one year after 
the Second World War, who experienced post-war food rationing during the first years of their 
lives. Factors such as maternal smoking and infant feeding have also changed over time; in 
BCS70, 35% of mothers smoked during pregnancy (from data), compared to just 12% in 
2010,418 while breastfeeding, which has been shown to be associated with lower risk of obesity 
in later life,419 declined between the 1940s and 1980s, but has increased again in recent years.418 
These early life exposures may have important implications for long-term health,182 and secular
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changes in their distribution limit the generalisability of findings from any given time period to 
another. There are also likely to be important differences in lifestyle behaviours that are 
implicated in obesity and related health outcomes. For example, physical activity levels among 
children have shown a secular decline over recent decades, while sedentary behaviours have 
increased.420 Crucially, there are key differences in the prevalence and severity of overweight 
and obesity between contemporary and older populations; obesity prevalence in childhood and 
adolescence ranged from 0.5- 2.4% in the birth cohorts used in this thesis, compared to 7-10% 
today.45 Contemporary child populations are also experiencing more extreme obesity, and at 
younger ages than in previous generations. Results from studies of older cohorts cannot explore 
the effects of these aspects of the childhood obesity epidemic or changing lifestyle behaviours 
on long-term health. However, the limitations of these cohorts have to be balanced against the 
wealth of data that they provide and the advantages of the study design.
First, these are national cohorts which cover the whole of Great Britain, providing a huge 
breadth of coverage. The cohorts are not ethnically representative of Britain, with fewer non­
white cohort members than in the general population, but in other respects are comparable to 
census data.252'254 They can therefore be considered to be reasonably representative of the target 
population. Second, in order to study the effects of childhood and adolescent exposures on 
chronic diseases, a long period of follow-up is required due to the late-onset nature of these 
conditions. Analysis of younger cohorts that are more comparable to contemporary populations 
is limited by the small numbers of cases that arise in them. While a number of studies have 
assessed cardiovascular risk factors,121 fewer have assessed clinically relevant disease end­
points. Third, the similarities between the three cohorts in terms of their target populations, the 
data collected and the frequency of follow-up mean that the datasets can be harmonised and 
analysed using the same models. They have all collected detailed information on socio­
demographic and lifestyle characteristics at several points, which allowed assessment of the 
effect of important confounders. Cross-cohort comparisons and tests for an interaction effect by 
cohort indicated that the pooling of data was appropriate, despite the differences in BMI 
trajectories and ages at follow-up. Other studies that have adopted similar approaches to 
pooling data have been limited by differences among the cohorts in the availability of variables, 
such as SEP.174 The great advantage of pooling data from these three cohorts is that study 
power has been increased without loss of information.
Data validity
The main limitations of the modelling aspects of this thesis relate to data validity issues, as 
described in Chapter 7. Disease and BMI distributions, and the associations between them, may 
change as a consequence of technological, medical or social changes, and data on the long-term 
effectiveness of obesity interventions are lacking. There are inherent limitations to this kind of
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projection exercise, due to the strong assumptions on which they are based. Relatively small 
changes in any of these assumptions can produce vastly different results. For example, 
inadequate adjustment for variation in relative risks of disease by age and sex can bias estimates 
attributable to obesity.421 There have been few attempts to model the long-term health 
consequences and healthcare costs associated with childhood obesity for these reasons. Cross­
cohort comparisons of the fit of model estimates to cohort data indicated that the fit of the 
model improved for younger cohorts, therefore it is proposed that the model is suited for 
estimating health outcomes in the current population. Furthermore, unlike other models of 
childhood obesity burden that have been described previously, the model used in this thesis 
incorporated the cumulative effect of exposure to overweight over the life-course. Estimates of 
obesity intervention effects modelled on existing interventions provide a starting point for 
discussion of resource allocation and prioritisation for public health policy.
Summary
In this section, the strengths and limitations of the thesis have been described, building on 
discussions in previous chapters. Important limitations that need to be borne in mind when 
interpreting the findings are that selection bias may lead to a non-representative sample, and 
there may be measurement biases associated with outcome measures. It would be expected that 
these limitations would generally result in underestimation of the true effects. A wider 
limitation concerns the generalisability of findings from older cohorts to more contemporary 
populations. However, these limitations are balanced against the advantages of using cohort 
data with follow-up in childhood, adolescence and adulthood to investigate long-term outcomes 
from a life-course perspective.
8.2 Summary o f findings
This thesis has examined the relationships between overweight and obesity in childhood and 
adolescence and long term health outcomes, and has explored the potential contribution of 
overweight in childhood to future health burden in the UK. The question of whether excess 
weight in early life contributes to future disease is important in light of the rising prevalence of 
childhood overweight. The answers to this question will help in our understanding of the 
implications of childhood obesity for future disease burden, and the impact that different 
interventions may have in mitigating these effects.
A systematic review of the literature revealed a gap in knowledge regarding the effects of 
obesity in childhood on adult health. In particular, the review highlighted the limitations of the 
methods that have been widely used to examine this topic. To address this evidence gap, pooled 
data from three cohorts were analysed, using methods designed to examine relationships 
between life-course exposures and later outcomes. The findings from these analyses showed
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that overweight in childhood and adolescence was associated with increased risk of type 2 
diabetes among obese adults, indicating that exposure to excess weight in childhood may 
contribute to long-tem risk, possibly through a cumulative exposure effect. There was weak 
evidence that overweight in childhood, adolescence and adulthood may also be associated with 
increased risk of CHD compared to obesity in adulthood alone. However, individuals that were 
overweight in childhood or adolescence but later became normal weight in adulthood did not 
have increased risk of these outcomes compared to those who had never been overweight. For 
the other outcomes examined in this thesis, there was little evidence for a contribution of 
overweight in childhood and adolescence to long-term risk.
Following on from these findings about the potential long-term effects of overweight in 
childhood and adolescence, it was of interest to know how overweight and obesity in the current 
child population may impact on health burden in the future, and to explore the potential effects 
of different approaches to obesity prevention in the population. Projections from a micro­
simulation model showed that overweight and obesity in the current child and adolescent 
population could account for a fifth of all obesity-related healthcare costs in the year 2050.
They also indicated that early interventions to reduce BMI in childhood may lead to reductions 
in health burden. The need for assessment of the long-term effectiveness and costs of 
interventions was highlighted.
8.3 The long-term  impact o f childhood overw eight
The findings of this thesis indicate that overweight impacts on different health outcomes at 
different stages of the life-course, and that the relationship between overweight and health 
should be viewed with a long-term perspective in mind. This is illustrated by the cardiovascular 
outcomes that have consistently been shown to be associated with overweight in childhood and 
in adulthood. Overweight in childhood and adolescence may be an important risk factor for 
type 2 diabetes when combined with obesity in adulthood, while hypertension risk appears to be 
more affected by weight status in adulthood. Given the relationship between type 2 diabetes 
and cardiovascular disease, childhood overweight may also have an impact on long-term 
cardiovascular outcomes. For the other outcomes considered in this thesis, there were 
associations with overweight and obesity in adulthood, but effects of childhood overweight 
were not evident.
Compared to studies which have used standard adjustment for weight status in adulthood to 
determine the independent effect of childhood overweight on long-term health,422 the approach 
adopted in this thesis has provided a different perspective on the role of childhood overweight, 
considering the more nuanced question of whether there is a contribution of childhood 
overweight to long-term outcomes. A study which used path analysis to examine the 
associations between BMI measurements at several points during childhood, BMI in adulthood,
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and systolic blood pressure in a Danish dataset, indicated that there was no direct effect of BMI 
in childhood on systolic blood pressure, i.e. the relationship between childhood BMI and 
systolic blood pressure in adulthood was entirely mediated through adult BMI.265 This study did 
not adjust for any potential confounders, and treated BMI and systolic blood pressures as 
continuous measures, therefore a direct comparison of results is difficult, but it lends support to 
the finding that weight status in adulthood contributes more strongly to hypertension risk than 
weight status in childhood. One previous study has assessed the relationship between 
overweight patterns from childhood to adulthood and cardiovascular risk outcomes.174 This 
study found contrasting effects to those reported in this thesis, with an effect of persistent 
overweight being observed for hypertension but not for type 2 diabetes. Key differences of this 
study include a younger mean age at follow-up than the British cohorts studied in this thesis, 
and adjustment for different confounders (notably, data on SEP were not available). In addition, 
this study assessed overweight at two points of the life-course (childhood and adulthood), rather 
than the three stages used in this thesis. The contrasting findings indicate a need for further 
research to clarify these relationships, and investigation of different models of disease 
progression for these outcomes.
Overweight in childhood and adolescence in non-obese adults was not associated with increased 
disease risk compared to not being overweight in childhood or adolescence and non-obese in 
adulthood. Therefore the effects of persistent overweight from childhood through to adulthood 
on cardiovascular risk may be attributable to the duration of exposure to overweight rather than 
any long-term change attributable to childhood overweight. A similar finding has been reported 
in a previous study, which showed that cardiovascular risk in individuals that were overweight 
in childhood but normal weight in adulthood was similar to the risk in normal weight adults that 
had not been overweight in childhood.174 Analysis of data from the Framingham Cohort Study 
indicated that the number of years lived with obesity in adulthood was associated with 
mortality, including cardiovascular mortality,247 indicating that the duration of exposure to 
overweight may be an important factor in cardiovascular risk. The evidence indicates that 
overweight isolated to early life does not lead to permanent changes in disease risk. However, 
early onset of overweight may have different implications for disease progression than 
becoming overweight in adulthood. For example, glucose tolerance may be more malleable at 
younger ages; it has been suggested that the progression from impaired glucose tolerance to 
type 2 diabetes is accelerated in adolescents compared to adults.87 This suggestion is especially 
pertinent in light of the increasingly young ages at which overweight and obesity are emerging 
in the population. Those with persistent overweight from childhood may be at increased risk of 
cardiovascular outcomes due to longer exposure, mediated to some extent by insulin resistance 
and type 2 diabetes at earlier stages. Combined with the evidence for the clustering of 
metabolic syndrome components in children, 37 67-74 their tracking into later life ,125 and the
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emergence of type 2 diabetes cases in adolescence,85 the findings of this study emphasise the 
importance of focusing on early life factors in the prevention of obesity, cardiovascular risk 
factors and CHD.
This thesis has considered the long-term health consequences of overweight in childhood and 
adolescence. The rationale for focusing on this period of the life-course was that current UK 
public health policy emphasises childhood obesity as a priority for intervention efforts.13 
However, weight status in childhood, adolescence and adulthood may be markers of exposures 
that occur in earlier life. As presented in the DOHaD framework, intergenerational effects may 
be important in the development of obesity and other health outcomes236; the effects of 
undernutrition in utero and catch-up growth in later life on long term cardiovascular outcomes 
including hypertension,286 376 cardiovascular disease, 173 248 288 423‘424 and type 2 diabetes 237425-426 
have been examined in a number of studies, which have consistently shown that small size at 
birth in combination with rapid childhood growth is associated with overweight and increased 
risk of these outcomes in later life. Recent studies have focussed on the effects of maternal 
obesity and glycaemic control during pregnancy on childhood obesity, 283 427 and have indicated 
that overnutrition, possibly through metabolic changes to the fetal environment, increase the 
risk of obesity and co-morbidities in the offspring in later life. 428-430 This is likely to be an 
important area for future research in light of the increasing prevalence of maternal obesity 431 
and gestational diabetes432“433; clinical diabetes was present in just 0.54% of mothers in the 
BCS70 cohort (89 cases), while recent estimates put the prevalence of gestational diabetes at 
more than 2%, with higher prevalence among Asian and Black mothers. 434 Furthermore, the 
family environment is likely to play a key role in the intergenerational transmission of 
overweight and health problems; children’s dietary and physical activity behaviours are shaped 
by early experiences and influenced by family members,435 and these behaviours may track over 
the life-course to impact on health outcomes in later life.436 In short, childhood obesity may be 
a marker of some underlying vulnerability to disease risk. This risk may be programmed by 
environmental exposures earlier in life, or there may be genetic influences underlying the 
associations between birth weight, weight status in later life, and disease risk.437 In addition, 
there may be obesogenic lifestyle behaviours which become established in early life that 
contribute to overweight and disease risk. Obesity is likely to be an embodiment of a collection 
of exposures over the duration of the life-course. Studying the effects of pre-childhood or 
genetic exposures was beyond the scope of this thesis, but they are an important consideration 
in understanding the development of obesity and its co-morbidities over the life-course. They 
also have significant implications for approaches to intervention, especially in the context of 
rising prevalence of obesity among pre-school children.56
Efforts to describe the nature of the future health burden associated with childhood obesity are 
necessary for public health planning and resource allocation. Projections based on recent trends
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in BMI distribution showed that overweight in the current UK child and adolescent population 
could present a substantial health and economic burden by the year 2050, with cases of 
hypertension, type 2 diabetes and cardiovascular diseases accounting for the majority of the 
disease and direct cost burden associated with overweight. If the rise in obesity prevalence 
could be stopped among this age group, direct healthcare costs in 2050 could be reduced by 
more than £1 billion. More research is needed to establish the best approaches to intervention. 
A study of several different childhood obesity interventions in Australia (the ACE-Obesity 
Project) showed that the largest net savings in costs were associated with interventions aimed at 
the general population, such as restrictions on advertising of junk food to children and school- 
based education programmes.438 However, evidence for the impact of such interventions on 
BMI is limited.380 Analysis of cohort data in this thesis showed that overweight isolated to 
childhood and adolescence did not increase disease risk compared to never being overweight. 
This finding highlights that effective intervention pre-adulthood could potentially bring the risk 
of future morbidity among overweight children in line with the level of risk in normal weight 
children, adding weight to the notion that a focus on early life should be the priority for 
reducing the impact of obesity on long-term health. The timing and target age-groups of 
interventions, and the long-term sustainability of their effects, are important considerations for 
obesity prevention strategies.
However, obesity represents just one risk factor among many which contribute to the 
morbidities included in this thesis. There will be health implications of changes in these other 
exposures, which may be independent of obesity. For example, while obesity prevalence has 
risen in recent decades, other known risk factors for cardiovascular disease have declined; 
average systolic blood pressure in Western Europe has fallen by more than 2 mm Hg per decade 
since 1980,404 while the prevalence of smoking has decreased by more than half since the 
1950s.439 Consequently, the age-standardised cardiovascular disease burden has fallen, despite 
the rise in obesity prevalence.404 Despite a current focus on obesity, reducing future disease 
burden will require a multifactorial approach, which takes into consideration the relationships 
between the various risk factors, and their changing distributions over time.
8.4 Im plications and future research
Overweight in childhood and adolescence may increase cardiovascular risk in obese adults. As 
cases of more severe and earlier onset obesity emerge in the population, the occurrence of 
persistent overweight over the life-course is likely to increase in future generations, with 
implications for cardiovascular disease burden. Interventions that promote healthy weight 
among young children and their families, with the aim of establishing lifestyle behaviours that 
will ensure long-term weight maintenance, are likely to be important priorities. Childhood may
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be an ideal time to implement obesity interventions because unhealthy lifestyle behaviours are 
less established, overweight is less entrenched, and disease progression is less advanced than at 
older ages. Although evidence for a contribution of childhood overweight to long-term risk is 
limited for non-cardiovascular outcomes, obesity in adulthood is an important risk factor for all 
the outcomes studied in this thesis; given that obese children are more likely to become obese 
adults than their healthy weight peers, the promotion of healthy weight in early life is likely to 
have benefits in terms of reducing adult overweight and its co-morbidities in later life, 
regardless of whether childhood obesity itself contributes to excess risk. Furthermore, the 
tracking of lifestyle behaviours over the life-course, and the potential intergenerational benefits 
of healthy weight and lifestyle, draw attention to the longer term implications of effective 
interventions in early life for reducing health burden.
These considerations emphasise that there is a strong basis and justification for the UK 
government’s focus on children as a priority group for obesity interventions. They also 
underline the need for a long-term perspective when considering the implications of childhood 
obesity and interventions for chronic disease prevention. However, focusing on childhood 
obesity in isolation is unlikely to yield the greatest success; it is also important to consider how 
the wider environment may present challenges to effective intervention. For example, the roles 
of urban design, the food and advertising industries, and cultural influences in creating an 
obesogenic environment need to be examined, and addressed in intervention efforts.440 Such 
approaches will have an impact on the whole population, with potentially wider-reaching 
benefits. At the same time, there remains a large and increasing number of children who are 
already overweight or obese, who will require more intensive interventions to manage their 
weight and reduce their risk of obesity co-morbidities. Future evaluations of childhood obesity 
interventions need to consider the benefits and costs associated with multiple interventions that 
are implemented simultaneously, including targeted interventions for high risk children and 
ecological or upstream approaches, in order to explore the optimal combinations of approaches. 
A priority area for future studies is to establish the sustainability of childhood obesity 
interventions, and to investigate ways in which intervention effects can be maintained over the 
life-course. It will also be important to identify individual-, family-, and community-level 
predictors of long-term intervention success, as weight regain is an important factor in 
determining the net benefits of any intervention.
A number of areas for further research have been identified. The finding in this thesis that 
childhood overweight contributes to type 2 diabetes, and possibly CHD risk, needs to be 
replicated in other studies, as the current evidence regarding these relationships is mixed. The 
relationships between childhood overweight and the other disease outcomes in this thesis also 
need to be confirmed. Further research is required to understand the roles of age at onset, 
duration and severity of overweight, and patterns of growth in early life in determining long­
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term health. A major issue with studying long-term outcomes of childhood exposures is the 
need for data from older cohorts, which are different to contemporary cohorts in terms of the 
distribution of obesity and other exposures. Analyses of such studies are further limited by the 
low prevalence of overweight and obesity that are typically observed, leading to a need for large 
sample sizes. Increasing availability of data from large cohorts internationally, including more 
recent birth cohorts with biomedical data, may provide one solution.
Characterisation of the relationships between overweight and other cardiovascular risk factors, 
such as blood pressure, lipids, and glucose, and their contributions to cardiovascular outcomes 
over the life-course, will add to our understanding of cardiovascular disease progression and the 
mechanisms underlying its relationship with overweight. Improved understanding of the 
evolution of obesity and other cardiovascular risk factors over the life-course, and their 
contributions to long-term health, will be important for identifying which modifiable risk factors 
should be targeted in the prevention of cardiovascular disease. It will also provide insight into 
how changing distributions of these risk factors in the population are likely to impact on disease 
burden.
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Summary
The objective of this study was to evaluate the evidence on whether childhood 
obesity is a risk factor for adult disease, independent of adult body mass index 
(BMP. Ovid MEDLINE 11948-May 1011), EM BASE 11980-2011 week 18) 
and the Cochrane Library (1990-20111 were searched for published studies of 
BMI from directly measured weight and height in childhood (2-19 years! and 
disease outcomes in adulthood. Data were synthesized in a narrative fashion. 
Thirty-nine studies (n 181-1.1 million! were included in the review. There was 
evidence for associations between childhood BMI and type 2 diabetes, hyper­
tension and coronary heart disease. Few studies examined associations indepen­
dent, of adult BMI; these showed that effect sizes were attenuated after 
adjustment for adult BMI in standard regression analyses. Although there is a 
consistent body of evidence for associations between childhood BMI and car­
diovascular outcomes, there is a lack of evidence for effects independent of 
adult BMI. Studies have attempted to examine independent effects using stan­
dard adjustment for adult BMI, which is subject to over-adjustment and prob­
lems with interpretation. Studies that use more robust designs and analytical 
techniques arc needed to establish whether childhood obesity is an independent 
risk factor for adult disease.
Keywords: Childhood obesity, morbidity, mortality, systematic review.
Abbreviations: BMI, body mass index; BMI-5DS, body mass index standard 
deviation score; CHD, coronary heart disease; CL confidence interval; HR, hazard 
ratio; IOTF, International Obesity Task Force; OR, odds ratio.
obesity  mVews (2012)
Introduction
Overweight and obesity in adulthood arc associated with 
multiple comorbidities, most notably type 2 diabetes, car­
diovascular disease and a number of cancers (1,2). Dramatic 
rises in childhood obesity prevalence over the last 20 years 
(2| have brought increasing attcnlion to the potential long­
term health consequences of childhood obesity. However, 
our understanding of the associations of childhood obesity 
with long-term health is incomplete. In particular, because of
the tracking of adiposity from childhood into later life (4), it 
remains unclear whether childhood obesity has an effect on 
adult health that is independent of adult wcjght status. 
Previous reviews have examined the relationship between 
childhood obesity and morbidity in adulthood (5), but have 
not considered whether the effects of childhood adiposity 
arc independent of adult overweight.
The objective of this review was to sy stematically evalu­
ate the current evidence on the contribution of childhood 
body mass index (BMI) to aduh disease risk, independent
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Appendix 3: Supplementary table: Odds ratio of coronary heart disease CHO for different overweight patterns 
through childhood, adolescence and in adulthood -  effect of adjusting for type 2 diabetes and hypertension. 
Analysis of pooled data from three British national birth cohorts.
Overweight Pattern Unadjusted Adjusted for 
hypertension
Adjusted for 
type 2 diabetes
Adjusted for 
hypertension 
and diabetes
OR
(95% Cl)
OR
(95% Cl)
OR
(95% Cl)
OR
(95% Cl)
Never overweight 1 1 1 1
Childhood only 0.44 0.48 0.48 0.52
(0.20, 1.89) (0.11,2.08) (0.11,2.04) (0.12, 2.22)
Adolescence only 1.63 1.70 1.68 1.75
(0.37,7.19) (0.38,7.57) (0.38,7.42) (0.39, 7.77)
Adulthood only 3.83** 3.53** 2.94 ** 2.66**
(1.98, 7.42> (1.79, 6.96) (1.55,5.59) (1.36,5.21)
Childhood + adolescence 3.43 3.47 3.37 3.39
(0.60, 19.64) (0.60, 19.99) (0.57, 19.81) (0.56, 20.32)
Childhood + adulthood 1.10 0.97 1.15 1.00
(0.14, 8.48) (0.11,8.53) (0.15,8.89) (0.11,8.78)
Adolescence + adulthood 3.74* 3.16* 3.20* 2.77
- (1.35, 10.35) (1.14, 8.70) (1.10, 9.33) (0.97, 7.90)
Persistent overweight 6.62** 6.87** 4.84* 4.95**
(1.94, 22.65) (2.14, 22.11) (1.41, 16.63) (1.61, 15.27)
Hypertension - 3.62** - 3.47**
(1.80, 7.25) (1.72, 7.00)
Type 2 diabetes - - 5.01** 4.78**
(2.35, 10.69) (2.28, 10.01)
OR is for odds of disease outcome compared to never overweight category; Adjusted for sex, 
year of birth, exact age and height at childhood BMI measurement, birth weight, S E P  at birth 
SE P  in adulthood, and smoking status in adulthood; adjusted for weighted sampling in NSHD; * 
p<0.05; ** p<0.01
When the CHD model was adjusted for hypertension, there was little change in the observed 
effect sizes. On adjustment for type 2 diabetes, effect sizes for obesity in adulthood only and 
persistent overweight were attenuated (OR for obesity in adulthood decreased from 3.83 to 2.94, 
and OR for persistent overweight decreased from 6.62 to 4.84).
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Appendix 4: UK mid-2007 population estimates: estimated resident population by single year of age and sex
United Kingdom
Thousands
Age Persons Males Females
2 716.7 366.9 349.9
3 706.1 361.9 344.2
4 682.1 350.2 331.9
5 663.8 339.3 324.5
6 665.0 339.2 325.8
7 680.6 348.8 331.8
8 700.9 -  358.6 342.3
9 713.9 364.5 349.3
10 733.4 375.2 358.2
11 728.6 372.6T 355.8
12 732.7 375.8 356.9
13 749.7 384.4 365.3
14 760.0 390.1 369.9
15 788.3 404.9 383.4
16 804.8 415.3 389.5
17 796.8 410.9 385.9
18 799.8 412.0 387.8
Appendix 5: Preliminary work for Chapter 7: systematic reviews of pharmacotherapy for childhood obesity
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Metformin for Obesity in Children and 
Adolescents: A Systematic Review
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OBJECTIVE —  To summarize the efficacy of metformin in reducing BM1 and cardiomcta- 
bolic nsk in obese children and adolescents without diabetes.
RESEARCH D E S IG N  A N D  M ETH O D S — We performed a systematic review and 
m eta-analysts of randomized controlled tnals (RCTs). Double-blind RCTs of > 6  momhs dura­
tion in obese subjects age i  19 years without diabetes were included. Our primary outcomes of 
interest include changes in BMI and measures of insulin sensitivity.
RESULTS — Five tnals met inclusion criteria (n =  320 individuals). Compared with placebo, 
metformin reduced BMI by 1.42 kg/m2 (95% C l 0.83-2.02) and homeostasis model assessment 
insulin of resistance (HOM A-IR) score by 2.01 (95% C l 0.75-3.26).
C O N C L U S IO N S —  Metformin appears to be moderately cfiicaaous in reducing BMI and insu­
lin resistance m hypcnnsukncmic obese dnldien and adolescents in the short term. Larger, longer- 
term studies in dillcrcnt populations arc needed to establish its role in the treatment of overweight 
children.
Metformin has been shown to reduce weight gain, hypcrtnsulincnua, and hyperglycemia in aduhs with type 2 
diabetes (1,2) and to reduce progression 
from impaired glucose tolerance to diabetes 
in those without diabetes (3). These benefits 
have led to an increase in the use of met­
formin in obese children with hypcnnsulin- 
cmia. However, obesity is not a licensed 
indication for metformin in the U.K. o r the 
U.S., and its use has proceeded faster than 
the evidence of its benefits. We undertook a 
systematic review' of randomized controlled 
trials (RCTs) investigating the efficacy' of 
metformin for reducing BMI and cardiom- 
ctabolic risk in obese children without 
diabetes.
RESEARCH DESIGN AND 
METHODS— Wc sea rch ed  O vid  
MEDLINE, EM BASE, the Cochrane Regis-
. Diabetes Care 32:1743-1745. 2009
ter of Controlled Tnals, the mctaRcgistcr of 
Controlled Trials, and key journals pub­
lished before December 2008 (online ap­
pendix Tables 1 and 2 available at http7/ 
carc.diabetcsjoumals.orgfcgi/content/full/ 
dc09-0258/DC1). W c included double- 
blind RCTs of ^ 6  months duration with 
obese subjects age ^ 1 9  years without dia­
betes and without secondary or syndromic 
causes of obesity. Pnmary outcomes of in­
terest w'crc BMI (weight in kilograms di­
vided by the square of height in meters) and 
measures of insulin sensitivity. Secondary 
outcomes included fat mass, blood pres­
sure, fasting lipids, and adverse effects.
Where three or more studies reported 
a common outcome, treatment effect was 
explored in a meta-analysis (Stata Statis­
tical Software 10.1; StataCorp, College 
Station, TX), pooling data from the end of 
the follow-up penod for tnal completers.
A random-effects model was selected. 
Sensitivity analyses were performed using 
fixed-effects models and by dose of met­
formin (1,000 vs. 2,000 mg), age of par­
ticipants (12 -19  vs. < 1 2  years), co- 
intervention (metformin vs. metformin + 
co-intcrvcntion), baseline BMI (mean 
^ 3 5  vs. < 3 5  kg/m2), and by excluding 
one study reporting greater treatment ef­
fects than the other studies (4).
RESULTS—  Five studies published 
between 2001 and 2008 mcl the inclu­
sion entena (4 -8 ) . This included one 
crossover trial (5).
Three studies look place in the U.S. 
(6 -8 ) , and one each in Australia (5) and 
Turkey (4). All tnals lasted 6 months with 
metformin doses from 1,000—2,000 mg/ 
day. Three studies used lifestyle co- 
intcrvcntions in either tnal arms (4,7,8). 
Two studies included adolescents (ages 
12-19 years) (6,7), one looked at younger 
children (ages 6 -1 2  years) (6), and the 
others spanned ages 9 -1 8  years. In the 
U.S. and Australian studies, a large pro­
portion of participants (45-90% ) were 
from ethnic backgrounds with high prev­
alence of metabolic syndrome (African 
Amcncan, Hispanic, or Asian). All partic­
ipants were hyperinsulinémie or insulin 
resistant. Sample size ranged from 2 8 -  
120 participants at randomization; in to­
tal there were 365 participants and 320 
tnal completers. Mean attntion rales were
11 % in metformin groups and 16% in 
placebo groups.
In the pooled analysis, metformin re­
duced BMI by a mean of 1.42 k ^ m 2 (95% 
Cl 0 .83-2 .02) compared wnh placebo 
(I2 =  56.2%; n = 342) (Fig. 1). Sensitivity 
analyses did not reveal notable differences 
by age, dose, or baseline BMI. When the 
outlier result was excluded, metformin 
reduced BM1 by 1.15 ka'm 2 (0.73-1.57,
12 =  0%). Reduction in lasting insulin was 
greater in metformin than placebo groups 
in three studies, but evidence for a treat­
ment effect was weak ( - 5 .3 0  ¿tU/ml 
|95% Cl -1 1 .9 6  to 1.36|, I2 =  78.7%; 
n = 257) (4 -7). Tooled metformin effect 
on the homeostasis model assessment of 
insulin resistance (HOMA-IR) score was 
-2 .0 1  (95% Cl -3 .2 6  to -0 .7 5 , I2 =  
49.5% ; n «  234) (4 ,6 ,8) and -1 .2 8
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Metformin fo r obesity in children and adolescents
Study %
ID WMD (95% O ) Weight
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Freemark
i
----------------------- -1.40 (-2.17. -0.63) 22.39
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NOTE: Weights are from random effects analysis
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Figure I—Forest plot comparing change in B Sil (kg/m 2)  in metform in and  placebo groups.
( -2 .5 5 1 0  - 0 .2 1 ,1* 12 =  0%) if the Turkish 
study was excluded.
Pooled mean metformin effect on to­
tal cholesterol was —0.19 mmol/1 (95% 
Cl -0 .3 8  to -0 .0 1 , I2 =  0%; n = 234) 
(4,6,7). Analyses did not provide strong 
evidence for a treatment effect on fasting 
glucose, HDL cholesterol, triglyceride 
levels, o r blood pressure. There was insuf­
ficient data to comment on body fat out­
comes. Gastrointestinal problems were 
the most common reported side effect (in 
20—30%) and were more frequently re­
ported in m clform in than in placebo 
groups (nsk difference 10-14% ) (6,7). 
Only one participant reported gastroin­
testinal problems as the reason for leaving 
a study (7).
CONCLUSIONS —  O ur meta-analy­
sis provides some support for a beneficial 
metformin effect on obesity outcomes 
among hyperinsuliném ie children and 
adolescents. Treatment over 6 months 
may be efficacious in reducing BMI by 
1.42 k ^ m 2 (equivalent to 0.4 SD, based 
on SD for BMI in U.K. and U.S. adoles­
cents) and HOMA-1R score by 2.01 (^-0.6 
SD) (9). Metformin use was also associ­
ated with a small reduction in total cho­
lesterol level (~-0.26 SD) (10), but these 
arc unadjusted measures, and it is not 
possible to determine whether the effects 
arc secondary to reductions in BMI and 
1IOMA-IR or attnbutablc to other factors.
To o u r knowledge, the effects of m et­
formin on BMI in obese children without 
diabetes have been synthesized in only 
one published review based on three 
studies (11), which identified no treat­
ment effect at 6 months ( - 0 .1 7  kg/m1 
(95% Cl -0 .6 2  to -0 .281).
Metformin may not be as effective as 
behavioral interventions in rcducingBMI: a 
meta-analysis of behavioral interventions m 
obese adolescents reported an effect of 
-3 .0 4  kg/m2 (95% Cl -3 .1 4  to -2 .9 4 )  at
6 months, which was maintained at 12 
months follow-up (12). W hen compared 
wnlh drugs that arc licensed for obesity, 
metformin has m oderate effect: meta- 
analyses of RCTs reported an orkstat effect 
of —0.76 kg/m2 ( —1.07 to —0.44) and a 
sibutraminc effect of — 1.66 kg/m2 ( —1.89 
to — 1.43) at 6 months (12).
The results of this review m ust be in­
terpreted writh caution: the studies were 
short-term and based on small samples; 
participants were mainly from the U.S., 
and large portions were from ethnic back­
grounds known to be at increased risk of 
metabolic disorders, limiting the gcncral- 
izabihty of findings; and the studies pre­
sented unad justed  m easures w ithout 
intention-to-trcai analyses, w hich may 
have overestimated treatment effects.
Metformin may be efficacious in re­
ducing BMI and insulin resistance among 
obese hypcnnsulincmic children and ad ­
olescents in the short term. Larger, long­
term studies across different populations 
arc needed to establish the role of met­
formin as therapy for obesity and cardio- 
mctabolic nsk  in young people.
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ABSTRACT
Objective: To examine the evidence on the efficacy and safety of anti-obesity drugs in obese 
children and adolescents.
Design: Systematic review and meta-analysis
Methods: Ovid MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and the 
metaRegister of Controlled Trials (inception-2009) were searched electronically. Double­
blind, randomized placebo-controlled trials of orlistat and sibutramine, of >6 mnnfhs duration 
in children and adolescents (age <19 years) with obesity, were eligible for inclusion.
Results: Six trials met inclusion criteria. Treatment with orlistat over 12 months (N=533) 
reduced BMI by 0.86 Igin3 (95% Cl: 0.46 to 1.26) more than placebo, and was associated 
with gastrointestinal side effects. Sibutramine treatment over 6 months (N=548) reduced 
BMI by 2.03 kgta2 (95% CL 1.31 to 2.75) more than placebo. Sibutramine use was 
associated with improvements in insulin resistance, but increased systolic blood pressure 
(+2.2 mm Hg; 95% CL 0.4 to 39).
Conclusions: Orlistat and sibutramine appear to be moderately efficacious in the short twm ¿1 
reducing BMI among obese adolescents. However, sibotramine use is associated with 
systemic side effects which could contribute to cardiovascular risk; gastrointestinal side 
effects of orlistat may limit its long-term use. Careful consideration of the potential risks and 
benefits should inform decisions to continue or initiate pharmacotherapy for obesity in 
children and adolescents.
INTRODUCTION
The prevalence of child and adolescent obesity worldwide has more than tripled since 
the 1980s.[l-2] Obesity in childhood is associated with increased risk of developing type 2 
diabetes, cardiovascular disease, respiratory problems, orthopaedic problems and liver 
disease, among other health problems.[3] These co-morbidities have been shown to track 
into adulthood,[4-6] and obesity may be an important preventable cause of death in 
adulthood. [7-9]
Anti-obesity drugs have been shown to be of benefit for weight loss [10-11] and 
weight maintenance in obese adults,[12] as well as slowing progression to chronic diseases 
such as diabetes.[13] Oiirstat and sibutramine are the most widely used drug treatments that, 
until recently, were approved for the treatment of obesity in adults.[14] Orlistat is a lipase
•4
inhibitor, which acts in die gut to reduce the absorption of fats from the diet.[15] Sibutramine 
acts systemically to inhibit the reuptake of hormones serotonin and norepinephrine, which 
enhances satiety and reduces food intake.[15] hi January 2010, marketing authorisations for 
sibutramine were suspended across Europe amid concerns about increased cardiovascular 
disease morbidity in adults.[16]
The evidence for the role of drags in management of childhood obesity is less well 
established than for adults. Anti-obesity drags are not licensed for use in children and 
in flic USA and Europe. Despite this, prescribing prevalence of orlistat and 
sibutramine among patients aged 0-18 years in England increased 15-fold between 1999 and 
2006, from an annual prevalence o f0.006 to 0.091 per 1000 person years;[17] orlistat 
»rrmintwf for 78% of all prescriptions. Prescribing of these drugs is in line with
recommendations from the National Institute of Health and Clinical Excellence (NICE) 
(2006) [18] and American Academy of Pediatrics (AAP) Expert Committee (2007),[19] 
which identify lifestyle modification as the first stage in treatment, but also recognise that 
pharmacological treatments (orlistat and sibutramine) may be appropriate for the 
management of older children and adolescents with certain co-morbidities.
Studies of anti-obesity drag treatment in children and adolescents have tended to 
emphasise efficacy.[20] The recent suspension of simbutramine from the European market 
indicate that a stronger focus on side effects may be warranted, especially in the case of 
children where use of these drags is unlicensed, and the potential benefit may be modest. We 
undertook a systematic review and meta-analysis of randomized controlled trials to establish 
the rale of anti-obesity drags for the management of obesity in children ami adolescents; we
aimed to update estimates of efficacy, and to summarise the side effect profiles for these
«*•
drugs. We focused on orlistat and sibutramine, as these are the drags which have previously 
been recommended for use in this age group.
METHODS
We performed electronic searches of Ovid MEDLINE (1950-May 2009), EMBASE 
(1980-May 2009), the Cochrane Register of Controlled Trials (1990-2009), and the 
metaRegister of Controlled Trials (inception-2009). Inclusion criteria were: children and 
aHnlecrentc (aged <19 years), and being overweight or obese. Exclusion criteria were: 
known genetic syndromes predisposing to obesity; diabetes mellitus; polycystic ovary 
syndrome; or other known chronic disease. Double-blind, randomized placebo-controlled 
trial* of orlistat or sibutramine of at least six months duration were selected. These criteria
were established to incorporate study quality into the analysis. Trials of drugs alone, and in 
combination with non-drug co-interventions were included. No limits were placed on 
language.
The primary outcome measure of interest was change in BMI (kgW). The outcome 
was expressed as change in raw BMI (kg/m:) rather than BMI standard deration score 
(SDS), as BMI SDS tends to show less variability over time in obese children compared to in 
lean children, while raw BMI is a more stable measure of adiposity change across levels of 
adiposily.[21] Secondary outcomes included waist circumference, blood pressure, fasting 
lipid profile, and adverse effects.
Initial abstract screening was earned out by one reviewer. Second stage screening
took place in a consensus meeting with two reviewers present. Data were extracted
•#
independently by two reviewers using a pre-designed form, and results compared. If 
extracted results differed, consensus was reached through discussion. If more two 
studies reported a common outcome of interest effect size estimates were pooled in a meta­
analysis. The principal summary measures were mean differences in BMI change and other 
outcome measures between treatment groups. Weighted mean differences were analysed for 
data at 6 or at 12 months follow-up. A random-effects model was specified a priori to 
incorporate the effect of trial heterogeneity. If not reported in the paper, standard deviations 
(SD) of BMI change were imputed using SDs of the mean baseline and endpoint 
me^qiwiwits and an estimate of the correlation between baseline and endpoint values. 
Statistical heterogeneity was assessed using a chi-squared test and the I-squared statistic. 
Publication bias was not assessed due to the small number o f studies included in the data
synthesis. All analyses were carried out using Stata 10.1 (StataCoip. 2007. College Station, 
TX: StataCoip LP).
RESULTS
840 publications were identified in the initial search, and seventeen papers were 
retrieved for further assessment (Figure 1). Six studies published between 2003 and 2006 
met the inclusion criteria, comprising two trials o f orlistat and four trials of sibutramine 
(Table 1). Follow-up ranged from 6 to 12 months duration. In all studies, drug intervention 
was used as an adjunct to lifestyle modification programs. Studies used a mixture of 
intention-to-treat (111), modified ITT, and completer analysis.
Orlistat trials
•<
Only two orlistat trials were identified flat met the inclusion criteria.[22-23] Both 
studies took place in North America, and participants were aged between 12 and 18 years. A 
dose of 120 mg three times daily (tds) was used in both trials. In view of the foct that there 
were only two included studies, and the small sample size of one study (n=40 individuals) 
[23], results were not meta-analysed and the effect estimates obtained from die larger study 
are principally reported.
In the study by Chanoine et al [22] orlistat (n-352 participants) reduced BMI by 0 86 
kg'm5 (95*/. Cl 0.46 to 1.26 k g V ) more than placebo (n=181) at 12 months follow-up. This 
corresponded to a reduction in weight of 2.64 kg (95% Cl 1.55 to 3.73 kg). 13.3% of those in 
the orlistat group had a reduction in BMI of >10% at 6 months follow-up, while only 4.5% of 
the placebo group had this level o f response (p=0.002). Attrition (randomised participants
who did not complete the study) was similar in trial arms, at 35% in die treatment group and 
36% among controls. There was no evidence of an effect of orlistat on other indicators of 
cardio-metabolic risk, including fasting insulin, fasting glucose, systolic blood pressure, total 
serum cholesterol, HDL-cholesteroL, LDL-chole sterol, triglycerides and body fat percent
In die other study, there was little evidence for a real effect of orlistat on BMI at 6 
months follow-up (effect size -0 JO kgdn2, 95% Cl -7.16 to 6.16 kgfoa2), based on a sm a ll 
number of participants (odistat n=16; placebo n=l 8) [23]. Attrition rates were 20 % in the 
treatment group and 10 % in the placebo group.
Adverse effects oforlistat
Treatment with orlistat 120 mg tds was associated with gastrointestinal (GI) adverse 
events. Approximately half of the oilistat-treated participants reported fatty or oily stools, 
compared to 854 of placebo contro!s.[22] Other adverse effects that were more common in 
orlistat groups than in placebo controls were oily spotting, oily evacuation, abdominal pain, 
fecal urgency, flatus with discharge and fecal incontinence. Despite this, there was no 
difference in the dropout rate due to adverse effects between treatment groups (3.7% in 
orlistat-freated groups discontinued treatment due to adverse effects, compared to 1.5% in 
placebo group). Neither study found a difference in vitamin levels between orlistat- and 
placebo-treated groups at follow-up. Similar proportions of participants in treatment arms 
(<1%) dropped out due to insufficient response to treatment, and there were no notable 
differences in non-GI adverse events.
Sibutraminc trials
In four abutramine trials, a total of 691 participants were randomized and 525 of 
these completed. Attrition rates ranged from 7 to 24% in treatment groups and from 13 to 
38% in placebo groups. Around a quarter of those who withdrew from trials were lost to 
follow-up. Sibutramine dosages ranged from 5 to 13 mg once daily (od). Two trials took 
place in North America [24-23], one in Mexico [26], ami one in Rnml [77] Participants were 
aged between 12 and 18 years.
In all four trials, sibutramine-treated groups had a greater mean reduction in BMI
controls. Meta-analysis of these data showed that sibutramine (n=377 participants) reduced
BMI by 2.03 kg/m3 (95% Cl 1.31 to 2.75 kg/m3) more than placebo (n=171), with moderately
low heterogeneity in the estimates (P=25.9%, 95% Cl 0 to 72%) (Figure 2). This estimate
combined outcome data at 12 months for one study [24] with data at 6 months for die
*
remaining three trials. When the 12 month trial was excluded in a sensitivity analysis, die 
effect size estimate was similar at 1.94 kg/m3 (95% Cl 1.08 to 2.81 kg'm3), with high«- 
heterogeneity in the estimates Between 40% and 48% of sibutramine-treated
groups lost at least 10% of baseline BMI, compared to 0 to 15% of controls.[24-27]
Expressed as change in weight, sibutramine reduced weight by 6.3 kg more than placebo 
(95% Cl 3.9 to 8.7 kg), with substantial heterogeneity in die estimates (I3*75J%).
All four studies reported change in waist circumference as an outcome.[24-27] Meta­
analysis of these data showed that sibutramine (n=377) reduced waist circumference by 5.72 
cm (95% Cl 4.49 to 6.94 cm; f= 0 , 95% Cl 0 to 85%) more than placebo (n=171). Two 
studies reported change in fasting insulin level [24,27], and both found that reduction in 
fasting iT»qdin was greater in sibutiamine-treated participants than in controls. Change in 
jpmlin resistance (HOMA-IR) was analyzed in one study, which reported a greater reduction
among sibutramine-treated participants than among placebo controls (-0.69 versus -0.02, 
p<0.001).[24] There was evidence for a small beneficial effect of sibutramine treatment on 
levels of HDL-cholesterol from two studies [24,27], with effect size +0.10 mmoll. (95% Cl 
0.06 to 0.14 mmol/L). These studies also reported a beneficial effect of sibutramine on 
triglyceride levels (effect size -0.30 zmnol/L, 95% Cl -0.44 to -0.16). These estimates were 
not adjusted for weight loss or other effects. There was no evidence for an effect of 
sibutramine on fasting glucose, total cholesterol, LDL-cholesterol, or body fat percentage.
A d verse effects o f sib u tra m in e
Sibutramine-treated groups did not experience more adverse events than placebo 
controls. However, treatment was associated with systemic side effects including increased 
pulse rate and blood pressure. Three studies reported a safety protocol that detailed blood 
pressure and pulse rate cut-offs that would be used to determine withdrawal of participants 
from the study or reduction of the drug dosage.[24-26] Dry mouth, constipation, dizziness, 
and insomnia were also more commonly reported in sibutramine than in placebo groups in 
one study.[24] Meta-analysis of outcome data from all four studies showed that sibutramine 
increased pulse rate by 5.2 beats per minute (95% Cl 1.95 to 8.4; i*=92.3%) compared to 
placebo, and increased systolic blood pressure by 22  mm Hg (95% Cl 0.4 to 3.9 mm Hg; 
I2=57.0%). However, these effects were not reflected in increased withdrawal: 5% of 
sibutramine-treated participants dropped out due to adverse events, compared to 3% of 
placebo controls.
DISCUSSION
This review of published trials provides evidence that orlistat and sibutramine are 
moderately efficacious in the short term reduction of BMI in obese adolescents. Treatment 
with orlistat over 12 months reduces BMI by an average of 0.86 kg'mJ more than placebo. 
Sibutramine is more efficacious, with effect s i»  of -2.03 kgin1, and is also associated with 
improvements in some indicators of carcho-metabolic risk, notably insulin resistance and 
dyslipidemia. Orlistat treatment is associated with gastrointestinal tract adverse events, 
which appear to be well tolerated in trials. Sibutramine is associated with notable systemic 
side effects including increased heart rate and raised blood pressure.
Comparison with other research
Two previous reviews have synthesised the evidence on anti-obesity drugs in 
childien_[20,28] The Cochrane review [20] meta-analysed data from the two odistat fri»ic 
identified in this review, and reported an effect size of -0.76 kgin2 (95% Cl -1.07 to -0.44) at 
6 months. McGovern et al [28] repented an effect of orlistat of -0.7 kg/m1 (95% Cl 0 J  to 
1.2) at 6 months, based on three studies, including one open-label trial that did not meet our 
inclusion cnteria.[29] ha both of these reviews, fire overall effect size estimate was largely 
driven by the results of fire single large trial on which we have based our estimates.[22] This 
trial has the advantage of providing outcome data at 12 months rather than at 6 months only.
As in our review, the other reviews reported a greater effect o f sibutramine on BMI 
than of orlistat The effect size estimate in tire Cochrane review was -1.66 kgin1 (95% Cl - 
1.89 to -1.43), based on a meta-analysis of outcome data at 6 months from two studies.[26- 
27] McGovern et al reported an effect size of -2.4 kg W  (95% Cl -3.1 to -1.8) at 6 months 
(sibutramine n=354, placebo n~148) based on a pooled analysis of three studies.[24-25,27]
Our effect size estimate of -2.03 kgfa2 was based on four trials, and included all of the 
studies included in die other renews.
Elevated blood pressure and pulse rate in sibutramine treated groups were reported in 
previous reviews, but these effects were not quantified as they were in our analyses. Our 
pooled results demonstrate that treatment nidi sibutramine is associated with clinically 
significant effects on systolic blood pressure and pulse rate, despite fire presence of safety 
protocols relating to these indictors. The gastrointestinal side effects o f odistat appear to be 
well tolerated in trials, but one population based study indicated that almost half of 
adolescents who begin or lis tat treatment cease use within one month (with average treatment 
duration of three months) [17], suggesting that potential for the long-term use of oriistat may 
be limited.
What should be the role o f  pharmacotherapy in management o f child and adolescent obesity?
An effect size of oilistat o f -0.86 kg/m2 is équivalait to a reduction of 0.2 SD, based 
on the BMI distribution in the UK adolescent population (one SD is approximately 3.3 kgfar2 
[30]), while the effect size of sibutramine (-2.03 kg/m2) is equivalent to a change of 0.6 SD. 
Indices of insulin sensitivity in obese children (age 6-14 years) have been shown to improve 
with reductions in BMI SDS of >0.5 over one year [31], while an increase in BMI in 
childhood of >2 kg/in2 above the median has been shown to be associated with a 60% 
increase in risk of all cause mortality in adulthood [32].
A systematic review of trials of metformin, an anti-diabetes drug which has been used 
for the treatment of obesity in children, reported an effect size of -1.42 kg/m2 (95% Cl -2.02 
to -0.83) at 6 months [33]. Used as an adjunct to lifestyle interventions, oriistat, sibutramine,
and other off-label anti-obesity drugs appear to offer moderate additional benefit in reducing 
overweight in obese adolescents in the short term. However, intensive behavioural 
interventions can also be efficacious in reducing BMI,[20] and these should mntini^ to be 
used as the first line treatment where feasible.
Furthermore, the potentially beneficial effects of BMI reduction on long-term 
must be weighed against die risks, especially in the case o f sibutramine: its long-term use has 
been associated with increased cardiovascular events in adults at high risk of heart disease 
[34]. Our findings of raised systolic blood pressure and pulse rate associated with 
sibutramine use appear to be consistent with die findings in adults, as increased blood 
pressure and pulse rate are established risk fee tors for cardiovascular disease, la light 0f  the 
potential long-term risks of sibutramine use and its suspension from the maiket in Europe, 
orlistat remains die only option in anti-obesity pharmacotherapy. Orhstat has its own side
■ 4
effects, and may not be well tolerated by children and adolescents outside of trial settings.
The trials included in this review had short-term follow up, which precludes any 
conclusions about die long-term effects of pharmacotherapy use in children. Trials in 
have indicated that orlistat and sibutramine can help reduce weight regain mH progression to 
chronic diseases in the long-term [13], but this evidence is as yet lacking for young people. 
Further research is needed to establish die role of pharmacotherapy in the management of 
obesity in children and adolescents; for example, to identify which young people are likely to 
benefit from treatment, and to establish how pharmacotherapy can fit in alongside other 
interventions for long-term management o f obesity.
Limitations
This systematic review was conducted using a strategy based on filters and search 
terms developed in Cochrane reviews. The inclusion of double-blind, randomized placebo- 
controlled trials ensured a minimum study quality. Reviewers were not blinded to the author 
or journal of publication, but neither reviewer had associations with any of die authors or 
journals that were reviewed. We however note that only one of the studies included in this 
review was non-industry sponsored.[23]
In conclusion, both orlistat and siboitramine appear to be moderately efficacious in the 
short-term treatment of obesity in adolescents, although less so than intensive behavioural 
interventions. Furthermore, sibutnunine use is associated with systemic side effects which 
could contribute to cardiovascular risk in the long-term and outweigh benefits of BMI 
reduction, while orlistat has gastrointestinal side effects which may limit its long-term use. 
Careful consideration of the potential risks and benefits should inform decisions about 
inflating pharmacological treatment for obesity in children and adolescents.
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Figure 1: Flow diagram of study selection
Figure 2: Forest plot comparing change in BMI (kg/nT) in sibutramine and placebo groups
Sibutramine and BMI change (kg/m2)
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T able 1: Table o f included studies
Study name Methods Participants 
and baseline 
characteristics
Length of 
intervention 
and follow-up
Intervention
(attrition
rate)
Co-
intervention 
in both 
treatment 
arms
Notes
Maahs 2056
[23]
Randomization 
according to 
statistician 
generated 
Sequence- 
Triple blind.
US outpatient 
clinic. 40 
individuals 
randomized, 34 
conçleted.
Age 14-18 
years. 6854 
female. BMI 
>85“” centile 
for are and
SCL
<5 mouth 
treatment 
period and 
follow-up
Qriistat 120mg 
tds (2054) vs. 
Placebo (105»)
Diet and 
exercise 
therapy*" daily 
mulâritamm 
sapplemæiiï
Sub) ecu 
reimbursed 
$20 per visit+  
$10 per kg lost 
at 6 months. 
Not ITT 
analysis. Non- 
indnstry 
sponsored.
Chanoine 2005 
[22]
Randomization 
at 2:1 ratio 
according to 
computer 
generated 
schedule. 
Triple blind
32 clinics in 
US and 
Canada. 539 
individuals 
randomized. 
349 completed. 
Age 12-16 
years. 6754 
female. BMI 
>2 units h itte r 
than US 
weighted mean 
for 95th c entile 
forage and 
sex.
12 month 
meatman 
period and 
follow-up (+2 
week sin gle 
blind placebo 
lead-in)
Qdistat 120mg 
t *  (3554) vs. 
Placebo (3654)
Diet + exeia.se 
♦  behaviour
therapy +■ dai!}' 
mnltfuTtamin
sapplenœnî
Modified ITT 
analysis 
(baseline and 
>1 post- 
baseline 
assessment: 
LOCF) 
Funded by
Hryffrrem-T 3
Roche.
Beriowitz 
2006 [24]
Randomization
at 3:1 ratio, 
stratified by 
centre and 
baseline BUL 
Double blind.
33 cimics in 
US. 498 
individuals 
randomized, 
361 completed 
Age 12-16 
years. 6454 
female. BMI 
>2 umts higher 
than US 
weighted mean 
ofthe 95th 
centile for age 
andsex, _ 
•:44kg‘m:
12 mondi 
treatment 
period, follow­
up at 3 ,6 ,9  
and 12 months
Sibutramme 
10 mg od, 
iptitratedif 
'T054 initial 
BMI lost at 6 
nymtHe (2454) 
vs-Pbcébo 
(3854)
Centre-specific
behavioural
program
Modified ITT 
analysis (>1 
dose study 
medication and 
>1 post- 
baseline BMI 
measurement): 
Sponsored by 
Abbott 
Laboratories.
Berkowitz 
2003 [25]
Raado miza tion 
not described. 
Double blind.
US university 
clinic 82 
individuals 
randomized, 
62 completed. 
Age 13-17 
years. 6754 
female. BMI 
range 32-44 
kgim .
6 month 
double-blind 
period (phase 
l )  +  6mondis 
open-label 
treatment
Sibutrannne 5- 
15mgod(754) 
vs. Placebo 
(1354)
Farmty-based
behavioural
program
i l  l  analysis
for BML
completers
analysis for
other
outcomes.
Sponsor:
Knoll
Pharmaceutical 
Co and Abbott 
Laboratories.
Garaa- 
Morales 200« 
[26]
Randomization 
according to 
conqiuter 
generated list. 
Triple blind.
Outpatient 
endocrinology 
department of 
children’s 
hospital in 
Mexico. 51 
individuals
«month 
treatment 
period and 
follow-up (+ 
run-in period 
o f unspecified 
length)
Sibutrannne 
1 t a g  od 
(1954) vs. 
Placebo (2454)
Diet +
physical 
activity advice
Modified FIT 
analysis 
(excluding 
dropouts 
before 1 month 
of treatment'
IO C ?)
randomized,
•40 completed. 
Age 14-18 
years. 5754 
female. BMI 
far age and sec 
>95* centile.
Sponsored by
Abbott
Laboratories.
Codov-Matos 
2005 [27]
Raudo miza tion 
not desa lted  
Tnple blind
Regular 
clinical setting 
inRioD e 
Janeiro, Brazil. 
60 individuals 
randomized 
50 completed. 
Age 14-17 
years. 80?» 
female. BMI 
30-45 k g n r.
6 month 
treatment 
period and 
follow-up (+4 
week placebo 
run-in)
Sibutramme 
lQmgodfTtó) 
vs. Placebo 
(2754)
Dietary 
counselling + 
brief physical 
activity 
instructions
Adolescents 
with adult 
bone age ITT 
analysis min» 
LOCF. 
Sponsored by- 
Abbott 
Laboratories.
t<k= three times daily, od = once daily: ITT = intention to treat; LOOT =  last observation earned forward
T a b le  1: S tudies excluded from  review
Study name Methods Participants Interventions Reason for 
exclusion
Appolmano 2003
P5]
12 week double blind 
randomized trial
60 obese oizpaaents with 
binge eating disorder, 
Brazil. Age 18-60 years
Sibutramiue 15 mg od vs. 
Placebo
Adult
participants
Bauer 2006 [36] 16 week double-blind 
randomized trial
73 obese participants with 
and without binge eating 
disorder, Switzerland Age 
18-75 years
Sibmraniine 15 mg od + 
CBT w  Placebo + CBT
Adult
participants
Broom 2002 [37] 54 week double blind 
randomized trial
531 paaents With BMI >28 
k g h r  and >1 obesity- 
associated cardtovasatlar 
risk factor. UK. Age 18-80 
years
Oriistat 120 mg tds + 
bypocaloric diet vs. Placebo 
+  hypocaloric diet
Adult
participants
Budd 2007 [38] 6 month double blind 
randomized trial
US clinic. 34 African 
American and 45 Caucasian 
obese adolescents.
Sibutramme 5 mg od +  
behavioural program vs. 
Placebo -t-behavioinal 
program
Secondary 
analysis o f data 
from trial [25]
Correa 2005 
[Portuguese] [39]
Analysis o f  visual 
analogue scores in 6 
month triple blind 
randomized trial
Brazilian dune. Obese 
adolescents
Sibuuamme lOrcg od +■ 
lifestyle advice vs. Placebo 
■♦•lifestyle advice
Repetition of 
data [27]
Darnels 2007 [40] 12 month double
blind T7mdr>rm:wpd trial
33 clinics in US.498 
adolescents. Age 12-16 
years BM I 281.-46.3 k g in i
Sibutmmme 10 mg od + 
behavioural therapy vs. 
Placebo +  behavioural 
therapy
Repetition o f 
data [24]
James 2000 [12] 2 year double-blind 
randomized trial
605 obese patients from 8 
European centres. Age 17- 
65 years
Sibutrarmne 10 mg od + 
individuiltied programme 
vs Placebo + uuhvidualrsed 
programme
Adult
participants
Mnls 2001 [41] 24 week double blind 
randomized trial
294 obese patients from 19 
centres in Belgium. Age 18- 
70 years
Oriistat 120 mg tds + LCD 
vs Placebo +LCU
Adult
participants
Ozkan 2004 [29] Randomization by 
alternation of 
successive patients. 
Open-label study.
Outpatient clinic in Turkey. 
42 participants. Age 10-16 
years. WFH >14054.
Oriistat 120 tpg tds + 
standard care vs. Standard 
care
Open-label 
trial no 
placebo
Van MU 2007 
[42]
12 week double blind 
pmAyrniTPd trial
Research centre m the 
Netherlands. 24 individuals. 
Age 12-17 years. BMI >97* 
centile and triceps skinfold 
thickness ^ 97* cennle far 
age and sex
Sibutramine 10 mg od (85 o) 
vs Placebo (2554)
ill week mal
Zhi 2003 [43] 21 day double blind 
randomized trial
32 adolescents with BMI 
>85th centile fix age and 
sex
Oriistat 120 mg td s+ 
hypocaloric diet vs. Placebo 
+ hypocalonc diet
21-day follow­
up (-6  months)
r ^ T  = mp\îmiphph.iii<Mral therapy: LCD = low calones diet: WFH= wei °h: for heigh;
A ppendix 1: Search terms used in review
D atabase
O vid M ED LIN E EM BA SE C ochrane  
C en tra l 
R eg ister o f  
C ontro lled  
T ria ls
m etaR egister
of
C ontro lled
T ria ls
1. (sibutrammS or reducUl o r  m en d u n  
o r  n e d a n a  or sibutramme 
hydrochloride monohydrate) u p .
2. (R im onabantorSR 141716or 
Acom pba or Bethin or M onaslim  or 
Remonabent o r  Riobanl or Slimona or 
Rim oslim  or Zirmilti) mp
3. (Orlistat or Xemcal o r A lb  or 
T  etraiydrolip;tatm).ri?>.
4- (Anorectic o r anorexigenic).inp. or 
appetite suppressanttw .
5. exp Appetite Depressants'
6 . exp M etform in1
7. exp Anti-Obesity Agents/
8 . or/1-7
9. (obesS o r  obesity).mp.
10. (Overweight o r  loss o f  
o v e rw e ig h t)^ .
11. (BMI or B ody m ass index or 
Body-mass-index o r W eight for height 
o r  W eight-for-hei ght or W eight to 
height ratio o r W eight-to-height ratio 
o r  W eight b righ t ratio or W eight- 
height rario).mp.
12. (W eight gain or W eight loss or 
W eight management or W eight 
maintenance o r W eight reduction or 
W eight decrease o r W eight 
controI).mp.
13. (Waist circumference o r W aist 
m easurem eut)m p.
14. (Body f i t  o r B ody f i t  percents or 
Percents body f i t  o r F at m ass or 
Adiposity o r Body cong>osition).mp.
15. (Skinfold thickness o r  skin fold 
thickness or skin-fold thickness or 
CaUiper$).mp.
16. (H>pennsulin?emia or Insulin 
resistance o r metabolic risk or 
metabolic syndrome) n?>
17. (Dyshpid^emia orH yperiipid?enna 
o r  H ypercholesterolem ia or 
Cholesterol o r  Total cholesterol or 
Low  density lipoprotein cholesterol or 
LD L cholesterol o r H igh density 
lipoprotein cholesterol or HDL 
cholesterol o r Tnglycende S). m p.
18. (Satiety o r Hunger o r  Appetite or 
B inge eating).mp.
19. ponderal index, rap.
20 . (adverse effectS o r  adverse 
reactions o r side e£fectS).tw.
1. (Sibutramine or sibutramm or 
reductil o r  meridian o r medaria or 
sibuhamine hydrochloride 
monohydrate).ngj.
2. (Rimonabant or SR141716 or 
A cam plia or Bethin or M onaslim  or 
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